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Abstract 
 
Lack of sensitive outcome measures is a major obstacle to clinical trials in many 
neuromuscular diseases (NMD).  Lower limb muscle MRI allows non-invasive 
visualisation of acute and chronic pathology in NMD.  This thesis aims to assess the 
reliability, validity and responsiveness of quantitative MRI in chronic neuromuscular 
diseases.  A comprehensive quantitative MRI protocol of lower limb muscles was 
developed including T1, T2, fat fraction and magnetisation transfer ratio (MTR) 
measurements.  The protocol was assessed for reliability and sensitivity to 
physiological variation in 47 healthy volunteers with 15 rescanned at a two week 
interval.  This protocol was then performed together with detailed clinical assessments 
and isokinetic/isometric dynamometry in 20 patients with inclusion body myositis (IBM), 
20 patients with Charcot-Marie-Tooth disease (CMT) and matched health volunteers 
twice at a 12 month interval.  In the healthy volunteers, the inter-scan and inter-
observer reliability was high (ICC 0.62-0.99) despite small observed physiological 
variation between subjects. Fat fraction, T2 and MTR showed significant correlations 
with subject age in thigh and calf muscles and with subject weight in thigh muscles 
whereas gender did not influence quantitative parameters.  Cross-sectional analysis 
showed strong correlations with both muscle strength and clinical severity measures 
demonstrating validity of MRI measurements as outcome measures.  Longitudinal 
assessment demonstrated excellent sensitivity to change of MRI measures; in 
particular muscle fat fraction quantification exceeded that of myometry and clinical 
measurements with standardised response mean (SRM) over 12 months of 1.1 in IBM 
and 0.8 in CMT indicating a high level of responsiveness.  Annual change in fat fraction 
could be predicted based on baseline MRI measurements, providing the opportunity to 
improve SRM further.  This thesis demonstrates the reliability, validity and 
responsiveness of quantitative MRI as an outcome measure providing a 
comprehensive practical protocol for clinical trials in NMD. 
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1 Background 
 Introduction 
Advances in knowledge of the pathogenesis of neuromuscular diseases (NMD) have 
led to the identification of potential therapies which require rigorous assessment in 
clinical trials.  Unfortunately, current outcome measures have limitations in reliability, 
validity or responsiveness which hamper translation of these advances to therapies for 
patients.  In other areas of neurology, most notably multiple sclerosis (Sahraian and 
Eshaghi, 2010), magnetic resonance imaging (MRI) is well established as a provider of 
sensitive surrogate outcome measures.  MRI in neuromuscular diseases is already 
established as a means to visualise both acute and chronic muscle pathology, allowing 
qualitative assessment to aid in diagnosis (Wattjes et al., 2010).  MRI therefore 
provides an excellent potential source of outcome measures in neuromuscular 
diseases, but requires the demonstration of reliability, validity and responsiveness prior 
to utilisation in clinical trials. 
This PhD thesis provides a comprehensive, systematic assessment of the reliability, 
validity and responsiveness of quantitative MRI measurements in neuromuscular 
diseases.  Chapter 2 provides the methods for all of the work presented.  The 
fundamental properties of quantitative MRI of lower limb muscles, including 
measurement reliability, were assessed in healthy volunteers (chapter 3).  The 
performance in patients with chronic neuromuscular diseases, including validity as an 
outcome measure, was assessed in a cross-sectional study in patients with inclusion 
body myositis (IBM) and Charcot-Marie-Tooth disease (CMT), chosen to be 
representative of chronic neuromuscular diseases (chapter 4).  Finally, and perhaps 
most importantly the responsiveness or sensitivity to change of quantitative MRI 
outcome measures was assessed in these patients longitudinally (chapter 5).  
Published literature relevant to each of these areas will be included in each section, 
whilst the remainder of this first section will provide necessary background to outcome 
measures and neuromuscular MRI more generally. 
 Neuromuscular diseases: the need for an outcome 
measure 
Knowledge in inherited neuromuscular diseases in the past 25 years has expanded 
exponentially following the scientific breakthroughs which allowed the identification of 
the causative genetic defects such as the mutations in dystrophin gene which causes 
Duchenne muscular dystrophy (DMD) in 1986 (Hoffman et al., 1987), mutations in the 
sodium channel gene which cause hyperkalaemic periodic paralysis in 1990 (Fontaine 
 
22 
et al., 1990) and the 1.4Mb duplication on chromosome 17 that is responsible for CMT 
type 1A (CMT1A) in 1991 (Lupski et al., 1991; Raeymaekers et al., 1991).  Over the 
same time period there have been similar advances in knowledge of the pathogenesis 
of inflammatory neuropathies (Lunn and Willison, 2009) and inflammatory myopathies 
(Dalakas, 2010). 
Together with these advances have come potential therapies for neuromuscular 
diseases.  Some therapies have proven efficacy mostly for the inflammatory conditions, 
with the notable exception of IBM for which there is no known effective treatment 
(Dalakas, 2010).  In the inherited neuromuscular conditions there are a few therapies 
which improve symptoms, in particular for the skeletal muscle channelopathies (Raja 
Rayan and Hanna, 2010); however with the exceptions of alglucosidase alfa for Pompe 
disease (Kishnani et al., 2007) and corticosteroids in DMD (Manzur et al., 2008) there 
are no medications which have been shown to alter disease progression.  Clinical trials 
in other neuromuscular diseases have had a negative outcome despite encouraging 
experimental data such as in recent large randomised trials of vitamin C in CMT1A 
(Pareyson et al., 2011a).  There are two possible reasons for a negative trial result: 
either the medication is not effective or the trial was not adequately designed to assess 
effectiveness.  In particular, a major issue in neuromuscular diseases is the difficulty in 
identifying suitable outcome measures, which may in part explain the difficulty in 
translating the scientific advances into patient benefit. 
1.2.1 General principles of outcome measures 
Whilst a health measurement instrument can be judged in terms of two basic 
principles: validity and reliability (Streiner and Norman, 2008), when intended as an 
outcome measure an additional vital characteristic is responsiveness, defined as the 
sensitivity of the outcome measure to detect change (Kirshner and Guyatt, 1985).  This 
in part relates to measurement reliability, but also depends on the likely magnitude of 
change in the measurement over the duration of the clinical trial (Streiner and Norman, 
2008). 
The ideal outcome measure in terms of validity is one which unequivocally reflects 
tangible benefit to the patient (De Gruttola et al., 1997), which can be referred to as a 
“true end-point”.  The alternative is a “surrogate end-point”, which can be defined 
simply as one used in lieu of the true end-point (Wittes et al., 1989).  However, for a 
surrogate end-point to be valid it needs to be shown to correlate with the true-end 
point.  Furthermore, a convincing surrogate should have biological relevance and face 
validity.  Statistical relationship alone is insufficient (Wittes et al., 1989).  The primary 
motivation for surrogate end-points is to reduce trial duration so that trials are feasible 
(Prentice, 1989).  However caution is needed when interpreting trials based on 
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surrogate outcome measures, as there are numerous examples in medical research 
where medications with demonstrated efficacy on a surrogate end-point subsequently 
fail when assessed against a true end-point (Fleming and DeMets, 1996). 
As a general rule end-points with higher validity are less sensitive to change, so 
choosing the most appropriate end-point for a study depends on balancing these two 
factors.  More sensitive surrogate end-points are often used in early-phase clinical 
trials (Phase I and II) to screen for efficacy, whereas regulatory bodies usually require 
true end-points to be used in phase III clinical studies prior to drug approval.  This is 
not absolute; the FDA for example will allow approval for a new drug under some 
circumstances if established that the drug has “an effect on a surrogate endpoint that is 
reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other 
evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint 
other than survival or irreversible morbidity” (Code of Federal Regulations, 2010).  
Even in these circumstances post-marketing studies must show benefits in a true end-
point or else drug approval can be withdrawn. 
Reliability of an outcome measure as traditionally expressed with an intra-class 
correlation coefficient (ICC) is not fixed but dependent on study design; in particular 
reliability studies with a more heterogeneous population will have greater ICCs with an 
otherwise identical trial design (Streiner and Norman, 2008).  This is as reliability is 
defined as the ratio of inter-subject variation to inter-subject variation plus 
measurement error so will appear higher (closer to 1 - nominally perfect reliability) if 
inter-subject variation is greater. 
This has led some health researchers to criticise the classical statistical method of 
quantifying reliability.  In particular Bland and Altman (Bland and Altman, 1986) 
developed a method for use in health research which defines reliability according to the 
limits of agreement independently of the overall inter-subject variation, which they felt 
was more meaningful in a medical setting.  The results however can be directly 
obtained from the ICC, so are in reality a different way of expressing the same 
statistical method (Streiner and Norman, 2008). 
Reliability =  
Intersubject Variation
Intersubject variation + Random Variation
 
Equation 1-1: General Reliability Formula 
Depending on the outcome measure and study design chosen, reliability will be a 
combination of test-retest reliability, inter-observer reliability if more than one observer 
and inter-site reliability if more than one site.  The reason that reliability is so important 
when a measurement instrument is to be used as an outcome measure is that it 
directly contributes to variation in apparent change seen between subjects.  This 
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variation has a significant negative effect on the responsiveness of an outcome 
measure.  Put simply, a large measurement error creates “noise” which can make it 
impossible to detect small amounts of change. 
Whilst responsiveness of an outcome measure to detect change can be expressed in 
many ways (Streiner and Norman, 2008), perhaps the most appropriate for chronic 
neuromuscular diseases is the standardised response mean (SRM) originally 
described by Liang and colleagues (Liang et al., 1990).  This can be derived from data 
from a natural history study and is a ratio calculated as the mean change over the 
duration of the study (δ) divided by the standard deviation of the change (σ) (Equation 
1-2: Standardised Response Mean Formula 
).  Whether the SRM is negative or positive is unimportant, it is the magnitude which 
describes responsiveness.  An absolute value of less than 0.2 is considered to have 
minimal responsiveness, between 0.2 and 0.5 small responsiveness, 0.5-0.8 moderate 
responsiveness and >0.8 large responsiveness. 
SRM =
δ
σ 
Equation 1-2: Standardised Response Mean Formula 
The SRM is a key factor in the power of a study as it determines (along with the 
efficacy of the intervention), the sample size required for a clinical study.  This can be 
seen with Lehr’s formula(Lehr, 1992) (Equation 1-3: Lehr's Formula 
) which estimates sample size required for a study: 
N =
16
(SRM x E)2
 
N = number required in each group for a study of 80% power with significance 
level p<0.05 
E = expected efficacy of treatment compared with natural history – e.g. 0.3 = 
30% reduced progression, 1.0 = halts progression, 1.5 = halts progression and 
improves at 50% of rate of progression (Petrie and Sabin, 2005) 
Equation 1-3: Lehr's Formula 
Table 1-1 lists sample sizes depending on SRM and treatment efficacy and 
demonstrates how important maximising SRM is in limiting the sample size needed for 
a clinical trial.  It is worth noting at this point that the standard deviation of the change 
in the outcome measure is a combination of the variation due to true variation in rate of 
progression between patients, and the apparent variation due to measurement error – 
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determined by the reliability of the measurement instrument.  In practical terms 
therefore the responsiveness of an outcome measure can be maximised by choosing 
one which changes as much as possible over the length of the trial and for this change 
to be consistent between subjects by limiting both true and erroneous inter-subject 
variation. 
Table 1-1: Sample size by SRM and efficacy 
SRM 
Treatment effect on chosen outcome measure (E) 
30% reduced 
progression 
(0.3) 
60% reduced 
progression 
(0.6) 
Halts 
progression 
(1.0) 
Improves 50% 
(1.5) 
0 Infinity Infinity Infinity Infinity 
0.1 17778 4444 1600 711 
0.2 4444 1111 400 178 
0.4 1111 278 100 44 
0.6 494 123 44 20 
0.8 278 69 25 11 
1 178 44 16 7 
2 44 11 4 2 
Sample size required in each group for a clinical trial of power 0.8, p<0.05, in a 
progressive disease as determined by standardised response mean (SRM) of outcome 
measure and efficacy of treatment. 
1.2.2 Challenges for outcome measures in NMD 
Many challenges confront a potential outcome measure for neuromuscular diseases. 
Progression is slow 
Most neuromuscular diseases are non-fatal, with a few notable exceptions including 
Guillain-Barré syndrome and motor neuron disease.  This means patient survival 
cannot be used as a true outcome measure as defined by the FDA, but an outcome 
measure must demonstrate prevention of irreversible morbidity (Code of Federal 
Regulations, 2010).  However, the slow progression of neuromuscular diseases 
necessitates long trial duration.  This increases expense and causes delays to 
treatment licensing for patient use. 
Treatments of hereditary or degenerative disorders are likely to primarily halt 
progression rather than cause improvement 
Axonal loss in peripheral nerves and fatty atrophy in muscles are unlikely to be easily 
reversed by treatments, which are more likely to slow or halt progression.  This limits 
the magnitude of difference which may be seen between treatment and placebo arms 
in a clinical study.  This means an even more reliable outcome measurement is needed 
for a study of an inherited or degenerative disease than in an inflammatory myopathy 
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or neuropathy where the treatment group may improve while the placebo group 
worsens (right column Table 1-1).  A potential advantage however is that the natural 
history of progression is relatively constant between patients and spontaneous 
improvement unlikely, which lessens inter-subject variation in longitudinal change. In 
CIDP or multiple sclerosis, fluctuation of disability levels due to the disease process 
itself can mask the beneficial effect of an intervention.  To maximise this advantage, 
measurement error must be minimised otherwise apparent improvement may be seen 
due to measurement error (poor test-retest reliability) rather than a true improvement, 
which similarly masks beneficial effects. 
Neuromuscular conditions are rare 
Neuromuscular diseases are relatively rare compared with some other disease groups, 
such as cardiovascular disease.  This limits recruitment and means a multi-centre or 
even a multi-national trial design may be needed.  This means both that an outcome 
measure needs to be evaluated in this trial design, and furthermore the addition of 
inter-site variability will reduce outcome measure reliability.  Rarity also makes disease-
specific scale validation more difficult.  The alternative is to use a generic scale, 
however these are generally less sensitive to change in specific patient populations 
(Streiner and Norman, 2008). 
1.2.3 Possible outcome measures in neuromuscular diseases 
This section will briefly review previously used and potential outcome measures in 
NMD in the context of the difficulties noted above.  Ratings in brackets represent the 
subjective ratings of the thesis author on a scale ranging A-E to indicate the relative 
strengths and weaknesses of current outcome measures. 
Patient survival (Validity = A, Reliability = A, Responsiveness = E) 
This is only practical in a small number of diseases such as motor neuron disease or 
severe Guillain-Barré syndrome.  It could potentially be applied to a study in DMD, but 
only to those with late stage disease where disease specific interventions are less 
likely to be effective.  Furthermore, using death as an outcome measure requires a 
large sample size which would not be practical in most neuromuscular diseases 
Disability (Validity A, Reliability B, Responsiveness D) 
Irreversible morbidity is considered a true outcome measure by the FDA (Code of 
Federal Regulations, 2011) so a direct measure of disability scores highly for validity as 
an outcome measure in neuromuscular disease.  However, disability measurement 
isn’t as straightforward as might first appear.  Even something as simple as wheelchair 
use is not dichotomous but a spectrum from occasional use to complete dependence.  
 
27 
Even the “date of first wheelchair use” is not solely determined by patient disability, but 
also by social and economic factors such as cost and availability of a wheelchair, and 
the patient’s willingness to use a wheelchair.  If rather than a dichotomous event, one 
instead decides to use a disability scale, there is the question of whether to use a 
disease-specific scale which may be more likely to detect change in the patients in 
question, or a generic scale which is generalisable across different conditions – known 
as the ‘fidelity versus bandwidth’ issue (Streiner and Norman, 2008), with advantages 
and disadvantages for each approach.  Perhaps most importantly regardless of which 
kind of measure is used, with a gradually progressive disease disability measures will 
change in a minority of patients over the likely time-course of a clinical trial so 
responsiveness will be poor. 
Disease-specific composite scales (Validity C, Reliability B, Responsiveness D) 
Disease-specific scales are attractive as they can combine many different disease 
measurements in a single score.  Validated measures exist for a number of chronic 
neuromuscular conditions such as the CMT Neuropathy Score (Shy et al., 2005), which 
has been used as an outcome measure in recent vitamin C trials.  However, they may 
contain aspects such as sensory examination which have poor inter-observer reliability 
and neurophysiology components which have less face validity.  Both individual 
components and the overall score have been shown to be relatively insensitive to 
change as demonstrated in the case study which follows (Pareyson et al., 2011a). 
Patient reported outcome measures (Validity B, Reliability C, Responsiveness C) 
These are defined as any outcome measure which the study participant self-
administers such as quality of life questionnaires or other self-rating scales (Streiner 
and Norman, 2008).  These certainly have an important place as secondary outcome 
measures in a clinical trial, but are affected by many non-disease specific factors and 
are unlikely to be sufficiently sensitive to show a significant difference in a chronic 
neuromuscular disease trial. 
Muscle strength (Validity C, Reliability C, Responsiveness C) 
Muscle strength is perhaps the most logical way to directly measure disease severity in 
chronic neuromuscular disorders, with the exception of pure or mainly sensory 
neuropathies.  However, strength measurement is not as straightforward as might be 
imagined.  Many studies have used manual muscle testing such as the Medical 
Research Council (MRC) scale of a varied combination of muscle groups as a primary 
or secondary outcome measure (Peng et al., 2000; Walter et al., 2000), but it has been 
shown that MRC scores have relatively poor inter-observer reliability, especially 
between mid-range scores (Vanhoutte et al., 2011).  Hand-held dynamometry has also 
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been used in a number of studies but test-retest and inter-rater reliability can be poor 
(Solari et al., 2008).  Fixed myometry may be more reliable but is time consuming and 
has been used in fewer neuromuscular trials (Dalakas et al., 1997).  Regardless of the 
method, accurate measurement is dependent on maximal patient effort which may vary 
between visits and affect results considerably. 
Investigations (Validity C-D, Reliability B-C, Responsiveness B) 
Whilst creatine kinase level, muscle biopsy, skin biopsy and neurophysiology have a 
critical and irreplaceable role in diagnosis, their use as surrogate outcome measures 
remains to be established.  Except in early phase studies, laboratory investigations 
have generally been used as secondary outcome measures in neuromuscular trials 
because they lack face validity.  Muscle or skin biopsy is invasive and samples only a 
small area tissue.  Neurophysiology can vary significantly between observers and 
longitudinal studies suggest it lacks sensitivity to change (Verhamme et al., 2009). 
1.2.4 Case study of use of an outcome measure in a clinical trial in 
NMD 
The Italian-British trial of ascorbic acid in CMT1A can be considered to exemplify the 
difficulties facing outcome measures used in clinical trials in neuromuscular diseases 
(Pareyson et al., 2011a).  Although the trial was negative, the natural history data from 
the control group can be used to assess the sensitivity to change of the outcome 
measures used in the study (Pareyson et al., 2011b).  The primary outcome measure 
used as recommended by the 2005 ENMC International Workshop in CMT1A was the 
CMT Neuropathy Score (CMTNS) (Reilly et al., 2006).  This is a validated composite 
scale consisting of reported symptoms (scored 0-12), physical signs (scored 0-16) and 
neurophysiology (scored 0-8) with a total score ranging 0-36, with <10 described as 
mild disease, 10-20 moderate disease and >20 severe disease (Shy et al., 2005). 
Previously partly retrospective longitudinal studies have suggested progression in 
CMT1A patients of 0.7 points per year (Shy et al., 2008).  However in the 133 patients 
in the placebo arm of the trial, mean change in CMTNS over two years was a 0.2 point 
worsening, standard deviation 2.7 points.  This equates to a standardised response 
mean of 0.07 (0.2/2.7), indicating negligible responsiveness of this outcome measure 
in CMT1A patients over two years.  The difference observed in per-protocol analysis of 
the placebo group (109 patients) was higher at 0.5 points over two years, however, the 
SRM is still in the minimal responsiveness range (Pareyson et al., 2011b).  
Interestingly, of the sub-components the symptom and signs parts of the score showed 
a small deterioration over two years, whereas the neurophysiology component in fact 
slightly improved over two years, further emphasising the difficulties in using 
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neurophysiology parameters as an outcome measure.  Of the secondary outcome 
measures ankle dorsiflexion strength measured using a hand-held myometer fixed to a 
custom frame showed most responsiveness (SRM: 0.42 – small responsiveness), with 
hand grip myometry, nine-hole peg test and pain by visual analogue scale also 
showing SRMs in the small degree of responsiveness range. 
In future trials, from Table 1-1 we can see that using outcome measures with SRM 0.2-
0.4 as was seen in this study would require 100-400 patients in each arm of the study 
to be powered to demonstrate effectiveness of a medication which stopped 
progression completely.  Even this in reality would signify an improvement since most 
of these measures would be expected to progress with normal ageing. 
To increase responsiveness of an outcome measure there are two options: either 
increase the amount of change seen over time or reduce the standard deviation of this 
change by improving the reliability of the measure (Equation 1-2).  This is already 
being applied through a new version of the CMTNS which is hoped to be both more 
sensitive to change and more reliable (Murphy et al., 2011a).  Changes to trial design 
can also increase responsiveness either by increasing trial duration or selecting a 
homogenous group of patients likely to show the greatest change in the planned 
primary outcome measure.  These approaches are limited by increased cost and 
reduced generalisability respectively. 
1.2.5 MRI as an outcome measure 
Quantitative MRI has many characteristics that make it attractive as an outcome 
measure in neuromuscular diseases.  MRI scanning does not involve exposure to 
ionising radiation and if routine precautions are followed MRI is very safe.  Unlike 
biopsy, it is non-invasive and is able to assess any or all muscles of interest rather than 
a tiny sample as is the case with biopsy.  Analysis is not limited to functional groups as 
is the case with manual strength testing or myometry – some muscles such as gracilis 
cannot be assessed at all by examination.  Perhaps most importantly raw data is 
stored, which means in the context of a clinical trial that all data can be analysed by a 
single examiner, which eliminates inter-observer variation as a source of error.  
Furthermore, if new analysis methods are developed they can be applied 
retrospectively.  None of these characteristics apply to clinical scales, patient-reported 
outcome measures, strength assessment or other examinations.  MRI therefore is 
potentially powerful as an outcome measure. 
MRI however is expensive and there are some technical challenges which need to be 
met.  Although costlier than other outcome measures, in the context of the costs of a 
clinical trial these are manageable, and performing a clinical trial without adequate 
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outcome measures is an inherently futile exercise.  There are many technical aspects 
which need to be addressed to reduce intra-scan variability such as ensuring identical 
patient positioning between scans, sequence parameters between scanners and 
analysis techniques. 
 Principles of qualitative neuromuscular MRI 
1.3.1 MRI as applied to muscle and nerve 
Magnetic resonance techniques were first applied to skeletal muscle as far back as 
1965 in an examination of the effect of contraction and relaxation on transverse T2 
times in the frog (Bratton et al., 1965).  The use of MRI to image the central nervous 
system expanded exponentially in the 1980s as scanners became commercially 
available, with the first large series of MRI brain scans reported in 1982 (Bydder et al., 
1982).  Research into MRI of neuromuscular disorders resulted in many publications in 
the 1990s and 2000s (Koltzenburg and Yousry, 2007; Mercuri et al., 2007; Wattjes et 
al., 2010), however far fewer than for the central nervous system and mostly regarding 
qualitative assessment of pattern for diagnostic purposes.  Basic MRI sequences as 
applied to nerve and muscle, and lower limb anatomy will now be briefly reviewed. 
Imaging techniques based on x-rays such as plain film radiography and computerised 
tomography (CT) are reliant on a single tissue characteristic to create contrast: its 
propensity to absorb x-rays (radiodensity).  The development of magnetic resonance 
imaging created contrast between tissues on the basis of entirely new tissue 
characteristics such as proton density, T1-recovery time, T2-relaxation time and 
magnetisation transfer.  This allowed much greater distinction between different soft 
tissues and also proved more sensitive to the detection of pathology, especially in the 
central nervous system (McRobbie et al., 2007).  A full discussion of MRI physics and 
sequences is beyond the scope of this thesis, but it is sufficient to understand that 
standard MRI sequences have been designed to create signal based on one or other 
of these MRI sequences: for example, a “T1-weighted” sequence is one where most of 
the tissue contrast is created by differences in T1-values between different tissues.  
Because of the way these images are generated, tissues with a short T1 value appear 
brighter on T1-weighted images, whereas tissues with a long T2 value appear brighter 
on T2-weighted images. 
Translated into neuromuscular MRI this means that on T1-weighted sequences normal 
muscle has low signal intensity and appears dark, whereas fat, whether subcutaneous 
or within the muscle, has high signal intensity and appears bright.  Abnormal muscle 
water (“muscle oedema”) cannot easily be distinguished from normal muscle on T1-
weighted sequences.  On standard T2-weighted sequences, normal muscle appears 
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dark and fat appears bright similar to a T1 sequence, however abnormal muscle water 
appears bright.  To better visualise abnormal muscle water on T2 sequences, an 
additional part is incorporated into the MRI sequence to suppress the fat signal – this is 
called Short-tau Inversion Recovery (STIR) – which means whilst abnormal muscle 
water remains brighter than normal muscle, fat is now darker than normal muscle 
(Koltzenburg and Yousry, 2007).  This is summarised in Table 1-2.  Most previously 
published clinical research on neuromuscular MRI has utilised T1-weighted sequences 
to describe the distribution and severity of fatty changes within the muscle, and STIR or 
other fat-suppressed T2 sequences to identify areas of muscle oedema, particularly in 
the inflammatory myopathies. 
It should be remembered that on conventional qualitative sequences these intensities 
are relative, so that the onscreen appearance can be adjusted by altering brightness 
and contrast parameters.  Tissue signal intensity can be standardised to an internal 
reference such as bone marrow (Ortiz-Nieto et al., 2010), or an external phantom 
scanned in the same field of view (Jurkat-Rott et al., 2009), but these standard 
clinically-used sequences are primary intended for qualitative analysis.  Neuromuscular 
anatomy of the lower limb is outlined in Figure 1-1 for reference. 
Table 1-2: Neuromuscular MRI Tissue Characteristics 
Sequence Healthy 
Muscle 
Muscle 
Oedema 
Fat Nerve Injured 
nerve 
T1 Dark Dark Bright Dark Dark 
T2 Dark Bright Bright Dark Bright 
STIR Dark Bright Very dark Dark Bright 
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Figure 1-1: Lower Limb Anatomy 
 
A: Transverse section left thigh 
 Bone: Fe- Femur 
 Anterior compartment: RF-rectus femoris, VM-vastus medialis, VI-vastus 
intermedius, VL-vastus lateralis, Sa-sartorius 
 Posterior compartment: G-gracilis, AM-adductor magnus, SM-
semimembranosus, ST-semitendinosus, BF-biceps femoris (long head at this 
level) 
B: Transverse section left calf 
 Bones: T-tibia, F-fibula 
 Anterior compartment: TA-tibialis anterior, EHL-extensor hallicus longus, EDL-
extensor digitorum longus 
 Lateral compartment: P-peroneal muscle group (peroneus longus at this level) 
 Posterior superficial compartment: LG-lateral head of gastrocnemius, MG-
medical head of gastrocnemius, So-soleus 
 Posterior deep compartment: TP-tibialis posterior, FHL-flexor hallicus longus, 
FDL-flexor digitorum longus 
 
1.3.2 MRI in inherited muscle diseases 
The primary use of MRI in neuromuscular disease to date has been diagnostic, mostly 
for inherited muscle diseases.  For this application the pattern of muscle involvement is 
assessed on T1-weighted lower limb sequences.  Degree of fatty infiltration is usually 
assessed on a semi-quantitative scale, for example that described by Fischer (Fischer 
et al., 2008) or Mercuri (Mercuri et al., 2002a).  The Mercuri scale is outlined in Table 
1-3.  In clinical practice, it is useful to assess which muscles are most affected or 
relatively spared and compare this with published patterns.  This approach has proven 
very useful in the congenital myopathies in particular (Wattjes et al., 2010).  For 
example in a series of MRI scans of 83 patients with one of five muscle disorders 
characterised, pattern analysis of the MRI identified the correct genetic diagnosis in 74 
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patients, with 8 scans uninformative and only one scan not in keeping with the genetic 
diagnosis (Mercuri et al., 2010).  MRI has also been suggested as being of diagnostic 
utility in myofibrillar myopathies (Fischer et al., 2008) and limb-girdle muscular 
dystrophies (Wattjes et al., 2010).  The imaging patterns have also been described in 
other diseases such as Duchenne muscular dystrophy or fascio-scapulohumeral 
muscular dystrophy (Wattjes et al., 2010), however as these diseases have a distinct 
clinical phenotype, MRI is probably only of additional benefit where there is diagnostic 
uncertainty. 
Table 1-3: Mercuri Scale 
Grade Description 
0 Normal appearance  
1 Scattered small areas of increased signal  
2a  Numerous areas of increased signal comprising less than 30%  
2b  Numerous areas of increased signal comprising 30–60%  
3 Washed-out appearance due to confluent areas of increased 
signal  
4 End-stage appearance  
Qualitative Grading Scale of Fat Infiltration on T1-weighted MRI (Mercuri et al., 2002a) 
1.3.3 MRI in inflammatory muscle diseases 
MRI has been used for the inflammatory muscle diseases both diagnostically and to 
aid in targeting muscle biopsy to an area of inflammation (Curiel et al., 2009).  For 
inflammatory myopathies, STIR sequences can identify areas of muscle oedema, and 
whole body STIR protocols can usually differentiate different types of inflammatory 
myopathy (Cantwell et al., 2005).  Diagnosis in inflammatory myopathies is currently 
based on a series of clinical and pathological criteria, as unlike in inherited myopathies 
there can be no single gold standard test.  Classification of exact diagnosis within the 
inflammatory myopathies is vital as whilst polymyositis and dermatomyositis respond to 
immunosuppressive therapy, inclusion body myositis does not, and these therapies 
can have severe side effects (Cox et al., 2010).  A recent series of 32 patients with IBM 
showed distinct imaging patterns (Cox et al., 2011a) but this needs to be confirmed 
prospectively and any criteria validated with other conditions within the differential 
diagnosis for IBM. 
1.3.4 Muscle MRI in inherited and acquired neuropathies 
There are also case reports and small series describing the pattern of muscle 
involvement in different subtypes of CMT (Berciano et al., 2008, 2010; Chung et al., 
2008; Gallardo et al., 2006; Kim et al., 2015; Pelayo-Negro et al., 2014) but MRI for 
diagnostic purposes does not have an established clinical role in CMT.  Secondary 
changes within muscles indicating both acute and chronic pathology have been 
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described in acquired neuropathies such as chronic inflammatory demyelinating 
polyneuropathy (Sinclair et al., 2012a). 
The changes seen within muscles of patients with neuropathic conditions are in 
general similar to those seen in diseases where the primary pathology is myopathic.  
That is, chronic neurogenic fatty atrophy is seen as a hyperintense signal on T1w 
images with reduced muscle size, whilst acute neurogenic changes are seen as 
hyperintensity within muscles on STIR sequences.  Whilst this lack of specificity is a 
limitation in terms of differentiating neuropathic from myopathic weakness for 
diagnostic purposes, it is potentially a great strength for quantitative assessment of 
disease severity and progression as the same methods can be utilised regardless of 
disease pathogenesis. 
 Quantitative neuromuscular MRI 
The studies described above have utilised standard MRI sequences, which are 
considered qualitative and are well suited to diagnosis.  Semi-quantitative scales, such 
as that of Mercuri for fatty infiltration described in table 1.3, may be utilised for an 
outcome measure but are not ideal for this purpose as there are only six discrete points 
on this scale, so they lack sensitivity to measure change over time, especially in a 
gradually progressive disease.  Furthermore, their assessment is subjective which is 
likely to increase both inter-observer and intra-observer variation in scoring.  Some 
researchers have quantified a T1 image by calculating the area of muscle with 
hyperintensity and the area of muscle with normal intensity, as applied to patients with 
spinal muscular atrophy (Sproule et al., 2011a).  Whilst this gives a result which is a 
continuous variable rather than an ordinal scale, so would be potentially sensitive to 
change over time, it is still utilising an inherently non-quantitative sequence with all the 
sources of variation noted above.  Despite excellent test-retest reliability reported 
(Sproule et al., 2011a) they were unable to show significant change in thigh muscle 
volume over six months using this technique (Sproule et al., 2011b), although other 
researchers have shown significant muscle volume loss in patients with diabetic 
neuropathy with this method (Andreassen et al., 2009). 
1.4.1 T1 and T2 mapping 
The alternative is to attempt to measure the specific tissue characteristics responsible 
for the signal in conventional MRI.  The simplest approach is to utilise MRI sequences 
which estimate either the T1-recovery times or the T2-relaxation times of tissue.  In 
healthy volunteers T1-recovery time is about 1300ms for muscle and 350ms for fat, 
whilst T2 relaxation times are 40ms and 180ms respectively (see section 3.2.1).  An 
image can then be constructed where the brightness of each pixel relates directly to 
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the estimated T1-relaxation time: a “T1-map”.  There are many different methods to 
estimate T1-relaxation time, but the general principle is to measure signal intensity 
from a volume of tissue repeatedly whilst varying a sequence parameter (for example 
flip angle), then calculating the T1 value which fits the observations.  Similarly, T2 time 
is estimated by fitting a model based on signal intensity measured whilst varying echo 
times. 
These maps can then be analysed in a number of ways to create potential outcome 
measures.  Mean values can be calculated of a region of interest (ROI) drawn within a 
muscle, comprising a whole muscle on a single slice, comprising a whole muscle 
across multiple slices or averaged against multiple muscles.  Alternatively, histogram 
analysis will produce the mode value, which can be applied to a whole slice using 
automated analysis which doesn’t require manual ROIs to be drawn.  These 
techniques have been applied to measure T2-relaxation times in muscle of patients 
with Duchenne muscular dystrophy.  These techniques have been applied to measure 
T2-relaxation times in muscle of patients with Duchenne muscular dystrophy (Huang et 
al., 1994; Kim et al., 2010a), juvenile dermatomyositis (Maillard et al., 2004a) and 
amyotropic lateral sclerosis (Bryan et al., 1998) and T1-recovery times in DMD (Huang 
et al., 1994).  These methods can be further developed by the addition of fat-water 
separation or fat suppression methods, for example the IDEAL-CPMG MRI pulse 
sequence (Janiczek et al., 2011).  This combines fat-water separation and T2 
relaxation time quantification in a single acquisition, allowing the T2 of the water 
component to be distinguished from that of fat, something that has not been possible 
up to this point. 
1.4.2 Fat quantification  
Two additional quantitative MRI tissue parameters have promising data in respect to 
muscle pathology.  The three-point Dixon fat/water separation method involves taking 
three acquisitions which can be later processed to create a fat-only image and a water-
only image (Glover and Schneider, 1991).  These may then be used to generate a fat-
fraction map where the relative proportion of fat to water within each voxel is calculated 
as a percentage (see Figure 1-2).  This can be used to create a visual image or 
analysed using ROI or automated techniques in a similar fashion to T1 or T2 
quantitative techniques described above.  This technique has been used extensively in 
the assessment of non-alcoholic steatohepatitis (fatty liver) and within the 
neuromuscular field in DMD (Wren et al., 2008), where it has been proposed as a 
better outcome measure than manual muscle testing or dynamometry. 
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Figure 1-2: Three-point Dixon  
 
Fat maps below corresponding T1-weighted conventional transverse MRI images 
through the mid-calf of a healthy volunteer, moderate and severe CMT1A patients (left 
to right).  Black represents voxels with 0% fat, white 100% fat. 
1.4.3 Magnetisation transfer imaging 
Whilst fat deposition is considered the end-stage of muscle pathology whether due to a 
myopathic or neurogenic process, earlier changes may be observed through analysing 
the distribution of water within the muscle tissues.  The traditional approach to this in 
qualitative neuromuscular MRI is to utilise a STIR sequence which is T2-weighted with 
fat suppression such that “muscle oedema” appears bright where normal muscle tissue 
and fat appear dark.  Some researchers have made a semi-quantitative analysis of this 
by measuring signal intensity with reference to a saline phantom (Jurkat-Rott et al., 
2009), but it isn’t possible to perform true quantitative analysis on the STIR sequence. 
Another approach is to utilise the principle of magnetisation transfer to analyse the 
muscle water distribution.  This technique is based on the presence of two pools of 
water within any tissue – a pool which is bound to macromolecules known as the 
bound pool and water which moves freely known as the free pool.  The source of the 
signal in conventional MRI is the hydrogen atoms within the water molecules in the free 
pool, whereas the hydrogen atoms in the water molecules of the bound pool are 
effectively invisible to conventional MRI due to a wide band of resonance frequencies.  
However, this pool can be indirectly assessed by applying a magnetic pulse to saturate 
this pool prior to obtaining an MRI acquisition.  This results in lower signal intensity 
than one acquired without the saturation pulse and this reduction may be expressed as 
the “magnetisation transfer ratio”, the magnitude of which is determined by the 
proportion of water molecules in the bound pool.  The MTR of healthy muscle is around 
40 percentage units (p.u.) and it has been shown to be reduced in skeletal muscle in a 
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variety of conditions where there is an alteration to normal muscle structure, for 
example in limb girdle muscular dystrophy (McDaniel et al., 1999) and in extra-ocular 
muscles in thyroid eye disease (Ulmer et al., 1998).  This technique may show 
abnormalities earlier than those due to fatty deposition, and these may be potentially 
reversible with appropriate therapy. 
 Aims of thesis 
In summary, neuromuscular diseases are in desperate need of an outcome measure 
which is reproducible and sensitive to change, and quantitative MRI has the 
characteristics necessary to fill this role.  The overall aim was to assess the utility of 
MRI as an outcome measure in neuromuscular diseases.  This was undertaken in 
three phases.  First, the fundamental properties of lower limb muscles quantified with 
MRI were determined in healthy volunteers, including inter-muscle variation, inter-
subject variation due to demographic variation, test-retest reliability, inter-observer 
reliability, relationships between quantitative MRI parameters and between qualitative 
and quantitative assessment.  These are presented and discussed in detail in chapter 
3.  These methods were then applied together with clinical assessment and myometry 
in patients with IBM and CMT, primarily to demonstrate the validity of quantitative MRI 
in patients with chronic neuromuscular diseases.  This is presented in chapter 4.  
Finally, longitudinal assessments were performed to assess the responsiveness of 
quantitative MRI measurements in neuromuscular diseases.  These are presented in 
chapter 5.  Undertaking these three steps has identified valid, reliable responsive 
outcome measures, ready for use in clinical trials of neuromuscular diseases.  
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2 Methods 
 Background 
2.1.1 Development of novel outcome measures 
The establishment of a novel outcome measure may be considered as a five step 
process: 1) basic scientific research to develop a new method of measurement; 2) 
assessment of the outcome measure in healthy volunteers to assess reliability; 3) 
cross-sectional assessment of the outcome measure in patients to assess validity; 4) 
longitudinal assessment of the outcome measure in patients to assess responsiveness; 
5) application of the outcome measure in an interventional clinical study.  These same 
steps can be applied to any outcome measure: from a simple quality of life 
questionnaire to the most complex MRI measurement technique. 
In practice the process may not be as linear as suggested in the schematic for MRI 
outcome measure development (Figure 2-1).  For example, results obtained during 
assessment in healthy volunteers may lead to further refinement of the MRI methods.  
Reliability should be assessed using patient data as well as healthy control data.  
Validity should also be demonstrated through correlation of clinical and MRI data 
longitudinally, and ultimately responsiveness is best demonstrated in an interventional 
study.  However, failure to adequately complete one of the first four steps before 
application in a clinical trial can be disastrous. 
Quantitative MRI sequences utilised in skeletal muscle imaging of neuromuscular 
diseases were initially developed for use in other tissues such as T2 mapping of the 
brain and Dixon fat-water separation method for the liver.  These have been applied to 
skeletal muscle previously by many centres including the MRC Centre for 
Neuromuscular Diseases, in a pilot study prior to the commencement of this thesis 
(Sinclair et al., 2012a).  The purpose of this thesis is to systematically move through 
the second, third and fourth steps, so that quantitative MRI might be considered ready 
for application in a clinical trial. 
The study was thus designed in three phases: 
1. Reliability study in healthy volunteers 
2. Cross-sectional study in patients and matched healthy controls 
3. Longitudinal study in patients and matched healthy controls 
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Figure 2-1: Outcome Measure Development Pipeline 
 
The major purpose of the first phase was to assess reliability of quantitative MRI 
measurements with assessment of both test-retest and inter-rater reliability.  Together 
with cross-sectional data from the healthy volunteers, phase 1 data also determined 
the normal variation of quantitative MRI measurements in healthy volunteers, both 
between muscles and between subjects.  The major purpose of phase 2 was to 
demonstrate outcome measure validity by correlating MRI and clinical measures, whilst 
also defining the range and patterns of abnormalities seen in patients.  Finally, the 
major aim of phase 3 was to assess outcome measure responsiveness, through 
longitudinal assessment of different MRI biomarkers. 
2.1.2 Disease group selection 
Previous studies of quantitative MRI in neuromuscular diseases have mostly focussed 
on a single disease group and only occasionally a mixed disease group (see 4.2.2).  
Most have focussed on myopathic conditions and the only previous paper of 
quantitative muscle MRI in Charcot-Marie-Tooth disease (CMT) was the pilot study 
using MTR from our group (Sinclair et al., 2012a).  In the present study, we wished to 
demonstrate the wide applicability of quantitative MRI and hence chose two very 
different conditions: CMT and inclusion body myositis.  They both are characterised by 
lower limb weakness, but are otherwise very different, respectively: inherited/acquired, 
neurogenic/myopathic, very slowly progressive/moderately progressive, 
symmetrical/asymmetrical, with predominant calf/thigh weakness.  Thus whilst 
maintaining homogeneity by including only two specific neuromuscular disease groups; 
between them they characterised a broad range of neuromuscular diseases. 
Development
•MRI Physics new sequence DEVELOPMENT (Previous work)
Volunteer
•Assessment of outcome measure RELIABILITY (Chapter 3)
Cross-sectional
•Assessment of outcome measure VALIDITY (Chapter 4)
Longitudinal
•Assessment of outcome measure RESPONSIVENESS (Chapter 5)
Clinical trial
•Use of outcome measure in CLINICAL TRIAL (Future work)
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2.1.2.1 Inclusion body myositis 
IBM is an acquired inflammatory myopathy with onset usually over 50 years of age with 
a male predominance and the quadriceps being the predominant muscle affected in 
the lower limbs.  There are currently no treatments with proven efficacy despite 
numerous trials (Hilton-Jones et al., 2010).  Disease progression is moderate with a 
median duration from symptom onset to wheelchair use of 15 years (Benveniste et al., 
2011; Cortese et al., 2013).  These characteristics would be predictive of greater 
evidence of active disease on MRI (T2/STIR/MTR), with evidence of disease 
progression likely over 12 months with a moderately responsive outcome measure.  
There are a number of proposed clinical trials of potential treatments in IBM, such as 
arimoclomol (Dimachkie et al., 2014), so a sensitive outcome measure is needed. 
2.1.2.2 Charcot-Marie-Tooth disease 1A 
Charcot-Marie-Tooth disease (CMT) is an umbrella term for the hereditary motor and 
sensory neuropathies with a combined prevalence of around 1:2500 and over 70 
causative genes identified.  The most common type is CMT1A representing 50% of all 
CMT with progressive distal weakness from childhood.  Progression is extremely slow 
with the vast majority of patients never losing ambulation (Reilly et al., 2011).  Recent 
trials have been hampered by insensitive outcome measures (see 1.2.4) (Pareyson et 
al., 2011a).  These characteristics would be predictive of a lesser degree of active 
pathology (denervation) on MRI with only a highly responsive outcome measure likely 
to show significant change over 12 months.  Despite the unsuccessful vitamin C trials, 
there are a number of other potential therapies(Patzkó and Shy, 2010) which will 
require rigorous assessment in clinical trials.  Highly responsive outcome measures 
would be needed to allow adequately powered studies with a feasible number of 
participants. 
2.1.3 Use of healthy controls 
Some quantitative MRI studies in neuromuscular diseases included a healthy control 
group (Gloor et al., 2011; Hiba et al., 2012; Huang et al., 1994; Kan et al., 2009; 
Maillard et al., 2004b; McDaniel et al., 1999; Sinclair et al., 2012a), whilst many have 
not (Gaeta et al., 2011; Kim et al., 2010a; Willis et al., 2013; Wren et al., 2008).  As in 
the first phase of this study, healthy controls may be used to assess inter-scan 
reliability, but healthy controls serve additional vital functions in both the cross-
sectional and longitudinal patient study phases. 
In a cross-sectional study, the inclusion of healthy controls allows direct comparison of 
patient data with values in healthy subjects.  As can be seen from the literature review 
in 3.2.1, reported values of muscle MRI measurements such as T1, T2, fat fraction and 
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MTR vary significantly between studies, due to differences in field strength, scanner 
manufacturer and model, sequence parameters, and analysis methods, so it is not 
possible to compare results in patients to those of healthy controls in the published 
literature.  Even to compare results from an earlier volunteer study at the same site 
may be problematic.  There may be changes in scanner hardware or software outside 
of the control of the investigators, such as that caused by the scanner software 
upgrade in this study (see 2.4.4.3.1).  This may introduce a systematic bias between 
the healthy controls scanned at an earlier time point and patients in a new study, or in 
a longitudinal study between baseline and follow-up scans.  Thus for quality control 
reasons, healthy controls are essential to any quantitative MRI study.  
There is an additional crucial consideration in longitudinal assessment of outcome 
measures in neuromuscular diseases: the confounding effect due to healthy ageing.  
The 5 year natural history study by Verhamme and colleagues (Verhamme et al., 2009) 
exemplifies this point.  This study looked at a range of clinical, myometric and 
neurophysiological measurements in both patients with CMT1A and healthy controls.  
Just considering the patient data, they identified two measurements with moderate 
responsiveness (SRM = -0.60) over 5 years: three-point grip strength and ulnar motor 
amplitude on neurophysiology.  However, their healthy control group also deteriorated 
on both these measures, and the change in patients was not significantly greater than 
in healthy volunteers, leading the authors to infer that these changes were due to the 
effects of ageing rather than disease progression.  Whilst the authors’ conclusion 
based on these results that there is no progression in CMT1A in adulthood beyond that 
resulting from normal ageing is at odds with clinical experience, this study 
demonstrates the crucial role of healthy controls in CMT1A natural history studies.  
Whilst in IBM the rate of progression is greater, the patient group is also significantly 
older so the confounding effects of ageing will likely also be greater. 
2.1.4 Sample size 
For the healthy volunteer study, n = 15 was chosen for test-retest assessment.  This is 
an adequate number to provide estimates of outcome measure reliability; previous 
studies have utilised 10 healthy controls for this purpose (Pfirrmann et al., 2004; 
Smeulders et al., 2010).  For the longitudinal study, 20 patients provide 80% power to 
detect significance of a mean change of 0.66 SD units, assuming 10% dropout using a 
paired t-test and a 5% significance level.  The patient data reported here is the start of 
a longer study with five years’ follow-up, with correspondingly greater power.  With 
extremely limited longitudinal quantitative muscle MRI data available in healthy 
subjects, we chose to include a healthy control group of equal size for both patient 
groups. 
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2.1.5 Ethical framework 
The study was approved by the local research ethics committee (see 
acknowledgements to Dr Sinclair, Dr Machado and Dr Miller).  All participants were 
provided with a written information sheet with regard to the study and provided signed 
informed consent after at least 24 hours consideration. 
 Study design 
Phase 1 was a prospective cross-sectional observational study in 18 healthy 
volunteers, with 15 of these able to undertake repeat imaging using an identical 
protocol at a two week interval.  Healthy volunteers enrolled in this phase undertook a 
screening history and examination to rule out neuromuscular disease, and completed 
standard MRI safety screening but did not undertake any other clinical assessments 
such as myometry.  Healthy volunteers in phase 1 were not enrolled as controls for 
subsequent study phases. The patient study (phases 2 and 3) utilised a prospective 
longitudinal observational study design with two sets of assessments at a 12 month 
interval. 
Figure 2-2: Flow chart of subject assessments and drop out for phases 2-3 
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2.2.1 Subject recruitment 
Patients meeting the inclusion criteria attending the inherited neuropathy or muscle 
clinic at the National Hospital for Neurology and Neurosurgery or the IBM research 
clinic at the MRC Centre for Neuromuscular Diseases were invited to participate.  
Healthy controls were recruited from hospital and research staff, and from the spouses, 
friends and relatives of the patients (blood relatives of CMT1A patients only included if 
genetic testing negative).  Subjects underwent initial assessments between January 
2010 and July 2011. The inclusion criterion for CMT1A patients was genetic 
confirmation of  chromosome 17p11.2 duplication, whilst for IBM patients the inclusion 
criterion was meeting pathologically or clinically definite by MRC IBM diagnostic criteria 
(Hilton-Jones et al., 2010).  Exclusion criteria related to concomitant diseases and MRI 
safety, listed in Figure 2-3. 
Sufficient controls were required to allow a subset of 20 to be age and gender matched 
to both the CMT1A patient group and the IBM patient group.  As the demographics of 
the two patient differed (IBM being a disease predominantly affecting men over 50), 
recruitment of a total of 29 control subjects was required to allow arrangement into two 
groups of 20, designated control (IBM) and control (CMT1A), 11 of which were controls 
to both groups. Age, gender, height and weight showed no significant differences 
between patients and their matched control subsets. 
Figure 2-3: Exclusion criteria for all subjects 
 
 Clinical assessments 
Patients and controls underwent clinical assessment, bedside strength testing and 
myometry at each baseline and follow-up visit.  Patients also performed a quality of life 
questionnaire and were scored on disease specific scales. 
 Concomitant neuropathy/myopathy 
 Very advanced disease state that precludes travelling 
 Severe cardiovascular, renal, or other end-stage-organ-disease states or any other 
major comorbidities (e.g. any active malignancy, definite cognitive impairment, 
psychiatric disease, heart or lung failure, orthopaedic or rheumatologic disorders) 
 Pregnancy and active nursing (breast feeding) 
 Inadequate contraception in women of child bearing age. 
 Contra-indication to MRI (metallic fragments, clips or devices in the brain, eye, 
spinal canal, etc; magnetically activated implanted devices, such as cardiac 
pacemakers, insulin pumps, neurostimulators and cochlear implants; 
claustrophobia) 
 Existing radiculopathy or lower back pain 
 Surgery to feet within 12 months of beginning of study or during the study 
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2.3.1 Disease specific scales 
A number of outcome measures have been utilised in natural history studies and 
clinical trials in CMT1A and IBM.  The CMT neuropathy score (CMTNS) is a 36 point 
scale, scored 0-4 on 9 items, with 3 history items, 4 examination items and 2 
neurophysiology items and has been shown to be an reliable and valid marker of 
disease severity (Shy et al., 2005).  In CMT1A the CMTNS was used as the primary 
outcome measure in the completed adult vitamin C trials (Lewis et al., 2013; Pareyson 
et al., 2011a) based on the recommendation of the 2005 ENMC International 
Workshop (Reilly et al., 2006).  The CMTNS performed poorly in both these studies, 
with the placebo group showing minimal change in one study (Pareyson et al., 2011a), 
and paradoxical improvement in the other (Lewis et al., 2013).  Neurophysiology 
measurements are a component of this score, and were used as the primary outcome 
measure in the paediatric study in vitamin C (Burns et al., 2009) but showed minimal 
responsiveness in the placebo arms of all three studies, and showed no significant 
deterioration compared with healthy controls in a large 5 year natural history study 
(Verhamme et al., 2009).  Standard neurophysiology techniques have not been 
proposed as an outcome measure in inclusion body myositis.  For these reasons, plus 
the added burden on participants, additional neurophysiology wasn’t performed as part 
of assessments in this current study.  The CMTNS without neurophysiology: the CMT 
Examination Score (CMTES) was therefore used as the main overall clinical severity 
measurement in CMT1A patients, using a version modified to improve sensitivity just 
prior to the commencement of the study (Murphy et al., 2011b). 
The IBM functional rating score is an IBM specific scale adapted from the ALS FRS 
(Jackson et al., 2008).  It is reliable, valid, and was the most sensitive measure of 
change in a study of high dose interferon-1a in IBM (Jackson et al., 2008).  Although 
physician-administered, it could easily be adapted to be a patient reported outcome 
measure.  For consistency, it was administered during the study by the thesis author in 
all cases. 
2.3.2 Myometry 
Patients and controls underwent detailed lower limb myometry on a HUMAC NORM 
dynamometer (CSMi, Massachusetts, USA).  The myometry assessment either 
occurred following the MRI or with at least a 60-minute gap if preceding to minimise 
any potential MRI effects secondary to physical activity.   
All but two initial assessments and all follow up assessments were performed by the 
thesis author. Myometry was performed according to Table 2-1. Knee extension, knee 
flexion, ankle dorsiflexion, ankle plantarflexion, ankle inversion and ankle eversion 
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were assessed bilaterally using both isometric and isokinetic protocols and the 
maximum torque in Nm recorded for analysis. Isometric assessments consisted of four 
attempts of 3 seconds duration with 10s interval of which the best attempt was 
selected. For the isokinetic assessments, following a practice run and 10s interval, 
three successive movements through full range were performed and the highest value 
obtained selected. The machine setup was recording at first visit using the included 
software, which was then retrieved to allow identical set-up on repeat testing. 
Table 2-1: Myometry protocol 
Joint Type Movement Angle 
Knee 
(right then left) 
Isometric 
Extension° 45° 
Extension 90° 
Flexion 45° 
Flexion 90° 
Isokinetic 
Extension/Flexion 60°/s 
Extension/Flexion 120°/s 
Ankle (left then right) 
Isometric 
Plantarflexion 10° 
Dorsiflexion 10° 
Isokinetic Plantarflexion/Dorsiflexion 60°/s 
Ankle (right then left) 
Isometric 
Eversion 0° 
Inversion 0° 
Isokinetic Inversion/Eversion 60°/s 
2.3.2.1 Myometry analysis 
All measurements are stored within the HUMAC NORM system, and were checked for 
artefactual values before being exported into IBM-SPSS for analysis. An additional 
overall strength for each movement was calculated by taking the mean of all 
assessment methods listed in Table 2-1. 
2.3.3 MRC strength grading 
The following movements were assessed: 
 Neck: flexion and extension 
 Upper limbs: shoulder abduction, elbow extension, elbow flexion, wrist 
extension, wrist flexion, finger extension, forefinger abduction, little finger 
abduction, thumb abduction, long finger flexors, short finger flexors 
 Lower limbs: hip flexion, hip extension, hip abduction, hip adduction, knee 
flexion, knee extension, ankle dorsiflexion, ankle plantarflexion, ankle eversion, 
ankle inversion, big toe extension 
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Muscle strength was assessed using a modified MRC scale (O’Brien, 2000) with 5: 
Normal strength, 5-: Barely detectable weakness, 4+: Gravity and moderate to maximal 
resistance, 4: Gravity and moderate resistance, 4-: Gravity and minimal resistance, 3: 
Full range of motion against gravity only, 2: Movement when gravity is eliminated, 1: 
Flicker of movement seen or felt, 0: No movement. Upper limb/neck and lower muscle 
scores were summed to obtain a total upper limb/neck and total lower limb score for 
each subject. For this purpose, 5- was scored as 4.75, 4+ as 4.25 and 4- as 3.75. The 
maximum score obtainable was 120 for upper limb/neck and 110 for lower limb. 
2.3.4 Other assessments 
Additional clinical assessments performed in both patient groups were: medical history, 
neurological examination, and SF-36 quality of life questionnaire (Ware and 
Sherbourne, 1992).  Upper limb strength tests and upper-limb functional tests were not 
performed, due to the lower limb focus of the study.  The 6 minute-walk test has 
subsequently become a commonly used measure in clinical trials of muscle diseases, 
being used to the primary outcome measure in a licensing trial of enzyme replacement 
therapy in Pompe disease (van der Ploeg et al., 2010).  It has not been validated in 
CMT1A, and is highly unlikely to be responsive as CMT1A patients maintain 
ambulation long term.  It has not been validated in IBM, and although may prove 
useful, is likely to be prone to the same non-linear relationship with disease 
progression due to a sudden drop off when patients become non-ambulant (McDonald 
et al., 2010). 
 MRI protocol 
The protocol was primarily developed by the MR Physics team involved in the project: 
Dr Sinclair and Dr Thornton (see acknowledgements). 
2.4.1 Hardware 
Subjects were examined lying feet-first and supine at 3T (TIM Trio, Siemens, Erlangen, 
Germany) using a multi-channel peripheral angiography coil (Siemens ‘PA Matrix’) and 
‘spine matrix’ coil elements. 
2.4.2 Subject positioning 
Before scanning, the distance between the anterior superior iliac spine and the 
superior border of the patella was measured and thigh-level imaging volumes were 
centred one third of this distance above the patella superior border. For phase 1, calf-
level imaging volumes were centred on the point of widest lower leg circumference.  
For phases 2 and 3 calf-level imaging volumes were centred below the tibial tuberosity 
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by one quarter of the total distance from the tibial tuberosity to the lateral malleolus. 
The derived distances at baseline were recorded and used for block positioning on 
follow up imaging. 
2.4.3 Anatomical coverage 
Lower limb muscles were chosen as the region for study as they are a key site of 
pathology in both CMT1A (lower calf) (Reilly et al., 2011) and IBM (quadriceps) (Hilton-
Jones et al., 2010) and weakness is these areas is a key cause of disability in these 
patient groups.  Furthermore, lower limb imaging has practical advantages over 
dedicated upper limb imaging: both limbs may be imaged simultaneously, lowering 
scanning times, and lower limb imaging is in our experience more comfortable for 
participants. 
Both limbs were scanned within the FOV.  Axial-slice matrices and fields of view (FOV) 
were 256x128 and 400x200mm (410x205mm in some phase 1 subjects) for thigh- and 
256x120 and 400x188mm for calf-level images, except for FF acquisitions where 
matrices were 512x256 and 512x240 pixels respectively. 
2.4.4 MRI sequences 
The total acquisition time was less than 60 minutes.  The following sequences were 
performed: T1-weighted and short-tau-inversion recovery (STIR) qualitative imaging, 
fat fraction measurement using three-point-Dixon technique (Glover and Schneider, 
1991), T1 relaxometry by DESPOT method with B1 correction (Deoni et al., 2003), 
pseudo-T2 relaxometry from dual-contrast turbo-spin-echo images, magnetisation 
transfer ratio derived from two 3D-FLASH images with and without an MT pre-pulse 
with B1 correction(Sinclair et al., 2012b). 
2.4.4.1 Fat fraction measurement 
For Dixon FF measurements (Glover and Schneider, 1991), three 2D gradient-echo 
acquisitions were performed with parameters (TE1/TE2/TE3=3.45/4.60/5.75ms, 
TR=100ms, flip angle=10o, bandwidth 420Hz/pixel, NEX=4, 10 x 10mm slices with 
10mm gap, 512x256 matrix (thigh), 512x240 matrix calf, iPat=2). Phase unwrapping 
was performed using PRELUDE (FSL, FMRIB, Oxford) (Smith et al., 2004) and after fat 
(F) and water (W) image decomposition, FF calculated as FF = 100% x F/(F+W).  
The TE=3.45ms image was used for the region of interest (ROI) placement and as a 
reference for inter-method image interpolation and registration (calf level only) using 
FLIRT (FSL, FMRIB, Oxford), such that that the same ROIs could be applied to extract 
data from all maps.  
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2.4.4.2 T1-Relaxometry 
DESPOT-1 (Deoni et al., 2003) T1-mapping used three 3D fast low-angle shot (3D-
FLASH) images S1,2,3 with nominal α1,2,3 of 5, 15 and 250, TR/TE=23/3ms, and 
BW=440Hz/pixel acquired in a single, non-selective slab with 80 x 5mm longitudinal 
phase-encoded partitions. Flip-angles were corrected using B1 maps obtained as below 
and T1 calculated according to Deoni (Deoni et al., 2003). 
2.4.4.3 T2-Relaxometry 
Dual-contrast turbo-spin-echo (TSE) images (6500/13/52ms or 6500/16/56ms; 
10x10mm slices with 10mm gap, iPat=2, BW=444Hx/pixel, refocusing flip angle 180º, 
NEX=1, 6/8 k-space sampling, 256x128 matrix (thigh), 256x120 matrix (calf)) were 
acquired. Pseudo-T2 was calculated from the respective pixel intensities ITE1 and ITE2 
from the TE1 and TE2 images as T2=
)/ln( 21
12
TETE II
TETE  . 
2.4.4.3.1 Software upgrade effects on T2 
The different echo times were the result of altered sequence timing constraints 
following a routine scanner software upgrade which occurred after 54 baseline and 6 
follow-up scans had been completed. Analysing control values pre- and post-upgrade 
suggested a systematic bias between pre- and post-upgrade T2 values (see Error! 
Not a valid bookmark self-reference.). By comparing the observed relationship 
between FF and T2 measurements pre- and post-software upgrade, a correction 
equation was determined separately for thigh muscles (corrected T2 = 1.0606 x post-
upgrade T2 + 1.1522) and calf muscles (corrected T2 = 1.0933 x post-upgrade T2 – 
0.0245). These corrections were applied to all post-upgrade T2 measurements to 
ensure pre- and post-upgrade T2 measurements were comparable. Parameters for the 
other quantitative sequences were not affected by this upgrade, and analysis of the 
control values pre- and post-upgrade indicated no systematic bias in these values was 
introduced by the software upgrade. 
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Figure 2-4: Analysis of Upgrade effects on T2 
 
2.4.4.4 B1 Mapping 
Separate TSE images (TR/TE=7000/11ms, 128x64 matrix, 40 contiguous 10mm slices, 
BW=429Hx/pixel, 1/2 k-space sampling) yielded image intensities V1 and V2 acquired 
with nominal excitation α1 and α2 of 60o and 120o. B1 deviation was mapped according 
to 1121 /)2/arccos( VVB Dev   (Stollberger and Wach, 1996). 
2.4.4.5 Magnetization transfer ratio 
MTRs were calculated from two 3D-FLASH images with (M1) and without (M0), an MT 
pre-pulse (500° amplitude, 1200Hz offset, 10ms duration) (TR/TE=65/3ms or 68/3ms, 
α=10º, BW=440Hz/pixel, NEX=1, 6/8 k-space sampling, iPat=2, 40x5mm longitudinal 
phase encoding partitions, 256x128 matrix (thigh), 256x120 matrix (calf)) according to 
MTR = (M0-M1)/M0 x 100 percentage units (p.u.). Percentage units were used by 
convention to avoid ambiguity with fractional change expressed as a percentage 
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(Barker et al., 1996). MTR maps were RF-inhomogeneity corrected using the B1 maps 
according using a mean-over-all-subjects B1 inhomogeneity correction factor of k = 
0.0085 (Sinclair et al., 2012b). 
2.4.4.6 T1 weighted imaging 
Standard T1-weighted images were acquired with a turbo-spin-echo readout prior to 
commencing the quantitative protocol (TR/TE=671/16ms, 10 slices, 10mm thickness, 
10mm slice gap, 256x192 matrix, iPat acceleration of 2, 444 Hz/pixel bandwidth (BW), 
TSE factor=3, refocusing flip angle (fa) 130º, NEX=2, acquisition time (TA) = 45s). 
2.4.4.7 Short-tau-inversion-recovery imaging 
STIR (TR/TE/Inversion Time = 5500/56/220ms, NEX=1, flip angle 180°, parallel 
imaging factor (iPat)=2) imaging was performed (10x10mm slices, 10mm gap, 256x128 
matrix (thigh), 256x128 matrix (calf)).  
 Qualitative image analysis 
Analysis of apparent fatty infiltration on the T1 weighted images was performed by 
grading using the 6-point Mercuri scale (Mercuri et al., 2002b) (0=normal,1=mild fatty 
streaks, 2a=early confluence, 2b=fatty infiltration 30-60%, 3=fatty infiltration >60%, 
4=complete fat replacement) and for STIR hyperintensity using a three-point scale 
(0=none, 1=mild, 2=marked) by a radiologist with 4 years post-speciality experience 
(Dr Fischmann, acknowledgements).  The observer was blinded to subject group 
(IBM/CMT1A/control).  Repeat scans were graded at a later time-point without 
reference to baseline scans.  The same muscles were assessed as in the quantitative 
analysis below, but the entire muscle volume imaged was assessed, rather than just a 
single slice. 
 Quantitative analysis 
2.6.1 Slice selection 
For the baseline scan the fifth most superior slice was used in the thigh and the sixth 
slice in the calf unless all the muscles were not visible, in which case an adjacent slice 
was selected. For the phase one participants who underwent test-retest imaging, ROIs 
for the second acquisition were drawn on the slice most similar in appearance to that 
used from the first acquisition.  For phase 3, the ROI were drawn on the slice closest to 
that used for the phase 2 scan, determined on the basis of measured distance from 
bony landmarks (tibial plateau or tip of the fibular head) identified on the 3D-FLASH 
images.  This was visually checked to confirm anatomical equivalence to the slice used 
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for the baseline scan by the radiologist, with agreement in every case.  Slice selection 
based on a measured distance from a bony landmark has been shown to be superior 
to surface anatomy based localisation (Fischmann et al., 2014). 
2.6.2 Region of interest definition 
A radiologist with 4 years’ post-specialist experience in neuromuscular imaging (Dr 
Fischmann, acknowledgements) defined “whole” and “small” regions of interest (ROI) 
for each phase 1 and phase 2 subject on the single slice defined above, at mid-thigh 
and mid-calf level of an unprocessed Dixon acquisition (TE=3.45ms) using ITK-SNAP 
(Yushkevich et al., 2006).  “Whole” ROIs were defined to encompass the entire muscle 
cross-sectional area to the fascia whilst “small” ROIs were defined in a consistent 
anatomical location within each muscle to avoid contamination with fascia or vessels 
and to allow minor movement between acquisitions (Figure 2-5).  Both types of ROI 
have been used by researchers previously (Hiba et al., 2012; Kan et al., 2009; Kim et 
al., 2010a; Sinclair et al., 2012a; Willis et al., 2013).  Left and right limb ROIs were 
defined for the rectus femoris, vastus lateralis, vastus intermedius, vastus medialis, 
semimembranosus, semitendinosus, biceps femoris, adductor magnus, sartorius, 
gracilis, tibialis anterior, peroneus longus, lateral gastrocnemius, medial 
gastrocnemius, soleus and tibialis posterior muscles. 
Figure 2-5: Region of interest definition 
 
Left:  Gradient echo (TE=345ms), one of the sequences used in three-point Dixon 
acquisition, of the left thigh (top) and calf (bottom).  Middle: “Whole” ROI.  Right: 
Small” ROI 
Thigh: RF-rectus femoris, VM-vastus medialis, VI-vastus intermedius, VL-vastus 
lateralis, Sa-sartorius, G-gracilis, AM-adductor magnus, SM-semimembranosus, ST-
semitendinosus, BF-biceps femoris (long head at this level) 
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Calf: TA-tibialis anterior, EHL-extensor hallicus longus, EDL-extensor digitorum longus, 
P-peroneal muscle group; peroneus longus (PL)at this level), LG-lateral head of 
gastrocnemius, MG-medical head of gastrocnemius, So-soleus, TP-tibialis posterior, 
FHL-flexor hallicus longus, FDL-flexor digitorum longus 
To assess inter-observer reliability, the thesis author independently defined ROIs on 
one acquisition from each of the 15 phase one subjects with repeat examinations.  ROI 
on the phase three scans were drawn by Dr Fischmann using the same procedure.  
This was done with direct reference to the ROI drawn on the phase two scans to 
ensure equivalent anatomical coverage. 
2.6.3 Application of region of interest to maps 
The small ROIs were transferred to the co-registered parameter maps (FF, T1, T2, 
MTR). Minor adjustments to small ROI were made where imperfect registration meant 
ROI were no longer wholly within the target muscle. Whole muscle ROIs were 
transferred to the inherently co-registered FF maps only. The whole muscle ROIs from 
the unprocessed Dixon acquisition were not used for T2 and MTR analysis to avoid 
ROI contamination with non-muscle tissue, a particular problem for these measures, at 
the region boundaries due to minor subject movement between acquisitions.  All 
generated maps were inspected visually for correct ROI placement and presence of 
artefact.  ROI values originating from areas of gross artefact were excluded from the 
analysis. 
 Data analysis 
For each muscle custom written software (Dr Sinclair, acknowledgements) extracted 
mean T1, mean T2, mean FF and mean MTR from small ROI and mean FF and cross-
sectional area (CSA) from whole ROI.  After extraction all data were cross-checked for 
outliers and errors identified rectified.  In addition to individual muscle values, summary 
measures for each parameter were created for relevant functional muscle groups 
(quadriceps, hamstrings, anterior tibial compartment and triceps surae) and for all 
muscles at thigh level and calf levels separately.  For small ROI this was a simple 
mean, whilst for large ROI a weighted mean based on relative CSA was calculated.  
Total CSA was also calculated.  Longitudinal changes were quantified on a muscle-by-
muscle, parameter-by-parameter basis, and combined as detailed above to create 
separate all-muscle summary variables at thigh- and calf-levels.  
To assess early pathological change in patients’ muscles for which IFA lay within the 
normal healthy range, additional analyses included only muscles with mean FF less 
than the 95th percentile of the healthy control FF values for thigh and calf muscles 
separately.  As a measure of the functional muscle CSA, the metric “remaining muscle 
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area”, defined as CSA x (100 – FF)/100%, was calculated, where CSA and FF refer to 
the whole muscle ROI values. 
Longitudinal data were assessed by comparing baseline and follow up values, 
corrected for exact duration of follow-up on a muscle by muscle, parameter by 
parameter basis and combined as per the baseline data to create summary variables 
for thigh or calf level. Responsiveness of outcome measures was evaluated using the 
SRM, calculated as the ratio of mean change to standard deviation of change (Liang et 
al., 1990).  SRM was categorised by magnitude according to Cohen’s suggestion: < 0.2 
minimal responsiveness; 0.2-0.5 small responsiveness; 0.5-0.8 moderate 
responsiveness; >0.8 large responsiveness. 
2.7.1 Data checking 
Overall the number of images excluded from the analysis was small: nine data-sets 
were missing or technically non-analysable: FF - thigh 1, calf 1; T1 - thigh 2, calf 4; T2 - 
none, MTR - calf 1.  In the remaining data small fractions of individual ROIs were 
excluded due to local artefact, mostly B1-related signal drop-out: FF - thigh 1.7% 
(16/920), calf 2.4% (13/540); T1 - thigh 24% (219/900), calf 12% (57/492), T2 - thigh 
5.4% (51/940), calf 0.2% (1/552), MTR - thigh 15% (142/920), calf 5.2% (28/540).  In 
all subjects asymmetric B1 deviations were observed with B1 reduced anteriorly on the 
right and posteriorly on the left.  This was evident at the calf level but more prominent 
in the thigh, particularly affecting the right rectus femoris and vastus medialis.  This 
artefact prevented measurement of T1 and MTR in these muscles for the majority of 
subjects.  See also Table 4-5 and Table 4-6 which included the number of subjects 
analysed for each muscle and sequence. 
2.7.2 Statistical analysis 
Phase one was analysed using SPSS 18 (SPSS inc., Chicago, Illinois), inter-muscle 
differences were assessed using ANOVA with post hoc comparisons using 
Bonferroni’s method.  Inter-scan and inter-observer overall mean value differences 
were assessed using paired t-tests and reproducibility determined as mean absolute 
inter-scan and inter-observer differences, displayed on Bland-Altman plots with 
calculation of limits of agreement (Bland and Altman, 1986) and intra-class correlation 
coefficients (ICCs).  Multivariate regression assessed the influence of demographic 
factors (age, gender, weight, height) on MRI measures: height showed no independent 
correlation with any MRI measure and was therefore excluded from the model.  
Pearson’s correlation coefficients between MRI measures were calculated. 
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Statistical analysis for phases two and three was performed using IBM-SPSS Statistics 
20 (IBM Corp. Armonk, NY).  The volunteer group of 29 subjects was arranged into two 
groups of 20 designated volunteer(IBM) and volunteer(CMT1A) (11 were controls to 
both groups).  Summary statistics for each group of each quantitative parameter on a 
per muscle, and overall thigh or calf level were calculated (mean ± standard deviation), 
using two-tailed t tests to assess for significant differences. Correlations were 
assessed using Pearson or Spearman correlation coefficients as appropriate.  Due to 
the strong interdependence of fat fraction with the other quantitative parameters (Table 
4-7), additional analysis was performed considering only muscles without significant fat 
infiltration, using a cut-off of 5% based on the volunteer data in this study.  Multivariate 
linear regressions were performed to assess separately, in these muscles without 
significant IFA, the dependence of T2 and MTR upon disease versus control status 
while adjusting for the influence of residual FF as a covariate. 
Baseline fat fractions were grouped into categories: <5%, 5-20%, 20-40%, 40-60% and 
>60% and rate of change in fat fraction compared according to these categories and 
the STIR categorisation.  One-way ANOVA with post-hoc Tukey analysis was used to 
identify if any baseline MRI muscle characteristics were predictive of subsequent 
change.  
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3 Quantitative MRI in healthy volunteers 
 Background 
It would be a mistake to rush to investigate quantitative MRI techniques in patients with 
neuromuscular diseases without assessing the methods’ characteristics and 
performance in healthy volunteers.  Whilst research involving patients is perhaps more 
immediately publishable and it is certainly true that ultimately the behaviour of outcome 
measures in patients is what matters most, characterising performance in healthy 
volunteers is a crucial step in rational outcome measure development. 
With regard specifically to quantitative MRI of lower limb muscles, what may be gained 
from studies of healthy volunteers?  First, at the simplest level a “normal range” can be 
established without which it is impossible to accurately judge if the results in patients 
are “abnormal”.  The terms are used in quotations as the reality is less straightforward 
than this.  Second, potential experimental confounds can be established: Do values 
vary between muscles studied?  Do values vary over the short term due to dietary 
intake or exercise for example?  Do values vary between subjects depending on age, 
gender or size?  All these are important questions since failure to consider the 
magnitude of these variations might reduce the responsiveness of an outcome 
measure, as over-large dependence on such factors could mask true differences 
related to a therapeutic intervention.  Third and perhaps most importantly, the reliability 
of a technique can be examined.  Within the more general class of health 
measurements, outcome measures are generally by definition longitudinal tools which 
means test-retest reliability (scan-rescan for MRI) is of the utmost importance.  Again 
apparent variation between assessments due to measurement error could easily 
obscure what in many neuromuscular diseases might be a small true change between 
the study time-points. 
It is beneficial to note at this early point the two fundamental categories of 
measurements possible with quantitative muscle MRI as they have different 
characteristics in healthy volunteers.  Measurements of muscle size (width, 
circumference, cross-sectional area or volume) would naturally have large variation 
between muscles and subjects.  Challenges to maximising their reliability mainly 
involve optimising repeatability of subject positioning, slice localisation and analysis 
methods.  On the other hand, measurements of a muscle tissue parameter such as 
T2 or FF should have less inter- and intra-subject variation, certainly less than the 
80,000 fold difference between the cross-sectional area of the smallest and largest 
muscles in the body (stapedius and gluteus maximus) (Voronov, 2003).  Maintaining 
the same sequence parameters, and minimizing variation in instrumental performance, 
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is of greater importance than positional factor in the reliability of tissue parameter 
measurements. 
3.1.1 Ideal outcome measure characteristics in healthy volunteers 
When considering fundamental characteristics of quantitative muscle MRI in healthy 
volunteers, it is helpful to review “ideal”  outcome measure characteristics in this 
context, which summarised simply are minimal variability and maximal reliability 
(Kirshner and Guyatt, 1985).  In order to maximise sensitivity, specificity, inter-scan 
reliability and responsiveness, an ideal outcome measurement would in healthy 
subjects have a narrow variance compared with the expected patient value ranges, 
and any physiological or inter-muscle or inter-subject variations subjects would be 
negligible, or at least of small magnitude and predictable. 
Those current neuromuscular disease outcome measures which are expressible in 
terms of continuous variables stack up poorly against these ideals.  Myometry 
assessments do not yield a narrow range of normal values, nor similar values between 
muscle groups in an individual subject.  There is significant inter-subject variation 
according to gender and size, but also due to genetic factors and training level.  
Strength reduction with age is well known and documented both cross-sectionally and 
longitudinally (Andreassen et al., 2009), and may be a significant confound with 
respect to detecting longitudinal disease-related change.  Neurophysiology-derived 
measurements, especially motor and sensory amplitudes, also show a wide normative 
range, with some of this variation dependent on demographic factors, and marked 
differences dependent on the specific muscle or nerve examined. 
Reliability may also be assessed in healthy volunteer studies.  Scan-rescan reliability is 
central to application of MRI as an outcome measure and should be maximised as far 
as practical.  Whilst inter-observer reliability is of interest, in the case of MRI, unlike 
myometry and neurophysiology, this source of variability can be eliminated thorough 
central analysis by a single observer.  Even in the event that a dataset was too large 
for analysis by a single observer, at least all time-points for each subject can be 
assessed by the same observer which, although it would be the aim for myometry and 
neurophysiology in multi-centre clinical trials, inevitably isn’t possible on occasion.  
Furthermore, digitised images can easily be anonymised with respect to time-point 
(baseline or follow up) whereas myometry and neurophysiology collection and data 
extraction occur simultaneously, so blinding to time-point is not possible unless 
different observers are used, with resultant observer bias or inter-observer variability 
Scan-rescan reliability in MRI measurements will be reduced by three categories of 
potential variation: physiological, acquisition and analysis.  Physiological variation 
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refers to genuine changes in the tissue value, due to physiological factors which might 
vary between scans such as diet and exercise.  Acquisition variation occurs during the 
scanning process, for example variation due to differences in patient positioning, 
sequence parameters or idiosyncratic artefacts.  Analysis variation is largely the 
difference due to the subjective aspect of drawing regions of interest for analysis.  
Intra-observer variation can be directly assessed by repeated analysis of identical 
scans, whilst the first two sources of variation are more difficult to separate or measure 
directly.  However, for use as an outcome measure it is their combined effect: scan-
rescan reliability that is the key parameter, which should be maximised by reducing all 
three sources of variation as far as possible. 
It is worth briefly distinguishing between random variation and systematic variation 
between scans, which in a longitudinal study may be a year or more apart.  Random 
variation can be considered “noise” which might mask detection of true change 
between baseline and follow–up, resulting in a type II error (false negative), whereas 
systematic variation between time-points can create the false appearance of a 
difference when it does not exist, a type I error (false positive).  Control groups and 
blinding are necessary components in the arsenal against this latter, potentially more 
serious error. 
Healthy volunteer scanning is therefore essential in outcome measure development to 
establish “normal values” against which to compare patients, to identify potential 
demographic confounders and to determine the scan-rescan reliability of these 
measurements.  This knowledge allows optimisation of study design, MRI protocol and 
analysis methods to maximise the potential of the outcome measures utilised.  This 
chapter will review previous literature relating to quantitative MRI of skeletal muscle in 
healthy volunteers, describe results from the healthy volunteers imaged as part of this 
thesis, and finally discuss how these results impact on the application of quantitative 
MRI outcome measures in patient studies. 
 Quantitative MRI variability and reliability in healthy 
volunteers 
This section will review published data on quantitative muscle MRI in healthy 
volunteers to provide context for the results which follow. 
3.2.1 Published values and variation between muscles 
The concept of a normal or reference range is central to health related measurements.  
A result such as a serum potassium concentration has no diagnostic utility without the 
frame of reference of the usual range of values in the healthy population.  This is 
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readily apparent when results are presented in unfamiliar units without a reference 
range.  Reference ranges of diagnostic measurements are not absolute, they may 
differ depending on the age, gender or ethnicity of the subject; and alterations to the 
method of analysis may change the reference range entirely. 
While still relevant, a reference range is not of primary importance for outcome 
measures where longitudinal change is of greater importance than the absolute values.  
Consider for example a weight loss intervention: the healthy population weight range is 
very wide, indeed the boundary between “normal” and “abnormal” weight is not defined 
based on the distribution of values in the general population, but on values associated 
with increased risk of disease.  However, the measurement of weight change is simple, 
and ideal as an outcome measure in a clinical trial of a weight loss intervention.  
Similarly, different normative ranges have been reported for quantitative muscle tissue 
MR parameters in healthy volunteers, depending upon the exact scanner configuration, 
sequence and analysis used.  This means that generally, a “reference range” defined 
in one study would be inappropriate to use to determine if a value obtained with 
different hardware, software or sequence parameters was abnormal.  However relative 
differences, for example between muscles, should be consistent between studies.  
Outcomes measured as continuous variables are most commonly a relative 
comparison between baseline and end of study.  This means for a longitudinal study, 
even if it is multi-site, scan-rescan reliability is more important than inter-scanner 
reliability. 
3.2.1.1  T2 time 
The most commonly reported quantitative MR parameter of muscle is T2 relaxation 
time.  Whilst exact sequence parameters vary between studies, the basic principle is 
the same.  Images are acquired at multiple echo times and by plotting signal intensity 
against echo time, an estimate of the T2 relaxation time can be obtained.  Values 
previously obtained in volunteers are listed in the table below.  Reported healthy T2 of 
skeletal muscle in the calf (10 studies), thigh (5 studies), foot (one study) and upper 
limb (one study) lie in the range 25-45ms, with small intra-study standard deviations 
within a study of between 0.5-5 milliseconds (Table 3-1).  It is fair to assume that the 
greater variation in values between studies owes more to methodological differences 
than true differences between the healthy volunteers.  One early large study across 
eight sites suggested that field strength was not responsible for differences in T2 
measurements (de Certaines et al., 1993), which is further supported comparing values 
obtained at 1.5T and 3T.  There is one outlier in terms of T2 values, where the healthy 
volunteers had mean T2 values of 72ms (Maillard et al., 2004a).  This suggests a 
difference in their methodology introducing a significant systematic difference in 
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measurements from all other studies, although the exact reason is not apparent in the 
paper.  It does however emphasise that the message presented in their paper “A score 
of greater than 86 ms indicates inflammation” should be qualified with: ‘using our 
scanner, sequence and analysis method’ instead of implying an absolute cut off 
between normal and abnormal. 
In all cases where a disease group was studied in addition to the volunteer group, the 
diseased group showed significantly higher values, suggesting that T2 measurement is 
effective at separating normal from abnormal skeletal muscle.  Only one study with five 
controls analysed both thigh and calf muscles, and found T2 values higher in the thigh 
(Gloor et al., 2011) so there is insufficient data to know whether this is generalisable.  
Studies which measured T2 in more than one muscle found small but significant 
differences between muscles as outlined in Table 3-2 (Gloor et al., 2011; Hatakenaka 
et al., 2001; Psatha et al., 2012; Schwenzer et al., 2009).  Compared with soleus, 
which is the most commonly analysed muscle, the reported T2 time in tibialis anterior is 
shorter.  Either increased intramuscular fat content or higher Type 1 fibre concentration 
is the given explanation.  These differences were small compared with values obtained 
in pathological muscle. 
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Table 3-1: Reported T2 in skeletal muscle of healthy volunteers 
Region Reference MRI Echo N Muscle Side ROI T2 value Patient 
Calf 
(Ababneh et 
al., 2008) 
3T 16 6 TA Right Small 32 ± 1.6ms Exercise 
Calf 
(Bryan et al., 
1998) 
NS 8 8 TA Both NS 33.4 ± 1.5ms ALS 
Calf 
(Hatakenaka 
et al., 2001) 
1.5T 4 59 So, GM Right Small 
26.9-30.3 ± 
0.6-1.8ms 
No 
Calf 
(Hatakenaka 
et al., 2006) 
1.5T NS 11 So, GM Right Small 
33.5 ± 1.7 
30.7 ± 1.1 
No 
Calf 
(Hiba et al., 
2012) 
1.5T 2 6 TA Both Whole 42.4 ± 2.9ms 
Myotonic 
dystrophy 
Calf 
(Huang et 
al., 1994) 
1.5T NS 2 TA Right Medium 25-27ms Duchenne 
Calf 
(Phoenix et 
al., 1996) 
1.5T 4 3 
TA, So, 
GM 
Both Full 28.5ms 
Muscular 
Dystrophy 
Calf 
(Ploutz-
Snyder et al., 
1997) 
1.5 64 9 TA Right Small 29.3 ± 0.7ms Exercise 
Calf 
(Psatha et 
al., 2012) 
3T 8 18 
TA 
So 
GM 
Single Medium 
27 ± 2.5ms 
34.6 ± 2.9ms 
34.4 ± 2.9ms 
Immobil-
isation 
Calf 
(Sakurai et 
al., 2011) 
1.5T NS 15 
TA 
So 
Single NS 
29.8 ± 1.6ms 
32.5 ± 1.3ms 
No 
Calf 
(Schwenzer 
et al., 2009) 
3T 32 23 
TA, So, 
GM, GL 
Right Medium 
32-35 ± 1-3ms 
34-40 ± 2-6ms 
Young 
Old 
Calf 
Thigh 
(Gloor et al., 
2011) 
1.5T 32 5 
10 calf 
11 thigh 
Both Whole 
38±1 ms calf 
33±1 ms thigh 
OPMD 
Thigh 
(de 
Certaines et 
al., 1993) 
0.1-
1.5T 
Var 100 8 thigh Right Medium 32-47 ± 1-4ms No 
Thigh 
(Maillard et 
al., 2004a) 
1.5T 16 20 
Ant/Post/
Med 
comp 
Left Medium 78 ± 2ms 
Juvenile 
DM 
Foot 
(Bus et al., 
2002) 
3T 11 8 
Whole 
CS 
Left Whole 40-50ms Diabetes 
Upper 
limb 
(Ploutz-
Snyder et al., 
2006) 
1.5 64 6 
Biceps 
Triceps 
Single Full 
29.9 ± 0.5ms 
30.4 ± 0.7 
Stroke 
NS: Not specified; TA: tibialis anterior; So: Soleus; GM: Gastrocnemius medial head 
GL: Gastrocnemius lateral head ROI: Region of interest type; Var: variable; CS: Cross-
section 
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Table 3-2: T2 times in different calf muscles 
Reference So TA MG LG 
(Schwenzer et al., 
2009) 
34 ± 1ms 32 ± 1ms 35 ± 3ms 35 ± 2ms 
(Hatakenaka et al., 
2001) 
29.4 ± 1.3ms X 27.2 ± 1.2ms X 
(Sakurai et al., 
2011) 
32.5 ± 1.3ms 29.8 ± 1.6ms X X 
(Hatakenaka et al., 
2006) 
33.5 ± 1.7ms X 30.7 ± 1.1ms X 
(Psatha et al., 
2012) 
34.6 ± 2.9ms 27 ± 2.5ms 34.4 ± 2.9ms X 
(Gloor et al., 2011) 42 ± 3ms 33 ± 1ms 43 ± 6ms 40 ± 5ms 
TA: tibialis anterior; So: Soleus; MG: Medial head of gastrocnemius; LG: Lateral head 
of gastrocnemius; X: not reported 
3.2.1.2 T1 time 
Within the quantitative MRI literature, the T1 relaxation time of healthy skeletal muscle 
is much less commonly reported.  T1 relaxation time is dependent on field strength, 
with theoretical models available to predict this, and demonstrated in an early 
multicentre trial (Henriksen et al., 1993).  There is insufficient data to make any 
assessment of differences between muscles.  Therefore, T1 values cannot be directly 
compared between studies, and multi-centre studies will need to ensure equivalent 
sequence parameters at the different sites with an appropriate inter-site 
standardisation process.  Careful corrections would need to be applied if scanners with 
different field strengths were used at different sites. 
Table 3-3: Reported T1 values in skeletal muscle of healthy volunteers 
Region Reference MRI N Muscle Side ROI T1 value Patient 
Calf 
(Bryan et 
al., 1998) 
NS 8 TA Both NS 861 ± 21 ms ALS 
Calf 
(Sakurai et 
al., 2011) 
1.5T 15 
TA 
So 
NS NS 
1219 ± 223 
1167 ± 203 
No 
Calf 
(Huang et 
al., 1994) 
1.5T 2 TA Right Medium 1300 ± 100 Duchenne 
Thigh 
(de 
Certaines et 
al., 1993) 
0.1 - 
1.5T 
100 8 thigh Right Medium 
202 ± 26 ms 
1109 ± 126 ms 
No 
NS: not specified; TA: tibialis anterior; So: soleus, ROI: region of interest type 
3.2.1.3 Fat fraction 
Intramuscular fat accumulation (IFA) is a feature of chronic muscle damage common to 
both neurogenic and myopathic diseases.  Quantification of IFA therefore represents a 
promising biomarker of disease progression in chronic neuromuscular diseases.  There 
are a number of publications quantifying fat content in skeletal muscle of healthy 
volunteers (Table 3-4), however direct comparisons are limited by different MR 
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methods (MRI vs MR spectroscopy), as well as differences in sequence and analysis 
method. 
3.2.1.3.1 Methods of fat fraction estimation 
The simplest method to estimate fat infiltration within a muscle is segmentation based 
on signal intensity on a T1w image.  This method has been used in both patients 
(Ravaglia et al., 2010) and volunteers (Holmbäck et al., 2002).  However, these 
sequences are prone to systematic artefact and the classification of each voxel is 
binary (muscle or fat), so this technique is less commonly used.  Another technique 
utilises T2 modelling to estimate tissue fat fraction (Gloor et al., 2011; Kan et al., 2009).  
An alternative method utilises sequence parameters to create an image where signal is 
primarily derived from protons in fat, then normalises to an internal reference with 
known fat concentration such as bone marrow.  With toHowever the most commonly 
used methods rely on differences in resonance frequencies between protons in fat and 
water caused by their  “chemical shift” differences (Reeder et al., 2012).  Chemical-shift 
can be exploited to separate fat and water signals using either MR Spectroscopy 
(MRS) or conventional MR imaging sequences.  Single voxel (SV) MRS methods 
examine the spectra of protons (1H) within a single voxel positioned within a muscle 
with reference to an anatomical reference image, from which the fat and water peak 
areas are compared to calculate a fat fraction for that volume of tissue.  If methods with 
adequate spectral resolution are used, intramyocellular and extramyocellular lipids can 
be recognised as separate spectral peaks and quantified separately.  Multi-voxel 
techniques apply the same methods across multiple voxels in the same acquisition to 
provide a degree of spatial resolution, although this greatly increases scanning time. 
The three-point Dixon fat-water separation method (Glover and Schneider, 1991) and 
other related MR imaging techniques take advantage of the chemical shift to design an 
acquisition scheme yielding “fat only” and “water only” images.  These two images are 
combined according to the formula: 
Signal Fat Fraction = Fat Signal/(Fat Signal + Water Signal) 
Equation 3-1: Fat fraction 
This may be expressed as a decimal or percentage fraction, with the latter notation 
used in this thesis.  This provides a fat fraction map with high spatial resolution which 
can then be analysed to determine the mean fat fraction within any desired region of 
interest.  If all possible sources of systematic error are reduced or eliminated in this 
process, then the measurements of signal fat fraction will correspond to visible proton 
density fat fraction.  This is defined as the ratio of the concentration of mobile protons 
from fat (triglycerides) and the total concentration of protons from mobile triglycerides 
and mobile water.  The PDFF is a fundamental property of tissue and reflects the 
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concentration of fat within that tissue.  It has been proposed as the best MR biomarker 
of fat infiltration (Reeder et al., 2012). 
The technical aspects of the different methods of quantification of fat infiltration are 
beyond the scope of this discussion.  However, it is important to note that widely 
different methods of acquisition and analysis exist in the literature and the units of 
measurement also vary.  Choice of method largely depends on the purpose of the 
study.  A time intensive MRS method which can distinguish intramyocellular and 
extramyocellular lipid components is important in metabolic (Shen et al., 2008) or 
sports (Tamura et al., 2008) research, but for neuromuscular disease biomarkers 
spatial resolution, reliability and acquisition time are more important considerations.  
Therefore MRI based methods such as Dixon are generally preferred in this context.  
As with T2 estimations, the fat quantification methods used need to be carefully taken 
into account when comparing studies. 
3.2.1.3.2 Reported values, variation between muscles 
Within the limitations noted above, reported values for fat fraction in skeletal muscle of 
healthy volunteers are summarised below.  Where possible values are converted to a 
“fat fraction percentage” to be more readily comparable.  Two studies comparing two 
different fat fraction estimation techniques (Gloor et al., 2011; Schick et al., 2002) are 
of particular interest. 
It is interesting to note differences in three studies which report fat fractions in tibialis 
anterior muscle using the Dixon fat-water separation method. Psatha and colleagues 
(2012) found a mean fat fraction in tibialis anterior of 3% using ROI drawn within the 
muscle avoiding fascia and vessels.  Gloor and colleagues (2011) had a mean value of 
5% using ROI drawn encompassing the whole cross section at a single slice, whilst 
Hiba and colleagues (2012) reported a median value of 11% when ROI were used to 
encompass the whole volume of muscle.  The differences may be due to the increasing 
amount intramuscular and extra-muscular fat included within ROI, although the 
application of these types of ROI on the same dataset would clarify this further. 
One focus of 1H-MR spectroscopy has been quantification of intramyocellular lipid, to 
investigate its role in metabolism, training and metabolic diseases such as diabetes.  
Intramyocellular lipid content varies between muscles, with higher concentrations in 
muscles with the highest proportion of Type 1 fibres, trained endurance athletes, obese 
individuals and if a high lipid diet is consumed.  However, the total amount of IMCL is 
small: 0.24% by volume on average (Howald et al., 2002), so even in muscles with 
high Type 1 content in trained athletes the concentration is less than 1% by volume.  
This amount is negligible compared with the total fat content reported in patients with 
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neuromuscular diseases, so is likely to be of less importance in this setting.  Some 
investigators provide estimates of total lipid content using MRS – although for small 
voxel sizes the EMCL varies depending on exact position (Shen et al., 2008) so for this 
purpose large voxels or a multi-voxel MRS technique are preferable.  Values of total fat 
fraction with MRS are very similar to those obtained using chemical-shift MRI methods. 
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Table 3-4: Reported fat fraction in skeletal muscle of healthy volunteers 
Reference MRI Method N Tissue Fat value Comment 
CHEMICAL SHIFT MRI METHODS 
(Psatha et 
al., 2012) 
3.0T 3pt Dixon 18 TA, So, MG 
(uncast leg) 
Moderate 
ROI 
3% 
5% 
5% 
In cast other 
leg day 5 but 
stable 
(Hiba et al., 
2012) 
1.5T 3pt Dixon 6 TA: both. Full 
muscle 
volume 
11 ± 2% Converted 
from ratio 
Myotonic 
dystrophy 
(Gloor et 
al., 2011) 
1.5T 2 pt Dixon 
And 
Steady State 
Free 
Precession 
5 Thigh and 
Calf muscles 
Full ROI 
2pt Dix: 8.3% ±1.8% 
thigh 
6.2 ±0.8% calf 
SSFP 4.1 ± 1.1% 
thigh 
2.6±0.6% calf 
OPMD 
(Hatakenak
a et al., 
2006) 
1.5T 2-pt Dixon 
method 
11F Right So, 
MG. Small 
ROI 
Fat deposition ratio 
0.915±0.014 
0.904±0.005 
Also rabbits 
1H-MRS METHODS 
(Torriani et 
al., 2012) 
3T SV-1H-MRS 
Lipid fraction 
8 Right TA and 
So 
Small ROI 
2.5 ± 2.0% 
7.4 ± 4.0% 
Duchenne 
(Ortiz-Nieto 
et al., 
2010) 
1.5T H1-MRS using 
bone marrow 
as internal 
reference 
20 Right Thigh 
Right Calf  
2.7/3.2±1.0/1.3%  
1.2/1.3±0.4/0.4% 
(M/F) 
Also IMCL. 
No difference 
Male:Female 
(Schick et 
al., 2002) 
1.5T MRS and Fat 
selective 
imaging (bone 
marrow ref.) 
30 Right TA, So 2.0/3.1±0.7/1.2% 
3.1/3.3±1.1/1.5% 
(M/F) 
Also examined 
correlation 
spectroscopic 
and imaging 
techniques 
(Pfirrmann 
et al., 
2004) 
1.5 SV-1H-MRS 30 Supraspinatu
s 
Apparent lipid 
content (FF) 13.7% 
Supraspinatou
s tears 
(Shen et 
al., 2008) 
1.5T SV-1H-MRS 
IMCL/Water 
5 
5 
Right TA 0.040 ± 0.010 
0.032 ± 0.002 
Obese 
Lean 
Also Multivoxel 
(Howald et 
al., 2002) 
1.5T SV-1H-MRS 
IMCL (%ww) 
10 Right TA 0.24 ml/100mLww Compared to 
biopsy 
(Sakurai et 
al., 2011) 
1.5T MRS for IMCL 15 TA 
So 
2.3 ± 1.3 
7.7 ± 3.5 
IMCL/Cr 
Side/ROI type 
not given 
(Forbes et 
al., 2014) 
3T SV-1H-MRS 31 VL 
Sol 
0.027 ± 0.017 
0.015 ± 0.006 
5-14 year old 
boys 
Duchenne 
(Tamura et 
al., 2008) 
? SV-1H-MRS 14 Right TA 
Right So 
IMCL (Fat-Cr ratio): 
1.15/1.81 TA 
5.1/5.92 So 
Sprinters/ 
Endurance 
athletes. Also 
different diets 
OTHER METHODS 
(Schwenze
r et al., 
2009) 
3T Spoiled 
gradient-echo 
sequence with 
spatial-
spectral 
excitation 
11 
+ 
12 
Right TA, So, 
MG, LG 
1.2-3.5 ± 0.4-1.1% 
+ 
2.3-10.7 ± 0.7-18.0% 
Young and old 
(Kan et al., 
2009) 
3T Multispin echo 7 Right Calf 
muscles 
2±2% TP 
9 ±5% MG 
FSHD 
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TA: tibialis anterior; So: soleus; MG: medial head of gastrocnemius; LG: lateral head of 
gastrocnemius; ROI: region of interest; SV: single voxel; IMCL: intramyocellular lipid; 
Cr: creatine 
3.2.1.4 MTR 
Measurements derived from the magnetisation transfer properties of skeletal muscle 
are less common.  From those listed in the table below it is clear that healthy muscle 
displays significant magnetisation transfer effect but as expected the value obtained is 
dependent on both field strength and sequence implementation.  With the limited data 
available there are not large differences between values of muscles in the lower leg, 
and no assessments have been published of thigh values in healthy volunteers. 
Table 3-5: Reported MTR in the skeletal muscle of healthy volunteers 
Reference MRI Method N Tissue MTR Comment 
(Schwenzer et 
al., 2009) 
3T TR 36ms, TE 
5.2ms, MT 
prepulse 
1200 Hz 
duration 
9.472 ms, flip 
angle MT 
pulse 750° 
11 
+ 
12 
Right TA, Sol, 
MG, LG 
Moderate ROI 
43-47 ± 3-4 
p.u. 
Young and old 
Difference in 
TA only but 
possible B1 
effects 
(McDaniel et 
al., 1999) 
0.5T TR 600ms, 
TE 30ms, MT 
prepulse 200 
Hz duration 
16 ms 
10 Right calf 
5 x muscles 
Small ROI 
38-41 ± 1-3 
p.u. 
Also LGMD 
No significant 
correlation 
with age 
(Sinclair et al., 
2010) 
3T Full qMT 10 Right Calf 
7 x muscles 
Small ROI 
27-36 ± 2-4 
p.u. 
Dedicated 
qMT protocol. 
Variation due 
to incorrected 
B1 
inhomogeneity 
(Sinclair et al., 
2012a) 
1.5T TR 1500ms, 
TE 14ms, flip 
angle 70°.  
10 Both calves, 
4x 
compartments 
51 ± 2 p.u. CIDP (39 
p.u.), CMT (42 
p.u.) 
TA: tibialis anterior; So: soleus; MG: medial head of gastrocnemius; LG: lateral head of 
gastrocnemius; ROI: region of interest; p.u.: percentage units; qMT: quantitative 
magnetisation transfer; LGMD: limb girdle muscular dystrophy; CIDP: chronic 
inflammatory demyelinating polyneuropathy; TR: repetition time; TE: echo time 
3.2.2 Physiological variation 
Physiological variation, if not characterized and controlled for is a major confounder in 
health measurements used both for diagnosis and as outcome measures.  For 
example, serum cortisol shows diurnal variation so timing of the sample is required for 
interpretation, and growth hormone levels show such wide variation that a random level 
is of little value and suppression or stimulation tests are required.  For skeletal muscle 
quantitative MRI measurements there are two major potential sources of physiological 
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variation within an individual: diet and exercise.  Both of these may be considered in 
the short term: physical activity or food intake in the 24 hours preceding the MRI; or 
considered in the medium term: effects of training or general diet.  These factors have 
been reported to some extent in the literature to date. 
3.2.2.1 Effect of exercise and training 
The effect of exercise on muscle T2 in volunteers has been examined in a number of 
studies.  Two studies have measured the T2 in tibialis anterior before and after 
exercising this muscle to fatigue within the scanner. These showed mean increases in 
T2 of 11ms (Ababneh et al., 2008) and 9ms (Ploutz-Snyder et al., 1997) with 
subsequent decay toward baseline with a half-life of 8 minutes (Ababneh et al., 2008).  
Other studies have seen a ~3ms increase in upper arm muscles (Ploutz-Snyder et al., 
2006)  and 2ms increase in thigh muscles (Maillard et al., 2005) following exercise, 
with this returning to baseline when repeated at 30 minutes in the latter study.  Taken 
together these studies do demonstrate an immediate effect of exercise on muscle T2, 
perhaps relating to changes in blood volume (Ababneh et al., 2008), however the effect 
lasts less than 30 minutes. 
Medium-term changes in muscle use, whether training or immobility, have also been 
investigated, though mostly with regard to muscle size, which not unexpectedly 
increases with training (Nakai et al., 2008) and reduces with immobility (Miokovic et al., 
2012).  One study, in addition to atrophy, quantified T2 in lower leg muscles following 
immobilisation due to ankle fracture.  They found greatest increase in T2 time in soleus 
muscle with a 10ms increase, with lesser increases in gastrocnemius and tibialis 
anterior at 5ms and 3ms respectively.  This effect seemed to develop after 15 days of 
complete immobilisation so would be less relevant in clinical trials in neuromuscular 
diseases unless joint arthrodesis was performed during the study period. 
3.2.2.2 Effect of diet 
The short term effect of diet on intramyocellular lipid content has been examined in 
athletes (Tamura et al., 2008).  Under extremes of diet (10% versus 60% calories from 
fat), differences in the intramyocellular lipid content in calf muscles can be detected in 
endurance athletes but not sprinters.  However intramyocellular lipid content is a small 
fraction of total muscle volume (0.24%) (Howald et al., 2002), and these differences 
occurred with combined training and diet extremes, so are unlikely to result in 
significant day-to-day variation when assessing total fat fraction (combined intra- and 
extracellular lipid content) in subjects with more typical lifestyles.  Long-term changes 
in diet will result in change in weight and body fat distribution, which may result in 
significant changes in extramyocellular lipid content, considered in 3.2.3.3 below. 
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3.2.3 Inter-subject variation 
One of the major limitations of current outcome measures in neuromuscular disease, 
such as strength, is the wide range of values which can be normal.  For example, knee 
extension strength varies hugely between a 20-year-old male professional rugby player 
and a healthy 80-year-old woman.  What follows is that the rugby player could lose 
75% of their strength in this muscle but still have “normal strength” if an age/gender 
specific reference range is not used, and even then a similar difficulty would apply with 
comparison of the 20-year-old professional rugby player to a sedentary 20-year-old.  
Proper interpretation of health measurements and optimal application of outcome 
measures is greatly aided by better understanding of these inter-subject differences.  
Furthermore, changes with increasing age will cause confounding in longitudinal 
studies. 
3.2.3.1 Effect of age on quantitative MRI parameters 
Changes with age can cause confounding in longitudinal studies of disease 
progression.  Whilst gender almost certainly stays constant through a longitudinal 
study, age certainly does not and so will influence outcome measure responsiveness.  
A recent publication in CMT suggested that the apparent progression observed in adult 
patients was not different from the effects of ageing in matched healthy volunteers 
(Verhamme et al., 2009).  This finding is at odds with clinical observations, and an 
alternative explanation is that the markers of progression used in this study, 
neurophysiology and muscle strength testing, were insufficiently sensitive to show 
change in the time-frame of the study, especially with changes of healthy ageing 
confounding measurement. 
As might be expected, total muscle mass is negatively correlated with age, and this is 
reflected in both cross-sectional and longitudinal studies involving size measurement 
of lower limb muscles.  Andreassen and colleagues (Andreassen et al., 2009) 
performed lower leg and foot imaging at a 9-12 year interval and found a loss of calf 
muscle volume of 1.7% per annum, although minimal (0.2%/annum) change in foot 
muscle volume.  In a cross-sectional MRI study (Jubrias et al., 1997) a 1.4% per year 
decline in quadriceps cross-sectional area was seen in subjects aged between 65 and 
80 years.  This result is consistent with a longitudinal CT study with 1678 participants 
aged 70-79 at baseline, where a 0.8% per annum reduction in muscle cross-sectional 
area at mid-thigh level was observed (Delmonico et al., 2009).  Interestingly, in both of 
these studies the reduction in muscle strength per annum was twice that of cross-
sectional area, indicating that reduction in force with age is not solely due to reduced 
muscle size, but also associated with a reduction in the specific force (maximum force 
 
69 
per unit area) of the muscle.  All these studies make clear that if a muscle size-based 
measurement is utilised as an outcome measure, decline with healthy ageing will be a 
potentially confounding factor similar to when neurophysiology or myometry are used. 
There are also some data available with regard to tissue parameter muscle 
measurements with age, though to date these are derived from cross-sectional 
analyses.  Schwenzer and colleagues (Schwenzer et al., 2009) have published data on 
quantitative MRI measurement of T2, Dixon fat fraction and MTR of the muscles in the 
right calf at 3T.  They compared a group of 12 younger adults, mean age 31, with 11 
older adults, mean age 66.  Utilising subtotal ROI of tibialis anterior, soleus, medial and 
lateral gastrocnemius muscles they showed T2 and fat fraction differed between the 
groups in all muscles.  The absolute difference however was small: with T2 in the 
younger group 34ms versus 37ms in the older group.  This corresponds to a less than 
0.1ms change in T2 per year of increasing age, although caution is needed when using 
cross-sectional data to predict longitudinal change.  Similarly, the mean fat fraction in 
the younger group was 2.8% versus 6.6% in the older group, corresponding to 
approximately 0.1% change per year.  For the MTR measurements a significant 
difference was only seen in tibialis anterior (47p.u. in the younger group, 44p.u in the 
older group) but not in other muscles.  A strong relationship between T2 and fat 
fraction was observed, leading the authors to conclude that the changes in T2 resulted 
from increased extramyocellular lipid content with age. 
Another study quantified T2 relaxation time in gastrocnemius and soleus muscles of 59 
volunteers aged 22 to 76 (Hatakenaka et al., 2001).  They showed a positive 
correlation between age and T2 in gastrocnemius but not soleus, which together with 
animal studies led them to conclude that the difference was due to age-related Type II 
fibre atrophy.  Again the absolute difference in T2 was small, increasing from 26 to 
29ms in the age range examined – much less than 0.1ms per annum.  Although 
caution is needed in interpreting cross-sectional data as a surrogate for longitudinal 
data, it is clear that changes in measured tissue parameters are likely to show minimal 
change over the likely duration of a clinical trial (1-5 years) compared with changes 
which might be seen in muscle size measurements. 
3.2.3.2 Effect of gender on quantitative MRI parameters 
As would be expected from muscle strength differences between the sexes, there are 
differences in muscle size measurements between males and females (Jubrias et al., 
1997).  Indeed in children, differences in strength observed between genders was fully 
explained by differences in muscle cross-sectional area (Wood et al., 2004).  The only 
study specifically examining whether tissue parameter measurements show gender 
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related bias did not show any gender difference in IMCL or EMCL of thigh and calf 
muscles (Ortiz-Nieto et al., 2010).  More information in this area is clearly needed. 
3.2.3.3 Effect of body habitus on MRI parameters 
It would be no surprise if larger people have larger muscles, though in fact this hasn’t 
been systematically examined.  It might also be hypothesised that obese individuals 
would have greater proportions of intramuscular fat and this has been examined in the 
metabolic literature, unsurprisingly given the global importance of obesity, diabetes and 
related conditions.  Perhaps surprisingly therefore, investigators have found no 
correlation between muscle fat and BMI for subjects with BMI less than 30 (kg/m2), 
although three subjects in the study with BMI >30 had increased muscle lipid content 
(Schick et al., 2002).  Similarly, there was no correlation between thickness of 
subcutaneous fat and lipid content in the muscle.  Other studies have examined more 
specifically the metabolically active intramyocellular lipid content and found higher 
IMCL levels in obese subjects (Shen et al., 2008), although as noted previously this is 
also true for highly trained endurance athletes and the absolute amount this contributes 
per weight muscle volume is small (Howald et al., 2002).  Overall therefore there is 
evidence which suggests that, similar to age and gender, any effect of body size of 
muscle tissue parameter measurements is small; however a more systematic 
assessment of this is warranted. 
3.2.4 Reliability 
As already discussed test-retest reliability is absolutely critical to outcome measure 
responsiveness: it determines the “noise” and as disease progression in many 
neuromuscular diseases is slow, can easily mask the “signal” we are trying to detect.  
For example if a measurement such as muscle strength testing shows variation of 10% 
or repeat testing the next day, it is very difficult to demonstrate a 2% annual change in 
strength without either a very large cohort of patients or a long follow up period.  
Optimising reliability is critical to maximising the responsiveness of any outcome 
measure, so the relative paucity of true scan-rescan reliability assessment in the 
quantitative muscle MRI literature needs redressing. 
For size measurements such as muscle  area or volume, intra-rater (Commean et al., 
2011; Delmonico et al., 2009; Fortin and Battié, 2012; Gille et al., 2011; Holmbäck et 
al., 2002; Hoyte et al., 2009, 2011; Hu et al., 2011; Humbert et al., 2008; Ranson et al., 
2006; Smeulders et al., 2010; Springer et al., 2011; Tingart et al., 2003; Wood et al., 
2004) and inter-rater (Commean et al., 2011; Gille et al., 2011; Hiba et al., 2012; 
Holmbäck et al., 2002; Hoyte et al., 2009, 2011; Hu et al., 2011; Kilgour et al., 2012; 
Smeulders et al., 2010; Springer et al., 2011; Tingart et al., 2003) reliability has been 
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reported and is generally excellent.  As would be expected intra-rater is higher than 
inter-rater reliability, although the latter source of variation can be eliminated through 
the trial design ensuring all scans from one individual are assessed by one observer.  
Inter-scan reliability has been assessed for cross-sectional area of neck muscles 
(Kilgour et al., 2012), which was high when reported as intra-class correlation 
coefficients (0.95-0.97) but the coefficients of variation were high, between 22 and 
26%.  Sproule and colleagues assessed thigh muscle volume in 8 patients with spinal 
muscular atrophy, with immediate rescanning finding extremely high ICC (>0.99), 
though without reporting limits of agreement or coefficients of variation to allow 
analysis of what interval change could be considered significant.  Inter-scan reliability 
of forearm muscle volume estimation has also been reported to be high with ICC 
>0.99, though this figure hides significant inter-scan variation such that the smallest 
detectable change in muscle volume was reported to be 7% (Smeulders et al., 2010).  
Finally Clark and colleagues (Clark et al., 2007) performed a useful assessment of test-
retest reliability over 4 weeks of a range of assessments of ankle plantarflexion 
function including muscle cross-sectional area of soleus, medial gastrocnemius and 
lateral gastrocnemius.  Again ICC were relatively high (0.96-0.99) but limits of 
agreement were variable 37%, 6% and 14% respectively.  These muscles vary in 
cross-sectional area relatively rapidly along their length, so inconsistent slice 
positioning is the most likely cause in this case.  All these examples show that while 
inter-scan reliability of size measurements is apparently high, this is due to the high 
inter-subject variation (see Equation 1-1) and limits of agreement which describe the 
range where apparent differences could be due to measurement error are in fact wide. 
Fewer studies have examined reliability for measurements of muscle tissue 
parameters.  One study examined Inter-observer and intra-observer reliability of mean 
T2 measurements within calf muscles in a mixed group of patients and volunteers, with 
variance of 1.1ms and 0.6ms respectively (Huang et al., 1994).  Another study showed 
fat-to-water ratio intra-observer variance of 2.5% in a group of patients with myotonic 
dystrophy, with high reliability in more severely affected patients.  Reliability was better 
than for residual volume measurements (5.2%) and myometry measurements (11.2%) 
(Hiba et al., 2012).  Scan-rescan reliability has been examined only for proton 
spectroscopy methods of lipid estimations: for total lipid content in supraspinatus 
muscle (Pfirrmann et al., 2004), and intramyocellular lipid content of tibialis anterior 
muscle (Shen et al., 2008).  For the remainder of quantitative MRI methods, inter-scan 
reliability has not been systematically reported, despite its key role in outcome 
measure performance. 
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3.2.5 Summary 
Published data of quantitative muscle MRI in healthy volunteers to date has 
established that for size measurements there is significant inter-subject variation which 
relates to gender and age, and that longitudinal change in muscle size can be 
quantified with training and immobility.  This high inter-subject variation results in high 
reliability of measurements when assessed by intra-class correlation coefficients, but 
rather less reliability when assessed by limits of agreement, which are more relevant 
indices of reliability for longitudinal outcome measure assessments.  On the other 
hand, tissue MRI parameters such as T1, T2 and MTR vary more between studies of 
healthy volunteers than between participants within studies, demonstrating that 
absolute “normal ranges” for these measurements are inappropriate.  Although data 
are sparse, it appears inter-subject variation in these measurements is small with little 
or no dependence on age/gender/weight.  Small differences between muscles and 
good reliability are suggested by small studies, but more rigorous assessment of this is 
needed. 
 Healthy volunteer phase aims 
The specific aims of phase 1 of this thesis, the healthy volunteer phase are to: 
1. Determine the normal range of quantitative muscle MRI parameters (size, T1, 
T2, MTR, fat fraction) with our methods (scanner, coil, positioning, sequences, 
post-processing and analysis)  
2. Assess between-muscle differences in quantitative muscle MRI parameters to 
demonstrate the sensitivity of our methods to small physiological variation 
3. Determine the inter-subject variation of quantitative muscle MRI parameters 
and the determinants of this variation 
4. Assess the reliability of these measurements: inter rater and scan-rescan 
5. Assess the relationship between the quantitative muscle MRI parameters and 
also the relationship between quantitative measurements and qualitative MRI 
assessments. 
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 Results 
3.4.1 Subjects and scan schedule 
With local research ethics committee approval and written consent 47 healthy 
volunteers were studied: 23 males, age 44.4 ± 17.0, 21.5-81.0y; height 171 ± 9, 150-
188cm; weight 73 ± 16, 44-115kg; body mass index 25 ± 4.7, 17-41 kg/m2 (mean ± SD, 
range).  Data presented includes 19 healthy volunteers scanned during phase 1 and 28 
healthy volunteers during phase 2 (see 2.2).  Fifteen healthy volunteers from phase 1 
underwent repeat imaging after approximately 2 weeks with identical imaging 
parameters. 
3.4.2 General appearance 
Sample parameter maps are shown in Figure 3-1.  Example ROI as drawn on one of 
the unprocessed Dixon acquisitions are shown in Figure 2-5.  Significant signal 
inhomogeneity is notable in this – with lesser signal intensity anteriorly on the right and 
posteriorly on the left for both thigh and calf, though the effect was greater for thigh 
than calf.  This was consistent amongst all subjects, and the same pattern was seen in 
the B1 field map (Figure 3-1-B).  The nature of the three-point Dixon method and T2 
mapping where the maps comprise a ratio of signal intensities or an estimated decay 
constant (see 1.4) meant the generated FF (Figure 3-1-C) and T2 (Figure 3-1-E) maps 
visually appeared free of this inhomogeneity, although occasionally artefact was 
present in the anterio-medial right thigh when there was complete signal drop-out.  
Both MTR and T1 maps were generating using a method with a correction based on 
the co-registered B1 field map (see 2.4.4.2 and 2.4.4.5) and the resulting maps (Figure 
3-1-D and Figure 3-1-F) visually appeared free of field inhomogeneity although for both 
these sequences signal drop-out antero-medially in the thigh made this area non-
analysable in the majority of subjects.  Specifically, artefact was present within right 
rectus femoris in 45/47 T1 maps, 41/47 MTR maps and within right vastus medialis in 
35/47 T1 maps and 33/47 MTR maps. 
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Figure 3-1: Sample images from a single healthy volunteer (24 year old male) 
 
A: B1 field map of both thighs and both calves demonstrating reduced B1 anteriorly on 
right and posteriorly on left (arrows). B: Fat fraction map left thigh and calf in %. C: T1 
map in ms at left thigh and calf level. D: T2 map left thigh and calf in ms. E: MTR map left 
thigh and calf in p.u.  All images are axial with standard orientation (anterior at top of 
image, right hand side at left of image).  
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3.4.3 Individual muscle values 
Individual muscle values from small ROI for each MRI measure in all 47 subjects are 
shown in Figure 3-2. FF were similar in the same muscles in left and right limbs, 
confirming B1 inhomogeneity did not unduly influence these measures.  Between 
muscles, FF differed significantly (ANOVA, p<0.001 at both calf- and thigh-level). 
Group-mean sartorius FF was higher than all other thigh-level muscles (p<0.01 for 
semimembranosus, p<0.001 for all other muscles) whilst the rectus femoris FF was 
lower than most other thigh muscles (p<0.01 vs. gracilis, vastus lateralis; p<0.001 vs. 
sartorius, semimembranosus, biceps femoris and adductor magnus).  Similarly in the 
calf, soleus FF was highest (p<0.05 vs. peroneal, p<0.01 vs. medial gastrocnemius, 
p<0.001 vs. each remaining muscle) whilst tibialis anterior FF was the smallest (p<0.01 
vs. medial and lateral gastrocnemius, p<0.001 vs. soleus and peroneal). However, the 
absolute inter-muscle differences were small, FF ranging from 0.6% in the rectus 
femoris to 2.9% in the sartorius. 
T2 values were also similar in the left and right limbs, confirming independence from B1 
inhomogeneity.  Inter-muscle T2 differences were also significant (ANOVA, p<0.001 at 
both calf and thigh-level), with the same muscles (sartorius, semimembranosus and 
biceps femoris in the thigh; soleus, peroneal in the calf) showing elevated T2 as 
elevated FF.  Whilst tibialis posterior and tibialis anterior T2 times were lowest in the 
calf, consistent with their low FF, gracilis T2 was lowest despite this muscle’s 
intermediate FF. 
MTR showed apparent left-right differences in some regions with lower values for right 
tibialis anterior, right rectus femoris and left semimembranosus, corresponding to the 
areas of maximum B1 deviation.  Excepting these ROIs, MTR was similar across all 
thigh and calf muscles (range 31.7-33.2 p.u.). 
Mean T1 similarly varied between left and right limbs in these muscles, suggesting 
incomplete B1 inhomogeneity correction, but was otherwise consistent across the 
remaining muscles (1240-1370ms). 
Fat fraction values obtained from full ROI were consistently higher than those obtained 
from small ROI (Table 3-7).  The overall mean obtained using whole ROI was 3.7% in 
the thigh and 2.8% in the calf versus for small ROI 1.5% in the thigh and 1.6% in the 
calf.  Combining the large ROI allowed calculation of the total cross-sectional area of 
muscles, this was 177±40cm2 for muscles at mid-thigh and 90±33cm2 at mid-calf level. 
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Figure 3-2: Individual muscle ROI values at thigh and calf levels for 47 healthy subjects  
 
Bars indicate median, 25th, 50th and 75th centiles, lines: range, o: minor outlier, *: major 
outlier. MTR: magnetisation transfer ratio, p.u. percentage units, blue: left limb, green: 
right limb 
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3.4.4 Scan-rescan and inter-observer reliability 
Scan-rescan reliability values are shown in Table 3-6, with inter-observer reliability in 
Table 3-8.  Mean values are shown for both summary measures and individual-muscle 
ROI values, together with scan-rescan and inter-observer ICCs and limits of agreement 
for both.  Intra-class correlation coefficients were 0.84-0.99 for inter-observer and 0.62-
0.99 for scan-rescan values, and were generally higher for the summary measures 
than for the individual muscle values.  The limits of agreement were consistently 
narrower for overall mean values and inter-observer comparisons than for individual 
ROI values and inter-scan comparisons.  Bland-Altman plots for both inter-observer 
and inter-scan reliability are shown in Figure 3-3. 
The limits of agreement for individual muscles are shown in Table 3-11.  For scan-
rescan measurements there was no evidence of systematic bias, however for inter-
observer measurements some muscles had evidence of systematic bias.  This was 
true for area measurements based on whole muscle ROI, suggesting one observer 
consistently included more voxels at the muscle boundary, which proved true on direct 
comparison of a sample of ROIs drawn.  This resulted in systematically higher fat 
fraction for the observer with larger ROI, due to partial volume effects with fat tissue 
adjacent to the muscle border.  For those sequences where B1 inhomogeneity was not 
completely corrected (MTR and T1) there were systematic inter-observer differences 
for muscles close to areas of remaining inhomogeneity – most notably right vastus 
medialis.  Review of these ROI showed that this was due to systematic variation in ROI 
placement within the muscle relative to the area of signal inhomogeneity. 
In general, inter-observer reliability whether assessed by limits of agreement or intra-
class correlation coefficients was better than inter-scan reliability.  For fat fraction 
assessments there was variation in inter-scan reliability between thigh muscles with 
rectus femoris, gracilis and sartorius showing widest limits of agreement – the smallest 
muscles.  In general reliability was similar for thigh-level and calf-level muscles. 
3.4.4.1 Muscle area 
Although there is wide variation in the absolute inter-scan difference in area between 
muscles, the relative amount is very similar +/- 10% for thigh muscles and +/-5% for 
calf muscles.  There was no systematic bias for inter-scan assessment. The inter-
observer reliability of area however shows an overall bias for both thigh and calf with 
Observer 1 approximately 10% greater than Observer 2 – likely due to including more 
muscle at the perimeter, but also variation between muscles, suggesting different slice 
selection.  Consistent with this, in the inter-observer comparison of large fat fraction, 
there was systematic bias with Observer 1 fat fractions approximately 1% higher than 
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Observer 2, with some variation in this between muscles. This is a consequence of 
partial volume effect by ROI including muscle boundaries for observer 1.  Thus both 
large ROI fat fraction and muscle area show lower inter-observer ICC than inter-scan 
ICC. 
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Table 3-6: Overall reliability table: inter-scan and inter-observer 
 For the overall mean across all ROI For an individual ROI 
Parameter Mean ± s.d. IO ICC IS ICC IS LOA Mean ± s.d. IO ICC IS ICC IS LOA 
Thigh 
Mean FF small (%) 1.53 ± 0.90 0.93 0.91 -0.50 to +0.27 1.53 ± 1.48 0.79 0.76 -1.25 to 1.01 
Mean T1 time (ms) 1279 ± 43 0.95 0.65 -45 to +53 1279 ± 98 0.93 0.79 -103 to 111 
Mean T2 time (ms) 42.9 ± 3.1 0.98 0.94 -1.38 to +1.70 42.9 ± 4.8 0.84 0.83 -3.42 to 3.83 
Mean MTR (p.u.) 32.0 ± 1.1 0.99 0.87 -1.27 to +1.64 32.0 ± 1.66 0.90 0.71 -2.39 to 2.49 
Mean FF large (%) 3.66 ± 1.43 0.52 0.94 -0.83 to +0.49 3.66 ± 2.33 0.59 0.83 -2.28 to 2.13 
Total Muscle Area (cm2) 227 ± 51 0.84 0.97 -17.2 to +23.1 NA 0.94 0.99 NA 
Calf 
Mean FF small (%) 1.58 ± 0.81 0.95 0.89 -0.54 to 0.08 1.58 ± 1.30 0.83 0.62 -2.01 to +1.50 
Mean T1 time (ms) 1258 ± 49 0.90 0.64 -64 to +92 1258 ± 78 0.95 0.65 -122 to +142 
Mean T2 time (ms) 40.9 ± 3.0 0.96 0.83 -1.70 to +2.34 40.9 ± 3.9 0.86 0.79 -3.11 to +3.80 
Mean MTR (p.u.) 32.3 ± 0.9 0.94 0.69 -0.61 to +0.82 32.3 ± 1.5 0.92 0.65 -1.90 to +2.04 
Mean FF large (%) 2.79 ± 1.19 0.62 0.84 -1.29 to +1.13 2.79 ± 1.69 0.66 0.80 -2.07 to +1.91 
Total Muscle Area (cm2) 121 ± 25 0.90 0.99 -5.4 to +5.9 NA 0.98 0.99 NA 
IO: inter-observer; IS: inter-scan; ICC: intra-class correlation coefficient; LOA: limits of agreement (+/- 2 s.d. Bland-Altman method); MTR: 
magnetisation transfer ratio; FF: fat fraction 
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Table 3-7: Mean quantitative parameters in 15 healthy volunteers and test-retest 
reliability 
Measure 
1st Scan 
Mean ± s.d. 
2nd Scan 
Mean ± s.d. 
ICC 
Limits of 
agreement 
N 
Thigh Level –mean across all ROIs for each subject 
Fat-Fraction (%) 1.36 ± 0.50 1.25 ± 0.58 0.91 -0.51 to +0.28 14 
T1 (ms) 1290 ± 32 1288 ± 30 0.65 -39 to +35 14 
T2 (ms) 42.01 ± 2.28 42.19 ± 2.29 0.94 -1.47 to +1.83 14 
MTR (p.u.) 32.23 ± 1.40 32.25 ± 1.19 0.87 -1.63 to +1.67 14 
Calf Level– mean across all ROIs for each subject 
Fat-Fraction (%) 1.54 ± 0.65 1.30 ± 0.56 0.89 -0.58 to +0.08* 15 
T1 (ms) 1276 ± 66 1283 ± 56 0.62 -100 to +114 13 
T2 (ms) 39.89 ± 1.75 40.23 ± 2.14 0.83 -1.84 to +2.54 15 
MTR (p.u.) 32.80 ± 0.57 32.91 ± 0.44 0.69 -0.67 to +0.89 14 
Thigh Level – individual ROI values 
Fat-Fraction (%) 1.32 ± 0.87 1.20 ± 0.82 0.76 -1.25 to +1.01* 254 
T1 (ms) 1282 ± 88 1286 ± 81 0.79 -103 to +111 190 
T2 (ms) 41.90 ± 3.17 42.11 ± 3.27 0.83 -3.43 to +3.83 255 
MTR (p.u.) 32.35 ± 1.79 32.40 ± 1.47 0.71 -2.39 to +2.49 224 
Calf Level individual ROI values 
Fat-Fraction (%) 1.51 ± 0.93 1.21 ± 0.85 0.62 -1.55 to +0.95* 166 
T1 (ms) 1271 ± 83 1281 ± 79 0.65 -122 to +142 119 
T2 (ms) 39.89 ± 2.60 40.23 ± 2.92 0.79 -3.11 to +3.80* 180 
MTR (p.u.) 32.82 ± 1.35 32.89 ± 1.03 0.65 -1.9 to +2.04 160 
OM – refers to an overall mean value at thigh or calf level for each patient (15 data 
points) 
ROI – analysing each region of interest individually (300 data points thigh, 180 data 
points calf) 
ICC – intra-class correlation coefficient – test re-test, same observer 
LOA – limits of agreement (+/- 2 s.d. by Bland-Altman method) 
MTR – magnetisation transfer ratio 
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Table 3-8: Inter-observer reliability of MRI measurements 
Measure 
1st Observer 
Group Mean ± SD 
2nd Observer 
Group Mean ± SD 
ICC 
Limits of 
agreement 
N 
Thigh Level – overall mean for each subject  
Fat-Fraction (%) 1.33 ± 0.50 1.24 ± 0.41* 0.93 -0.39 to +0.21 15 
T1 (ms) 1293 ± 33 1287 ± 34 0.95 -26 to +14 15 
T2 (ms) 41.97 ± 2.20 42.01 ± 2.22 0.98 -0.93 to +1.00 15 
MTR (p.u.) 32.29 ± 1.37 32.34 ± 1.27 0.99 -0.49 to +0.59 15 
Calf Level– overall mean for each subject  
Fat-Fraction (%) 1.54 ± 0.65 1.51 ± 0.57 0.95 -0.41 to +0.33 15 
T1 (ms) 1275 ± 63 1276 ± 66 0.99 -23 to +24 14 
T2 (ms) 39.89 ± 1.75 39.75 ± 1.79 0.96 -1.08 to +0.80 15 
MTR (p.u.) 32.75 ± 0.57 32.84 ± 0.56 0.95 -0.25 to +0.43 15 
Thigh Level – individual ROI values  
Fat-Fraction (%) 1.32 ± 0.91 1.23 ± 0.91* 0.79 -1.04 to +1.22 281 
T1 (ms) 1289 ± 88 1284 ± 94 0.93 -62 to +72 221 
T2 (ms) 41.96 ± 3.19 42.00 ± 3.61 0.84 -3.82 to +3.75 280 
MTR (p.u.) 32.36 ± 1.80 32.34 ± 1.91 0.90 -1.59 to +1.63 248 
Calf Level individual ROI values  
Fat-Fraction (%) 1.55 ± 0.97 1.50 ± 0.98 0.83 -1.08 to +1.17 172 
T1 (ms) 1269 ± 81 1269 ± 81 0.95 -48 to +50 138 
T2 (ms) 39.89 ± 2.60 39.75 ± 2.69 0.86 -2.59 to +2.88 180 
MTR (p.u.) 32.76 ± 1.36 32.83 ± 1.31 0.92 -1.15 to +1.00 175 
ICC – Intra-class correlation coefficient 
Limits of agreement (+/- 1.96 s.d. by Bland-Altman method) 
* - Evidence of systematic difference between scans/observers (p<0.001, Bland-Altman 
method) 
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Table 3-9: Inter-scan paired two-tailed t-tests for each modality for each ROI  
Scan A vs Scan B T1 T2 MTR Dixon 
Calf overall 0.686222 0.071556 0.081639 0.117694 
Right Tibialis Anterior 0.511788 0.135722 0.023583 0.011669 
Right Peroneus Longus 0.923607 0.300702 0.025239 0.285734 
Right Lateral Gastroc 0.355663 0.163292 0.232022 0.493376 
Right Medial Gastroc 0.495875 0.520808 0.946239 0.09956 
Right Soleus 0.12952 0.75991 0.23096 0.757039 
Right Tibialis Posterior 0.167532 0.433371 0.014074 0.103283 
Left Tibialis Anterior 0.250432 0.002136 0.087645 0.053944 
Left Peroneus Longus 0.803196 0.075515 0.151114 0.879453 
Left Lateral Gastroc 0.622861 0.322725 0.11571 0.723469 
Left Medial Gastroc 0.947682 0.958217 0.393997 0.722407 
Left Soleus 0.833965 0.182258 0.122588 0.320411 
Left Tibialis Posterior 0.592735 0.021276 0.174642 0.185291 
Thigh overall 0.442009 0.222237 0.890963 0.799299 
Right Vastus Lateralis 0.413587 0.511788 0.838585 0.27058 
Right Vastus Medialis 0.511719 0.923607 0.563317 0.717175 
Right Semitendonosis 0.996142 0.355663 0.19361 0.816024 
Right Biceps Femoris 0.743214 0.495875 0.889797 0.831138 
Right Gracilis  0.098822 0.12952 0.860393 0.289765 
Right Adductor Magnus  0.375422 0.167532 0.699227 0.769177 
Left Vastus Lateralis 0.849544 0.250432 0.253618 0.754825 
Left Vastus Medialis 0.951723 0.803196 0.20126 0.260122 
Left Semitendinosus 0.482759 0.622861 0.880393 0.404881 
Left Biceps Femoris 0.962006 0.947682 0.232704 0.344563 
Left Gracilis 0.756815 0.833965 0.255686 0.141896 
Left Adductor Magnus 0.82796 0.045815 0.80465 0.490707 
By Bonferroni correction for multiple comparisons for A vs B, for overall thigh/calf (8 
measures), p < 0.005 significant 
For individual ROIs = 98 measures, p<0.0005 significant. 
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Table 3-10: Inter-observer paired two-tailed t-tests for each modality for each ROI  
Observer JM vs AF T1 T2 MTR Dixon 
Calf overall 0.026567 0.425262 0.000389 0.963717 
Right Tibialis Anterior 0.943776 0.519198 0.0248667 0.015239 
Right Peroneus Longus 0.069205 0.82444 0.2717706 0.072279 
Right Lateral Gastroc 0.213473 0.038125 0.0210748 0.308883 
Right Medial Gastroc 0.029217 0.09544 2.594E-06 0.020724 
Right Soleus 8.2E-06 0.469978 6.154E-06 0.710177 
Right Tibialis Posterior 0.233925 0.205691 0.7090662 0.397646 
Left Tibialis Anterior 0.737573 0.772459 0.000349 0.056573 
Left Peroneus Longus 0.642802 0.615909 0.1594877 0.021507 
Left Lateral Gastroc 0.341964 0.291414 2.719E-06 0.174703 
Left Medial Gastroc 0.174344 0.167993 0.0002975 0.84026 
Left Soleus 2.57E-05 0.030163 0.0030535 0.704276 
Left Tibialis Posterior 0.342517 0.320739 0.8132651 0.345205 
Thigh overall 1E-05 3.56E-06 7.99E-07 0.005391 
Thigh except RVM 0.144547 0.556217 0.556217 0.005364 
Right Vastus Lateralis 0.063717 0.086323 1.08666E-07 0.516385 
Right Vastus Medialis 3.37E-06 9.87E-10 4.88213E-08 0.147516 
Right Semitendonosis 0.022863 0.000573 0.002083682 0.206134 
Right Biceps Femoris 0.297453 0.379295 0.029008818 0.628404 
Right Gracilis  0.003531 0.046685 0.403574767 0.381144 
Right Adductor Magnus  0.053915 0.014977 0.734102468 0.981188 
Left Vastus Lateralis 0.321522 0.173646 0.387337283 0.097238 
Left Vastus Medialis 0.297033 0.097951 0.995662242 0.013892 
Left Semitendinosus 0.001631 0.082517 0.002884189 0.314158 
Left Biceps Femoris 0.091009 0.10806 0.002406375 0.457314 
Left Gracilis 0.760466 0.807736 0.00011095 0.136857 
Left Adductor Magnus 0.023151 0.517997 0.819727905 0.216598 
By Bonferroni correction for multiple comparisons for O1 vs O2, for overall thigh/calf (8 
measures), p < 0.005 significant. For individual ROIs = 98 measures, p<0.0005 
significant. 
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Figure 3-3: Bland-Altman plots for inter-scan and inter-observer analyses 
 
  
  
  
Horizontal lines denote the mean difference and 95% confidence limits.  
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Table 3-11: Limits of agreement (LOA) for each quantitative parameter for each ROI 
individually 
Reliability IS FF LOA IS T1 LOA IS T2 LOA IS MTR LOA IO FF LOA IO T1 LOA IO T2 LOA IO MTR LOA 
Units % ms ms p.u. % ms ms p.u. 
L RF  -0.85 to 0.93 -122 to 174 -3.14 to 3.02 -2.02 to 2.76 -0.82 to 0.81 -91 to 99 -2.05 to 1.8 -1.88 to 1.22 
R RF  -2.04 to 2.41 X -2.79 to 2.28 X -0.76 to 1.22 X -0.67 to 2.76 -0.52 to -0.52 
L VM  -0.66 to 0.33 -184 to 195 -2.87 to 3.77 -2.27 to 2.64 -0.57 to 0.89 -89 to 41 -2.89 to 4.19 -1.79 to 1.18 
R VM  -0.88 to 1.18 X -4.91 to 3.5 0.64 to 0.64 -1.37 to 1.26 -16 to -16 -5.63 to 7.54 -0.66 to -0.54 
L VI  -0.81 to 0.56 -83 to 105 -2.44 to 2.61 -2.05 to 2.09 -0.48 to 0.62 -54 to 79 -2.75 to 3.79 -1.63 to 1.09 
R VI  -0.84 to 1.06 -19 to 37 -1.91 to 2.67 -3.71 to 2.29 -0.89 to 1.08 -65 to 103 -3.84 to 3.06 -2.12 to 0.35 
L VL -1.04 to 0.7 -93 to 110 -3.01 to 2.95 -1.8 to 2.25 -0.57 to 0.88 -53 to 59 -1.47 to 2.48 -1.23 to 1.2 
R VL -0.57 to 0.29 -43 to 58 -2.18 to 2.62 -2.5 to 1.62 -0.73 to 0.8 -70 to 73 -2.59 to 3.29 -2.06 to 2.23 
L SM  -1.72 to 1.23 -78 to 133 -3.13 to 2.84 -1.34 to 2.46 -1.29 to 1.38 -50 to 75 -4.74 to 2.84 -0.68 to 1.78 
R SM  -1 to 0.63 -96 to 85 -4.83 to 6.11 -1.43 to 2.01 -1.09 to 1.26 -36 to 72 -4.15 to 3.86 -1.08 to 1.55 
L ST  -0.83 to 0.69 -91 to 99 -1.24 to 2.13 -3.62 to 2.81 -0.52 to 0.88 -34 to 47 -2.07 to 1.67 -0.98 to 1.39 
R ST  -0.56 to 0.42 -108 to 106 -3.24 to 2.68 -1.89 to 2.35 -0.48 to 0.63 -39 to 36 -2.2 to 2.84 -0.96 to 0.68 
L BF  -1.07 to 0.69 -137 to 91 -2.91 to 3.98 -2.99 to 2.62 -0.94 to 0.6 -52 to 73 -3.16 to 1.82 -1.3 to 1.36 
R BF  -0.8 to 0.77 -87 to 91 -3 to 4.36 -2.77 to 2.47 -0.72 to 1.06 -45 to 31 -4.51 to 4.57 -1.16 to 0.92 
L AM  -0.66 to 0.62 -118 to 111 -2.54 to 4.25 -3.04 to 3.53 -1.06 to 1.12 -63 to 35 -4.81 to 4.11 -2.74 to 2.64 
R AM  -1.79 to 1.44 -54 to 51 -3.51 to 5.07 -2.03 to 2.04 -1.78 to 2.71 -51 to 27 -4.84 to 6.86 -1 to 0.38 
L Sa  -1.44 to 0.5 -76 to 80 -6.24 to 5.94 -2.21 to 3.23 -1.72 to 2.05 -40 to 104 -6.43 to 4.93 -0.9 to 1.63 
R Sa  -1.8 to 1.55 -126 to 144 -5.5 to 5.43 -2.49 to 0.93 -1.13 to 1.62 -78 to 123 -4.77 to 3.82 -1.17 to 2.39 
L  GR  -1.63 to 0.75 -161 to 112 -3.66 to 3.82 -3.33 to 4.01 -0.56 to 0.83 -39 to 111 -2.37 to 2.07 -1.5 to 3.1 
R GR -2.05 to 1.26 -74 to 117 -3.72 to 3.21 -0.97 to 1.15 -1.74 to 1.04 -63 to 75 -3.81 to 2.46 -0.99 to 1.16 
Thigh Total -1.25 to 1.01 -103 to 111 -3.43 to 3.83 -2.39 to 2.49 -1.04 to 1.22 -62 to 72 -3.82 to 3.75 -1.59 to 1.63 
L TA  -1.05 to 0.52 -126 to 146 -1.28 to 4.07 -2.48 to 1.74 -0.33 to 0.49 -7 to 14 -1.68 to 2.36 -0.76 to 0.55 
R TA  -1.19 to 0.47 -248 to 210 -3.24 to 1.97 -1.46 to 4.34 -0.24 to 0.31 -135 to 106 -0.64 to 0.82 -1.95 to 1.27 
L PL  -1.53 to 1.32 -148 to 186 -2.21 to 3.82 -2.3 to 1.82 -2.18 to 1.22 -54 to 53 -3.89 to 2.13 -0.83 to 0.86 
R PL -3.67 to 1.88 -117 to 177 -6.1 to 5.39 -2.07 to 2.58 -1.93 to 2.48 -36 to 45 -4.3 to 5.07 -1.85 to 1.51 
L LG  -1.66 to 1.32 -70 to 161 -3.88 to 4.69 -2.05 to 2.88 -1.1 to 1.06 -67 to 50 -4.57 to 4.19 -1.62 to 1.5 
R LG  -0.73 to 0.3 -149 to 128 -3.78 to 4.84 -1.58 to 1.37 -0.39 to 0.83 -47 to 76 -1.94 to 4.34 -0.88 to 0.45 
L MG  -1.02 to 0.46 -90 to 69 -2.61 to 3.43 -1.19 to 0.69 -0.81 to 0.68 -39 to 36 -1.81 to 2.23 -0.96 to 1.43 
R MG  -1.05 to 0.65 -127 to 154 -3.6 to 4.26 -1.1 to 1.5 -0.94 to 1 -54 to 29 -2.22 to 1.95 -1.22 to 1 
L So -1.31 to 0.4 -76 to 81 -1.94 to 2.59 -0.91 to 0.51 -0.99 to 1.73 -46 to 35 -1.01 to 2 -0.88 to 0.46 
R So -0.82 to 0.65 -131 to 138 -2.24 to 2.56 -1.07 to 1.1 -0.18 to 0.93 -39 to 17 -0.38 to 1.98 -0.67 to 0.28 
L TP  -1.22 to 0.66 -124 to 162 -1.78 to 3.38 -1.95 to 1.46 -0.71 to 0.41 -33 to 55 -2.3 to 1.73 -0.61 to 0.84 
R TP  -1.19 to 0.64 -179 to 147 -2.19 to 2.2 -1.54 to 2.06 -0.41 to 0.28 -30 to 63 -1.2 to 0.56 -0.44 to 0.75 
Calf Total -1.55 to 0.95 -122 to 142 -3.11 to 3.8 -1.9 to 2.04 -1.08 to 1.17 -48 to 50 -2.59 to 2.88 -1.15 to 1 
IS: inter-scan, IO: inter-observer, FF: fat fraction, MTR: magnetisation transfer ratio, R: right, L: 
left, RF: rectus femoris, VM: vastus medialis, VI: vastus intermedius, VL: vastus lateralis, Sa: 
sartorius, SM: semimembranosus, ST semitendinosus, BF: biceps femoris (long head), AM: 
adductor magnus, G: gracilis, TA: tibialis anterior, TP: tibialis posterior, PL: peroneus longus, So: 
soleus, MG: medial head of gastrocnemius, LG: lateral head of gastrocnemius, X: Insufficient 
data for analysis due to B1 field inhomogeneity. Thigh and calf totals are the limits of agreement 
with all muscles at that level combined and correspond to values in Table 3-7. 
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3.4.5 Dependence upon age, gender and weight 
Multivariate linear regression modelling the MRI measures at each level against the 
assumed explanatory variables age, gender and weight results are shown in Table 
3-12 for the all-muscle summary measures, and for individual muscles in Table 3-13.  
There was significant positive dependence of both FF and T2 upon age at both 
anatomical levels, and upon weight in the thigh but not calf.  MTR showed strong 
negative dependence upon age (p<0.001) for both thigh and calf (Figure 3-4), 
illustrating the univariate Pearson correlation between overall muscle mean MTR and 
age), and significant correlation with weight and notably gender in the thigh.  T1 did not 
depend significantly upon any demographic parameter, except for an association with 
weight in the thigh only (p<0.05). Although FF correlated positively with T2, and 
negatively with T1 and MTR (table 4), the MTR-age correlation remained significant 
when the other quantitative parameters were included as covariates (p<0.01 thigh, 
p<0.001 calf).  As expected, muscle size correlated negatively with age and female 
gender (Table 3-12, Figure 3-5) 
Multivariate linear regression models for individual muscles (Table 3-13) most 
consistently demonstrated positive correlations between FF or T2 and weight in the 
thigh, and negative correlations between MTR and age/gender/weight in the thigh, and 
age in the calf. 
Figure 3-4: Relationship between MTR 
and age 
 
Overall mean thigh (x) and calf (+) MTR 
is negatively correlated with subject age 
(p<0.001) 
Figure 3-5: Thigh area vs age in males 
and females 
 
Cross-sectional thigh area reduces with 
age and is lower in females (green) 
than males (blue) 
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Table 3-12: Multivariate regression analysis of muscle MRI measures with subject 
demographics 
 Thigh Calf 
FF R=0.58, p=0.001 R=0.42, p<0.05 
Co-eff p  Co-eff p 
Constant -0.942 .150 0.573 0.399 
Gender -0.125 .597 -0.329 0.174 
Age 0.016 .026 0.014 0.047 
Weight 0.025 .003 0.008 0.374 
T1 R=0.50, p=0.01 R=0.43, p=0.10 
Co-eff p  Co-eff p 
Constant 1356.9 .000 1278.0 0.000 
Gender 15.98 .189 31.34 0.051 
Age -0.519 .149 -0.132 0.770 
Weight -0.858 .035 -0.366 0.468 
T2 R=0.60, p<0.001 R=0.57, p=0.001 
Co-eff p  Co-eff p 
Constant 34.44 .000 34.97 0.000 
Gender -0.163 .839 -1.175 0.142 
Age 0.074 .003 0.067 0.006 
Weight 0.073 .009 0.049 0.064 
MTR R=0.75, p<0.001 R=0.61, p<0.001 
Co-eff p  Co-eff p 
Constant 35.90 .000 33.707 0.000 
Gender -0.878 .000 0.164 0.485 
Age -0.029 .000 -0.032 0.000 
Weight -0.030 .000 -0.002 0.789 
CS Area R=0.85, p<0.001 R=0.79, p<0.001 
Co-eff p  Co-eff p 
Constant 208.2 .000 76.6 0.000 
Gender -52.1 .000 -22.7 0.000 
Age -1.408 .000 -0.117 0.431 
Weight 1.468 .000 0.834 0.000 
R = overall model correlation coefficient; Co-eff = partial regression coefficient; p = 
significance level (coefficients with p < 0.05 are indicated in bold type-face). 
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Table 3-13: Multivariate regression of individual muscle MRI measures with demographic 
factors 
Parameter FF T1 T2 MTR 
Correlate Age Gender Weight Age Gender Weight Age Gender Weight Age Gender Weight 
Side R L R L R L R L R L R L R L R L R L R L R L R L 
TA +      -       +   + +  ---     
PL   -      +          - ---     
GL     ++   ++    -- + +   ++  ---     - 
GM  ++  - +   + +  - - ++ ++   +  --- ---     
SO   - -     +      - -   -- - +    
TP         ++    + +++     - --     
Calf +      ++   ---   
RF  +    +        +  ++ - +  -  ---  --- 
VM +    ++     +   + +    +    --  --- 
VI     + +        ++  ++  +++ --     -- 
VL +    ++ +        ++ ++  ++ + - -- - --- -- -- 
SM  +  - ++ + -     -- +   - +++  --- --   - - 
ST  +           +   -   - --- ---  --  
BF +++ +   ++ +++  -     +++ +    ++ --- --- -- -- -  
AM     ++ + -   +    +   ++ ++ - - -  ---  
SA            -       - -    - 
GR     + +      -     + +    -- - -- 
Thigh +  ++   - ++  ++ --- --- --- 
 
Regression performed on each muscle separately.  Calf and Thigh columns refer to 
mean of all ROIs for each subject, full regression parameters for this are outlined in 
Table 3-12.  The most consistent correlations are: positive between subject weight and 
thigh muscle F.F., subject age and calf or thigh muscle T2, subject weight and thigh T2, 
and negative between subject age and MTR in thigh and calf, female gender and MTR 
in thigh, subject weight and MTR in thigh. 
 
+ = positive correlation, 0.01>p>0.05 
++ = positive correlation, 0.01>p>0.001 
+++ = positive correlation, p<0.001 
- = negative correlation, 0.01>p>0.05 
-- = negative correlation, 0.01>p>0.001 
---= negative correlation, p<0.001 
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3.4.6 Relationship between quantitative parameters 
Expected correlations were seen between quantitative parameters within individual 
small ROI, with fat fraction showing positive correlation with T2 time, negative 
correlation with T1 time and MTR (Table 3-14).  Strongest correlation was seen 
between T2 time and fat fraction (Figure 3-6).  Multivariate regression showed that 
MTR remained negatively correlated with T2 time independent of correlation with fat 
fraction or demographic parameters (p<0.001). 
Table 3-14: Pearson correlation coefficients between quantitative parameters 
Calf T1  T2 MTR 
Dixon FF -0.28 0.61 -0.30 
T1   -0.18 0.42 
T2   -0.47 
Thigh T1 T2 MTR 
Dixon FF -0.42 0.62 -0.41 
T1  -0.21 0.48 
T2   -0.51 
Each small ROI from each volunteer is a data point.  All correlations significant 
p<0.00001 
Figure 3-6: Scatter-plot showing correlation between fat fraction and T2 time in the calf 
 
R=0.6, p<1x10-53  
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3.4.7 Qualitative imaging 
On blinded analysis 18.4% of thigh muscles and 15.0% of calf muscles were scored 1 
or 2a on Mercuri grading, most commonly semimembranosus and semitendinosus in 
the thigh and peroneus longus and soleus in the calf (Table 3-15).  Muscles which were 
graded as “abnormal” on Mercuri grading had increased fat fraction on whole muscle 
ROI analysis (Figure 3-7) and shortened T1 time, (calf 1204ms vs 1269ms, p<0.001, 
thigh 1193ms vs 1277ms, p<0.001).  This confirms that the T1 hyperintensity on 
qualitative imaging resulting in grade 1 assignment is due to increased fat deposition. 
STIR hyperintensity was noted in only 2.8% of thigh muscles (exclusively one of the 
hamstring muscles or adductor magnus) but in 14.2% of calf muscles, most commonly 
medial or lateral gastrocnemius (Table 3-15, Figure 3-9).  Volunteers with STIR 
hyperintensity in medial gastrocnemius had a greater BMI but age and gender did not 
affect the likelihood of STIR hyperintensity (Table 3-16).  The small ROI in those medial 
gastrocnemius muscles with STIR hyperintensity on qualitative assessment had 
prolonged T2 times and reduced MTR.  T1 times and fat fractions were not significantly 
different (Table 3-16).  When combining all calf regions, those with qualitative STIR 
hyperintensity had significantly prolonged T2 times (Figure 3-10).  These findings 
demonstrate that mild STIR hyperintensity can be seen in calf muscles of healthy 
volunteers, especially the medial and lateral gastrocnemius, which is reflected in 
increased T2-times on quantitative imaging. 
Table 3-15: Frequency of Mercuri grades in different muscle groups 
ROI 
Grade 
0 
Grade 
1 
Grade 
2a 
Rectus Femoris 100% 0% 0% 
Vastus Medialis 79% 21% 0% 
Vastus 
Intermedius 
86% 14% 
0% 
Vastus Lateralis 78% 21% 1% 
Semimembranosu
s 
56% 35% 9% 
Semitendinosus 62% 36% 2% 
Biceps Femoris 75% 21% 4% 
Adductor Magnus 83% 17% 0% 
Sartorius 96% 4% 0% 
Gracilis 89% 11% 0% 
Thigh overall 80.3% 18.1% 1.6% 
Tibialis Anterior 91% 9% 0% 
Peroneus Longus 69% 29% 2% 
Lateral Gastroc 99% 1% 0% 
Medial Gastroc 79% 21% 0% 
Soleus 64% 34% 2% 
Tibialis Posterior 100% 0% 0% 
Calf overall 83.7% 15.6% 0.7% 
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Figure 3-7: Box-plot of whole muscle Dixon versus Mercuri grade for thigh and calf 
 
Increasing fraction is measured in calf and thigh muscles from healthy volunteers with 
increasing Mercuri grades. Bars indicate median, 25th, 50th and 75th centiles, lines: 
range, o: minor outlier, *: major outlier 
Figure 3-8: STIR hyperintensity in medial gastrocnemius 
 
Mild STIR hyperintensity (arrows) is seen in both medial gastrocnemius muscles in this 
healthy volunteer 
Figure 3-9: Frequency of STIR hyperintensity in calf muscles of volunteers 
 
Percentage of volunteers with STIR hyperintensity is shown for each muscle. TA-tibialis 
anterior; P-peroneal muscle group; LG-lateral head of gastrocnemius; MG-medical 
head of gastrocnemius; So-soleus  
MG 
37% 
LG 27% 
So 
TA 
3% 
TP 
0% 
P 13% 
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Table 3-16: Demographic and MRI associations of right medial gastrocnemius STIR 
hyperintensity 
Parameter 
Normal 
STIR 
Hyperintens
e STIR 
p-value 
Female 46% 61% 0.34 
Age 38 51 0.01 
Height 172 169 0.44 
Weight 70 77 0.10 
BMI 23.6 26.7 0.03 
Dixon FF (%) 1.3 1.7 0.08 
T1 time (ms) 1238 1235 0.87 
T2 time (ms) 39.4 42.8 0.002 
MTR (p.u.) 33.6 32.2 0.002 
Quantitative parameters are for right medial gastrocnemius.  FF: fat fraction; MTR: 
magnetisation transfer ratio; STIR: short-tau-inversion-recovery.  Significant differences 
are in bold. 
 
Figure 3-10: Box-plot of T2 times in calf muscles grouped by qualitative STIR 
classification 
 
Calf muscles with STIR hyperintensity on qualitative imaging have higher T2 time on 
quantitative imaging.  Bars indicate median, 25th, 50th and 75th centiles, lines: range, o: minor 
outlier, *: major outlier 
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 Discussion 
These data establish the very good reproducibility of quantitative lower limb muscle 
MRI obtained using standard acquisition sequences suitable for deployment in NMD 
treatment trials. The biological sensitivity of the measures is illustrated by 
demonstrating their dependence upon specific muscle compartment, age, weight and 
gender in healthy individuals.  Even within the narrow range of values seen in healthy 
volunteers, convergent validity is demonstrated through correlation between the 
quantitative parameters, and between qualitative and quantitative parameters.  
Quantitative MRI muscle tissue parameters perform well in terms of the ideal outcome 
measure characteristics in healthy volunteers: minimal variability and maximal 
reliability. 
3.5.1 Intramuscular fat accumulation 
This study utilised three methods expected to be specifically sensitive to intramuscular 
fat accumulation: three-point Dixon method derived fat fraction, T1-mapping and 
qualitative T1-weighted imaging.  Whilst T2 mapping and magnetisation transfer 
imaging are also sensitive to IFA, they are additionally sensitive to changes in muscle 
water distribution so will be discussed separately. 
3.5.1.1 Dixon fat fraction 
Overall a low fat fraction within thigh and calf muscles of healthy volunteers was 
observed, with an overall mean value for small ROI at thigh and calf level of 1.54% and 
1.57% respectively. Inter-subject variation was small with standard deviation 0.90% 
thigh and 0.81% calf.  An overall mean fat fraction of >3.3% in thigh or calf can be 
considered outside the “normal range” using this protocol.  These values are similar to 
those previously reported in healthy volunteers (see 3.2.1.3.2) and are much lower 
than values reported in previous patient studies (see 4.2.2.1).  Thus measurement of 
fat fraction meets the first characteristic of an ideal outcome measurement in healthy 
subjects: a narrow range of values compared with the expected patient values. 
3.5.1.1.1 Variation between muscles 
Minor variation between muscles in fat fraction range was demonstrated.  The total 
range of this variation however was small, with the lowest mean fat fraction within the 
small ROIs of 0.8% in rectus femoris to the highest of 2.8% in sartorius.  Generally, the 
quadriceps had slightly lower fat fractions than hamstring muscles in the thigh and 
soleus more than tibialis anterior and tibialis posterior in the calf.  This is in agreement 
with a previous study which determined the proportion of fat in the calf of patients with 
FSHD, which included six control subjects in whom the medial gastrocnemius had the 
highest fat fraction whilst the tibialis posterior had the least (Kan et al., 2009).  In the 
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present study the highest 95% confidence interval for any muscle was 6%, so values 
higher than this in any muscle could be considered “abnormal” using this protocol.  
3.5.1.1.2 Variation between subjects 
Within the narrow range of fat fractions across subjects, this study was able to 
demonstrate correlation between fat fraction and age in both thigh and calf and 
between fat fraction and weight in the thigh. Again this variation is very small compared 
with the range of values already reported in patients.  This is consistent with the study 
of Schwenzer and colleagues who demonstrated higher calf-level FF in an older group 
of healthy subjects (Schwenzer et al., 2009). 
Longitudinal changes which occur in healthy aging is another difficulty with a number of 
other outcome measures in neuromuscular diseases.  Verhamme for example 
demonstrated progressive reduction of CMAP amplitudes in patients with CMT1A over 
five years, but also saw reductions in CMAP amplitudes of healthy volunteers and was 
unable to show that progression was faster in CMT1A than volunteers (Verhamme et 
al., 2009).  Similarly, muscle strength and sensory clinical examination are both known 
to be age dependent.  In this cross-sectional study, regression analysis suggests mean 
annual change for fat fraction within small muscle ROI of 0.014% or alternatively a 1% 
increase would occur over approximately 71 years. This means that any significant 
change over the length of a typical clinical study is unlikely to be due to normal ageing, 
although this of course needs to be confirmed through longitudinal assessment in 
phase 2 (chapter 4). 
There was no effect of gender on muscle fat fraction within small ROI at thigh or calf 
level.  Interestingly subject weight correlated with thigh but not calf muscle fat fraction, 
presumably reflecting preferential lipid accumulation in the thigh. These quantitative 
imaging findings are consistent with 1H-MRS showing muscle fat increase with weight 
(Schick et al., 2002; Shen et al., 2008) but not gender (Ortiz-Nieto et al., 2010).  The 
regression analysis showed that a difference in weight of 40kg was associated with a 
1% difference in thigh muscle fat fraction.  These differences are at least an order of 
magnitude less than changes in NMDs, and too small to cause significant confounding 
in longitudinal studies. 
There additionally seems to be a differential effect at an individual muscle level of these 
demographic variables.  Fat fraction within biceps femoris appeared most associated 
with age and weight, whilst sartorius and semitendinosus showed no such association.  
Fat fraction within quadriceps muscles showed moderate association with subject 
weight, but inconsistent association with age. This differential susceptibility to 
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physiological stressors might provide insight into the marked differential susceptibility of 
muscle to disease processes, the cause of which has been elusive to date. 
3.5.1.1.3 Small versus whole cross-section ROI  
Mean fat fraction was higher with whole cross-section ROI in both thigh (3.70% vs 
1.54% small ROI) and calf (2.79% vs 1.57% small ROI) levels.  This is likely due to the 
inclusion of fat which runs along intra-muscular septa, as small ROI were defined to 
avoid these septa, and also due to inclusion of voxels on the muscle perimeter whose 
volume includes a proportion of inter-muscular fat.  This is reinforced by the 
observation that whole fat fraction results for the second observer were systematically 
lower than for the main observer, and that the total cross-sectional area of the ROI was 
marginally smaller which must logically be at the periphery. 
Although not assessed in this study, when whole muscle volumes have been assessed 
for fat infiltration, slightly larger fat fraction values have been obtained (Hiba et al., 
2012), presumably due to an increase in intramuscular fat or an increase in the partial 
volume effect near muscle origins and insertions.  A final interesting observation is that 
overall the test-retest limits of agreement for full cross-sectional ROI are wider than for 
the small ROI.  This is likely due to variability in decisions to include/exclude voxels at 
the muscle edge. 
Previous authors have variously used small ROI, sub-total ROI, full cross-section ROI 
and whole muscle volume ROI (see Table 3-1), often without specifying the reason for 
this decision.  The potential advantages and disadvantages are listed in Table 3-17.  
Ultimately the performance of different types of ROI needs to be tested in reliability and 
longitudinal studies in patients.  It is likely that different ROI may be preferable 
depending on the disease and research question, but their choice requires justification. 
Table 3-17: Advantages of different ROI types 
Method Speed 
of 
creating 
Atrophy 
assessment 
Reliability 
heterogeneous 
pathology 
Reliability 
homogenous 
pathology 
Transferability 
between maps 
Single slice small 
ROI 
++++ - + +++ +++ 
Single slice large 
ROI 
++ + ++ ++ + 
Single slice 
whole CSA ROI 
+ ++ ++ + - 
Whole muscle 
volume ROI 
- +++ ++++ + - 
Ratings are subjective opinion of author, scaled best to worst: ++++, +++, ++, +, -  
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3.5.1.2 T1 measurements 
By comparison with three-point Dixon fat fraction, T1 mapping performed much more 
poorly in healthy volunteers.  Despite correction for B1 inhomogeneity, antero-medial 
muscles in the right thigh had signal dropout artefact, meaning these muscles had to 
be excluded from analysis in the majority of cases, and those that were not excluded 
on the basis of visual inspection of the maps, still showed significantly lower values 
than their right-sided counterparts, which was also seen in right versus left tibialis 
anterior in the calf.  Therefore, in spite of mathematical correction and visual checking, 
the T1 maps generated by this method have intermuscular variation due to B1 
inhomogeneity.  Furthermore, the T1 values showed lowest inter-scan reliability of 
overall mean values judged by intra-class correlation coefficients.  The method was not 
sensitive enough to show inter-muscle variation, nor significant correlations with 
demographic factors, which were apparent using the Dixon-derived fat fraction.  Finally, 
conceptually, muscle T1 values are more difficult to interpret as although they will be 
reduced with increased intramuscular fat accumulation, abnormalities in water 
distribution would be expected to increase T1.  This would mean that if both acute and 
chronic pathologies were occurring simultaneously in a patient, an apparently normal 
T1 time may result.  Compared with T2 and fat fraction measurement, relatively few 
previous studies have measured T1 time of muscle in patients with neuromuscular 
diseases.  This work in healthy volunteers suggests that for this T1 quantification 
method at least, few additionally useful data are obtained with T1 mapping. 
3.5.1.3 Qualitative assessment of T1-weighted images 
The minor variation in fat content of normal muscles, however, is extremely relevant 
when applying semi-quantitative scales of fatty infiltration on qualitative T1 images 
such as the Mercuri scale, where the distinction needs to be made between “normal 
muscle” and “scattered small areas of increased signal” (Mercuri et al., 2002b).  As in 
any area of medicine, there is overlap in the range of “normal” and “abnormal”, as is 
demonstrated in the 17% of muscles of healthy volunteers which were graded as 
“abnormal” when the observer was blinded to the presence or absence of disease by 
including subjects with CMT1A which may have mild abnormalities.  The grading of 
muscles from healthy volunteers as having “scattered small areas of increased signal” 
was not an error, demonstrated by the reduced T1 time and increased fat fraction 
observed in the quantitative assessment of these same muscles (Figure 3-7). 
The distribution of muscles with most Mercuri grades greater than 0 also matched with 
quantitative analysis. In the thigh the hamstring muscles were most commonly 
assigned Mercuri grade 1 and occasionally 2A, and these muscles had higher 
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quantitative fat fractions than the quadriceps muscles.  In the calf tibialis anterior and 
tibialis posterior had the lowest quantitative fat percentages and also fewest Grade 
1/2A Mercuri scores.  At both thigh and calf levels there were significant correlations 
between the qualitative and quantitative scoring.  This is consistent with the limited 
data previously available which demonstrated lower fat fraction in tibialis anterior than 
soleus.  This was attributed to increased intramyocellular lipid concentration (Sakurai et 
al., 2011).  However, the absolute variation in intramyocellular lipid concentration is 
relatively small (Shen et al., 2008; Tamura et al., 2008), and this would not be 
detectable by qualitative T1w image assessment.  Rather the increased fat fraction is 
likely due to extramyocellular lipid.  On qualitative assessment of the T1w this generally 
appears as thin streaks of hyperintensity within the muscle, presumably along 
intramuscular septa, most commonly seen in the soleus and peroneus longus in the 
calf and hamstring semimembranosus and semitendinosus muscles in the thigh. 
These findings have important implications in the diagnostic applications of muscle 
MRI.  The original Mercuri scale utilised in this thesis defines grades as in Figure 3-11 
below (Mercuri et al., 2002b) 
Figure 3-11: Original Mercuri grades 
Stage 0: normal appearance. 
Stage 1: early moth-eaten appearance, with scattered small areas of increased 
signal. 
Stage 2a: late moth-eaten appearance, with numerous discrete areas of 
increased signal with beginning confluence, comprising less than 30% of the 
volume of the individual muscle. 
Stage 2b: late moth-eaten appearance, with numerous discrete areas of 
increased signal with 
beginning confluence, comprising 30–60% of the volume of the individual 
muscle. 
Stage 3: washed-out appearance, fuzzy appearance due to confluent areas of 
increased signal. 
Stage 4: end-stage appearance, muscle replaced by increased density 
connective tissue and fat, with only a rim of fascia and neurovascular structures 
distinguishable. 
This paper was concerning patients with Bethlem myopathy, and the described texture 
of a “moth-eaten appearance” may not be a feature in early stage pathology of all 
diseases. In a subsequent review paper (Mercuri et al., 2007), Mercuri contracted the 
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six point scale to four points, but with identical descriptions allowing a direct conversion 
as follows: 
Table 3-18: Conversion of Mercuri Scales 
Original Mercuri Scale 
(2002) 
Revised Mercuri Scale 
(2007) 
0 1 
1 2 
2a 2 
2b 3 
3 4 
4 4 
Other authors have used slightly different scales, for example Fischer (Fischer et al., 
2008) utilised a scale which allowed CT and MRI appearances to be graded using the 
same five point scale. 
Stage 0: normal appearance 
Stage 1 (mild): traces of increased signal intensity on the T1-weighted MRI* 
Stage 2 (moderate): increased signal intensity (MRI*) with beginning confluence 
in less than 50% of the muscle 
Stage 3 (severe): increased signal intensity (MRI*) in more than 50% of an 
examined muscle 
Stage 4 (end-stage disease): entire muscle replaced by increased signal 
intensity (MRI*) 
*Or reduced signal intensity in the case of CT imaging 
In both of these scales a similar description is used to distinguish grade 1 from grade 0: 
“traces” or “scattered small areas” of increased signal intensity.  The difficulty in 
applying this scale is apparent in our publication on the qualitative MRI appearance of 
lower limb muscles in patients with non-dystrophic myotonia (Morrow et al., 2013), 
where 8/19 healthy volunteers had at least one muscle graded as grade 1.  The 
volunteer cohort in this thesis had overall 15.8% of muscles Mercuri grade 1 and 0.7% 
of muscles Mercuri grade 2A.  This thesis for the first time is able to correlate these 
“abnormal” Mercuri grades with quantitatively increased fat, and show a similar 
distribution. 
This raises the question of whether to interpret Mercuri grade 1 as showing scattered 
small areas of increased signal intensity, greater than that seen in healthy subjects.  
This increases the subjectivity of the scoring as it relies on the rater having a 
knowledge of the usual range of signal hyperintensity in each individual muscle, and 
how this might vary with demographic factors such as age, gender, BMI and level of 
activity.  Another option would be to use quantitative sequences such as three-point 
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Dixon for diagnostic imaging so that a numerical value can be obtained.  The 
disadvantage of this is that it would be very difficult to ensure that methods were 
standardised enough to prevent normal values needing to be established on each 
scanner.  The best solution perhaps is to consider both grade 0 and grade 1 as 
potentially normal, and to include a control group of healthy subjects, especially if the 
patient group demonstrate relatively mild abnormalities, which is the approach we took 
in our non-dystrophic myotonia cohort (Morrow et al., 2013). 
3.5.2 Correlation between quantitative MRI measurements 
It is timely to pause between discussion of measurements sensitive to intramuscular fat 
accumulation and measurements sensitive to abnormal muscle water distribution to 
consider the inherent relationship between these measures.  T1-weighted images are 
generally considered insensitive to muscle water changes, but in fact, muscle oedema 
may result in prolongation of T1 which would result in a slightly hypointense 
appearance on T1-weighted images, but this relatively small difference is dwarfed by 
marked hyperintensity of intramuscular fat accumulation.  Accurate T1 measurement 
may be able to quantify this increased T1 with muscle oedema but would be 
confounded by any chronic intramuscular accumulation, with the associated T1 
reduction.  Three-point Dixon derived fat fraction would reduce if the volume of water in 
muscle increased (“diluting” the fat content).  This may occur with muscle expansion in 
acute exercise due to hyperaemia or the swelling associated with rhabdomyolysis but 
is unlikely to be significant in most neuromuscular diseases.  Overall therefore the 
three methods utilised to quantify chronic muscle pathology are expected to be 
relatively independent to changes in muscle water. 
Conversely the water sensitive measures utilised here are influenced by intramuscular 
fat accumulation.  On T2-weighted images both intramuscular fat and muscle oedema 
appear hyperintense, motivating the use of the STIR sequence utilising a T1-specific 
nulling method to suppress high signal from fat. The assumption then is that the 
remaining hyperintensity is due to muscle oedema, although such findings remain non-
specific as to the underlying cause (inflammation, acute denervation, other).  Within 
muscle tissue with fat accumulation, the protons within the water and fat components of 
each voxel each have different T2 relaxation times.  The apparent T2 time based on 
the dual echo method employed in this study (without any fat suppression or fat water 
separation techniques included) reflects a combination of  the T2 of the water and fat 
components.  Based on this one would predict a strong correlation between measured 
fat fraction and measured T2 in a muscle – and this was indeed evident with R=0.61 
calf, R=0.62 thigh, both p<0.000001 (see Table 3-14). 
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Similarly, fat tissue does not display significant magnetisation transfer effects, and the 
MTR measured within the subcutaneous fat ROI in this study was 0.2p.u.  Any 
intramuscular fat accumulation would therefore be expected to result in a reduction in 
measured MTR, and indeed in this study (Table 3-14) MTR and fat fraction show a 
strong negative correlation (R=-0.41 thigh, R=-0.30 calf, both p<0.000001). 
There are many methods to measure the T2 of the water component of tissue only: 
 Using a fat suppression pulse (Willcocks et al., 2014) 
 Using 1H-MRS at different TEs and modelling the decay of the water peak 
(Forbes et al., 2014) 
 Using a fat-water separation method in parallel to T2 quantification such as the 
IDEAL-CPMG method developed at UCL in collaboration with GSK (Janiczek et 
al., 2011) 
 Through acquiring data at a large number of echo times (16 or more) to allow 
estimation of two separate T2 decay constants 
 By performing separate fat fraction quantification and T2 mapping, and 
modelling the T2-fat fraction relationship post–acquisition. 
Each of these methods has advantages and disadvantages, a full discussion of which 
is beyond the scope of this thesis.  The key aspect to consider in the interpretation of 
the quantitative water sensitive measures used in this study are that they are whole 
tissue T2/MTR measurements and as such sensitive to intramuscular fat accumulation 
in addition to changes in muscle water distribution.  The STIR sequence utilised, 
although qualitative, is able to assess muscle oedema independent of fat intramuscular 
fat accumulation. 
3.5.3 Water sensitive measures 
This study also provides good data to support quantitative assessment of water 
distribution in muscle as an outcome measure in NMD and important messages in 
terms of qualitative assessment of this on STIR images.  Although both MTR and T2 
relaxation times as measured here are influenced by intramuscular fat accumulation in 
addition to abnormal water distribution, it is envisaged that these measurements will 
prove both more sensitive to early pathology and more responsive to intervention than 
fat infiltration.  This is supported by previous studies (4.2.2.2) of both T2 relaxation time 
and MTR and is further supported by observations in this study.   
3.5.3.1 T2 measurement 
The overall mean T2 value of 42.9±3.1ms in the thigh and 40.9±3.0ms in the calf 
demonstrates a narrow range compared with expected values in patients and is within 
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the range of T2 values previously reported for healthy muscle (Table 3-1), though as 
T2 values are scanner and sequence specific, these should not be considered a 
universal reference range. 
3.5.3.1.1 Variation between muscles 
There were minor variations between T2 time of muscles with the lowest value of 39ms 
in the tibialis anterior to 45ms in biceps femoris.  The mean T2 correlated strongly with 
the mean fat infiltration within the same ROI (Figure 3-6), and furthermore a similar 
pattern of differential involvement between muscles was observed (Figure 3-2), which 
suggests that a good deal of the variation in the T2 time of muscle of healthy 
volunteers is explained by minor variation in the fat fraction.  Conversely the lowest 
thigh T2 was observed in gracilis, which had intermediate fat fraction suggesting 
variation between muscles in T2 in addition to that resulting from difference in fat 
fraction. The observation that left and right mean T2 values are similar for all ROI 
demonstrates that despite the simplistic technique employed to estimate T2, B1 field 
inhomogeneity was not a source of artefact. 
In the calf the increased soleus T2 compared to tibialis anterior is consistent with 
previous results (Gloor et al., 2011; Psatha et al., 2012; Sakurai et al., 2011; 
Schwenzer et al., 2009) attributed to differing proportions of Type 1 muscle fibres 
(Johnson et al., 1973) with increased intramyocellular lipid (Sakurai et al., 2011).  The 
differences in total fat fraction between these muscles observed in the present work, 
suggests that extramyocellular lipid may account for some of this difference.  
Regardless, for outcome assessment, whilst anatomical specificity far exceeds that 
provided by non-imaging outcome measures such as myometry (Meldrum et al., 2007) 
and neurophysiology (Robinson et al., 1991), the inter-muscular differences in T2 
measurement are far less than the variation in muscle strength or CMAP observed in 
healthy controls. 
3.5.3.1.2 Variation between subjects 
Muscle T2 showed very similar correlations to demographic parameters as were seen 
with fat fraction measurements: at thigh level with age and weight, and at calf level with 
age only, whilst there were no significant gender associations.  A similar pattern was 
also seen when muscles were considered individually.  This study therefore failed to 
identify any age-related changes in T2 independent of the effects of intramuscular fat 
accumulation, though there may be minor effects if a more sophisticated T2 
measurement method, as outlined in 3.5.2 was utilised. 
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3.5.3.2 MTR measurement 
Excepting those muscles for which B1 deviations were too severe for effective 
correction, MTRs were consistent with previous calf-muscle studies (McDaniel et al., 
1999; Schwenzer et al., 2009). However, T1 and MTR were in some muscles less 
consistent comparing left and right limbs, reflecting the increased sensitivity to B1 
variation. 
3.5.3.2.1 Variation between muscles 
Despite B1 correction by an established method (Sinclair et al., 2012b), there were 
clear left-right differences in MTR values for rectus femoris, semimembranosus and 
tibialis anterior, which are the areas of greatest inhomogeneity based on our B1 
mapping sequence (mean B1: tibialis anterior = 0.88 right, 1.28 left, rectus femoris 0.60 
right, 1.24 left, semimembranosus 1.21 right, 0.85 left), indicating that there is a 
residual artefact due to B1 inhomogeneity.  Apart from these muscles MTR is similar in 
all muscles of thigh of calf, 31.3-33.0 p.u. by this protocol.  Values of MTR of less than 
10 p.u. have been reported in patients (Sinclair et al., 2012a), demonstrating that the 
variability seen within and between healthy controls in minor compared with that 
expected in disease. 
3.5.3.2.2 Variation between subjects 
A novel finding in this study is that MTR of muscle is reduced with increasing age.  This 
observation is robust in that it is true in both calf and thigh muscles (Table 3-12, Figure 
3-4, p<0.001) and remains true if fat fraction is included as a covariate, indicating that 
this reduction of MTR is independent of the slight increase in fat fraction with age noted 
above.  Again the overall decrease with age suggested by this cross-sectional study is 
modest – from the regression analysis a decrease of 1.0 p.u over 25-30 years (Table 
3-14), however it does indicate that MTR is sensitive to changes in the macromolecular 
architecture of muscle independent of fatty infiltration.  Schwenzer et al. did not 
demonstrate differences in calf-level MTR in older subjects (Schwenzer et al., 2009).  
Our contrasting observation may be due to acquisition differences, or the advantage of 
performing B1 correction (Sinclair et al., 2012b).  MTR was the measure most sensitive 
to demographic factors, the negative correlation with age being highly significant 
(p<0.001) for both overall means and many individual muscles, and remaining 
significant with T2 and FF included as covariates. 
MTR also correlated with increasing weight in the thigh, which is likely attributable to an 
associated increase in fat fraction.  However, gender had a significant effect on thigh 
muscle MTR: overall 0.90p.u. lower in females by regression analysis.  When 
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examined on an individual muscle basis, the presence of correlation appeared different 
in right and left thighs, which together with the fact that no similar correlation is 
apparent at calf level raises the possibility that this effect is perhaps in some way 
artefactual. 
3.5.3.3 Qualitative STIR imaging 
Also of note is the observation of apparent STIR hyperintensity on blinded qualitative 
analysis in a third of all medial gastrocnemius muscles and a quarter of all lateral 
gastrocnemius muscles (Figure 3-9).  Whether medial gastrocnemius is analysed 
separately or all calf muscles considered together, those with qualitative STIR 
hyperintensity have significantly prolonged T2-times on quantitative assessment of the 
same muscles, suggesting by convergent validity that this is a true variation in the 
normal population rather than artefactual.  The average BMI of those with STIR 
hyperintensity in medial gastrocnemius is significantly higher than those subjects, 
suggesting that increased muscle strain may be a contributing factor.  In any case this 
mild STIR hyperintensity in the gastrocnemius needs to be recognised as part of the 
spectrum of findings in normal individuals.  The finding of STIR hyperintensity did not 
correlate with fat fraction, again supporting that these measures of abnormal water 
distribution are able to show differences in muscle composition independent of fat 
infiltration. 
3.5.4 Muscle size measurements 
3.5.4.1 Cross-sectional muscle area 
Muscle size measurements, although not the focus of this work, are of interest in order 
to quantify muscle atrophy in patients.  As whole muscle volumes were not imaged, 
only cross-sectional muscle areas could be calculated in this study.  However, other 
work has shown very strong correlations between cross-sectional area measurements 
and whole muscle volumes (Miokovic et al., 2012).  
3.5.4.1.1 Variation between muscles 
Cross-sectional area measurements come with the same difficulties present in strength 
and neurophysiology assessments, i.e. marked between-muscle variation.  However, 
as MRI can quantify the size of individual muscles, for example is able to quantify the 
size of medial gastrocnemius, lateral gastrocnemius and soleus separately, MRI 
provides greater anatomical specificity than myometric assessment of ankle 
plantarflexion, or neurophysiology assessment of the motor function of the tibial nerve.  
Thus MRI may be able to demonstrate focal atrophy in patients and is size parameters 
are worthy of assessment in patient studies. 
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3.5.4.1.2 Variation between subjects 
There was significant inter-subject variation in gender, age and weight with predictable 
influence of these demographic parameters upon muscle area.  The mean±SD total 
cross-sectional area of thigh muscles was 227±51cm2 and of calf muscles was 
121±25cm2.  The variation between subjects of the measured size of an individual 
muscle was even greater with a standard deviation of on average 30% of the mean 
CSA.  Much of this variation could be explained on the basis of subject age, weight and 
gender.  There was significant positive correlation with weight at both thigh and calf 
level (+1.5cm2/kg thigh, +0.8cm2/kg calf).  Overall females had cross-sectional area 
52cm2 lower in the thigh and 23cm2 lower in the calf than males independent of the 
effects of age and weight which were included as covariates.  There was also a 
significant negative correlation with age at thigh level (-1.4cm2/year), but interestingly 
the correlation at calf level was not significant. 
These results are consistent with a large body of literature on the effects of aging on 
muscle strength, and in keeping with a longitudinal CT study which showed a 
0.8%/year reduction in thigh muscle cross-sectional area (Delmonico et al., 2009).  An 
MRI study of calf muscle volume did show a 1.7%/year decline in calf muscle size over 
10 years.  This involved a smaller number of healthy volunteers, and did not control for 
changes in weight with age, but as a longitudinal study is a direct measurement of the 
change with age.   It therefore seems very likely that measurements of muscle size 
would be significantly confounded by the effects of ageing in longitudinal studies. 
Levels of physical activity were not recorded in the present work so were not included 
in the regression analysis.  However, it is well established that training increases 
muscle size, and it has been established with MRI that immobility reduced muscle size, 
so activity level is a significant additional confounder to longitudinal studies using 
muscle size as an outcome measurement. 
3.5.5 Reproducibility 
The inter-scan limits of agreement provide a measure of sensitivity to detect 
meaningful change; e.g. for the thigh level, a change in the overall mean measures in 
FF, T2, T1 or MTR of +0.28%, +1.8ms, -39ms or -1.63p.u. is a significant change at the 
95% level for an individual subject.  Rates of change of these with specific NMD 
progression will be confirmed in future natural history studies, but the detectable 
change thresholds our data suggest are small compared with cross-sectional disease-
dependencies (Gloor et al., 2011; Hiba et al., 2012; Huang et al., 1994; Phoenix et al., 
1996; Sinclair et al., 2012a) and are in the range of one-year changes in 
oculopharyngeal muscle dystrophy (Fischmann et al., 2012). 
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3.5.5.1 Reproducibility of measures of intramuscular fat accumulation 
Fat fraction measurements showed excellent test-retest reliability.  The limits of 
agreement for the different quantitative parameters listed in Table 3-6 and Table 3-7 
can be interpreted as the minimum apparent change which could be considered true 
change rather than measurement error in a longitudinal study, whether natural history 
or interventional.  For example, an increase in the overall mean of thigh fat of greater 
than 0.29% would be considered significant, whereas for an individual thigh muscle 
ROI an increase of greater than 1.03% would be considered significant.  These values 
are low enough that a significant change in a measurement such as mean fat fraction 
might be detectable over a single year in a single patient, something which is not 
possible with any other current outcome measures in a disease such as CMT1A.  
Reliability measures for a single muscle are generally lower as would be expected, but 
still sufficiently accurate to reliably distinguish between degree of involvement in 
different muscles and detect change longitudinally with slightly higher rates of change. 
These figures necessarily apply to the low levels of intramuscular fat seen in the 
healthy volunteers of this study, but indicate small changes in muscle fat can be 
detected with the three-point Dixon technique.  In an interventional study, the greater 
number of subjects in each group decreases the difference that would be statistically 
significant for the group as a whole and these data may be used to aid in sample size 
calculations. 
These results demonstrate that quantitative MRI has excellent reliability and a tight 
range of values in healthy volunteers so is an excellent candidate outcome measure in 
NMD.  Previous studies have examined the inter-observer or intra-observer reliability 
by repeating their analysis on the same set of acquired images (see 3.2.4) but this is 
the first study to assess test-retest reliability of quantitative MRI parameters in muscle 
across separate scanning sessions.  Test-retest reliability is of primary relevance to 
interventional studies where the outcome measure is generally expressed as a change 
from baseline to follow-up, and any measurement error will mask any genuine 
treatment effect. 
Inter-scan differences exceeded inter-observer differences as a source of variation, the 
former potentially driven by small scan-scan position inconsistencies. Compliance with 
a predefined positioning protocol could improve scan-scan consistency (Fischmann et 
al., 2014). Mean all-muscle summary measures provide superior reliability to individual 
muscle measures, an approach which would be appropriate in NMD with diffuse rather 
than specific muscle involvement. 
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3.5.5.2 Reproducibility of water sensitive measures 
As for fat infiltration quantification, the MRI sequences expected to be sensitive to 
pathological changes in water distribution — T2 mapping and magnetisation transfer 
imaging — showed good inter-scan reliability in this study.  A two-week interval 
between test-retest scans was chosen here to encompass any short-term physiological 
variation in these parameters which would potentially confound detection of long-term 
changes in a longitudinal study.  Previous studies (see 3.2.2.1) have demonstrated that 
T2-relaxation times, muscle volumes and magnetisation transfer all increase following 
exercise of muscles to exhaustion, however this effect was already reducing 10 
minutes after exercise.  Furthermore, other studies failed to show significant difference 
in either children with dermatomyositis or healthy volunteers 0, 30 or 60 minutes 
following a standard exercise session (Maillard et al., 2005). 
The subjects undergoing the test-retest reliability assessments were not specifically 
instructed to rest or otherwise prior to scanning, but still had excellent test-retest 
reliability of T2 measurements, with limits of agreement on repeat assessment for the 
overall mean in calf or thigh of about 2ms.  Together with the published literature this 
suggests that only repetitive loading of individual muscles has a significant effect on 
quantitative MRI parameters and that this effect is short-lived.  Therefor while it may be 
sensible to follow the same testing protocol on repeat assessments with regard to 
timetabling of strength testing and MRI scan, ordinary physical activity should not have 
a detrimental effect on the reliability of the quantitative MRI assessment. 
Factors such as recent exercise (Ababneh et al., 2008; Ploutz-Snyder et al., 1997) or 
diet (Tamura et al., 2008), known to influence muscle T2 and fat content respectively, 
were not explicitly controlled. Nevertheless, the high reproducibility and sensitivity to 
subtle demographic dependencies demonstrated suggest that in practice such 
variations may be low, an observation that is important for experimental trials where 
such factors may be hard to control.  
3.5.5.3 Inter-observer reliability 
Results from different assessors are prone to systematic bias due to differences in 
exact strategies for ROI placement; for the small ROI this was due to placement 
relative to areas of artefact, whilst for the large ROI this was due to decisions regarding 
inclusion or exclusion of voxels at muscle boundaries.  Inter-observer reliability is likely 
to be worse in patients than in healthy controls due to the heterogeneous distribution of 
pathology.  The practical implications of this are that within a single study a single 
observer should do all ROI if possible.  If this is not practical, there should be precise 
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instructions as to ROI definition with a phase of training to ensure inter-observer 
consistency. 
In a longitudinal study where change in a measurement over time is the primary 
outcome, a single observer should do all ROI definitions for the same subject, with 
direct comparison to the initial ROI placement to ensure the same volume of muscle is 
assessed at both time points.  This ROI placement should occur blinded to time-point 
to eliminate possible bias. That is, the observer should have a series of acquisitions to 
define ROI which are all from the same subject, but without any information included 
which identifies scan order or interval. 
3.5.5.4 Methods to optimise reliability 
Whilst inter-scan reliability here was good, it is worth considering potential sources of 
the variation seen, and considering if measurements could be improved with 
optimisation of these.   
3.5.5.4.1 Predictable physiological differences during the inter-scan 
interval 
Examples include recent and long-term diet, training, physical activity immediately prior 
to scanning, temperature, time of day.  Of note, none of these were specifically 
controlled for in our healthy subjects who underwent repeat scanning, though none 
would have undertaken significant exercise in the hour prior to scanning.  Other studies 
suggest that acute changes in muscles following exercise return to baseline within 30 
minutes, whilst changes in diet may have an effect on intramyocellular lipid content, 
which makes only a small contribution to total muscle fat fraction.  Further studies 
which quantify these effects or assess whether reliability is improved through 
controlling these variables would be of interest.  Certainly in the context of a clinical trial 
where strength or aerobic assessments are part of the clinical protocol, it would be 
preferable for the MRI to occur before these assessments, or after a significant rest 
period. 
3.5.5.4.2 Random physiological variation 
There is likely to exist true variation in measurements which cannot be predicted or 
modelled, and therefore cannot be eliminated. 
3.5.5.4.3 Differences due to differences in subject positioning 
This will cause anatomical distortion due to muscle deformation and was qualitatively 
evident during the reliability phase of the study, most commonly due to the 
gastrocnemius being displaced by the scanning table to different degrees.  Due to the 
orientation of the lower limbs within the scanner, the majority of distortion will be within 
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the axial plane whereby it should be possible for ROI on repeat scanning to be defined 
to contain an equivalent volume of tissue; however it is a source of variability avoidable 
through a precise subject positioning protocol.  This was investigated in collaboration 
with a visiting radiologist, and the reader is directed to this publication for more 
information (Fischmann et al., 2014).  An alternative way to compensate for this is to 
acquire and analyse whole muscle volume. 
3.5.5.4.4 Differences due to slice positioning 
Qualitative imaging studies have demonstrated that muscle abnormalities are not 
uniform along the length of a muscle – not surprising considering the typical clinical 
findings of distal predominant weakness in neuropathies and proximal predominant 
weakness in myopathies.  It is therefore apparent that if analysis is undertaken of a 
single slice, as in this thesis, ensuring that this slice is at the same proximal-distal 
location is critical to reliability. The critical aspect here is in the acquisition, where it is 
vital that at least one sequence includes clear bony landmarks such as the knee or 
ankle joint so that slice location on baseline and follow-up scans can be determined 
with reference to this point.  It was fortuitous in this study that one of the sequences 
which was part of the MTR acquisition included a field of view which encompassed the 
knee joint, and that inter-slice distance for this sequence was 5mm rather than the 
20mm distance for most of the other sequences.  Because of variability in the 
reproducibility of surface anatomy-based positioning as used for the acquisitions in this 
study (see 6.1.3.2), we selected slices for analysis based on a combination of visual 
inspection for equivalent anatomy and calculated distance of slices from knee joint (see 
2.6.2).  We investigated the relative accuracy of surface anatomy versus fixed distance 
from scout image in collaboration with a visiting radiologist, and the reader is directed 
to the same publication for more information (Fischmann et al., 2014).  In future 
studies, we employed and recommend timproved positioning and slice localisation 
methods together with reducing inter-slice distance to no more than 10mm to improve 
these aspects of reliability. 
3.5.5.4.5 Differences due to scanner field strength, manufacturer, model, 
coil, software, exact sequence parameters 
All of these parameters can and do affect quantitative measurements to some degree.  
In this healthy control reliability study performed over a two-week interval, there were 
no such changes, but in follow-up studies of longer duration, this can introduce 
significant systematic bias, which was indeed noted in T2 measurements in this project 
following a software upgrade towards the end of the baseline patient scanning phase 
(see 2.4.4.3.1).   Multicentre trials are likely to take place using scanners from multiple 
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manufacturers, and it is important that rigid processes to ensure cross-site 
standardisation are employed.  We have successfully applied this using fat fraction 
assessment across four sites in LGMD2I (Willis et al., 2014).  Other researchers have 
recently published quantitative MRI protocols for boys with DMD standardised across 
multiple sites (Forbes et al., 2014).  Ultimately however, for an outcome measure it is 
the longitudinal change measurement which is most critical.  Taking the example of a 
weight loss intervention study, a systematic difference in scales between sites of 2kg is 
of less importance if each subject uses the same scales throughout the study.  Similar 
MRI trials may be designed so that all assessments for an individual participant occur 
at the same study site, but consideration must be given that one of the factors above 
may change during the course of the study beyond the control of investigators.  It is for 
this reason that for natural history studies the inclusion of healthy controls is critical, 
whilst in clinical trials the placebo arm together with adequate randomisation and 
blinding will mitigate against any systematic bias which may otherwise occur following 
for example a scanner software upgrade.  It is worth noting also that some methods 
such as the three-point Dixon method are likely to be more robust in the face of such 
alterations, and a more sophisticated T2 mapping method, using 16 echoes for 
example, may be more robust than the dual-echo method employed in this study. 
3.5.5.4.6 Differences due to image post-processing/map generation 
This should not have been an issue in this study as all post-processing occurred using 
the same algorithms at the same time (Dr Sinclair, acknowledgements).  However, in 
multi-centre studies centralisation of these aspects to a single site would eliminate any 
variability related to this.  If this is to occur locally, procedures will be required to ensure 
this step does not introduce systematic bias between study sites, as always most 
crucially the process should be identical for multiple scans of the same participant. 
3.5.5.4.7 Differences due to selection of slice for analysis 
As discussed above (3.5.5.4.4), this is crucial due to proximal-distal gradients of 
pathology within muscle.  Ideally the scanning will be acquired with the image blocks 
centred in the same position, but if this did not occur, as long as the slices obtain 
overlap, a slice common to test and retest scans can be chosen for analysis post-
acquisition.  How closely these will correspond will depend on the inter-slice distance 
(half this distance will be the maximum proximal-distal distance between baseline and 
follow-up slices), and how accurately slice location can be determined.  In future 
studies we have utilised at most a 10mm inter-slice distance and where possible a 
5mm slice distance, and further analysis of this latter “3D Dixon” data set will be able to 
analyse the effect of these different methods in detail. 
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3.5.5.4.8 Region of interest definition within the slice 
As this work shows, there is variability introduced by different observers drawing 
regions of interest on identical images.  Other studies have examined intra-observer 
reliability and found this to be superior to inter-observer reliability.  To maximise 
reliability, one observer should be used wherever possible, certainly for longitudinal 
assessments within a single subject.  If whole muscle ROI are utilised, clear rules with 
regard to defining ROI boundaries are important, for example are only voxels 
appearing to wholly lie within the fascia included, or should voxels with at least 50% 
volume within the fascia be included.  The choice will depend on the sequence and 
research question, but consistency is important.  For some muscles such as the 
hamstrings, the inter-muscular boundary is indistinct – and in case of the portions of 
the vasti, arbitrary.  If individual muscle ROI are drawn, it is important to be able to 
draw ROI with direct comparison to the other ROI in the same subject to ensure 
consistent decisions are made with regard to anatomy. 
3.5.5.4.9 Extraction of data from ROI and subsequent data processing 
Once maps are created and ROI are defined, the data extraction is an automated 
process.  There does however need to be a process where maps are checked for 
artefact within the ROI so that these values can be excluded.  The data may then 
require transfer to a platform which allows analysis.  As far as possible these 
processed should be automated – and certainly not involve manual data transcription 
which may introduce transcription errors.  Finally, there should be a process to cross-
check the final data set back to the original data in the case of outliers and also of a 
random sample to make sure there are no analysis/processing errors which could have 
a major effect on reliability. 
3.5.5.4.10 Optimising reliability summary 
Optimising reliability necessarily involves consideration of all the above potential 
sources of measurement variability in a systematic way and eliminating or reducing 
each of them as far as possible.  Additional variation in longitudinal change introduced 
by poor test-retest reliability will increase the standard deviation in the change 
measurement, resulting in a significant reduction in outcome measure responsiveness, 
critical to study power. 
3.5.6 Feasibility/Study limitations 
To facilitate widespread applicability, sequences were chosen to be readily 
implemented on standard scanner hardware and software, and with which 
comprehensive anatomical coverage in a practical examination time was possible.  
This necessarily limited the measurement sophistication, e.g. multi-echo T2 
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measurement sequences allowing analysis of multiple T2 decay components (Ploutz-
Snyder et al., 1997) did not meet the requirements of ready availability and anatomical 
coverage vs. acquisition times. However, we showed that these sequences chosen are 
adequate to provide sensitive and reproducible measures of FF, T2 and MTR relevant 
to muscle pathology. 
A limitation of quantitative MRI in the legs is the inherent B1 inhomogeneity, particularly 
at field strengths of 3T and higher. While the dual-contrast TSE T2-relaxometry 
sequence and Dixon FF measurements were reasonably robust to this, MTR and T1-
relaxometry data were more affected despite our adoption of B1-correction strategies.  
Nevertheless, MTR proved highly sensitive to age, weight and gender dependencies, 
although the B1 correction proved insufficient for meaningful T1 and MTR quantification 
in regions of maximum B1 deviation: worse anteriorly in the right thigh using our 
scanner-coil configuration.  With the methods used, T1 was the least reproducible 
measure, the least sensitive to demographic variations, and did not add explanatory 
power for these factors. While this low sensitivity may reflect B1-related measurement 
error rather than fundamental insensitivity, we conclude that muscle T1 may not be 
useful as a NMD outcome measure.  
It should be noted that T1, T2, FF and MTR values may be partially method 
implementation dependent and the values presented here cannot be considered an 
absolute reference range if alternative methods, scanner platforms or field strengths 
are used, and multi-centre patient trials should confirm inter-centre value comparability 
during study initiation. 
 Conclusions 
These data demonstrate significant strengths of quantitative MRI as an outcome 
measure in neuromuscular diseases.  We have shown tight range of normal values, 
minimal variation with subject demographics and excellent test-retest reliability.  The 
data also reveal normal variation between muscles of fat fraction and T2 relaxation 
times which correlate with qualitative T1 and STIR assessments and should be taken 
into consideration when making these assessments. 
There are of course a number of different quantitative methods (see Table 1-1) to 
measure fat infiltration in muscles which have already been applied to neuromuscular 
diseases, including T1 measurement, measurements based on T2 mapping, proton 
spectroscopy, a dual-echo dual-flip-angle spoiled gradient-recalled MR imaging 
technique, as well as those based on the Dixon technique such as this thesis.  All of 
these techniques have shown good correlation to clinical markers of severity, muscle 
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strength and muscle biopsy, which demonstrates validity as an outcome measure (see 
4.2.4). 
Similarly, there are variations in methods to measure T2 relaxation time, with the 
method chosen here using two echo times theoretically less precise than those utilising 
a greater number of echo times.  However, value as an outcome measure should be 
judged upon validity, reliability and  responsiveness (Kirshner and Guyatt, 1985) 
balanced against practicality in terms of scan duration, hardware and software 
requirements and time taken for analysis.  The protocol presented here is intended to 
be able to quantify both early changes of abnormal water distribution which would be 
potentially responsive to intervention and also the progressive changes of fatty 
infiltration to demonstrate reduced progression of disease in a clinical trial, while also 
being practical to implement and analyse on standard MRI hardware in a reasonable 
length of time.  This quantitative neuromuscular MRI protocol was considered 
appropriate to progress to use in cross-sectional (chapter 4) and longitudinal (chapter 
5) studies in patients. 
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4 Cross-sectional quantitative MRI in neuromuscular disease 
 Introduction 
Cross-sectional patient studies are the crucial second step of outcome measure 
development.  The measurement needs to be shown to be sensitive to “abnormallty”, 
that is significantly different in patients than in controls.  Distinguishing subjects with 
disease from healthy subjects is key for measurements undertaken for diagnostic 
purposes, and determines the sensitivity of a diagnostic test.  Specificity, which is 
distinguishing patients with one disease from those with another, is also very important 
in diagnostic tests, however is a less important quality for outcome measures.  Indeed, 
measurements being consistently abnormal across multiple diseases may be seen as 
an advantage since this allows these measurements to be applied as outcome 
measures across many diseases, in comparison with a disease-specific measure which 
is necessarily limited in its application.  
4.1.1 Validity 
An abnormal measurement however is insufficient for an outcome measure; it must 
also be shown to have validity.  Direct measures of mortality or morbidity are preferred 
by regulatory bodies such as the FDA but “surrogate” outcome measures are allowed 
in some circumstances.  Surrogate outcome measures are most often used as an 
intermediary endpoint, for example anti-hypertensive medications may now be licensed 
on a blood pressure lowering endpoint, which has been extensively shown to have 
long-term benefits in reduction of mortality from cerebrovascular and cardiovascular 
disease.  To be accepted as a surrogate, the biomarker must be shown to have a 
critical role in pathogenesis.  For example, deoxysphingolipid levels are elevated in 
Hereditary Sensory Neuropathy type 1 (HSN1) caused by mutations in serine palmityl 
carnitine transferase.  Treatment with serine has been shown to reduce plasma 
concentrations of deoxysphingolipids (Garofalo et al., 2011), but it remains to be shown 
that this translates to patient benefit. 
Muscle MRI cannot be considered a “true” outcome measure as it is not a direct 
measure of patient mortality or morbidity.  However, neither is it a surrogate outcome 
measure in the usual sense, as it is not intended in general as a predictor of future 
morbidity or mortality, but rather as a more reliable and sensitive measure of current 
morbidity than direct measures of function.  A similar example might be measurement 
of spirometry parameters such as FEV1 in chronic obstructive pulmonary disease (Ben 
Saad et al., 2008).  This is a highly relevant functional measure with established 
correlations to exercise tolerance and hospital admissions, both of which are direct 
morbidity measures.  However, if FEV1 can be more reliably measured than a six-
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minute walk test due to greater test-retest reliability it would prove a more sensitive 
outcome measure.  Usually such “proxy” outcome measures would be utilised as 
primary outcome measures in phase 2 clinical trials, or secondary outcome measures 
in phase 3 clinical trials.  However, they might be accepted by regulatory bodies as a 
primary outcome measure in a phase 3 trial through an orphan drug programme. 
Validity is simply defined as the degree to which an instrument measures what we 
intend it to measure (Roach, 2006). In the present context this means the degree to 
which our MRI measurement is an accurate measurement of disease severity, and 
longitudinally of disease progression.  If we wish the outcome measure to be 
considered as evidence for drug licensing, validity should be with reference to patient 
function (or survival), but for phase 2 clinical trials, validity with reference to disease 
severity may be adequate.   Validity is not an inherent characteristic of the 
measurement instrument itself and can be determined only in relation to a particular 
question in a defined population (Roach, 2006).  For example, fat accumulation may be 
a valid measure of disease severity in skeletal muscle or the liver, but not in cardiac 
muscle or the brain.  Even for skeletal muscle IFA may be a valid measure of disease 
severity in some neuromuscular diseases but not others.  Finally, for a particular 
neuromuscular disease such as Duchenne muscular dystrophy, MRI measured IFA 
may be a valid measure for a long term intervention such as gene therapy, but not valid 
for short term assessment of the same intervention. 
There are many dimensions in which validity can be considered and demonstrated 
(Kirshner and Guyatt, 1985; Roach, 2006).  Face validity is the extent to which a test 
appears to measure what it is intended to measure.  As measures of IFA, three-point 
Dixon fat quantification would have superior face validity than T1-mapping, since it is a 
direct attempt to measure the underlying disease process.  Content validity is the 
degree to which a test includes all the items necessary to represent the concept being 
measured.  This differs by population: for example, it may be that in some diseases 
muscle atrophy is the primary cause of weakness whilst in another it is intra-muscular 
fat accumulation.  However, if both processes are involved a measure which 
incorporates both would have greater content validity.  Similarly, a measure like T2 
which is sensitive to both acute and chronic pathology may have higher content validity 
for overall disease severity.  Face and content validity cannot be directly examined 
experimentally, and are therefore considered by some as lower levels of validity 
(Roach, 2006). 
Criterion and construct validity can be examined experimentally.  For criterion validity, 
outcome measure validity is tested by comparing the results of the outcome measure 
to a gold standard or criterion test (Kirshner and Guyatt, 1985).  In the case of 
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neuromuscular disease, patient function is the gold standard for treatment efficacy.  
Correlation to strength measurements would be another example of a means to assess 
criterion validity of quantitative MRI.  Construct validity reflects the ability of a test to 
measure the underlying concept of interest to the researcher (Roach, 2006).  This can 
be assessed with the known groups method, by assessing if the measurement differs 
in groups known to differ in construct of interest.  The simplest assessment here is to 
compare measurements in a patient group to a healthy control group, although 
comparing results between different patient groups would also provide construct 
validity.  Construct validity can also be assessed by looking for convergent validity.  
This is demonstrated when results of the test being examined are highly correlated to 
results of a test thought to measure similar or related concepts.  For neuromuscular 
MRI this might be assessed by comparing the measurements from novel quantitative 
MRI methods to those obtained with the established qualitative MRI methods.  For 
example, quantitative fat quantification using three-point Dixon could be compared with 
Mercuri grading of qualitative T1-weighted sequences. 
A cross-sectional study including more than one patient group and matched controls, 
including novel and established MRI measures, and including additional clinical 
measures of disease severity and function, provides ideal data to assess outcome 
measure validity. 
 Background literature 
4.2.1 Qualitative MRI studies in CMT1A/IBM 
With the exception of the pilot study from our Centre of the magnetisation transfer ratio 
of calf muscle in patients with CMT1A (Sinclair et al., 2012a), there are no previous 
quantitative muscle MRI publications in CMT or IBM.  Publications reporting the 
appearances of lower limb muscles using qualitative MRI sequences are relevant in 
predicting the distribution and type (acute vs chronic) of pathology present, and 
therefore ensuring that the quantitative sequences applied are likely to adequately 
cover the pathology present.  In this way qualitative MRI may be considered the 
precursor to a quantitative study, and we have used qualitative MRI in studies 
performed concurrently to this thesis in diseases not previously studied with muscle 
MRI: non-dystrophic myotonia (Morrow et al., 2013) and congenital myasthenic 
syndromes (Finlayson et al., 2016).   
4.2.1.1 Published reports in CMT1A 
There are six published papers regarding the lower-limb muscle appearance on 
qualitative MRI in CMT1A (Berciano et al., 2008, 2010; Chung et al., 2008; Gallardo et 
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al., 2006; Kim et al., 2015; Pelayo-Negro et al., 2014) reporting a total of 69 patients.  
These studies have all included T1w images, and report with this sequence a distal 
predominant accumulation of intramuscular fat in the lower limbs, consistent with the 
clinical phenotype.  In the mildest patients, calf musculature is normal with only foot 
musculature affected (Berciano et al., 2008; Gallardo et al., 2006).  In the most severe 
patients, calf musculature shows end stage changes with near complete fat 
replacement of calf muscles.  In subjects with an intermediate clinical severity and calf 
involvement on MRI, there is a predilection to the anterior and lateral compartments 
with a distal gradient of involvement within these muscles (Chung et al., 2008; Gallardo 
et al., 2006).  Only one study included sequences sensitive to acute denervation (T2-
weighted and GAD), which showed acute changes in a subset of the subjects (Gallardo 
et al., 2006). 
Taken together these studies would predict that the calf musculature would be the most 
informative scanning area in CMT1A patients overall, although in severely affected 
patients the thigh musculature and in mildly affected patients the foot musculature, may 
prove more helpful.  Sequences sensitive to fat infiltration are confirmed by all studies 
to be likely to be informative, whilst one study shows qualitative sequences sensitive to 
abnormal water distribution are abnormal in a subset of patients, which may also be 
worthy of quantitative assessment. 
4.2.1.2 Published qualitative MRI reports in IBM 
Five studies have reported qualitative MRI in skeletal muscle of IBM patients (Cantwell 
et al., 2005; Cox et al., 2011a; Phillips et al., 2001; Reimers et al., 1994; Sekul et al., 
1997), the largest of which enrolled 32 patients (Cox et al., 2011a). A selective pattern 
of muscle involvement has been reported, where similar to the clinical distribution of 
weakness, there is preferential intramuscular fat accumulation of flexor digitorum 
profundus within the forearm (Cantwell et al., 2005; Cox et al., 2011a; Phillips et al., 
2001; Sekul et al., 1997); with quadriceps predominantly affected in the thigh (Cox et 
al., 2011a; Phillips et al., 2001; Reimers et al., 1994).  Some authors report relative 
preservation of rectus femoris within the quadriceps (Cox et al., 2011a; Phillips et al., 
2001). Within the lower leg, the medial head of the gastrocnemius has maximal 
intramuscular fat accumulation (Cox et al., 2011a; Phillips et al., 2001; Reimers et al., 
1994); a feature hidden clinically because the soleus and the lateral gastrocnemius 
with lesser involvement compensate in ankle plantarflexion strength.  STIR sequences 
have been performed in three studies with hyperintensity reflecting active inflammation 
commonly seen, but in a smaller number of muscles than are affected by fat 
accumulation (Cantwell et al., 2005; Cox et al., 2011a; Sekul et al., 1997). 
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These publications suggest that both fat and water quantitative MRI sequences will be 
of interest in IBM patients, with both thigh and calf musculature in the lower limbs likely 
to be involved, though the thigh involvement may be functionally relevant in a greater 
proportion of patients. 
4.2.2 Studies of quantitative MRI in neuromuscular diseases 
Although there is a paucity of previous literature on quantitative MRI in CMT1A and 
IBM, there is an increasing literature in a range of other neuromuscular disorders.  The 
first assessment should be whether the measure is abnormal in patients versus the 
healthy population. 
4.2.2.1 Quantitative MRI measures of chronic muscle pathology 
A number of studies have used MRI to quantify chronic muscle damage in 
neuromuscular disease.  Pathologically chronic muscle damage whether due to 
primary muscle disease or denervation results in atrophy, fat infiltration and fibrosis of 
muscle to varying degrees.  Whilst any MRI sequence can measure muscle size, those 
with highest resolution and best tissue contrast, especially for fascial boundaries, will 
do so most accurately.  There are a number of fat quantification methods, as discussed 
in chapter 3, whilst a robust way to quantify muscle fibrosis with MRI remains elusive. 
Some investigators have used a semi-quantitative method to estimate fat infiltration 
where a standard qualitative T1w sequence is segmented based on signal intensity – 
as fat as higher signal intensity than healthy muscle.  This allows calculation of residual 
muscle volume, fat-infiltrated muscle volume, total muscle volume and hence the 
percentage of muscle which is fat infiltrated.  This has been performed in myotonic 
dystrophy (Hiba et al., 2012), DMD (Torriani et al., 2012) and spinal muscular atrophy 
(Sproule et al., 2011a) and demonstrated abnormalities compared with controls (Hiba 
et al., 2012; Torriani et al., 2012) or between patient subtypes (Sproule et al., 2011a).  
The potential advantage of this method is the easy availability of a T1w sequence on 
any scanner, but as the resultant signal intensities are relative, standardisation across 
different platforms is difficult.  B0 field inhomogeneity, especially at higher field 
strengths (3T), confounds analysis; the method relies on presence of normal muscle as 
a reference which may not be available in more severely affected patients, and the 
binary result for each voxel (normal/fat) may reduce sensitivity if fat infiltration is 
diffuse.  Some of these issues may be addressed by estimating the underlying T1 
recovery time – i.e. T1 mapping.  This was applied to DMD in 1994 (Huang et al., 
1994), but subsequent studies have preferred other methods of fat quantification. 
T2 relaxation time is significantly greater for fat than healthy muscle, meaning muscle 
T2 measurement is also a potential surrogate measurement for fat infiltration.  Whole 
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tissue T2 (i.e. without any attempt at separation or suppression of the fat signal) has 
been shown to be elevated initially in a mixed population of muscular dystrophies 
(Phoenix et al., 1996), and subsequently in oculopharyngeal muscular dystrophy (Gloor 
et al., 2011), DMD (Huang et al., 1994; Kim et al., 2010a; Triplett et al., 2014), and 
Bethlem myopathy (Triplett et al., 2014).  One of the disadvantages of T2 
measurement is that T2 is also influenced by changes in muscle water (e.g. 
inflammation or acute denervation), and indeed has been used to measure this effect in 
juvenile dermatomyositis (Maillard et al., 2004b).  By utilising a larger number of echo 
times in T2 modelling, a bi-exponential fit can be calculated, which allows an estimation 
of contribution to T2 relaxation of fat and water components, and thence a fat fraction 
to be calculated.  This has been applied to patients with FSHD (Kan et al., 2009). 
The three-point Dixon fat-water separation method is the most commonly used 
technique of fat quantification, and has been used to show increased fat content versus 
healthy controls in myotonic dystrophy (Hiba et al., 2012), oculopharyngeal muscular 
dystrophy (Gloor et al., 2011), Duchenne muscular dystrophy (Triplett et al., 2014; 
Wren et al., 2008), Bethlem myopathy (Triplett et al., 2014) and in LGMD2I (Willis et 
al., 2014).  Many of these studies have been multi-centre, proving the method robust to 
use across different sites and platforms. 
Another common but not universal feature of chronic muscle disease is reduction in 
muscle size – atrophy.   This can be assessed with almost any MRI sequence but there 
are some difficulties in its application.  Two main approaches are possible: 
measurement of a whole muscle (or limb) volume, or measurement of muscle cross-
sectional area.  The former is labour intensive unless automatic segmentation protocols 
are developed, and the definition of muscle boundaries at their proximal and distal 
ends may be challenging, whilst the latter is dependent upon exact positioning in the 
superior-inferior direction and can be affected by tissue deformation (Fischmann et al., 
2014).  Within neuropathies, volumetric assessment has been applied to foot muscles 
in diabetic neuropathy (Andersen et al., 2004) and differences in total muscle volume 
have been shown in SMA (Sproule et al., 2011a).  In muscle diseases  differences in 
total muscle volume or CSA are less marked with no significant difference seen in CSA 
of calf muscles in mixed NMD (Phoenix et al., 1996), DMD (Torriani et al., 2012; Wokke 
et al., 2014) and myotonic dystrophy (Hiba et al., 2012), although residual muscle 
volume measured using some method of fat quantification above is reduced.  The other 
difficulty in using size-based measurements as outcome measures is the confounding 
effects of age, gender and physical activity/inactivity – which are common of course to 
direct strength measurements. 
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Overall these studies demonstrate that MRI measures sensitive to intramuscular fat 
accumulation are abnormal in patients with a broad spectrum of neuromuscular 
diseases.  Results from MRI measurement of muscle size are more varied, but are also 
significantly different to controls, especially in neuropathies. 
4.2.2.2 Quantitative measures of acute muscle pathology in 
neuromuscular diseases 
There are overall fewer studies which have attempted to quantify acute pathology in 
neuromuscular diseases.  Measures of abnormal muscle water distribution are 
confounded by the effect of fat: T2 is increased in acute denervation and acute muscle 
inflammation but even more so with fat infiltration; similarly MTR is reduced in acute 
pathology, but near zero in fat tissue.  The situation is analogous to qualitative imaging 
where a fat suppressed T2 weighted sequence such as STIR is used to separate acute 
from chronic muscle pathology.  A semi-quantitative STIR method using a saline 
phantom as reference has been used to evaluate abnormal muscle water distribution in 
hypokalaemic periodic paralysis (Jurkat-Rott et al., 2009), whilst studies of focal 
neuropathies have used nearby healthy muscle as an internal reference. 
Other authors have utilised quantitative methods.  In myotonic dystrophy type 1, the T2 
of “residual muscle tissue” segmented based on T1w voxel signal intensity, showed 
increasing tibialis anterior muscle T2 values with increased disease severity (control T2 
42.4ms vs 49.9ms, 59.7ms 92.0ms for mild/moderate/severe patient groups)(Hiba et 
al., 2012).  Thigh muscle T2 was also found to be greater in children with active 
juvenile dermatomyositis than children with inactive disease or healthy children (~85ms 
vs ~80ms, p<0.05).  No method to account for the presence of fatty infiltration was 
employed, although the significant difference between patients with active and inactive 
disease is notable (Maillard et al., 2004a).  More recently, T2 has been quantified in 
using T2 mapping with fat suppression in a very large cross-sectional study of boys 
with Duchenne muscular dystrophy – this showed increase “water-T2” in lower limb 
muscles which reduced with increasing age as fatty infiltration increased (Forbes et al., 
2014). 
Two studies have examined the magnetisation transfer ratio of muscle in 
neuromuscular diseases: an early study in patients with limb girdle muscular 
dystrophies (McDaniel et al., 1999) and a pilot study performed at our centre in patents 
with CMT1A and CIDP (Sinclair et al., 2012a).  In both these studies MTR was reduced 
in muscles appearing normal on qualitative imaging, suggesting an early disease 
marker.  Quantitative MT may be performed to model magnetisation transfer effects 
and derive the underlying parameters such as the restricted proton pool fraction 
(Sinclair et al., 2010), but these methods take significantly longer than methods to 
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estimate the magnetisation transfer ratio.  Overall, both T2-relaxometry and 
magnetisation transfer imaging show promise as tools to probe abnormal muscle water 
distribution, and merit further study. 
4.2.3 Correlation between MRI parameters 
4.2.3.1 Quantitative vs qualitative 
In DMD, Kim and colleagues showed strong correlation between T1w fat infiltration 
score and T2 time within gluteus maximus (p<0.001)(Kim et al., 2010a).  Willis and 
colleagues showed overlapping sequential ranges of fat fraction corresponding to 
qualitative Mercuri T1w grades (Willis et al., 2014).  In DMD, Wokke and colleagues 
showed strong correlation between Dixon method measured fat fraction and T1w 
qualitative assessment in patients with DMD, with a tendency of the qualitative 
assessment to over-estimate fat fraction (Wokke et al., 2013). 
4.2.3.2 Quantitative vs quantitative 
A number of studies have compared a variety of quantitative MRI parameters and have 
without exception shown strong correlation.  Triplett and colleagues showed strong 
positive correlations between muscle T1, T2, chemical-shift fat fraction and MRS fat 
fraction in a mixed group of DMD and Bethlem myopathy patients and controls (Triplett 
et al., 2014).  Three fat estimation methods (2-point Dixon, T2 mapping, steady-state 
free precession) were highly correlated in oculopharyngeal muscular dystrophy (Gloor 
et al., 2011).  T2 measures and 2-point Dixon showed fewer outliers in the correlations 
so were thought to be superior.  Overall, it is clear that there is significant 
interdependence of T1 time, T2 time related to tissue fat fraction. 
4.2.4 Correlation with clinical parameters 
4.2.4.1 Strength 
Prior to the commencement of this study, there were few publications correlating MRI 
measurements with patient strength, but such studies have recently exploded in 
number.  Some qualitative studies have shown a correlation between muscle strength 
and T1w MRI appearance, for example in myotonic dystrophy type 1 (Coté et al., 
2011).  A negative correlation between muscle MRC strength grade and muscle MRI 
fat fraction has been shown in FSHD (Kan et al., 2009), and between myometry 
measurement and muscle fat fraction in myotonic dystrophy (Hiba et al., 2012) and 
DMD (Wokke et al., 2014).  The best correlation however has been found with 
measures of residual muscle volume based on automatic T1w segmentation for both 
DM1 (Hiba et al., 2012) and SMA (Sproule et al., 2011a).  Excellent correlation was 
also seen between thigh muscle area determined by Dixon sequence and both knee 
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flexion and extension in FSHD (Janssen et al., 2014).  Other authors have failed to 
show correlation, for example no correlation was seen between muscle fat infiltration 
and manual muscle grading or hand held myometry in DMD (Wren et al., 2008), and no 
correlation between isokinetic dynamometry and muscle T1 and T2 values in patients 
with previous polio (Tollbäck et al., 1996).   The lack of correlation may be due to 
inaccuracy in MRI or strength measurement, or difference in disease pathogenesis.  
Correlation was found between muscle T2 times and MMT scores in juvenile 
dermatomysoitis (Maillard et al., 2004a), between muscle T2 and maximal isometric 
strength in MND (Bryan et al., 1998) and between MTR and MRC grade in CMT1A 
(Sinclair et al., 2012a).  None of these studies utilised fat separation or suppression 
methods, so correlation may have been due to changes in both water and fat 
distribution, as both affect MTR and T2 measurements.  These studies have been 
limited in scope in terms of the number of muscles assessed, the separation of the fat 
and water effects, including muscle size as a covariate, and the method of strength 
measurement, so a more comprehensive analysis is warranted. 
4.2.4.2 Functional measures 
Quantitative MRI has been correlated with functional scales and tests in a number of 
neuromuscular diseases.  Many of these are in DMD; for example in DMD there is 
strong correlation between gluteus maximus T2 and the clinical function score 
(p<0.001) and the timed Gower score (p<0.05) (Kim et al., 2010a). Other authors have 
shown thigh fat fraction correlates with the Brooke functional scale (Wren et al., 2008) 
and calf lipid fraction with 6MWT and 10m walk (Torriani et al., 2012).  Timed 6MWT 
has also been shown to negatively correlate with hamstring fat fraction in LGMD2I 
(Willis et al., 2014). 
It is of note that all of these measures are sensitive to either direct or indirect measures 
of muscle fat infiltration, which would therefore appear to be a valid measure of disease 
severity.  For some it seems likely that the muscle chosen is able to demonstrate the 
spectrum of disease severity and therefore correlate with a functional measure, rather 
than necessarily be the primary determinant for that functional measure.  For example, 
neither calf nor hamstring muscle fat fraction is the prime determinant of a six minute 
walk time.  One study correlated muscle volume with the Hammersmith motor scale in 
spinal muscular atrophy (Sproule et al., 2011a).  It is likely that both muscle atrophy 
and intramuscular fat infiltration are determinants of muscle weakness and disability, 
although their relative contribution may differ between patients and diseases.  The 
difficulty with muscle size measurements, whether volume or cross-sectional area, is 
that as shown in chapter 2 these show marked intra-subject variation, though 
longitudinal measurements may be highly relevant. 
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4.2.4.3 Neurophysiology 
Few studies have directly compared quantitative MRI with neurophysiology parameters 
in neuromuscular diseases.  Neurophysiology is not central to the diagnosis of primary 
muscle disorders.  One early study showed congruence between EMG and different 
imaging modalities including MRI in patients with a range of myopathic conditions 
(Alanen et al., 1994).  In neurogenic disorders, Jonas and colleagues examined the 
correlations between T1w and STIR MRI sequence and EMG in tibialis anterior muscle 
of 20 patients with axonal polyneuropathy (Jonas et al., 2000).  The measured signal 
intensity on the STIR images showed excellent correlation (rho=0.81, p<0.001) with the 
degree of pathological spontaneous activity, a marker of acute denervation.  The T1w 
signal intensity showed correlation with the motor unit amplitude, a marker of axonal 
loss, though this correlation was less strong, particularly if the values from healthy 
subjects were excluded.  Deroide and colleagues examined patients with a focal lower 
limb neuropathy using T1w and STIR MRI sequences and EMG spontaneous activity 
and interference pattern (Deroide et al., 2015).  Whilst both EMG and MRI parameters 
correlated with patient strength, there were no positive correlations between EMG and 
MRI parameters, perhaps limited by the wide range of muscles included. 
In animal studies, longitudinal assessment is possible in controlled conditions, and a 
close relationship between spontaneous activity on EMG and T2 prolongation on MRI 
is observed, associated with enlargement in the capillary bed on muscle histology 
(Wessig et al., 2004).  In spinal muscular atrophy, lower limb muscle volume 
measurements showed strong correlations (p<0.01) with both motor unit number 
estimation and compound motor unit action potential amplitude (Sproule et al., 2011a).  
One early study in ALS was able to show correlation between muscle T2 CMAP 
amplitude both at baseline and in terms of longitudinal change in these parameters 
over 4 months (Bryan et al., 1998).  No studies have compared quantitative sequences 
with fat fraction with neurophysiological parameters. 
4.2.4.4 Pathology 
Gaeta and colleagues (Gaeta et al., 2011) compared MRI measured fat fraction using a 
dual-echo dual flip-angle fat-water separation method, with measured fat fraction in a 
muscle biopsy in 27 consecutive patients with a range of neuromuscular diseases.  
Biopsy site was marked during the MRI protocol to ensure MRI measurement of as far 
as possible occurred of the tissue subsequently biopsied.  There was extremely close 
correlation between the two fat estimates with Pearson correlation coefficient of 0.995, 
and Bland-Altman 95% limits of agreement (-2.9%; 2.3%).  There are no other studies 
which have directly compared biopsy data with quantitative MRI methods, but a 
correlation between extensor digitorum muscle histology fat score and qualitative MRI 
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Mercuri grade has been shown in patients with Duchenne muscular dystrophy (Kinali et 
al., 2011), and correlation with MRI STIR abnormality and muscle inflammation (CD8+ 
T-cells) on biopsy in patients with FSHD (Frisullo et al., 2011). 
4.2.5 Summary 
There is a growing literature on quantitative muscle MRI in neuromuscular diseases in 
cross-sectional studies.  Collectively these have shown that MRI can quantify 
intramuscular fat accumulation through a variety of methods and generally correlations 
with both patient strength and function are found, demonstrating validity of these 
outcome measures.  Studies of abnormal water distribution are less numerous; the 
confounding effect of intramuscular fat on these measures needs to be considered. 
Qualitative studies in CMT1A and IBM suggest that quantitative methods to measure 
both acute and chronic pathology should be relevant to these diseases, and that lower 
limb muscles are an appropriate anatomical target. 
 Cross-sectional data aims 
The aims of the second phase of this thesis are to: 
1. Use MRI measures of intramuscular fat and muscle size to quantify chronic 
pathology in CMT1A and IBM patients versus their matched control groups. 
2. Assess for early pathological abnormalities by analysing T2 and MTR in muscles 
without significant intramuscular fat accumulation. 
3. Demonstrate criterion validity of quantitative MRI outcome measures through 
correlation with strength and functional measures.  
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 Results 
4.4.1 Subjects 
Age, gender, height and weight showed no significant differences between the two 
patient groups and their respective matched controls (Table 4-1). 
Table 4-1: Subject demographics  
Measure CMT 
Control 
(CMT) 
p 
IBM Control (IBM) 
p 
Gender 9F, 11M 9F, 11M 1 4F, 16M 8F, 12M 0·17 
Age 42·8 ± 13·9 45·8 ± 14·2 0·51 66·7 ± 8·9 61·8 ± 10·3 0·12 
Height 167 ± 12 171 ± 11 0·34 175 ± 8 17·± 10 0·28 
Weight 70 ± 16 75 ± 19 0·44 84 ± 16 77 ± 19 0·22 
BMI 25·1 ± 4·6 25·4 ± 4·9 0·84 27·4 ± 4·0 26·0 ± 4·6 0·30 
4.4.2 MRI data 
Sample parameter maps for fat fraction, T1, T2 and MTR for each group are shown in 
Figure 4-1.  Summary MRI measures at thigh and calf levels in patient and matched 
control groups are given in Table 4-2. 
Figure 4-1: Sample images 
 
Sample axial images of left lower limb 
at mid-thigh and mid-calf level. A) Fat 
fraction map of a subject from each 
group. B) T2 map of a subject from 
each group. C) MTR map of a subject 
from each group 
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Table 4-2: MRI data summary results at thigh and calf level 
Measure CMT Control (CMT) p IBM Control (IBM) p 
Quantitative MRI parameters at thigh level 
FF (%) 3·7 ± 6·8 1·7 ± 1·3 >0.1 26·6 ± 15·5 2·0 ± 1·2 <0·0001 
T1 (ms) 1212 ± 131 1266 ± 48 >0.1 916 ± 189 1264 ± 50 <0.0001 
T2 (ms) 45·7 ± 9·1 41·8 ± 3·1 0·08 83·5 ± 17·7 43·1 ± 2·5 <0·0001 
MTR 30·8 ± 3·0 32·0 ± 0·8 0·09 22·9 ± 5·0 31·6 ± 0·7 <0·0001 
FF whole (%) 5·8 ± 8·5 3·3 ± 1·8 >0.1 27·5 ± 15·7 4·0 ± 1·6 <0·0001 
CSA (cm2) 201 ± 53 219 ± 56 >0.1 169 ± 46 212 ± 51 0·009 
Qualitative MRI at thigh level 
Mercuri (0-5) 0.6 ± 0.8 0.3 ± 0.3 >0.1 2.7 ± 1.0 0.4 ± 0.3 <0.0001 
STIR (0-2) 0.2 ± 0.3 0.0 ± 0.1 >0.1 0.8 ± 0.4 0.1 ± 0.1 <0.0001 
MRI parameters at calf level 
FF (%) 15·8 ± 25·5 1·6 ± 1·0 0·02 18·0 ± 13·2 2·0 ± 0·9 <0·0001 
T1 (ms) 1080 ± 314 1247 ± 52 <0.05 999 ± 202 1249 ± 54 <0.001 
T2 (ms) 59·7 ± 29·3 40·2 ± 3·6 0·005 71·1 ± 21·4 41·9 ± 3·8 <0·0001 
MTR 26·1 ± 9·0 32·1 ± 1·0 0·007 23·7 ± 5·7 31·6 ± 0·9 <0·0001 
FF whole (%) 15·5 ± 24·0 2·7 ± 1·5 0·03 19·2 ± 13·7 3·5 ± 1·3 <0·0001 
CSA (cm2) 100 ± 26 123 ± 27 0·01 112 ± 26 120 ± 31 >0.1 
Qualitative MRI at calf level 
Mercuri (0-5) 1.5 ± 1.5*** 0.2 ± 0.3 <0.001 1.9 ± 1.0*** 0.3 ± 0.3 <0.001 
STIR (0-2) 0.4 ± 0.3 0.3 ± 0.3 >0.1 0.7 ± 0.4** 0.4 ± 0.3 <0.01 
Data are presented mean ± standard deviation by subject.  Significant differences to 
matched controls are indicated: * p<0.05, ** p<0.01, *** p<0.001.  CMT: Charcot-Marie-
Tooth disease; IBM: inclusion body myositis; FF: fat fraction; FFw: whole muscle fat 
fraction; MTR: magnetisation transfer ratio; STIR: short-tau-inversion-recovery 
4.4.3 Measures of chronic fatty atrophy 
Whilst all MRI sequences utilised in this study are sensitive to intramuscular fat, the 
qualitative T1-weighted sequence, and quantitative T1-mapping and three-point Dixon 
sequences were included as the primary measures of intramuscular fat accumulation. 
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4.4.3.1 Qualitative T1w sequences 
Figure 4-2: Qualitative imaging and Regions of Interest 
 
Sample axial T1-weighted (A) and STIR (B) images of right mid-thigh and mid–calf. 
Within muscles fat infiltration appears hyperintense on T1w images, whilst muscle 
oedema appears hyperintense on STIR images. Left) The healthy volunteer has low 
signal intensity on both sequences, however field homogeneity is evident which hinders 
quantitative analysis of T1w and STIR sequences Middle) In this typical CMT1A patient 
thigh muscle returns normal signal intensity, but there is fat infiltration at calf level, most 
marked in tibialis anterior, peroneus longus and both heads of gastrocnemius, and 
muscle oedema in tibialis anterior. Right) In this typical IBM patient fat infiltration and 
muscle oedema is present at both thigh and calf level, most markedly in quadriceps 
muscle where there is also muscle atrophy.    
 
127 
The frequency of Mercuri grading of T1w images within thigh and calf muscles are 
given in Table 4-3.  In the healthy controls, no muscles were graded Mercuri 2b or 
higher at thigh or calf level.  Whilst the overall median grades for both T1w images 
were not significantly different in the CMT1A group as a whole, some muscles were 
graded 2b (4.5%) and 3 (2.0%).  These were from just 3/20 patients, whose T1w thigh 
scans could therefore be considered qualitatively abnormal.  By contrast at calf level 
the full spectrum of Mercuri grades were assigned to CMT1A patients’ muscles, with 
only 39.6% of muscles grade 0.  This is consistent with the length dependent 
distribution of weakness observed clinically in CMT1A patients.  The IBM patients 
showed more marked T1w abnormalities with Mercuri grade 3 most commonly 
assigned at thigh level, with slightly lesser grades in the calf, but over half of muscles 
graded 2a or higher. On qualitative assessment, the distribution of chronic pathology in 
IBM is therefore more widespread, but overall with greater thigh than calf involvement. 
Table 4-3: Distribution of qualitative Mercuri grading by subject group 
Thigh Mercuri 
Total 0 1 2a 2b 3 4 Art. 
D
ia
g
n
o
s
is
 
CMT1A Count 219 118 26 18 8 0 11 400 
% within Diagnosis 54.8% 29.5% 6.5% 4.5% 2.0% 0.0% 2.8% 100% 
IBM Count 36 80 68 57 116 43 0 400 
% within Diagnosis 9.0% 20.0% 17.0% 14.3% 29.0% 10.8% 0.0% 100% 
Volunteer Count 423 137 15 0 0 0 5 580 
% within Diagnosis 72.9% 23.6% 2.6% 0.0% 0.0% 0.0% 0.9% 100% 
Total Count 678 335 109 75 124 43 16 1380 
% within Diagnosis 49.1% 24.3% 7.9% 5.4% 9.0% 3.1% 1.2% 100.0% 
           Calf Mercuri 
Total 0 1 2a 2b 3 4 Art. 
D
ia
g
n
o
s
is
 
CMT1A Count 95 52 34 14 24 21 0 240 
% within Diagnosis 39.6% 21.7% 14.2% 5.8% 10.0% 8.8% 0.0% 100% 
IBM Count 55 64 40 31 32 18 0 240 
% within Diagnosis 22.9% 26.7% 16.7% 12.9% 13.3% 7.5% 0.0% 100% 
Volunteer Count 279 65 4 0 0 0 0 348 
% within Diagnosis 80.2% 18.7% 1.1% 0.0% 0.0% 0.0% 0.0% 100% 
Total Count 429 181 78 45 56 39 0 828 
% within Diagnosis 51.8% 21.9% 9.4% 5.4% 6.8% 4.7% 0.0% 100.0% 
Art.: Artefact. Description of Mercuri grades are in Figure 3-11. 
4.4.3.2 Overall quantitative MRI results 
Summary quantitative MRI data on a per subject basis are in Table 4-2.  The direction 
of differences seen in patients was consistent with that expected with intramuscular fat 
accumulation: increased FF and T2 and reduced T1 and MTR.  In IBM patients all 
quantitative MRI parameters were significantly different (p<0.001) from controls at thigh 
and calf level.  Total cross-sectional area was reduced at thigh (p<0.01) but not calf 
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level.  In CMT patients, with the length dependent clinical phenotype, and consistent 
with the qualitative findings, there were significant (p<0.05) differences in all 
quantitative measure at calf but not thigh level.  Total calf cross-sectional area was also 
reduced.  These data demonstrate quantifiable abnormalities consistent with chronic 
fatty atrophy of lower limb muscles. 
4.4.3.3 Distribution of MRI abnormalities 
Muscle-specific results in both patient groups and their matched control groups for 
cross-sectional area are given in Table 4-4 and quantitative MRI parameters in Table 
4-5 (CMT1A) and Table 4-6 (IBM). 
Table 4-4: Cross-sectional area by muscle in patients and matched controls 
Group 
CMT 
Control 
(CMT) 
IBM 
Control 
(IBM) 
Thigh 
Rectus Femoris 571±275 735±304 405±304 618±280 
Vastus Medialis 2075±805 2206±786 1251±458 1898±903 
Vastus Intermedius 2200±675 2817±775 1773±601 2633±971 
Vastus Lateralis 2928±876 2966±882 1969±681 2448±857 
Semimembranosus 1218±489 1482±511 1467±894 1452±563 
Semitendinosus 971±371 1155±458 1034±424 1058±429 
Biceps Femoris 2054±619 2251±739 2045±894 2213±893 
Adductor Magnus 2547±1079 2378±813 2337±1307 2291±931 
Sartorius 576±144 550±186 491±204 538±226 
Gracilis 565±195 559±213 360±180 561±229 
Total 15700±10500 17100±10750 13130±9660 15710±10470 
Calf 
Tibialis Anterior 1117±322 1643±429 1479±520 1524±684 
Peroneus Longus 855±286 868±260 802±348 839±399 
Lateral Gastrocnemius 1026±298 1310±530 1097±544 1097±564 
Medial Gastrocnemius 1819±635 2234±685 1369±657 1848±880 
Soleus 2993±1023 3410±718 3229±1285 3098±1343 
Tibialis Posterior 425±122 644±217 678±246 558±280 
Total 8238±5946 10110±6354 8652±6528 8964±6798 
Results are mean ± s.d. in mm2  
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Table 4-5: Muscle-specific MRI parameters in CMT1A and matched controls 
Expressed as mean ± s.d (n); FFw: fat fraction from whole muscle ROI, other values from small ROI 
Muscle 
CMT1A Volunteer (CMT1A) 
FF (%) T1 (ms) T2 (ms) MTR (p.u.) FFw (%) FF (%) T1 (ms) T2 (ms) MTR (p.u.) FFw (%) 
Right Rectus Femoris 3.6 ± 12.1 (20) 511 ± 0 (1) 46.8 ± 13.7 (16) 28.9 ± 9.3 (5) 6.3 ± 13 (20) 0.7 ± 1 (20) 1158 ± 0 (1) 40.8 ± 5.5 (17) 33.3 ± 1.9 (3) 2.7 ± 1.9 (19) 
Right Vastus Medialis 2 ± 2.9 (20) 1270 ± 170 (7) 43.8 ± 7.8 (20) 31.6 ± 2.2 (10) 4.4 ± 8.1 (20) 1 ± 0.8 (20) 1343 ± 80 (8) 40.9 ± 3.9 (19) 32.6 ± 1.9 (8) 2.2 ± 1.1 (19) 
Right Vastus Intermedius 3 ± 5.8 (20) 1232 ± 175 (9) 44.6 ± 11.5 (20) 30.3 ± 4.8 (14) 4.3 ± 10.4 (20) 1 ± 1.1 (20) 1376 ± 110 (10) 38.4 ± 2.8 (20) 33.2 ± 1.8 (14) 2 ± 1.6 (19) 
Right Vastus Lateralis 5.4 ± 19.1 (20) 1293 ± 262 (16) 49.6 ± 26.2 (19) 31 ± 6.6 (20) 6.2 ± 14 (20) 1.2 ± 0.9 (20) 1368 ± 54 (11) 42.2 ± 4.8 (18) 32.5 ± 1.3 (19) 2.6 ± 1.3 (19) 
Right Semimembranosus 3.5 ± 4.5 (20) 1175 ± 145 (18) 48.5 ± 8.8 (19) 30.5 ± 2.9 (20) 6.7 ± 5.5 (20) 2.5 ± 3.1 (20) 1212 ± 116 (17) 44.9 ± 6.4 (20) 31.4 ± 1.6 (18) 4.6 ± 2.9 (19) 
Right Semitendinosus 2.3 ± 2.7 (20) 1219 ± 141 (17) 47.4 ± 8.3 (20) 31.2 ± 2.8 (20) 6.3 ± 5.3 (20) 1.1 ± 0.7 (20) 1306 ± 86 (18) 43.3 ± 4 (20) 32.1 ± 1.1 (18) 3.6 ± 2.7 (19) 
Right Biceps Femoris 2.7 ± 3.5 (20) 1253 ± 130 (17) 47.8 ± 7.4 (19) 30.5 ± 2.6 (20) 4.6 ± 4.7 (20) 2 ± 1.4 (20) 1283 ± 86 (18) 46.5 ± 5 (18) 31.2 ± 1.3 (18) 3.7 ± 2.4 (19) 
Right Adductor Magnus 2.3 ± 4 (20) 1303 ± 116 (17) 45 ± 7.3 (20) 31.9 ± 2.2 (20) 5.1 ± 7.3 (20) 2 ± 3 (20) 1308 ± 109 (16) 43 ± 5.6 (20) 32.1 ± 1.6 (18) 3.8 ± 3.4 (19) 
Right Sartorius 5.9 ± 10.6 (20) 1149 ± 208 (13) 48.3 ± 11.1 (20) 27.7 ± 5.4 (13) 9.5 ± 8.6 (20) 3.6 ± 3.8 (20) 1245 ± 101 (12) 43.6 ± 6.1 (19) 31.9 ± 1.8 (8) 5.9 ± 2.8 (19) 
Right Gracilis 3.1 ± 4.6 (19) 1188 ± 146 (16) 44 ± 7.5 (20) 31.8 ± 3.2 (19) 6.8 ± 5.7 (20) 1.8 ± 1.7 (20) 1285 ± 85 (16) 39.5 ± 3.5 (20) 32.8 ± 1.4 (17) 4.1 ± 2.3 (18) 
Left Rectus Femoris 2.7 ± 8.2 (20) 1257 ± 258 (12) 45.4 ± 17.1 (20) 31.6 ± 4.6 (16) 6 ± 11.4 (20) 1.1 ± 1.6 (20) 1384 ± 76 (8) 38.4 ± 4.8 (18) 32.8 ± 1.9 (18) 3 ± 2.3 (19) 
Left Vastus Medialis 2.7 ± 5.4 (20) 1284 ± 151 (15) 44.3 ± 9.2 (20) 31.5 ± 3.4 (19) 5.3 ± 9.3 (20) 1.2 ± 1.3 (20) 1359 ± 45 (12) 42 ± 4.7 (20) 32.3 ± 1.2 (18) 2.7 ± 1.4 (19) 
Left Vastus Intermedius 8.2 ± 21.7 (20) 1210 ± 322 (15) 51.8 ± 29.6 (20) 29 ± 7.7 (19) 6.1 ± 12.6 (20) 1.3 ± 1 (20) 1331 ± 65 (13) 42.3 ± 5.5 (19) 31.7 ± 1.4 (19) 2 ± 1.3 (19) 
Left Vastus Lateralis 4.8 ± 15.1 (20) 1213 ± 194 (19) 44.5 ± 18.7 (20) 30.8 ± 5.6 (19) 7.2 ± 15.1 (20) 1.6 ± 1.2 (20) 1286 ± 56 (17) 40.6 ± 3 (19) 32.1 ± 1.2 (19) 3.4 ± 1.7 (19) 
Left Semimembranosus 3 ± 1.8 (20) 1077 ± 81 (16) 43.5 ± 4.4 (20) 29.6 ± 2.4 (16) 6.9 ± 5.5 (20) 2.3 ± 1.8 (19) 1130 ± 66 (18) 42 ± 5.1 (20) 30.9 ± 1.1 (17) 4.2 ± 2.6 (17) 
Left Semitendinosus 2.6 ± 3.1 (20) 1116 ± 87 (18) 42.7 ± 5.6 (20) 31.1 ± 2.6 (18) 6.4 ± 5.4 (20) 1.4 ± 1.2 (19) 1168 ± 60 (19) 40.8 ± 4.3 (20) 31.9 ± 1 (18) 4.1 ± 2.3 (17) 
Left Biceps Femoris 3 ± 4.2 (20) 1162 ± 123 (19) 44.8 ± 7.4 (20) 30.7 ± 3.2 (19) 6.1 ± 5.7 (19) 2.6 ± 2.2 (20) 1201 ± 72 (18) 43.5 ± 6.4 (20) 31.8 ± 1.4 (19) 4.8 ± 2.8 (19) 
Left Adductor Magnus 2 ± 2.2 (20) 1194 ± 112 (17) 41.9 ± 4.2 (20) 30.7 ± 2.1 (18) 6.2 ± 8.9 (19) 2 ± 2.3 (20) 1246 ± 49 (15) 42.4 ± 5.2 (20) 31.6 ± 1.3 (18) 3.9 ± 3.3 (19) 
Left Sartorius 5.5 ± 9.9 (20) 1210 ± 245 (12) 47.4 ± 13.2 (20) 30.2 ± 4.6 (17) 9.1 ± 9.1 (20) 2.7 ± 2.9 (20) 1266 ± 77 (11) 42 ± 6 (20) 31.8 ± 2.3 (16) 6.7 ± 3.5 (19) 
Left Gracilis 5 ± 11.5 (20) 1161 ± 198 (13) 43.7 ± 13.4 (20) 30.4 ± 4.2 (18) 7.5 ± 9.7 (20) 1.8 ± 1.6 (20) 1254 ± 74 (17) 38.1 ± 3.8 (20) 32.4 ± 1.4 (18) 5 ± 2 (19) 
Right Tibialis Anterior 12.6 ± 23.6 (20) 845 ± 272 (10) 57.2 ± 29.7 (20) 23.4 ± 8.4 (16) 14 ± 21.2 (20) 0.7 ± 0.7 (19) 1133 ± 115 (9) 36.9 ± 2.3 (20) 30.5 ± 1.4 (17) 1.5 ± 0.9 (19) 
Right Peroneus Longus 21.9 ± 30.5 (20) 895 ± 355 (14) 66.4 ± 36.1 (20) 24.2 ± 10.9 (20) 24.4 ± 28.6 (20) 1.6 ± 1.5 (19) 1218 ± 104 (14) 40.6 ± 5.1 (19) 31.9 ± 1.6 (18) 3.1 ± 2.4 (19) 
Right Lateral Gastrocnemius 15.1 ± 29 (20) 1081 ± 383 (18) 60.2 ± 34 (20) 25.8 ± 10.2 (20) 15.8 ± 27.3 (20) 1.3 ± 0.9 (19) 1238 ± 69 (15) 40.4 ± 4.7 (20) 32.1 ± 0.9 (17) 2.5 ± 1.5 (19) 
Right Medial Gastrocnemius 18.2 ± 29.1 (20) 1021 ± 386 (16) 61.5 ± 30.8 (20) 25.3 ± 10.2 (19) 18.6 ± 28.1 (20) 1.5 ± 0.9 (18) 1220 ± 44 (17) 40.2 ± 3.5 (20) 32.7 ± 1.3 (17) 2.5 ± 1.2 (18) 
Right Soleus 13 ± 25.8 (20) 1086 ± 343 (16) 56.4 ± 29.6 (20) 27.6 ± 9.4 (19) 12.6 ± 23.7 (20) 2.7 ± 2.9 (19) 1231 ± 68 (13) 43 ± 6.5 (20) 32 ± 1.6 (18) 3 ± 2.7 (19) 
Right Tibialis Posterior 12.4 ± 25.9 (20) 1052 ± 353 (13) 56.5 ± 34.2 (19) 27.7 ± 9.5 (20) 12.4 ± 22.6 (20) 1 ± 0.9 (19) 1278 ± 86 (12) 38.9 ± 2.8 (20) 32.9 ± 1.1 (18) 1.5 ± 1 (19) 
Left Tibialis Anterior 16.8 ± 28.4 (19) 1056 ± 343 (18) 64.5 ± 35.5 (19) 25.4 ± 9.4 (20) 15.7 ± 22.2 (19) 0.9 ± 0.7 (19) 1298 ± 83 (17) 40.3 ± 5.9 (20) 32 ± 1.4 (18) 2 ± 1 (19) 
Left Peroneus Longus 18.9 ± 30 (20) 1057 ± 325 (18) 61.1 ± 32.5 (19) 25.8 ± 10.4 (20) 22.4 ± 27.8 (20) 2 ± 1.6 (19) 1212 ± 103 (17) 41.1 ± 5.8 (20) 32 ± 1.8 (19) 3.7 ± 2.3 (19) 
Left Lateral Gastrocnemius 16.8 ± 29.3 (20) 1087 ± 395 (17) 60.1 ± 34 (19) 26 ± 10.6 (20) 17.8 ± 27.7 (20) 1.8 ± 1.6 (19) 1274 ± 78 (17) 39.4 ± 3.9 (20) 32.1 ± 1.1 (18) 2.8 ± 1.7 (18) 
Left Medial Gastrocnemius 20 ± 32.5 (20) 1024 ± 389 (17) 64 ± 33.8 (19) 25.8 ± 10.8 (20) 19.7 ± 29.8 (19) 1.9 ± 1.3 (19) 1248 ± 49 (17) 39.7 ± 3.6 (20) 32.4 ± 1 (18) 3.9 ± 1.6 (19) 
Left Soleus 12.3 ± 23.3 (20) 1136 ± 324 (18) 55.6 ± 27 (19) 28 ± 8.7 (20) 13.3 ± 22.9 (19) 2.4 ± 1.8 (19) 1254 ± 75 (17) 41.5 ± 4.2 (20) 32 ± 1.4 (19) 2.9 ± 2.3 (17) 
Left Tibialis Posterior 11.5 ± 21.8 (20) 1143 ± 324 (18) 58.6 ± 30.2 (19) 27.1 ± 8.5 (20) 14.1 ± 22 (20) 1.4 ± 0.8 (19) 1295 ± 80 (17) 39.5 ± 2.5 (20) 31.9 ± 1.6 (19) 2.3 ± 1.3 (19) 
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Table 4-6: Muscle-specific MRI parameters in IBM and matched controls 
Expressed as mean ± s.d (n); FFw: fat fraction from whole muscle ROI, other values from small ROI. 
Muscle 
IBM Volunteer (IBM) 
FF (%) T1 (ms) T2 (ms) MTR (p.u.) FFw (%) FF (%) T1 (ms) T2 (ms) MTR (p.u.) FFw (%) 
Right Rectus Femoris 19 ± 16.8 (20) 881 ± 159 (8) 81.3 ± 29.1 (19) 20.6 ± 8.2 (9) 26.8 ± 17.6 (20) 0.6 ± 0.7 (19) 1201 ± 60 (2) 41.8 ± 4.5 (16) 30.7 ± 2.3 (3) 3.1 ± 1.5 (19) 
Right Vastus Medialis 31.4 ± 22.7 (20) 799 ± 248 (13) 101.2 ± 27.6 (19) 16.9 ± 6.6 (9) 37.4 ± 17.5 (20) 1.4 ± 0.7 (19) 1342 ± 94 (7) 43.8 ± 4.3 (17) 31.9 ± 2.4 (5) 2.7 ± 1 (19) 
Right Vastus Intermedius 37.6 ± 26.5 (20) 648 ± 224 (15) 99.4 ± 30.7 (20) 15.5 ± 9.1 (15) 33.9 ± 20.5 (20) 1.1 ± 0.9 (19) 1394 ± 69 (8) 39.3 ± 2.4 (18) 32.8 ± 1.8 (14) 2.7 ± 1.6 (19) 
Right Vastus Lateralis 49.2 ± 27.8 (20) 634 ± 289 (18) 115.9 ± 31.3 (20) 12.8 ± 8.6 (16) 44.1 ± 24 (20) 1.5 ± 0.9 (19) 1366 ± 58 (13) 42.7 ± 3.7 (17) 32 ± 1.2 (18) 3.2 ± 1.1 (19) 
Right Semimembranosus 19.6 ± 23.8 (20) 944 ± 307 (17) 71.2 ± 28.4 (20) 23.6 ± 8.9 (18) 23 ± 22.6 (20) 3.1 ± 2.9 (19) 1183 ± 123 (16) 47.4 ± 6.6 (18) 30.8 ± 1.6 (16) 5.7 ± 2.4 (19) 
Right Semitendinosus 19.1 ± 28.3 (20) 1135 ± 352 (17) 68.6 ± 29.1 (20) 26.4 ± 7.5 (17) 23.5 ± 25.8 (20) 1.1 ± 0.6 (19) 1303 ± 72 (17) 43.5 ± 3.5 (18) 32.1 ± 0.8 (17) 4.4 ± 2.5 (19) 
Right Biceps Femoris 6.6 ± 10.2 (20) 1257 ± 180 (17) 59.7 ± 17.2 (19) 28.6 ± 4.3 (18) 9.5 ± 8.4 (20) 2.6 ± 1.2 (19) 1268 ± 101 (17) 48 ± 4 (17) 30.5 ± 1.1 (17) 4.1 ± 2.2 (19) 
Right Adductor Magnus 34.3 ± 38.5 (20) 857 ± 505 (12) 89.1 ± 41 (19) 22.3 ± 11 (16) 34.5 ± 32.8 (20) 2.4 ± 3 (19) 1282 ± 112 (16) 44.4 ± 5.7 (18) 31.5 ± 1.7 (17) 4.6 ± 3.3 (19) 
Right Sartorius 22.4 ± 24.7 (20) 977 ± 291 (12) 74.4 ± 24.3 (20) 24.6 ± 5.5 (11) 26.7 ± 22.6 (20) 3.5 ± 3.4 (19) 1248 ± 133 (10) 44.1 ± 5.8 (16) 30.8 ± 1.5 (10) 6.7 ± 2.8 (19) 
Right Gracilis 27.4 ± 31.1 (20) 973 ± 350 (17) 71.8 ± 30.1 (20) 24 ± 8.6 (15) 29.1 ± 26.4 (20) 1.6 ± 1.2 (19) 1306 ± 81 (16) 40.4 ± 3.5 (17) 32.9 ± 1.6 (17) 4.5 ± 2 (17) 
Left Rectus Femoris 29.5 ± 25.5 (20) 736 ± 282 (15) 98.3 ± 39.6 (19) 18.7 ± 7.4 (10) 33.8 ± 22.9 (20) 1 ± 0.7 (19) 1383 ± 65 (7) 39.4 ± 5 (17) 32.6 ± 1.8 (18) 3.3 ± 1.8 (19) 
Left Vastus Medialis 37.5 ± 25.5 (20) 646 ± 239 (13) 114.2 ± 39.1 (19) 16.4 ± 9.3 (13) 39.2 ± 20.7 (20) 1.4 ± 1.1 (19) 1377 ± 49 (12) 42.3 ± 4.2 (19) 32.4 ± 1.2 (18) 3.2 ± 1.2 (19) 
Left Vastus Intermedius 38.4 ± 27.5 (20) 695 ± 284 (15) 119.4 ± 41.4 (18) 17.4 ± 8.1 (13) 38 ± 21.7 (20) 1.4 ± 1 (19) 1346 ± 78 (14) 43.4 ± 5 (19) 31.6 ± 1.7 (18) 2.4 ± 1.1 (19) 
Left Vastus Lateralis 46.4 ± 28.5 (20) 621 ± 302 (17) 108.4 ± 32.1 (19) 14.7 ± 9.2 (14) 44.2 ± 21.1 (20) 2 ± 1 (19) 1286 ± 61 (17) 42 ± 2.1 (19) 31.7 ± 0.9 (18) 3.9 ± 1.3 (19) 
Left Semimembranosus 10.9 ± 15.3 (20) 1067 ± 163 (18) 55.8 ± 15.9 (20) 27.6 ± 2.5 (16) 17.5 ± 14.5 (20) 2.8 ± 1.7 (18) 1114 ± 67 (17) 44.5 ± 5.4 (19) 29.9 ± 1.4 (15) 5.1 ± 2.5 (18) 
Left Semitendinosus 16.1 ± 26.1 (20) 1031 ± 266 (18) 60.3 ± 24 (20) 28.1 ± 4.5 (15) 21 ± 23.3 (20) 1.4 ± 0.8 (19) 1167 ± 62 (18) 42.3 ± 4.6 (19) 31.4 ± 0.9 (16) 4.8 ± 2 (18) 
Left Biceps Femoris 6.1 ± 8.2 (20) 1177 ± 173 (19) 54.9 ± 14.4 (20) 29.6 ± 1.7 (16) 11.4 ± 8.7 (20) 2.9 ± 2.1 (19) 1209 ± 69 (18) 44.8 ± 6.1 (19) 31.4 ± 1.2 (18) 5.3 ± 2.7 (19) 
Left Adductor Magnus 33.9 ± 36.4 (20) 828 ± 414 (16) 87.5 ± 41.5 (19) 20.3 ± 11.4 (14) 29 ± 28.5 (20) 2.5 ± 2.3 (19) 1224 ± 44 (15) 44 ± 4.9 (19) 31.1 ± 1.2 (17) 4.7 ± 3.2 (19) 
Left Sartorius 25.8 ± 27.4 (20) 995 ± 376 (14) 81.5 ± 33.3 (20) 24.7 ± 7 (13) 29.9 ± 25.6 (20) 3.4 ± 3 (19) 1263 ± 73 (10) 43.7 ± 6.2 (19) 31.1 ± 1.4 (15) 7.7 ± 3.3 (19) 
Left Gracilis 21.2 ± 23.2 (20) 1046 ± 323 (14) 63.4 ± 22.1 (20) 26.6 ± 5.8 (12) 24.5 ± 19.3 (20) 1.7 ± 1.4 (19) 1250 ± 82 (16) 39.4 ± 3.8 (19) 31.9 ± 1.6 (16) 5 ± 2 (19) 
Right Tibialis Anterior 7.1 ± 14.6 (17) 1031 ± 190 (12) 64.2 ± 35 (18) 25.3 ± 7.1 (13) 7.4 ± 10.6 (17) 1 ± 0.5 (18) 1096 ± 53 (9) 38.5 ± 2.5 (19) 29.9 ± 1.2 (15) 1.9 ± 0.9 (17) 
Right Peroneus Longus 9 ± 13.4 (17) 1004 ± 244 (13) 65.4 ± 32.5 (18) 26.6 ± 6.6 (18) 12.4 ± 10.6 (17) 1.7 ± 1.5 (18) 1203 ± 117 (10) 41.5 ± 4.8 (18) 31.4 ± 1.6 (15) 4 ± 2.5 (17) 
Right Lateral Gastrocnemius 20.9 ± 29 (17) 1015 ± 342 (15) 75.4 ± 37.8 (19) 23.6 ± 9.9 (18) 23.3 ± 25.5 (17) 1.6 ± 1 (18) 1248 ± 79 (15) 43.2 ± 6.6 (19) 31.4 ± 1.2 (16) 3 ± 1.4 (17) 
Right Medial Gastrocnemius 53 ± 32 (17) 613 ± 337 (15) 106.4 ± 29.8 (18) 12.9 ± 9.7 (18) 50.6 ± 25.7 (17) 1.6 ± 0.8 (18) 1224 ± 49 (15) 42.3 ± 4.5 (19) 32 ± 1.7 (16) 3.2 ± 1.4 (17) 
Right Soleus 9.2 ± 17.1 (17) 1161 ± 253 (12) 59.8 ± 26.7 (18) 27.5 ± 6.7 (16) 13.1 ± 15.1 (17) 3.1 ± 2.7 (18) 1210 ± 62 (13) 43.9 ± 6.2 (19) 31.5 ± 1.4 (17) 3.9 ± 2.6 (17) 
Right Tibialis Posterior 3.8 ± 7.2 (17) 1216 ± 135 (10) 48.6 ± 15.6 (18) 30.8 ± 3.5 (16) 5.8 ± 9.2 (17) 1.3 ± 0.7 (18) 1283 ± 77 (14) 39.8 ± 2.2 (19) 32.6 ± 1.1 (17) 2.1 ± 0.7 (17) 
Left Tibialis Anterior 8.9 ± 14.7 (18) 1201 ± 278 (12) 66.6 ± 33.7 (18) 26.2 ± 7 (17) 9.4 ± 11.4 (18) 1.2 ± 0.7 (18) 1296 ± 93 (17) 41.9 ± 5.8 (19) 31.5 ± 1.5 (16) 2.5 ± 1 (17) 
Left Peroneus Longus 11 ± 12.3 (18) 1046 ± 234 (17) 64.7 ± 32.2 (19) 25.7 ± 7.7 (19) 15.2 ± 11.4 (18) 2.4 ± 2.1 (18) 1200 ± 103 (17) 42.7 ± 6 (19) 31.2 ± 1.6 (17) 4.6 ± 2.8 (17) 
Left Lateral Gastrocnemius 18.5 ± 28.3 (18) 1053 ± 353 (16) 70.7 ± 34.2 (19) 22.9 ± 10.1 (19) 23.2 ± 24.5 (18) 2.1 ± 1.8 (18) 1312 ± 80 (17) 42.2 ± 5.2 (19) 31.5 ± 1.1 (16) 3.5 ± 1.6 (16) 
Left Medial Gastrocnemius 54.7 ± 29.7 (18) 616 ± 290 (16) 111 ± 28.9 (19) 12.5 ± 8.5 (19) 52.9 ± 24.5 (18) 2.9 ± 2.1 (18) 1268 ± 63 (17) 42.1 ± 6.4 (19) 32 ± 0.9 (16) 4.6 ± 1.7 (17) 
Left Soleus 14.1 ± 20 (18) 1078 ± 286 (15) 63.6 ± 30.3 (19) 26.4 ± 8.3 (19) 17.8 ± 18.8 (18) 3.2 ± 1.7 (18) 1246 ± 74 (17) 43.2 ± 4.9 (19) 31.6 ± 1.4 (17) 4.1 ± 2.1 (15) 
Left Tibialis Posterior 6.5 ± 17.5 (18) 1315 ± 83 (14) 54.3 ± 29.8 (19) 29.1 ± 6.2 (18) 9.3 ± 14.7 (18) 1.6 ± 1 (18) 1283 ± 84 (16) 40.5 ± 2.3 (19) 31.5 ± 1.6 (17) 2.9 ± 1.4 (17) 
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4.4.3.3.1 Disease distribution in IBM 
The significant atrophy of thigh musculature (Table 4-2) was predominantly in the 
quadriceps muscle, but was unexpectedly most marked in gracilis muscle, where 
patient cross-sectional area was 64% of their matched controls (p<0.01).  There was 
no significant difference in CSA of the hamstring muscles, adductor magnus or 
sartorius.  Fat fraction was similarly highest in the quadriceps muscle (Figure 4-3), with 
relative sparing of rectus femoris.  The hamstrings were generally spared, especially 
biceps femoris, though there were many outliers.  Adductor magnus showed the widest 
variability with the fourth lowest median FF, but highest 75th percentile.  The other 
quantitative parameters showed the same distribution as fat fraction, due to their high 
inter-correlation. The same pattern of IFA was seen qualitatively (Figure 4-4). 
Although total calf cross-sectional area was not reduced in IBM patients, there was 
selective atrophy of medial gastrocnemius, also the muscle with highest fat fraction.  
This raises the possibility of compensatory hypertrophy in the less affected muscles.  
Lateral gastrocnemius had second greatest fat fraction, with relative sparing of tibialis 
posterior.  Overall mean values were similar in right and left lower limbs, but there was 
significant asymmetry in some muscles of some patients. Whole muscle fat fraction 
was generally higher than small ROI fat fraction.  This was true for all muscles in 
controls, but not all muscles in patients (Table 4-6). 
4.4.3.3.2 Disease distribution in CMT1A 
In CMT1A there was overall atrophy at the calf (Table 4-2), with all assessed muscles 
of reduced size compared with controls except peroneus longus (Table 4-4).  Peroneus 
longus however had the highest mean fat fraction – suggesting some discordance 
between the pathological processes underlying atrophy and intramuscular fat 
accumulation.  The pattern in individual patients however was quite variable (Figure 
4-5).  Some patients had severe fat infiltration of all calf muscles (blue lines in Figure 
4-5) whilst some had low fat fraction in all muscles (green lines in Figure 4-5).  As with 
IBM patients, fat fractions from whole ROI were overall slightly higher than small ROI 
FF, whilst T2, MTR and T1 distribution of abnormalities was the same as for FF. 
Within the thigh, whilst the group statistics didn’t differ significantly, in the two patients 
who had severe changes at the calf level, there were abnormalities at the thigh level, 
with relative predilection for quadriceps muscles. 
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Figure 4-3: Distribution of intramuscular fat accumulation in thigh of IBM patients 
 
Bars indicate median, 25th, 50th and 75th centiles, lines: range, o: minor outlier, *: major outlier 
Figure 4-4: Qualitative and quantitative pattern of IFA in IBM 
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Figure 4-5: Distribution of intramuscular fat accumulation in calf muscles of CMT1A 
 
Each line represents a single patient.  Right and left legs are averaged for each 
muscle. Lines are coloured into high (blue), intermediate (red) and low (green) levels of 
fat fraction as a visual aid.  
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4.4.3.4 MRI correlations 
There were strong correlations between mean Mercuri grades and mean slice fat 
fraction (Figure 4-6).  There was however significant overlap in FF recorded for 
adjacent Mercuri grades.  FF values for the same Mercuri grade were similar in all 
three subject groups. 
Figure 4-6: Correlation between FF and Mercuri grade 
 
   THIGH         CALF 
Box plot of fat fraction measured according to Mercuri grade assigned in thigh and calf 
muscles, grouped by diagnosis.  Measured fat fraction increases with higher Mercuri 
grades and is consistent across thigh and calf and diagnoses.  Bars indicate median, 
25th, 50th and 75th centiles, lines: range, o: minor outlier, *: major outlier 
There were strong correlations between the quantitative MRI parameters of individual 
muscles (Table 4-7).  All correlations were greater than R = 0.89, and all highly 
significant (p<0.0001).  The strongest correlations are between T2 and MTR at both 
thigh and calf level.  T1 overall has the weakest correlations.  In the thigh, at a nominal 
0% fat fraction T1 is 1267ms, T2 is 42.6ms and MTR is 31.8 p.u.  For every 1% 
increase in FF, T1 reduces by 12.5ms, MTR by 0.38 p.u. and T2 increases by 1.35ms.  
Inter-parameter relationships are similar at calf level.  Whilst T2 and MTR will have 
additional influence from water distribution changes and the relationship is not strictly 
linear, these are reasonable estimates of the confounding effect of intramuscular fat 
accumulation on T2 and MTR measurements. 
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Table 4-7: Correlation of quantitative MRI parameters 
Thigh 
Dependent variable 
FF T1 T2 MTR 
In
d
e
p
e
n
d
e
n
t 
v
a
ri
a
b
le
 
FF 
R   0.91 0.92 0.93 
Constant   1267 42.6 31.8 
Slope   -12.5 1.35 -0.38 
T1 
R 0.91 0 0.89 0.93 
Constant 86 0 166 -1.8 
Slope -0.067 0 -0.096 0.026 
T2 
R 0.92 0.89 0 0.95 
Constant -26 1610 0 42.2 
Slope 0.633 -8.343 0 -0.253 
MTR 
R 0.93 0.93 0.95 0 
Constant 73 220 155 0 
Slope -2.266 33.169 -3.548 0 
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Dependent variable 
FF T1 T2 MTR 
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FF 
R   0.95 0.93 0.96 
Constant   1265 41.6 31.7 
Slope   -11.7 1.19 -0.35 
T1 
R 0.95 0 0.92 0.95 
Constant 98 0 162 -4.2 
Slope -0.076 0 -0.095 0.028 
T2 
R 0.93 0.92 0 0.97 
Constant -29 1620 0 43.2 
Slope 0.73 -8.93 0 -0.28 
MTR 
R 0.96 0.95 0.97 0 
Constant 84 240 149 0 
Slope -2.613 31.927 -3.376 0 
Linear regression of pair-wise comparison of quantitative MRI parameters on an 
individual muscle basis at thigh and calf level. For example, at thigh level the equation 
T2 = 42.6 + 0.92 x fat fraction fits data best, with R = 0.92. All quantitative MRI 
parameters are highly significant (p<0.001 for all). Constant and slope are similar at 
thigh and calf level for equivalent correlations. FF: fat fraction; MTR: magnetisation 
transfer ratio; R: model fit parameter. 
4.4.4 Probing water distribution abnormalities 
The STIR sequence allows the most straightforward assessment of abnormalities in 
muscle water distribution due to the suppression of fat signal within this sequence, but 
is a qualitative sequence.  MTR and T2 mapping are quantitative sequences sensitive 
to changes in muscle water distribution, but the confounding effect of intramuscular fat 
accumulation (Table 4-7) needs to be taken into consideration. 
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4.4.4.1 Qualitative STIR sequences 
Within the thigh muscles, in controls and CMT1A patients marked STIR hyperintensity 
was not seen and mild hyperintensity was uncommon.  Conversely in IBM patients over 
a third of muscles are mildly hyperintense with an additional 20% markedly 
hyperintense on STIR.  Distribution of calf STIR grades in IBM were roughly similar to 
the thigh, whilst 6.3% of CMT1A calf muscles were graded as showing marked STIR 
hyperintensity, versus 0.5 % of control calf muscles (Table 4-8).   
Table 4-8: Frequency of STIR grades in thigh and calf muscles 
Thigh STIR Total 
None Mild Marked Art. 
 
Diagnosis CMT1A Count 352 19 0 29 400 
% within Diagnosis 88.0% 4.8% 0.0% 7.3% 100% 
IBM Count 176 141 80 3 400 
% within Diagnosis 44.0% 35.3% 20.0% 0.8% 100% 
Controls Count 553 16 0 11 580 
% within Diagnosis 95.3% 2.8% 0.0% 1.9% 100% 
Total Count 1081 176 80 43 1380 
% within Diagnosis 78.3% 12.8% 5.8% 3.1% 100% 
        Calf STIR Total 
None Mild Marked Art. 
 
Diagnosis CMT1A Count 162 60 15 3 240 
% within Diagnosis 67.5% 25.0% 6.3% 1.3% 100% 
IBM Count 107 93 38 2 240 
% within Diagnosis 44.6% 38.8% 15.8% 0.8% 100% 
Controls Count 304 49 2 17 372 
% within Diagnosis 81.7% 13.2% 0.5% 4.6% 100% 
Total Count 573 202 55 22 852 
% within Diagnosis 67.3% 23.7% 6.5% 2.6% 100% 
The distribution of STIR abnormalities in IBM patients is shown in Figure 4-7.  The 
pattern in the thigh is similar to the pattern of intramuscular fat accumulation except 
gracilis, which is relatively spared but moderately affected by fat.  Of note, 100% of 
vastus medialis shows STIR hyperintensity. 
Within the calf muscles, medial gastrocnemius which almost universally shows greatest 
fat accumulation has only the fourth highest frequency of STIR hyperintensity, with 
tibialis anterior the most commonly STIR affected muscle.  Tibialis posterior least 
commonly shows STIR hyperintensity, congruent to its relative sparing from IFA. 
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Figure 4-7: Distribution of STIR abnormalities in IBM patients 
 
4.4.4.2 Early water abnormalities in muscles without significant 
intramuscular fat accumulation 
As noted in section 4.4.3.4, the measures selected to quantify abnormal muscle water 
distribution in this study: T2 and MTR, are significantly influenced by intramuscular fat 
accumulation.  One approach taken was to assess muscles without significant IFA, 
defined here as the 95% percentile of IFA levels of the muscles of control subjects.  For 
the 29 control subjects, the FF 95th percentiles were 4·8% for thigh muscles and 4·7% 
for calf-level muscles, defining the upper thresholds for IFA in these healthy controls.  
Muscles with “normal” levels of intramuscular fat are also an important group to study 
as they represent an early phase in the disease process before irreversible muscle 
damage has occurred. 
Within just this subset of muscles without significant intramuscular fat accumulation, 
significantly increased T2 and reduced MTR were seen in both thigh and calf muscles 
of both IBM and CMT patients compared with matched controls (Table 4-9).  In the 
same subgroup, T2 and MTR measurement differed by qualitative STIR assessment: 
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increased STIR signal was associated with increased T2 and reduced MTR in both 
thigh and calf muscles in IBM patients and in calf muscles in CMT patients (Table 
4-10).  This association was also evident in the control group.  Notably, T2 was 
significantly elevated in IBM patients at both thigh and calf level and in CMT1A patients 
at calf level, even when STIR assessment was normal.  These T2 and MTR 
abnormalities prior to significant fat infiltration provide means to quantify early NMD 
pathology, with abnormalities quantifiable even in muscles without STIR hyperintensity. 
Table 4-9: Quantitative parameters in muscles without significant IFA 
Group CMT Control (CMT) IBM Control (IBM) 
Thigh FF 1.5 ± 1.0* 1.4 ± 1.1 2.5 ± 1.2*** 1.6 ± 1.1 
Thigh T2 42.6 ± 4.7*** 41.2 ± 4.5 48.7 ± 7.9*** 42.5 ± 4.4 
Thigh MTR 31.7 ± 1.9** 32.1 ± 1.5 29.6 ± 2.3*** 31.7 ± 1.6 
Calf FF 1.9 ± 1.1*** 1.4 ± 1.0 2.2 ± 1.2*** 1.6 ± 1.1 
Calf T2 42.2 ± 4.6*** 39.2 ± 3.0 45.5 ± 7.0*** 40.9 ± 3.8 
Calf MTR 31.4 ± 1.7*** 32.3 ± 1.2 30.4 ± 2.3*** 31.7 ± 1.3 
Comparison of mean values of quantitative MRI parameters between patient and 
control groups.  Significant differences (*p<0.05, **p<0.01, ***p<0.001) are apparent 
even in these muscles without significant fat infiltration.  CMT: Charcot-Marie-Tooth 
disease; IBM: inclusion body myositis; FF: fat fraction; MTR: magnetisation transfer 
ratio. 
Table 4-10: Quantitative parameters in muscles without significant IFA grouped by STIR 
Group IBM CMT Control (All) 
STIR signal Normal Increased Normal Increased Normal Increased 
Thigh FF 2.3 ± 1.2 2.7 ± 1.2 1.5 ± 1.0 1.7 ± 1.1 1.4 ± 1.0 2.2 ± 1.4** 
Thigh T2 46.6 ± 6.3 51.9 ± 9.0*** 42.6 ± 4.6 42.7 ± 5.3 41.6 ± 4.3 44.3 ± 3.7* 
Thigh MTR 30.1 ± 2.0 28.8 ± 2.5** 31.7 ± 1.9 31.6 ± 1.7 32 ± 1.6 31.1 ± 1.1* 
Calf FF 2.0 ± 1.1 2.3 ± 1.2 1.7 ± 1.1 2.2 ± 1.2* 1.4 ± 1.0 1.6 ± 1.0 
Calf T2 42.6 ± 3.5 48.2 ± 8.3*** 41.4 ± 3.8 44.5 ± 5.7*** 39.7 ± 3.6 41.8 ± 3.9*** 
Calf MTR 31.7 ± 1.3 29.2 ± 2.5*** 31.7 ± 1.3 30.6 ± 2.4*** 32.2 ± 1.3 31.6 ± 1.3*** 
Comparison of mean values of quantitative MRI parameters of muscles without 
significant fat infiltration according to qualitative findings on STIR imaging.  Significant 
(*p<0.05, **p<0.01, ***p<0.001) increases in T2 and decreases in MTR are seen in 
muscles with qualitative STIR hyperintensity in IBM, CMT and control groups. 
However, even in this subgroup of muscles without significant intramuscular fat 
accumulation, patients had slightly higher FF than their respective controls (Table 4-9).  
To account for this, regression analysis was performed including muscle FF as a 
covariate.  Regression analyses were performed separately for the IBM and CMT 
groups, combined with their respective controls, including only data from individual 
patient and control muscles with FF below the “normal” FF thresholds.  On this 
analysis, T2 and MTR remained significantly dependent upon FF (Table 4-11); 
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however the dependencies for control versus disease status were also significant in 
each case, with increased T2 (thigh: +4·0±0·5ms [co-eff±SE], calf: +3·5±0·6ms) and 
reduced MTR (thigh: -1·5±0·2p.u., calf: -1·1±0·2p.u.) independent of FF in this 
regression model, in IBM versus matched controls. Smaller but significant FF-adjusted 
dependencies were also observed in CMT1A versus matched-controls, especially at 
calf-level (T2 thigh: +1·0±0·3ms; T2 calf: +2·0±0·3ms; MTR thigh -0·3±0·1p.u.; MTR 
calf -0·7±0·1p.u.). 
Table 4-11: Linear regression T2 and MTR in muscles fat fraction in the healthy control 
range 
A Thigh Calf 
T2 
R=0·62, p<0·001 R=0·52, p<0·001 
Co-eff Std Error p Co-eff Std Error p 
Constant 38·4 0·43 <0·0001 38·0 0·53 <0.0001 
IBM 4·0 0·54 <0·0001 3·5 0·57 <0.0001 
FF 2·52 0·21 <0·0001 1·78 0·25 <0.0001 
MTR 
R=0·61, p=<0·001 R=0·39, p<0·001 
Co-eff Std Error p Co-eff Std Error p 
Constant 32·9 0·16 <0.0001 32·3 0·20 <0·0001 
IBM -1·5 0·19 <0.0001 -1·1 0·21 <0·0001 
FF -0·74 0·07 <0.0001 -0·33 0·09 0·0007 
B Thigh Calf 
T2 
R=0·49, p<0·001 R=0·59, p<0·001 
Co-eff Std Error p Co-eff Std Error p 
Constant 38·4 0·29 <0·0001 36·6 0·31 <0·0001 
CMT1A 1·0 0·31 0·0008 2·0 0·33 <0·0001 
FF 2·07 0·15 <0·0001 1·87 0·17 <0·0001 
MTR 
R=0·40, p<0·001 R=0·38, p<0·001 
Co-eff Std Error p Co-eff Std Error p 
Constant 33·0 0·12 <0·0001 32·8 0·14 <0·0001 
CMT1A -0·3 0·13 0·04 -0·7 0·15 <0·0001 
FF -0·65 0·06 <0.0001 -0·40 0·08 <0·0001 
Muscles with FF < 4·8% thigh; FF < 4·7% calf in IBM (A) and CMT1A (B) patients and 
matched controls   Determinants of T2 and MTR in muscles with normal FF. FF 
remains strongly correlated to both T2 and MTR, however subject group (patient = 1, 
control =0) also has a significant effect. R: Overall model correlation coefficient; 
CMT1A: Charcot-Marie-Tooth disease type 1A; IBM: inclusion body myositis; FF: fat 
fraction; MTR: magnetisation transfer ratio; Co-eff: partial regression coefficient; p: 
significance level. 
4.4.4.3 Assessment of T2 values relative to FF levels 
The relationship between FF and T2 for higher levels of FF was also assessed.  Within 
thighs of IBM patients, T2 was higher for equivalent FF in muscles with STIR 
hyperintensity (Figure 4-8).  This is demonstrated on a scatter plot and also by 
grouping FF within the ranges: <5%, 5-20%; 20-40%, 40-60% and >60% (Figure 4-9). 
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Figure 4-8: T2 vs Fat Fraction in thigh muscles of IBM patients grouped by qualitative 
STIR rating 
 
Loess best fit lines for different STIR ratings are shown. 
Figure 4-9: Thigh FF range vs T2 in IBM patient grouped by STIR positivity 
  
 
141 
4.4.5 Clinical data 
Baseline clinical measures are summarised in Table 4-12.  CMT1A patients had a 
median age of onset of 6 years, ranging from 1 year to a 27 year old asymptomatic 
patient (diagnosed on family testing).  The CMT patients covered a broad range of 
severity, with CMT-examination score ranging from 0-18/28 (mean 8.0, standard 
deviation 5.1).  In IBM subjects, the median IBM-FRS was 28.5, range 18-35, so were 
overall of mild to moderate severity. 
Table 4-12: Clinical data summary 
Measure CMT IBM 
Age of onset 6·0 ± 4·4 59·0 ± 8·5 
Disease duration 35·8 ± 17·5 7·7 ± 3·1 
CMTSS (0-12) 3·1 ± 2·0 NA 
CMTES (0-28) 8·0 ± 5·1 NA 
MRC LL (0-110) 95·4 ± 15·4 93·4 ± 15·7 
MRC UL (0-120) 112·4 ± 7·9 95·2 ± 12·8 
MRC Total (0-230) 207·8 ± 21·8 188·6 ± 27·1 
SF36 (0-100%) 73·9 ± 15·2 61·5 ± 15·3 
SF36-PF (0-100%) 65·3 ± 23·2 39·5 ± 19·1 
IBMFRS-LL (0-12) NA 5·9 ± 2·4 
IBMFRS (0-40) NA 27·6 ± 5·4 
MRC: Medical Research Council bedside strength assessment; SF-36: Short Form 
Health Survey; PF: physical functioning domain; CMTES: CMT Examination Score; 
IBM-FRS: IBM Functional Rating Score; NA: Not applicable. 
4.4.5.1 Myometry 
In both patient groups the baseline myometric muscle strength was significantly 
reduced in all muscle groups compared with their matched controls (Table 4-13 and 
Table 4-14, all p<0.01). 
Table 4-13: Baseline myometry statistics by group 
Measure CMT Control (CMT) p IBM Control (IBM) p 
Knee extension 93·6 ± 44·1 134·9 ± 43·5 0·005 26·8 ± 26·0 119·9 ± 43·0 <0·0001 
Knee flexion 47·2 ± 20·1 66·1 ± 20·4 0·006 35·3 ± 19·9 60·6 ± 20·1 <0·0001 
Ankle plantarflexion 26·0 ± 14·3 62·0 ± 19·1 <0·0001 29·6 ± 15·7 51·6 ± 18·4 <0·0001 
Ankle dorsiflexion 10·8 ± 7·5 30·0 ± 9·8 <0·0001 13·2 ± 10·8 28 ± 10·6 <0·0001 
Values are mean ± standard deviation in Nm of all isometric and isokinetic 
measurements combined for each movement. 
As expected, in CMT patients, weakness was greater for ankle movements (calf 
muscles).  In CMT overall ankle dorsiflexion was, relative to controls, weaker than 
ankle plantarflexion as per the classical clinical description (Reilly et al., 2011); 
however this difference was only observed in isometric strength assessment (at 10 
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degrees plantarflexion) whereas with isokinetic strength measurement both ankle 
plantarflexion and ankle dorsiflexion were similar, roughly half of control values when 
assessed.  Furthermore, the angle of peak isokinetic strength in CMT1A patients was 
at a significantly greater degree of plantarflexion than in the matched controls (30 
degrees versus 10%), suggesting that the reduced isometric strength observed for 
ankle dorsiflexion may be partly due to the angle chosen for assessment combined 
with reduced range of ankle dorsiflexion.  A similar pattern was seen for ankle eversion 
which was weaker than ankle inversion, especially with isometric assessment.  The 
observed knee weakness in CMT1A patients is somewhat unexpected, given the 
general lack of fatty infiltration observed in the thigh muscles, and in 18/20 CMT1A 
patients, knee movements were graded full strength on bedside examination (MRC 
grade 5).  This does concur with a small reduction in thigh muscle size observed in 
CMT1A patients (Table 4-2 and Table 4-4), and may therefore be related to 
deconditioning due to a reduction in general physical activity compared with the healthy 
controls in the study 
In IBM patients weakness was greater for knee movements (thigh muscles), especially 
knee extension, as expected from the clinical phenotype (Hilton-Jones et al., 2010).  All 
ankle movements were also weak, with marginally greater weakness of ankle eversion.  
Unlike the CMT1A patients, isokinetic and isometric reductions in strength versus 
matched controls were of similar magnitude in IBM patients. 
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Table 4-14: Baseline isokinetic and isometric myometry by group 
Movement Type Side/angle CMT Control (CMT) IBM Control (IBM) 
Knee 
Extension 
Isometric 
Right at 45° 111.1 ± 48.9 (24-209) 155.6 ± 47.3 (73-259) 35.4 ± 38.4 (0-146) 138.6 ± 60 (18-259) 
Left at 45° 109.7 ± 47.6 (38-217) 152.2 ± 45.5 (73-231) 33.5 ± 38.3 (0-145) 138.9 ± 48.7 (62-218) 
Right at 90° 112.2 ± 58.4 (45-290) 159.3 ± 62.6 (84-292) 29.2 ± 23.9 (2-91) 136.6 ± 55.4 (18-252) 
Left at 90° 106.6 ± 60.8 (43-277) 142 ± 50.5 (72-247) 28.3 ± 26.5 (0-94) 128.5 ± 43.3 (72-216) 
Isokinetic 
Right at 60°/s 87 ± 45 (12-184) 133.5 ± 49.1 (49-239) 25 ± 22 (0-87) 116.8 ± 45.4 (18-190) 
Left at 60°/s 87.4 ± 42.1 (23-165) 127.6 ± 40 (52-202) 24.2 ± 24.4 (0-94) 115.7 ± 38 (52-174) 
Right at 120°/s 70 ± 32.5 (27-138) 106.9 ± 40.8 (41-206) 20.2 ± 18.3 (0-71) 93 ± 38.5 (13-170) 
Left at 120°/s 68.6 ± 35.3 (26-138) 102.5 ± 35.2 (45-165) 19 ± 19.7 (0-80) 91.4 ± 32.8 (45-145) 
Knee 
Flexion 
Isometric 
Right at 45° 65.8 ± 26.9 (33-115) 86.6 ± 28.9 (53-141) 49.6 ± 27.4 (2-110) 80 ± 29.1 (33-140) 
Left at 45° 66.3 ± 27.5 (33-113) 81.8 ± 22.9 (35-132) 48.8 ± 25.5 (2-106) 74.9 ± 27.7 (35-132) 
Right at 90° 47.9 ± 20.4 (14-92) 64.7 ± 27.1 (31-127) 28.9 ± 18.1 (0-68) 54.7 ± 18.9 (26-106) 
Left at 90° 45.4 ± 20.9 (15-83) 57.8 ± 24.3 (28-110) 31.3 ± 20.9 (0-77) 49.3 ± 18.3 (24-95) 
Isokinetic 
Right at 60°/s 46.6 ± 18.8 (9-81) 70 ± 21.7 (28-123) 34.9 ± 21.4 (0-81) 64.5 ± 21 (27-99) 
Left at 60°/s 45.1 ± 20 (8-85) 62.9 ± 17.3 (20-85) 37 ± 21.5 (0-80) 62.4 ± 22.7 (20-104) 
Right at 120°/s 35.1 ± 16.8 (14-72) 55.5 ± 19.7 (22-102) 26.1 ± 17.7 (0-72) 50.8 ± 17.8 (22-87) 
Left at 120°/s 34.5 ± 18.6 (12-75) 50 ± 14.9 (20-77) 25.9 ± 17 (0-57) 48.5 ± 18.2 (20-84) 
Ankle 
Plantar-
flexion 
Isometric 
Right at 10° 33.7 ± 19.6 (1-64) 66.6 ± 20.8 (35-106) 34.4 ± 18.7 (3-64) 56.2 ± 19.1 (28-92) 
Left at 10° 32.7 ± 19.8 (0-64) 65.1 ± 19.5 (33-108) 33.6 ± 16.7 (4-60) 57.2 ± 23.7 (33-110) 
Isokinetic 
Right at 60°/s 18.7 ± 12.8 (5-58) 57.7 ± 21.6 (24-107) 24.1 ± 14.3 (0-54) 46.1 ± 17 (22-75) 
Left at 60°/s 19 ± 12.4 (4-53) 58.6 ± 21.7 (22-115) 29.2 ± 17.2 (7-71) 46.9 ± 20.5 (8-79) 
Ankle 
Dorsi-
flexion 
Isometric 
Right  9.7 ± 8.1 (0-31) 35.7 ± 13.7 (16-60) 15 ± 12.9 (0-38) 33 ± 14.9 (7-60) 
Left at 10° 10 ± 7.8 (0-27) 34.5 ± 13.1 (12-58) 15.4 ± 12.5 (0-38) 32.6 ± 14.2 (8-58) 
Isokinetic 
Right at 60°/s 11.9 ± 8.4 (0-30) 25.4 ± 8.5 (12-42) 11.8 ± 12.5 (0-50) 23.3 ± 9.2 (9-42) 
Left at 60°/s 11.9 ± 11 (0-43) 24.5 ± 8.7 (7-37) 11.8 ± 8.3 (0-26) 23.2 ± 9 (7-35) 
Ankle 
Inversion 
Isometric 
Right at 0° 15.6 ± 10 (0-37) 20.4 ± 7.1 (9-33) 11.9 ± 7.3 (0-27) 18.1 ± 6.4 (9-33) 
Left at 0° 14.8 ± 10.4 (0-45) 20.1 ± 7.1 (7-30) 11.5 ± 6.7 (0.15-26) 17.7 ± 6.7 (7-30) 
Isokinetic 
Right at 60°/s 16 ± 9.9 (0-38) 25.4 ± 7.9 (11-39) 14.9 ± 9.6 (3-34) 22.7 ± 7.8 (9-34) 
Left at 60°/s 14.3 ± 9.5 (3-35) 25.6 ± 8.9 (11-43) 17.1 ± 10.2 (3-35) 21.8 ± 8.6 (11-39) 
Ankle 
Eversion 
Isometric 
Right at 0° 7.1 ± 4.1 (1-14) 22 ± 7.6 (9-37) 9.6 ± 5.9 (0-22) 19 ± 7.6 (9-34) 
Left at 0° 7.7 ± 4.8 (0-18) 21.4 ± 7.1 (11-34) 10.2 ± 6.5 (0-20) 17.5 ± 6.9 (8-31) 
Isokinetic 
Right at 60°/s 8.4 ± 4 (1-15) 17.3 ± 5.6 (9-28) 9.2 ± 5 (0-20) 15.1 ± 5.6 (8-23) 
Left at 60°/s 7.8 ± 3.1 (3-14) 17.4 ± 5.8 (9-30) 9.3 ± 5.8 (0-24) 16.2 ± 7.1 (8-33) 
Data are mean ± standard deviation (range). Isometric values are the peak torque at the fixed 
angle listed whilst isokinetic values are the peak torque at the fixed speed noted. Both CMT1A 
patients and IBM patients have significantly (p<0.01 for all) reduced strength than their 
matched control groups for all measurements. 
4.4.6 MRI - clinical correlations 
There were significant correlations in both CMT1A and IBM patient groups between 
overall clinical measures and summary MRI FF measurements, and between specific 
myometric strength measurements and quantitative MRI measurements in relevant 
functional groups.  
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4.4.6.1 Correlations between overall MRI and clinical measures 
In IBM patients, all-muscle thigh-level FF correlated with disease duration (rho=0·50, 
p=0·03, Figure 4-10), IBM-FRS (rho=-0·53, p=0·02), IBM-FRS lower limb components 
(rho=-0·64, p=0·002, Figure 4-11), the total MRC score lower limb (rho=-0·60, 
p=0·005), and the physical function domain of the SF36 (rho=-0·60, p=0·007).  There 
were not significant correlations with overall SF36 (rho=-0·11, p=0·66) or age 
(rho=0·14, p=0·55). 
In CMT, all-muscle calf-level FF correlated with disease duration (rho=0·89, p<0·0001, 
Figure 4-10), age (rho=0·84, p<0·0001, Figure 4-12), CMTES (rho=0·63, p=0·003, 
Figure 4-13), lower limb motor component of the CMTNS (rho=0·77, p<0·0001) and 
reduced total MRC score lower limb (rho=-0·76, p<0·0001). The correlation between 
all-muscle calf FF and total SF36 score was not significant (rho=-0·34, p=0·18), 
however the correlation with the SF-36 physical function domain score was significant 
(rho=-0·63, p=0·007). 
Figure 4-10: Correlation of fat fraction with disease duration in IBM and CMT1A patients 
          
Scatter plot of disease duration versus thigh-level (□) and calf-level (x) fat fraction in 
IBM and CMT1A patients. In IBM patients positive correlation between disease 
duration and mean fat fraction is seen at thigh level (rho=0.50,p=0.03) but not calf level 
(rho=0.27, p=0.28).  In CMT1A patients, strong positive correlations at both levels are 
seen (thigh: rho=0.81, p<0.0001 ; calf: rho=0.89, p<0.0001).  The relationship between 
disease duration and fat fraction appears non-linear in the CMT1A group. 
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Figure 4-11: Correlation between IBM-FRS (lower limb) and thigh FF in IBM patients 
 
Figure 4-12: Relationship between age and calf FF in CMT1A patients 
 
Figure 4-13: Correlation of calf fat fraction with severity score (CMTES) in CMT1A 
patients 
 
There is significant correlation between calf muscle fat fraction and CMTES in CMT1A 
patients (rho=0.63, p=0.003).  The relationship appears non-linear.  
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Figure 4-14: Correlation matrix of MRI FF and IBM-FRS domains in IBM patients 
 
It was informative to assess the cross-correlation matrix in the IBM patients between 
lower limb FF, thigh FF and the individual domains which make up the IBM-FRS 
(Figure 4-14).  Although thigh fat fraction did correlate with the overall IBM-FRS (rho=-
0.48, p=0.03), it did not significantly correlate with the swallowing domain or any of the 
domains which predominantly assess upper limb function.  Indeed, even between the 
IBM-FRS components, the upper limb components generally correlated with each 
other, and the lower limb components correlated with each other, but there was no 
correlation between upper and lower limb components. 
4.4.6.2 Correlation between MRI measures and myometry 
In all subgroups for all movements assessed, muscle strength showed strong positive 
correlation with total cross-sectional area of the corresponding muscle group (Table 
4-15).  In regions where patient fat fraction was elevated (IBM thigh and calf level, CMT 
calf level), muscle fat fraction (whole ROI) showed strong negative correlation with 
muscle strength (Table 4-15).  The combined parameter “remaining muscle area” (an 
overall measure of fatty atrophy) had the strongest correlation with muscle strength 
(Figure 4-15, Table 4-15). 
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Table 4-15: Correlation of muscle strength with MRI parameters in each subject group 
 
IBM CMT Control 
Area FF RMA Area FF RMA Area FF RMA 
Right 
Quadriceps 
Pearson ICC 0.665** -0.551* 0.809** 0.780** -0.323 0.791** 0.903** -0.407* 0.907** 
p 0.001 0.012 0.000 0.000 0.165 0.000 0.000 0.035 0.000 
Left 
Quadriceps 
Pearson ICC 0.727** -0.778** 0.917** 0.848** -0.286 0.860** 0.900** -0.251 0.905** 
p 0.000 0.000 0.000 0.000 0.222 0.000 0.000 0.207 0.000 
Right 
Hamstrings 
Pearson ICC 0.702** -0.561* 0.800** 0.469* -0.252 0.539* 0.647** -0.264 0.670** 
p 0.001 0.010 0.000 0.043 0.298 0.017 0.000 0.183 0.000 
Left 
Hamstrings 
Pearson ICC 0.706** -0.579** 0.790** 0.587** -0.295 0.664** 0.635** -0.247 0.660** 
p 0.001 0.007 0.000 0.008 0.220 0.002 0.000 0.215 0.000 
Right Anterior 
Compartment 
Pearson ICC 0.780** -0.509* 0.833** 0.607** -0.544* 0.775** 0.600** -0.195 0.622** 
p 0.000 0.037 0.000 0.004 0.013 0.000 0.001 0.339 0.001 
Left Anterior 
Compartment 
Pearson ICC 0.675** -0.538* 0.796** 0.606** -0.634** 0.759** 0.672** -0.376 0.677** 
p 0.002 0.021 0.000 0.005 0.004 0.000 0.000 0.058 0.000 
Right Triceps 
Surae 
Pearson ICC 0.476* -0.626** 0.769** 0.531* -0.609** 0.719** 0.589** -0.235 0.613** 
p 0.039 0.007 0.000 0.016 0.004 0.000 0.001 0.248 0.001 
Left Triceps 
Surae 
Pearson ICC 0.452 -0.556* 0.681** 0.741** -0.681** 0.834** 0.493** -0.010 0.540** 
p 0.052 0.017 0.002 0.000 0.001 0.000 0.008 0.963 0.004 
IBM: inclusion body myositis; CMT: Charcot-Marie-Tooth disease; FF: fat fraction; RMA: remaining muscle area (see methods for 
definition); Pearson ICC: Pearson inter-class correlation coefficient; * significant correlation p<0.05; ** significant correlation p<0.01. 
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Figure 4-15: Correlation of MRI measured remaining muscle area with isometric muscle 
strength 
A B 
  
C D 
 
MRI measured RMA of lower limb muscle groups show strong correlation with corresponding 
strength in IBM (x), CMT1A (+) and controls (o).  A: Right quadriceps. IBM: rho=0.81, p<0.0001; 
CMT: rho=0.79, p<0.0001; controls: rho=0.91, p<0.0001.  B: Right hamstrings. IBM: rho=0.80, 
p<0.0001; CMT: rho=0.54, p=0.02; controls: rho=0.67, p<0001.  C: Right anterior compartment. 
IBM: rho=0.83, p<0.0001; CMT: rho=0.78, p<0.0001; controls: rho=0.62, p=0.0007.  D: Right 
triceps surae.  IBM: rho=0.77, p<0.0001; CMT: rho=0.72, p<0.0001; controls: rho=0.61, 
p=0.0009. 
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4.4.6.3 Assessment of muscle quality 
To account for the confounding effect of differences in muscle size, some papers 
define a metric for “muscle quality” as being the maximum torque generated per cross-
sectional area: 
Specific Strength = Strength / Muscle Cross-sectional Area 
Equation 4-1: Muscle quality formula 
This type of assessment has been used in measuring the effect of ageing (Delmonico 
et al., 2009; Jubrias et al., 1997), longitudinally in diabetic neuropathy (Andreassen et 
al., 2009) and also in myotonic dystrophy (Hiba et al., 2012).  Reduced muscle quality, 
beyond even the effect of intramuscular fat accumulation can be seen in Figure 4-15, 
where the patient best fit lines for the remaining muscle area to strength correlation is 
lower than that in healthy controls, demonstrating that patient muscles are weaker even 
when the fatty atrophy is taken into account.  The distribution of muscle quality 
(isometric torque per unit cross-sectional area) is shown in Figure 4-16 with clearly 
reduced muscle quality in both IBM and CMT1A patients compared with controls.  
There is one outlier in the control group. 
Figure 4-16: Muscle quality of tibialis anterior in the three subject groups 
 
Distribution of tibialis anterior muscle quality, defined as maximum isometric ankle 
dorsiflexion torque (Nm) per cm2 of total muscle area across the three subject groups. 
A potential advantage of this assessment is that it allows analysis of correlation with 
any of the quantitative parameters, by using the value derived from the small ROI for 
T1/T2/MTR and the cross-sectional muscle area from the full ROI.  Thus one can 
assess if MTR or fat fraction estimates “muscle quality” better or if the addition of T2 
values adds to estimation of “muscle quality” from fat fraction alone. 
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Correlations between isometric and isokinetic torque per unit area and MRI parameters 
for tibialis anterior muscle are shown in Table 4-16.  There is a negative correlation 
with age and BMI (decreasing muscle quality as age or BMI increase) and a positive 
correlation with height.  All quantitative parameters showed strong, highly significant 
correlations with muscle quality.  Whole ROI FF had stronger correlations than small 
ROI FF, but the best performing quantitative parameter was MTR followed by T2 time – 
the measures which are sensitive to both chronic and acute pathology.  Considering 
just the IBM patients, who had greatest degree of acute changes quantifiable, MTR and 
age provided a more accurate model of muscle quality than FF and age (Figure 4-17). 
Table 4-16: Correlates of tibialis anterior muscle quality  
 
Parametric correlation of tibialis anterior specific force (Nm/cm2) with quantitative MRI 
and demographic parameters in all subjects 
Figure 4-17: Regression analyses of tibialis anterior muscle quality for IBM patients 
MTR and 
age 
R=0·78, p=<0·001 
Co-eff Std Error p 
Constant 0.43 1.17 <0.001 
Age -0.030 0·010 <0.001 
MTR 0.148 0·030 <0.001 
 
FF and 
age 
R=0·68, p<0·001 
Co-eff Std Error p 
Constant 5.33 0·61 <0·001 
Age -0.042 0·010 <0.001 
FF -0.051 0·017 <0.001 
The dependent variable is maximum isometric torque per cross-sectional area in 
Nm/cm2, a measure of “muscle quality”.  Age is significantly related.  The addition of 
MTR (top) measurement results in a more accurate model than the addition of FF 
(bottom).  
Factor 
Isometric torque per area Isokinetic torque per area 
Pearson ICC p-value Pearson ICC p-value 
Age (y) -0.29 0.001 -0.39 <0.001 
Height (cm) 0.26 0.003 0.06 0.47 
Weight (kg) 0.01 0.91 -0.13 0.13 
BMI (kg/m2) -0.18 0.04 -0.23 0.009 
FF-small (%) -0.52 <0.001 -0.50 <0.001 
T1 time (ms) 0.53 <0.001 0.53 <0.001 
T2 time (ms) -0.62 <0.001 -0.59 <0.001 
MTR (p.u.) 0.66 <0.001 0.63 <0.001 
FF-whole (%) -0.57 <0.001 -0.54 <0.001 
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 Discussion 
In the cross-sectional phase of the study, fat infiltration strongly correlated with 
strength, function and overall severity, demonstrating high criterion validity for these 
measurements.  T2 and MTR were abnormal in muscles without significant fat 
infiltration quantifying early and potentially reversible pathological changes.  In 
additional to specific insights into CMT1A and IBM, the published literature 
demonstrates that these methods will have wide applicability across a broad spectrum 
of neuromuscular diseases. 
4.5.1 Validity of MRI measures of fatty atrophy 
Demonstration of validity is the central aim of this cross-sectional study phase.  These 
data provide direct support for both criterion and construct validity of quantitative MRI 
measures in these representative neuromuscular diseases.  In addition, the data 
suggest which measures will have best content validity for these diseases. 
4.5.1.1 Construct validity 
Construct validity is the ability of a test to measure the underlying concept of interest to 
the researcher.  This was assessed in this study by both the known groups method and 
through demonstration of convergent validity. 
4.5.1.1.1 Known groups method 
The known groups method assesses whether the measurement differs in groups 
known to differ in the construct of interest.  In this study we can consider the 
quantitative MRI measurements between the CMT1A group and their matched 
controls, between the IBM group and their matched controls, and also directly between 
the CMT and IBM patient groups. 
The MRI measures in the CMT1A group are all significantly different from the matched 
controls at calf level but not thigh level (Table 4-2).  All measures are similarly affected 
due to the well-known strong interdependencies of these measures, demonstrated 
again in this study (Table 4-7), an example of convergent validity.  There was also 
measurable muscle atrophy at the calf level (Table 4-2), consistent with clinical 
observations in this disease (Reilly et al., 2011).  A small effect on T2 and MTR 
independent of and predating intramuscular fat accumulation was seen at calf level 
(Table 4-9, Table 4-11), demonstrating construct validity for these methods in detecting 
early abnormalities relating to muscle denervation. 
In the IBM group, greater changes in quantitative parameters were seen at thigh than 
calf level (Table 4-2), again consistent with the observed clinical phenotype (Hilton-
Jones et al., 2010).  The pattern of involvement within the thigh with predominant 
affliction of quadriceps (Table 4-6) is also one of the key clinical features of IBM, and 
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thus provides construct validity.  Significantly abnormal T2 and MTR in muscles without 
significant fat infiltration is consistent with inflammatory changes seen on muscle 
biopsy.  Again the ability to demonstrate the clinically expected pattern of involvement 
provides construct validity for these measurements.  These findings are consistent with 
previous studies which have applied fat quantification methods to neuromuscular 
diseases (4.2.2). 
This cross-sectional study is unique in including a large number of patients with two 
completely dissimilar neuromuscular diseases.  Most previous quantitative studies 
have included either a single disease, or occasionally a large number of diseases each 
with only a few subjects.  This study allows assessment of construct validity through 
direct comparison of results between the two patient groups.  Again the measurements 
are as would be expected from these diseases: a greater degree of fatty atrophy in 
thigh muscles in IBM than in CMT1A, similar levels of IFA in the calf muscles, and 
overall greater T2/MTR abnormalities independent of fat infiltration in the IBM group. 
4.5.1.1.2 Convergent validity 
Convergent validity is demonstrated when results on the test being administered are 
similar to those thought to measure the same underlying construct.  In this study the 
correlation observed between established qualitative MRI methods and novel 
quantitative MRI methods is a demonstration of convergent validity. 
Consistent with other studies (Willis et al., 2014; Wokke et al., 2013) there are clear 
relationships between qualitative Mercuri grading of IFA and quantitative FF in the 
same muscle (Figure 4-6) and the relationship between STIR abnormality and measure 
T2 and MTR (Figure 4-8, Figure 4-9, Table 4-10). 
Although the qualitative and quantitative measures show a clear relationship, the 
advantages of the quantitative assessment are clear.  Consistent with previous studies, 
the qualitative gradings overestimate the fat content compared with that qualitatively 
measured.  For example, grade Mercuri grade 2b is defined as 30-60% fat 
replacement, but the median FF of muscles scored 2b was 24 (IQR 17-37).  Similarly, 
the majority of muscles graded 3 scored less than the 60% FF designated as the lower 
boundary of this category.  Significant overlap is seen between adjacent Mercuri grade 
categories, and wide ranges of FF within one Mercuri grade.  Both of these emphasise 
that qualitative grading is more useful for diagnostic than outcome measure purposes, 
which will be directly assessed using longitudinal data in chapter 5.  Qualitative data 
however does provide sufficient information for patient stratification.  This is already 
used for muscle biopsy site selection where normal muscles or severely affected 
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muscles are avoided, and may prove useful at a screening phase in a clinical trial 
should a homogenous patient group be desired. 
4.5.1.2 Criterion validity 
Criterion validity is assessment of the novel measurement against a gold standard, and 
is perhaps the most important demonstration of validity in a medical context.  In 
particular outcome measure validity should be demonstrated through correlation to 
relevant patient function.  This is vital for both drug licencing agencies and the patient. 
We demonstrated strong clinical-MRI correlations for both overall subject and individual 
muscle measures.  In both CMT1A and IBM there are strong correlations between 
overall MRI measures and quality of life indices, functional or composite scales 
(IBMFRS and CMTES) and bedside strength examination, consistent with previous 
research (Hiba et al., 2012; Huang et al., 1994; Kim et al., 2010a; Willis et al., 2013).  
As might be expected, correlations were stronger with more closely related functional 
measures – for example mean fat fraction correlated with the physical function domain 
of the quality of life score, but not the total score; for CMT1A patients within the 
CMTES, correlation was strongest with the lower limb motor function score, and for 
IBM patients correlation was strongest with the lower limb motor relevant aspects of the 
IBM-FRS (sit-to stand, walking and stair climb).  Indeed, there was no significant 
correlation between lower limb FF and function in the swallowing or upper limb 
domains – which may have been expected on an overall disease severity basis. This 
suggests that upper limb and lower limb function progress independently, and may 
therefore have different pathogenic mechanisms.  Conversely in CMT1A, correlations 
are seen between FF and all aspects of the CMTES, including domains such as 
sensory impairment not directly related to what MRI has measured, suggesting that 
pathogenesis of this disease is more homogenous, with more uniform patterns of 
disease progression. 
At the individual muscle level, the intuitively expected correlation between CSA and 
strength in healthy controls was demonstrated here as previously (Maughan et al., 
1983).  In patients there was an additional negative correlation between strength and 
FF, demonstrated previously in myotonic dystrophy for ankle dorsiflexion (Hiba et al., 
2012) and here for both ankle and knee movements in both diseases.  Muscle CSA 
and level of fat infiltration combined as the “remaining muscle area” metric correlated 
most strongly with strength  Thus MRI provides indices of chronic muscle pathology 
which are highly correlated to muscle strength, but independent of subject effort or 
operator involvement which lead to the poor test-retest and inter-observer reliability 
(Solari et al., 2008) of direct muscle strength measures.  MRI therefore provides a 
valid, reliable surrogate measure of muscle strength. 
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4.5.1.3 Face validity 
Both reduction in muscle size and replacement of muscle with fat have excellent face 
validity as being measures of disease severity.  MRI-measured muscle fat has 
previously been shown to correlate strongly with biopsy-measured muscle fat with a 
correlation coefficient of 0.995 (Gaeta et al., 2011).  As the structure of skeletal muscle 
is relatively straightforward, reduction of contractile cross-sectional area (remaining 
muscle area) through fat replacement or muscle atrophy is a very plausible measure of 
disease severity.  Conversely T2, MTR and T1 measurements have less face validity, 
and their validity requires greater justification through the other means mentioned. 
4.5.1.4 Content validity 
Content validity is the degree to which the measurement includes all aspects relevant 
to the concept being measured. This needs to be considered for each disease 
separately. 
In CMT1A the distribution of weakness is length dependent, and hence predominantly 
lower limb, although upper limb weakness does occur at later stages of the disease 
(Reilly et al., 2011).  On the one hand, only muscle abnormalities are detectable with 
the MRI protocol used and the protocol will not directly measure sensory deficit, which 
is an important feature of CMT1A. On the other hand, calf muscle fat fraction correlated 
with all components of the CMTES – including the sensory symptoms, sensory signs 
and upper limb weakness domains.  Although correlation was highest for the lower limb 
motor domain, correlation with all domains suggests some overall uniformity in disease 
progression across the domains, and an accurate measure of one domain may then be 
considered an appropriate marker of overall disease severity. 
The validity of a pure motor measurement in CMT1A will also be dependent on the 
intervention being assessed.  Lower limb MRI would not have content validity for a drug 
which benefited only sensory nerves, or a physiotherapy intervention targeting only 
upper limb muscles.  If a lower limb muscle assessment is considered valid, a second 
issue is, does a single slice at thigh level and a single slice at calf level have content 
validity – or should whole muscle measurements be performed.  A particular 
consideration is the ceiling effect, where a number of patients with CMT1A (green lines 
in Figure 4-5) have similar intramuscular fat at the calf level to healthy controls, 
whereby MRI quantification of intramuscular fat does not adequately define disease 
severity in these patients, although the findings of T2 and MTR abnormalities before 
IFA may provide some coverage for this group of patients.  A potential solution would 
be to measure more distally in the calf, or measure the foot musculature, both of which 
are planned in future projects.  Ultimately, poor content validity will have a negative 
impact on outcome measure responsiveness, and is considered further in Chapter 5. 
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Patients with IBM classically have a distinctive pattern of involvement: quadriceps 
weakness, poor finger grip and difficulty swallowing.  A lower limb MRI protocol is only 
able to measure the first of these.  The IBM-FRS includes questions which address all 
these domains.  Whilst the lower limb MRI indices correlate with total IBM-FRS as well 
as the lower limb domains, they did not correlate with the upper limb or swallowing 
domains, and further the upper limb domains did not show significant correlation with 
the lower limb domains (Figure 4-14).  An intervention which improved upper limb 
function independent of lower limb function would not be measurable with the protocol 
in this study.  A protocol including both upper limb and lower limb muscles would have 
greater content validity.  Other authors (Cantwell et al., 2005; Cox et al., 2011a; Phillips 
et al., 2001; Sekul et al., 1997) have demonstrated intramuscular fat accumulation on 
qualitative T1-weighted sequences of forearm muscles, most marked in flexor 
digitorum profundus.  Together with colleagues at the Institute of Child Health, we have 
quantified forearm muscle fat fraction in Duchenne muscular dystrophy (Ricotti et al., 
2014), so it would be straightforward to improve content validity by including coverage 
of forearm muscle groups if desired. 
Beyond the simple metrics such as muscle fat fraction or muscle size, this thesis has 
examined combined metrics which might be considered to have superior content 
validity.  Remaining muscle area is a metric which is influenced both by muscle size 
and intramuscular fat accumulation, and demonstrated strongest correlation with 
muscle strength.  Whilst T2 and MTR could be criticised as being influenced by both 
acute water changes and chronic intramuscular fat accumulation, they have higher 
content validity since they encompass both processes, and notably had stronger 
correlations to muscle quality (specific muscle force) than fat fraction alone (Table 
4-16). 
4.5.1.5 Validity conclusions 
Quantitative MRI measures of fatty atrophy have high validity in these exemplar 
neuromuscular diseases.  Most importantly they demonstrate criterion validity through 
excellent correlation with patient strength and function in both CMT1A and IBM.  They 
also show strong construct validity both through known groups method assessment 
and convergent validity.  They also have clear face validity and content validity, with the 
only potential concern in this regard that for IBM, only the lower limbs were imaged, 
though the same fat quantification methods can and have been applied to the upper 
limbs. 
4.5.2 Measures of abnormal muscle water distribution 
Even after adjusting for residual FF, T2 was increased and MTR reduced in muscles 
without significant IFA in both patient groups compared to controls, suggesting 
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sensitivity to early and potentially reversible oedematous changes.  Since the T2 of fat 
markedly exceeds that of muscle-tissue water, and vice versa for MTR, non-fat-
supressed T2 and MTR are influenced by both FF, exemplified by the strong inter-MRI 
parameter correlations, and potentially independent early tissue water distribution 
changes.  For this reason T2 obtained in this manner has been referred to as total T2 
(Carlier, 2014).  Our data from muscles with FF below the 95th percentile of the control 
range suggest that adjusting for T2 and MTR dependence upon residual FF reveals 
significant differences between patient and control groups independent of FF.  These 
differences, greater for the IBM group but also significant in CMT1A, may reflect early 
changes in muscle water distribution occurring prior to significant IFA.  These changes 
may be reversible with effective therapy (Jurkat-Rott et al., 2009), and muscle T2 and 
MTR may thus provide useful biomarkers in clinical trials focussed upon early or active 
disease.  There are now methods to separate the fat and water components of T2 at 
the acquisition stage (Janiczek et al., 2011).  These sequences have longer acquisition 
times but may be included when abnormal water measurement is a focus of the study. 
Whilst T2 and MTR have lower face validity that fat fraction assessment, they may 
have superior content validity as they are measures of both acute and chronic muscle 
pathology.  Relative T2 and MTR measures in IBM and CMT1A versus controls 
matches the pattern expected by disease phenotype, demonstrated by construct 
validity through the known groups methods.  Correlations between STIR hyperintensity 
and increased T2, and between STIR hyperintensity and reduced MTR (Table 4-10, 
Figure 4-8, Figure 4-9) are a demonstration of the convergent validity of these 
methods.  Finally, MTR appears a better measure than FF of muscle quality, i.e. 
predictor of muscle strength, a demonstration of criterion validity.  This work therefore, 
even with the limitations of the methods used, provides a number of lines of evidence 
for the validity of T2 and MTR in neuromuscular diseases. 
4.5.3 Insights into CMT1A 
Although utilised here as an exemplar neuromuscular disease, this study provides 
specific insights into CMT1A, the commonest inherited neuromuscular disease.  As 
expected from the clinical phenotype, the disease distribution observed was very much 
distal predominant, with only 3/20 patients having clear abnormalities in quantitative 
MRI parameters at the thigh level (full ROI thigh FF >5%).  All these patients had 
severe changes of all muscles at calf level.  Whilst distal predominance is generally 
true for most CMT subtypes, this absolute gradient is not always the case, for example 
qualitative MRI in CMT2F with HSPB1 mutations (Gaeta et al., 2012). 
At the other end of the spectrum seven patients had normal fat fraction in all muscles at 
the calf level analysed.  This is consistent with previous qualitative MRI reports in 
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CMT1A where in the mildest patients, abnormalities were only evident in the foot 
muscles (Berciano et al., 2008; Chung et al., 2008; Gallardo et al., 2006).  As the 
protocol used was insufficient to show abnormalities, a protocol including quantitative 
foot imaging would be needed to fully characterise this group of patients.  The 
relationship between age and calf intramuscular fat accumulation (Figure 4-12) is of 
particular interest in this regard.  Albeit from a small sample size, CMT1A patients less 
than 35 had no significant fat accumulation at the calf level imaged, with intermediate 
levels of IFA in patients 35-55 and high levels in patients >55.  This is counter to the 
notion put forward by Verhamme and colleagues (Verhamme et al., 2009) that the 
majority of disease progression in CMT1A occurs in childhood and that changes in 
function during adulthood are due to normal ageing processes with reduced reserve.  It 
also suggests that MRI studies in children should focus on foot musculature, unless 
inclusion criteria target the more severe end of the spectrum. 
The distribution of fat infiltration within muscles of the mid-calf when involvement is 
intermediate is worthy of consideration (see red lines in Figure 4-5).  Similar to previous 
qualitative reports (Chung et al., 2008; Gallardo et al., 2006), generally peroneus 
longus shows maximum intramuscular fat accumulation, often followed by tibialis 
anterior. However, in some patients, medial gastrocnemius is the most affected 
muscle, which is clinically undetectable as soleus is universally one of the least 
affected muscles in patients with intermediate levels of calf involvement.  As all fat 
quantification was performed at the same anatomical level, the differential effect is 
something other than location of the muscle in a proximal-distal axis, but may perhaps 
relate to different localisation of motor endplates on calf muscles and therefore different 
axon length.  A small number of cases had significant asymmetry, sometimes in 
association with a clear cause such as ankle arthrodesis, and presumably in the other 
cases due to unidentified environmental factors such as soft tissue injuries.  The 
greater affliction of ankle everters than ankle inverters has been proposed as important 
in the pathogenesis of pes cavus and other foot deformities.  A study specifically 
looking at the relationship between MRI pattern of muscle involvement and foot 
deformity would certainly be of interest. 
The main purpose of inclusion of myometry in the cross-sectional study was to assess 
validity for the MRI measures.  However, isokinetic myometry has not previously been 
reported in CMT1A and provides some valuable insights.  First, despite the length-
dependent phenotype, there was a consistent reduction in knee extension and flexion 
strength for both isometric and isokinetic measurements in CMT1A patients compared 
with age matched controls (see Table 4-13).  Averaged across all measurement 
methods, CMT1A patients were 31% weaker in knee extension and 29% weaker in 
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knee flexion than matched controls.  It is notable that although this difference was 
highly significant (p<0.01), due to the wide range of normal strength in healthy controls, 
this weakness was not apparent on an individual patient basis, especially on manual 
muscle testing where almost all knee movements were graded as normal (grade 5).  
This discrepancy is partly explained by a 10% reduced cross-sectional area of thigh 
muscles in CMT1A patients versus matched controls, a difference which may be due to 
differences in activity levels between patients and controls and which may be reversed 
by an appropriate exercise and strengthening programme.  Part of the reduced 
strength in the overall group relates to the increase fat fraction in thigh muscles of a 
small subset of the cohort (3/20) patients, but there remains a deficit in “muscle quality” 
(maximum force per unit cross-sectional area, seen where the correlation line between 
strength and remaining muscle area in patients runs below that of healthy controls. 
A reduction in measured muscle quality is even more marked at calf level (see Figure 
4-15, Figure 4-16).  There are a number of plausible explanations for this finding, 
including muscle pathology distal to the level analysed, or mechanical considerations 
due to reduced range of motion of the ankle joint for example, which may also be 
amenable to some improvement with intervention.  These mechanical effects are also 
the likely explanation for the relative isokinetic preservation (50% of control strength) of 
ankle eversion versus isometric at a neutral position (33% of control strength).  This 
also highlights some of the difficulties in measuring calf muscle strength where there is 
a significant influence of ankle and foot deformity. 
Finally, whilst all the discussion above relates to parameters of chronic denervation 
(fatty atrophy), which is not unexpected given the slowly progressive nature of this 
disease, there was also evidence of acute denervation on the water-sensitive 
sequences.  On STIR, at the calf level there was a greater proportion of muscles 
graded mildly or markedly hyperintense than in controls (Table 4-8, mild 25.0% vs 
13.2%, marked 6.3% vs 0.5%).  Such occasional changes have been reported in 
CMT1A previously, in 4/11 patients in one series (Gallardo et al., 2006).  In this thesis 
we have been able to quantify this using T2 and MTR sequences, with consideration of 
the confounding effect of fat infiltration.  Specifically, through considering only calf 
muscles with less than 4.7% FF, muscles of CMT1A patients had significantly longer 
T2 and smaller MTR than matched controls (Table 4-9), which was still significant in 
regression analysis to account for any residual effect of small differences in FF (Table 
4-11). 
The magnitude of the differences observed was as expected smaller than in IBM 
patients (T2: +2.0ms CMT, +3.5ms IBM; MTR -0.7pu CMT, -1.1pu IBM) but the 
observation was highly significant (p<0.0001).  Within this same subgroup of muscles 
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without significant fat infiltration, STIR positive muscle had longer T2 and smaller MTR 
in CMT1A patients, IBM patients and controls.  However, a significant difference was 
observed even in the muscle without STIR hyperintensity (Table 4-10) demonstrating 
that these quantitative techniques can demonstrate abnormalities even in normal 
appearing muscle, which may be helpful in judging early treatment effects which 
reverse acute denervation.  There are now advanced methods of T2 (Janiczek et al., 
2011) and MTR (Sinclair et al., 2010) estimation which can separate the effects of fat 
and water at the point of acquisition and are certainly worthy of further investigation in 
CMT1A, even in this most “chronic” of diseases. 
4.5.4 Insights into IBM 
Inclusion body myositis was chosen as a neuromuscular disease with little commonality 
with CMT1A, but many interesting insights may still be gained from this detailed cross-
sectional data set.  Unlike in CMT1A, all MRI scans in IBM patients were qualitatively 
and quantitatively abnormal, with greater frequency and degree of acute disease, as 
might be expected with muscle inflammation being one of the hallmarks of disease 
pathology, and a greater rate of progression than in CMT1A. 
In terms of the pattern of fat infiltration, this quantitative study showed findings similar 
to previous qualitative reports.  Figure 4-18 shows the pattern from the previous largest 
series of 32 patients (Cox et al., 2011a), with data from this thesis presented in the 
same way. Within the thigh muscles, the overall pattern is very similar to previous 
reports: maximal affliction of quadriceps with relative sparing of rectus femoris within 
this group.  The slight differences are that biceps femoris was relatively spared within 
hamstrings of patients reported in this thesis but not in the previous series, and 
adductor magnus, which is reported to be spared in the previous publication but shows 
a very wide range of severity in the patients reported in this thesis.  The pattern within 
the calf muscles is identical to that previously reported, with medial gastrocnemius 
most affected, tibialis posterior least affected, and the remainder of muscles variably 
affected.  It should be noted that as medical gastrocnemius works as part of the larger 
functional group triceps surae to plantarflex the ankle, this MRI disease pattern is not 
evident in the clinical phenotype, whereas predilection for quadriceps involvement is 
recognised as a key clinical feature.  This common pattern raises the question as to 
whether MRI may have utility in IBM diagnosis, a question addressed in another project 
performed in parallel to this thesis. 
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Figure 4-18: Distribution of IFA in IBM in the literature (left) and this thesis (right) 
 
This thesis also reports detailed isometric and isokinetic lower limb myometry of 
patients with IBM for the first time.  At thigh level, the knee extension is weakest, 
approximately 20-25% of the strength of matched controls, which is consistent across 
different joint angles (isometric) and speed of movement (isokinetic).  Knee flexion is 
also significantly weak, broadly similar with isometric (63% of control value) and 
isokinetic assessment (52% of control value).  All ankle movements were also 
significantly weaker than controls with a similar degree of weakness (roughly 50%) of 
ankle plantarflexion, dorsiflexion and inversion, with some sparing of ankle inversion 
(70% of control value), consistent with the relative sparing of tibialis posterior on MRI.  
Degree of ankle weakness was more variable than at the knee, with some patients 
having normal strength and others close to no strength in all ankle movements.  The 
pattern of weakness has important consequences on gait and function, and this 
relationship would be of interest in future studies. 
Muscle inflammation is a key aspect of muscle histology in IBM, and although its 
relevance and usefulness as a therapeutic target is debated, it may be quantified on 
MRI.  Overall 55% of muscles from IBM patients were at least mildly hyperintense on 
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STIR imaging at both thigh and calf level, which far exceeds that previously reported 
with a median of two muscles per patient (Cox et al., 2011b) using a whole body 
protocol.  This difference might be explained by reduced sensitivity of their sequence 
due to the wider coverage, or excess sensitivity of our sequence, given the 13.7% rate 
of STIR positivity in calf muscles of our controls.  This STIR positivity however was rare 
within the thigh muscles of controls, where patient abnormalities were as frequent, and 
is demonstrated to represent a quantifiable difference in muscle tissue MRI parameters 
even in healthy controls (see 3.4.7), so is not artefactual.  In IBM patients the 
distribution of STIR abnormalities mirrored that of T1w abnormalities in the thigh, but in 
the calf tibialis anterior showed STIR abnormalities most commonly, with medial 
gastrocnemius only fourth most commonly.  The explanation for this may be that the 
muscle tissue within medial gastrocnemius is end-stage, and therefore is no longer 
showing STIR positivity, which may have predominantly occurred when the patient was 
pre-symptomatic.  The temporal relationships between STIR positivity and 
intramuscular fat accumulation are explored using longitudinal observation in chapter 5. 
This thesis quantifies abnormal muscle water through T2 and MTR measurements, 
with due consideration to the confounding effect of intramuscular fat required.  The 
observations for CMT1A within the calf apply also to IBM, but at both thigh and calf 
level and with a greater magnitude of effect, as might be expected from knowledge of 
the disease distribution, pathogenesis and rate of progression (Table 4-8, Table 4-9, 
Table 4-10, Table 4-11).  One specific example is that in calf muscles without 
significant fat infiltration, muscles which are STIR positive have T2 values of 41.8ms in 
controls, 44.5ms in CMT1A patients and 48.2ms in IBM patients.  This greater degree 
of abnormal water distribution allows analysis of changes beyond those where there is 
not significant IFA.  In Figure 4-8 we see the additional effect of STIR positivity on the 
T2 value beyond that due to the fat fraction measurement, with up to 25ms increase in 
T2 for STIR positive muscles versus STIR negative muscles in the same FF range.  
Whilst it is possible to calculate “T2 excess” through concurrent acquisition of T2 and 
FF data, the separation of fat and water effects on T2 and point of acquisition would be 
possible and is technically feasible, albeit with longer acquisition times (Janiczek et al., 
2011). 
4.5.5 Challenges and study limitations 
There were a number of limitations in this study.  We analysed data from only single 
slices of thigh and calf blocks, with only small ROI for T2 and MTR sequences. This 
may contribute variation if muscle pathology is anatomically non-homogenous.  To 
ensure consistency in the volumes of tissue assessed longitudinally, slice positions 
were defined by measured distance from bony landmarks, a more reliable method than 
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surface-anatomy-based slice positioning (Fischmann et al., 2014), and follow up ROI 
drawn with direct reference to baseline ROI. T2 estimation by sampling two turbo-spin 
echo images is potentially less accurate than Carr-Purcell-Meiboom-Gill multiple-spin-
echo methods. However, our approach provides time-efficient, wide-coverage 
quantification of T2 change using a method that can be implemented on standard MR 
systems without specialist modification.  
4.5.6 Future application 
Any proposed outcome measure must be quantitatively abnormal in patients compared 
with controls.  For example mortality is not suitable as an outcome measure in 
diseases with normal life span such as CMT1A (Reilly et al., 2011) and IBM.  The 
cross-sectional data have shown that quantifiable abnormalities of chronic pathology 
such as fat fraction and muscle atrophy would be applicable to studies requiring 
quantification of disease progression.  In addition, measures of early abnormalities 
have been quantified with T2 and MTR differences in muscles without significant fat 
infiltration.  These latter methods are sensitive to changes in water distribution which 
are reversible with effective therapy (Jurkat-Rott et al., 2009), so will be useful 
biomarkers in clinical trials enrolling patients with early or active disease. 
Chronic IFA is common to a wide range of neuromuscular diseases.  Although the 
precise molecular events responsible for IFA are not fully understood, one recent 
mechanistic study (Agley et al., 2013) suggests that a range of different primary genetic 
muscle diseases, and potentially denervation, stimulates myo-precursor stems cells to 
differentiate into adipose cells and fibroblasts.  That IFA seems to be a common 
pathway in many genetic and acquired NMD contributes to the lack of diagnostic 
specificity of muscle MRI in NMD, but underlines its utility as an outcome measure that 
may be useful across NMD.  As an example, we have shown here that the same types 
of changes can be quantified in these two very different diseases: an acquired late-
onset progressive proximal and distal myopathy and an inherited childhood-onset 
slowly progressive distal predominant neuropathy. 
Although differences between diseases result in different distributions and degrees of 
muscle abnormalities, their presence, direction and clinical correlations are consistent, 
making these outcome measures applicable across any neuromuscular disease with 
lower limb weakness.  Through selection of MRI parameters targeted to disease and 
intervention, MRI outcome measures can be optimised to provide maximum 
responsiveness for a specific clinical trial.  For example, the optimal MRI protocol for 
CMT1A would necessarily include assessment of fat infiltration of calf muscles with a 
sequence such as three-point Dixon.  In IBM, to assess if an intervention reversed 
acute pathological processes, additional water-sensitive sequences such as T2 and 
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MTR quantification should be included.  For any specific NMD, understanding of basic 
pathomechanisms, disease distribution and treatment mechanisms will enable trial-
tailored selection of specific MRI outcome measures and appropriate anatomical 
imaging levels providing optimal responsiveness.  
 Conclusions 
The second phase of this thesis study has examined cross-sectional MRI and clinical 
data and demonstrated excellent validity of quantitative MRI of the lower limb muscles 
in both CMT1A and IBM.  T2 and MTR have additional sensitivity to disease processes 
prior to significant intramuscular fat accumulation.  Beyond reliability and validity, which 
are found in other existing measures in neuromuscular diseases, outcome measure 
responsiveness is crucial to study power.  This will be assessed using longitudinal data 
presented in chapter 5. 
  
 
164 
5 Longitudinal quantitative MRI in neuromuscular 
disease 
 Introduction 
Whilst demonstration of reliability (chapter 3) and validity (chapter 4) is sufficient to 
determine that a health measurement is useful for descriptive or predictive purposes, 
knowledge of an outcome measure’s responsiveness is needed before we can be 
confident about its application in a clinical trial (Kirshner and Guyatt, 1985).  
Responsiveness is often the domain where outcome measures in neuromuscular 
diseases are weakest (see 1.2.3) due to their slowly progressive nature.  This is 
particularly so in CMT1A, where all outcome measures have shown low or moderate 
responsiveness (Pareyson et al., 2011a). 
Responsiveness is simply defined as the ability of an instrument to detect when change 
has occurred (Roach, 2006).  This can be divided into internal and external 
responsiveness.  Internal responsiveness examines the change in the outcome 
measure over a specified time-frame, either by assessing the natural history of the 
disease as in this thesis, or assessing change in response to a known effective 
treatment (Roach, 2006).  Comparing t-statistics for a known effective treatment is a 
preferred way to assess relative responsiveness of different measurements (Deyo et 
al., 1991; Roach, 2006), but this is not possible in diseases such as CMT1A and IBM 
where there are no known effective treatments.  Alternative methods include looking at 
the “effect size”, which is the mean change divided by the standard deviation of 
baseline scores (Deyo et al., 1991).  Subsequently Guyatt (Guyatt et al., 1987) 
suggested the ratio of mean change to standard deviation of change (Equation 1-2, 
page 23), the responsiveness coefficient or standardised response mean.  The 
standardised response mean is a key determinant of study power by Lehr’s formula 
(Equation 1-3, page 23).  The standardised response mean will be used as the main 
measure of responsiveness in this chapter. 
These measures of responsiveness say nothing about whether the change is clinically 
meaningful: the “longitudinal validity” (Roach, 2006).  One assessment of this is the 
external responsiveness, that is the degree to which changes in the measure correlate 
with changes in other measures of health status (Roach, 2006).  It is worth noting that 
like validity and reliability, responsiveness is dependent on the specific group of 
patients being measured (Roach, 2006).  It is not possible to assume that because an 
outcome measure is responsive in one disease, it will be equally responsive in another 
disease.  Even within a single disease, responsiveness will vary for the same 
measurement depending on inclusion criteria.  The SRM formula shows ways to 
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increase responsiveness through patient selection: by including those where the 
primary outcome measure is likely to change by the greatest magnitude and by the 
most uniform amount. 
 Background literature 
There are significantly fewer longitudinal than cross-sectional quantitative MRI studies 
in neuromuscular diseases.  As background, they will be briefly reviewed after 
reviewing all longitudinal qualitative studies in IBM and CMT. 
5.2.1 Longitudinal qualitative MRI studies in CMT/IBM 
There are no longitudinal qualitative MRI natural history studies in IBM.  In CMT1A, one 
recent study from Pelayo and colleagues examined T1w MRI, neurophysiology, muscle 
strength and other clinical measures in 14 patients with CMT1A over 2 years (Pelayo-
Negro et al., 2014).  Although many measurements showed cross-sectional correlation, 
none of the potential outcome measures including qualitative MRI showed significant 
change over two years. 
5.2.2 Natural history quantitative MRI studies of muscle size 
Two natural history studies have looked at muscle size longitudinally, both in 
neuropathic conditions.  Long-term natural history data are available in a small group of 
patients with diabetic neuropathy and controls.  This showed a loss of muscle volume 
in ankle dorsiflexors and plantarflexors of 4.5% and 5.0% per year respectively in 
patients with diabetic neuropathy versus 1.7% and 1.8% annual loss in healthy controls 
(Andreassen et al., 2009).  Standard deviations were not reported with small patient 
numbers but appeared to be approximately 1%, which would give an SRM of 
approximately 3 for the excess loss of muscle volume over one year in the patient 
group (highly responsive).  This figure is inflated by the duration of follow-up 
assessment of 9-12 years after the original assessment, which would be impractical for 
a clinical trial, but there may be a good SRM over a shorter length of time. By contrast 
a study of patients with spinal muscular atrophy failed to show any change in thigh 
muscle volume over a six month interval (Sproule et al., 2011b). The study used a 
semi-automated segmentation method based on signal intensity of a T1w imaged and 
included 11 clinically heterogeneous subjects, which would have limited power to show 
significant change. 
5.2.3 Interventional studies including muscle size measurements 
Perhaps surprisingly given the lack of natural history data there are a number of 
interventional studies using muscle size as an outcome measure in myopathic 
conditions.  The earliest interventional study in a neuromuscular disease to include 
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quantitative MRI as an outcome measure was in fact performed in patients with IBM.  
In a small study of five patients with IBM undertaking a progressive resistance strength 
training programme for 12 weeks, Spector and colleagues report performing both lower 
and upper limb MRI at baseline and at study end, quantifying remaining muscle cross-
sectional area based on signal intensities on a T1w sequence (Spector et al., 1997).  
The authors report that “significant changes in whole muscle cross-sectional area 
assessed by MRI were not seen in any of the muscles of patients as a result of 
training”, although no numerical values are given (neither cross-sectional nor 
longitudinal), nor details of which muscles were assessed, nor what change would be 
considered significant.  Interestingly there were significant improvements in strength 
over the course of the study (Spector et al., 1997).  If these two observations are 
accurate, it would imply an increase in the specific force of the muscle tissue (strength 
per cross-sectional area) indicating an improvement in muscle quality rather than 
quantity.  However, the number of patients was very small, and with no control group 
the potential for significant systematic bias, such as with a learning effect, is high, so 
any conclusions form this study must be guarded. 
Right thigh muscle volume measured on a proton density weighted MRI sequence was 
chosen as the primary outcome measure in a phase 2 clinical trial of bimagrumab in 
inclusion body myositis (Amato et al., 2014).  Bimagrumab is an ActRII inhibitory 
antibody which blocks downstream signalling of TGFβ, a pathway which leads to 
muscle atrophy.  A single dose was given to 11 patients whilst three patients received a 
placebo.  Right thigh muscle volume increased by 6.5% compared with placebo 
(p=0.024).  Change in clinical outcome measures such as muscle strength and six 
minutes walking distance was more variable and generally not significant, as might be 
expected in a small short-duration trial.  There was however a significant correlation 
between change in muscle volume and change in six minutes walking distance (r=0.61, 
p=0.036), demonstrating longitudinal validity.  The standard deviation of the change in 
volume measurement was relatively high (approximately 4%), suggesting either poor 
reliability or significant variation in treatment response.  Regardless, this study shows 
the potential power of volumetric assessment of muscle size if the intervention is 
expected to affect this parameter, though the functional benefit of simply increasing 
muscle size needs to be proven in a longer study. 
Conversely a clinical trial of a myostatin inhibitor, also biologically predicted to increase 
muscle size, failed to show any significant effect on muscle volume using MRI in a 
mixed group of patients with muscular dystrophy.  No significant change in lean body 
mass measured by DEXA was observed, suggesting the negative result may have 
been an ineffective drug rather than insensitive outcome measure.  Good repeatability 
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of measurements was observed with standard deviation of change in volume 
measurements of approximately 1%. 
MRI has also been used by an Italian group to investigate the effect of enzyme 
replacement therapy (ERT) in Pompe disease (Pichiecchio et al., 2009; Ravaglia et al., 
2010), one of the few licensed drug therapies in an inherited neuromuscular disorder. 
They utilised segmentation of T1w lower limb MRI in 11 patients with Pompe disease 
receiving open label ERT for up to two years.  They found a small increase in muscle 
volume of the less affected anterior compartment of the thigh (+7.5%) and an even 
larger increase in muscle strength (+45%), interpreted as an increase in both muscle 
size and quality (strength per unit volume) (Lynch et al., 1999), though some caution is 
needed in interpretation of the increased muscle strength due to the open-label 
uncontrolled design.  The more affected posterior compartment of the thigh showed no 
increase in muscle volume.  There was also overall increased intramuscular fat despite 
ERT.  One explanation of these data is that there may be a “point of no return” in terms 
of intramuscular fat accumulation, where treatment is no longer effective, though this 
would need confirmation in larger blinded studies. 
Considered together these trials highlight some of the advantages and disadvantages 
of primary use of muscle size parameters as outcome measures in neuromuscular 
diseases.  The main advantage is that the images for analysis are relatively easy to 
obtain, as any sequence with adequate tissue contrast may be used.  Most 
investigators have used T1w sequences to allow some estimation of the intramuscular 
fat accumulation using segmentation based on signal intensity, but this is a less precise 
means to quantify fat than a directly quantitative sequence such as three-point Dixon.  
The main disadvantages are the lack of natural history data to demonstrate that muscle 
atrophy is a primary marker of disease progression with the exception of diabetic 
neuropathy; the confounding effect of muscle atrophy associated with ageing; wide 
variation in muscle size between individuals; difficulties in precise measurement of 
muscle volume with relatively high standard deviations in longitudinal change 
observed; unclear relationship between muscle size and function; and an unclear role 
for drugs whose mechanism is not to directly promote muscle hypertrophy.  Therefore, 
whilst muscle size may be helpful as a complementary measurement for some 
interventions in some diseases, it remains to be shown that it is universally applicable, 
indeed is likely not to be so for the reasons listed above. 
5.2.4 Natural history studies of quantitative tissue parameters 
The alternative to using muscle size outcome measures is utilising muscle tissue MRI 
parameters such as T2 relaxation time or fat fraction.  An early study published in 1998 
showed progression in T2 measurements from tibialis anterior muscle over a four 
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month interval in 11 patients with motor neuron disease (Bryan et al., 1998).  Muscle 
size and T1 time did not change over this interval.  Furthermore, T2 time correlated 
with motor amplitude on neurophysiology both cross-sectionally and longitudinally (r=-
0.63, p=0.037).  Unfortunately, the magnitude of change in T2 over 4 months was not 
reported, so responsiveness of this outcome measure cannot be calculated from the 
data provided. 
Four more recent studies have measured quantitative muscle tissue MR parameters in 
muscular dystrophies: T2 in Duchenne (Willcocks et al., 2014), T2 and 2-point Dixon 
FF in oculopharyngeal muscular dystrophy (Fischmann et al., 2012), multi-spin echo 
FF in fascio-scapulo-humeral dystrophy (Janssen et al., 2014), and three-point Dixon 
FF in limb girdle muscular dystrophy type 2I including patients from our Centre (Willis 
et al., 2013).  All four studies showed significant change in quantitative tissue 
parameters over the duration of the study. 
In Duchenne, soleus whole tissue T2 was measured over 2 years in 15 ambulatory 
boys with Duchenne (Willcocks et al., 2014).  This increased by 5.5 ± 6.6% over 1 year 
(SRM 0.83) and 9.5 ± 7.4% over 2 years (SRM 1.28).  The absolute increase over 2 
years was 4.5 ± 3.6ms (SRM 1.25), with significant increase in T2 also seen in 
peroneal muscles but not tibialis anterior.  Change in soleus T2 was significantly 
correlated with change in three functional measurements undertaken (R=0.66-0.87, 
p<0.01), even though for only one of these (supine to stand time) was the change in 
the functional measure itself statistically significant.  A limitation of the study was that 
only cross-sectional control data were collected.  Fat-supressed T2 values changed to 
a small degree over 2 years, suggesting most of the whole tissue T2 increase related 
to progression in intramuscular fat accumulation. 
In OPMD, both T2 and 2-point Dixon FF were measured in all multiple thigh and calf 
muscles in 8 patients and 5 controls over a 13-month interval.  Whilst functional 
measures showed no significant change over this interval, there was a 2.2ms increase 
in all muscle T2 and a 1.5% increase in fat fraction (both p<0.001).  Standard deviation 
was not reported directly, but estimated SRM from data depicted in figures was 1.1.  FF 
and T2 were highly correlated.  These data demonstrate that MRI can detect 
subclinical disease progression over a short time period with high responsiveness. 
In FSHD, 41 patients were imaged  with 11 of these reimaged at a 4 month interval 
(Janssen et al., 2014).  A single thigh was imaged using both qualitative techniques 
and a fat fraction estimation based on multi-spine echo sequence (in muscles without 
oedema).  The overall increase in fat fraction was 1.8 ± 4% (SRM =0.45), although this 
was greater when only muscles with intermediate baseline fat-fraction between 25 and 
75% were considered (6 ± 5%).  The inclusion of multiple muscles from individual 
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patients within the statistical calculation, the different technique needed for muscles 
with oedema and short follow up were limitations of this study. 
Finally, in LGMD2I, 32 patients across 4 international sites were studied using three-
point Dixon fat fraction quantification to quantify thigh and calf muscle fat fraction of a 
single lower limb over a 12 month interval.  Significant increases in fat fractions were 
seen in 9/14 muscles examined, but no significant change in functional measures.  
Increases ranged from 2% in biceps femoris to 0% in tibialis anterior.  This study again 
demonstrated superior responsiveness of MRI over functional outcome measures. 
5.2.5 Interventional studies including quantitative muscle tissue 
parameters 
There are three intervention studies with quantitative muscle tissue MR parameter 
measures included as outcome measures: two with steroids in Duchenne (Arpan et al., 
2014; Kim et al., 2010b) and one with exercise in juvenile dermatomyositis (Maillard et 
al., 2005).  The study in juvenile dermatomyositis utilised T2 quantification as a safety 
parameter with measurements before, and 30 and 60 minutes after exercise in a 
physiotherapy-led exercise programme (Maillard et al., 2005).  No significant change 
was seen in MRI, muscle strength or blood parameters in 20 children in juvenile 
dermatomyositis or 20 controls, suggesting the exercise programme did not induce 
muscle oedema. 
Corticosteroid treatment is recognised as an effective treatment in Duchenne muscular 
dystrophy. Benefits include prolonged ambulation, improved muscle strength, improved 
pulmonary function, delayed cardiomyopathy onset and reduced need for scoliosis 
surgery (Gloss et al., 2016).  It is therefore a logical intervention to assess using MRI, 
although its proven efficacy means a randomized placebo controlled trial design would 
be unethical.  The first study performed T2 mapping of right gluteus maximus muscle in 
11 boys with DMD before and after commencing corticosteroid treatment with a mean 
duration of 14.6 months (Kim et al., 2010b).  Qualitative T1w and water sensitive 
sequences were also performed.  The changes were variable: 2 boys had increases in 
fat infiltration on conventional imaging associated with an increase in T2.  Of the 9 who 
showed no change on qualitative imaging, three showed an increase in T2, two 
showed no change in T2 and four showed a reduction in T2 within gluteus maximus 
muscle.  Since T2 time is affected by both changes in both water and fat distribution 
within muscle, the changes may relate to alterations in either, and the study 
emphasises the need for multi-parameter quantitative MRI assessment to allow 
disambiguation of effects.  The study population was quite heterogeneous with an age 
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range of 5-14 years, so without a control group it is difficult to separate the effect of the 
corticosteroid treatment from natural disease processes. 
The later study overcame these limitations by including both fat fraction and T2 time, 
assessing a homogenous patient group (aged 5-6.9 years), and longitudinal 
assessment of patients who did and did not start steroid therapy, although treatment 
assignment was not randomized (Arpan et al., 2014). Cross-sectional analysis included 
15 boys on corticosteroids and 15 corticosteroid naïve patients and showed 
significantly increased T2 and fat-fraction in the latter group.  Six boys who remained 
off corticosteroids had a significant increase in fat fraction over 12 months (+7% in 
vastus lateralis and +3% in soleus), which was significantly greater than 9 boys who 
remained on corticosteroids (+1% in vastus lateralis and +0% in soleus).  Finally, 
previously corticosteroid naïve boys who started treatment had a significant decrease 
in muscle T2 at both 3 and 6 months without a change in measured fat fraction.  
Although observational rather than randomised, these data demonstrate the potential 
of MRI to quantify a reduction in muscle oedema over a short time interval and a 
reduction in progressive intramuscular fat accumulation over a longer time interval in 
response to an intervention. 
5.2.6 Summary 
Over recent years there is a growing body of longitudinal data on quantitative MRI in 
neuromuscular diseases.  Overall quantitative muscle tissue parameters appear more 
responsive than size-based measurements, particularly in primary muscle disorders, 
though the inclusion of size-based measurements is attractive, particular if the 
intervention is expected to have a biological effect on muscle size.  The importance of 
multi-parameter assessment in interventional studies is emphasised to allow separation 
of the effects of treatment on muscle water distribution in the short term and 
intramuscular fat accumulation in the longer term.  Studies consistently show MRI 
outcome measures to be more responsive that clinical outcome measures, though 
some studies are able to show longitudinal correlation between outcome measures.  
The overall scope of the studies in terms of range of diseases investigated and patient 
numbers is relatively small. 
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 Longitudinal study aims 
The primary aim of the longitudinal study phase is to assess internal responsiveness by 
calculating standardised response means for quantitative MRI parameters and 
comparing these with those of clinical and myometric measures.  External 
responsiveness will be assessed by correlating significant changes in MRI and clinical 
or myometric parameters.  Finally, any significant predictors of change will be 
determined as a means of optimising responsiveness in future trials. 
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 Results 
5.4.1 Study subjects 
Repeat assessments were performed after a mean interval of 12.4 months (s.d. 1.0 
months) in 62/69 (90%) subjects (CMT1A: 18/20, 1 was withdrawn due to ankle 
surgery, 1 withdrew from the study; IBM: 18/20, 2 withdrew as no longer able to travel; 
controls: 26/29, 3 had attended with patients who withdrew). Figure 2-2 (page 41) 
shows a flow chart of participants through the study. 
5.4.2 Overall longitudinal data 
Longitudinal change of clinical, myometric and qualitative and quantitative MRI 
outcome measures are summarised in Table 5-1 below.  Change in patients was 
considered both whether it was significantly different from 0 (paired t-test, p1 in table) 
and whether it was significantly different to that seen in matched controls (student two-
tailed t-test, p2 in table).  In CMT1A patients, only change in whole ROI calf FF was 
significant in both tests, whilst in IBM change was significant in many quantitative 
parameters. 
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Table 5-1: Overall longitudinal data 
Measure CMT 
Control 
(CMT) 
p1 p2 IBM 
Control 
(IBM) 
p1 p2 
Thigh MRI 
FF (%) 0.4 ± 1.0 0.0 ± 0.3 0.15 0.12 3.3 ± 4.0 -0.1 ± 0.4 0.005 <0.001 
T1 (ms) 23 ± 39 14 ± 42 0.03 0.52 -44 ± 44 19 ± 44 0.002 <0.001 
T2 (ms) 1.3 ± 1.5 0.6 ± 1.6 0.003 0.21 2.6 ± 4.2 0.5 ± 1.6 0.03 0.07 
MTR (p.u.) 0.0 ± 0.7 -0.1 ± 0.3 0.96 0.55 -0.9 ± 1.6 0.0 ± 0.5 0.06 0.06 
FF whole (%) 0.2 ± 0.8 0.2 ± 0.8 0.38 0.97 3.3 ± 3.2 0.2 ± 0.8 <0.001 <0.001 
CSA (% change) -0.6 ± 5.3 -0.7 ± 7.2 0.62 0.96 -2.7 ± 7.9 0.2 ± 5.7 0.08 0.23 
Mercuri grade -0.02 ±0.21  0.01 ±0.21  0.72 0.72 0.00 ± 0.30 -0.01 ± 0.26 0.97 0.91 
STIR 0.09 ± 0.23 0.05 ± 0.07 0.45 0.45 0.25 ± 0.31 0.05 ± 0.05 0.005 0.01 
Thigh Myometry 
Knee ext. (Nm) 1.0 ± 8.1 -5.2 ± 10.2 0.57 0.06 -6.0 ± 5.2 -4.2 ± 11.4 <0.001 0.55 
Knee flex. (Nm) 2.5 ± 6.8 1.7 ± 7.6 0.15 0.75 -1.7 ± 4.3 2.9 ± 7.1 0.08 0.02 
Calf MRI 
FF (%) 1.1 ± 2.4 0.0 ± 0.4 0.07 0.07 2.6 ± 2.7 0.0 ± 0.4 0.004 <0.001 
T1 (ms) 22 ± 44 37 ± 43 0.14 0.40 1 ± 55 23 ± 44 0.94 0.27 
T2 (ms) 1.4 ± 2.6 0.3 ± 1.1 0.05 0.13 4.5 ± 3.7 0.0 ± 1.5 <0.001 <0.001 
MTR (p.u.) -0.2 ± 0.6 0.0 ± 0.7 0.30 0.28 -0.7 ± 0.7 0.2 ± 0.8 0.004 0.003 
FF whole (%) 1.2 ± 1.5 0.2 ± 0.4 0.002 0.008 2.6 ± 2.4 0.1 ± 0.4 0.002 <0.001 
CSA (% change) 0.6 ± 6.6 0.0 ± 4.4 0.67 0.74 -2.5 ± 3.9 0.1 ± 5.0 0.01 0.11 
Mercuri grade 0.01 ± 0.44 0.06 ± 0.12 0.92 0.68 0.18 ± 0.29 0.07 ± 0.09 0.03 0.17 
STIR 0.14 ±0.28 0.09 ± 0.20 0.05 0.53 0.27 ± 0.32 0.05 ± 0.18 0.003 0.02 
Calf Myometry 
Ankle PF (Nm) 3.8 ± 7.6 2.1 ± 10.8 0.05 0.59 -0.7 ± 3.9 5.6 ± 14.6 0.42 0.09 
Ankle DF (Nm) 2.1 ± 4.0 0.5 ± 3.8 0.06 0.24 -0.4 ± 4.2 2 ± 5.3 0.65 0.14 
Ankle Inversion 1.8 ± 5.4 0.4 ± 5.0 0.18 0.45 -1.5 ± 2.5 0.3 ± 4.5 0.02 0.14 
Ankle Eversion 1.4 ± 2.1 0.9 ± 2.3 0.02 0.53 -0.1 ± 1.7 0.5 ± 2.4 0.77 0.40 
Overall Clinical measures 
Lower Limb MRC -0.4 ± 3.8 NA 0.65 NA -3.4 ± 5.6 NA 0.02 NA 
SF-36 (%) -2.5 ± 15.2 NA 0.51 NA -1.1 ± 7.0 NA 0.55 NA 
SF-36 PF (%) -0.9 ± 12.3 NA 0.77 NA -4.1 ± 18.5 NA 0.39 NA 
CMTES (points) -0.3 ± 1.3 NA 0.37 NA NA NA NA NA 
IBM FRS (points) NA NA NA NA -2.8 ± 2.9 NA <0.001 NA 
p1: p-value of paired t-test in patient group; p2: p-value of two-tailed t-test patient vs 
matched control; CMT: Charcot-Marie-Tooth disease; IBM: inclusion body myositis; FF: 
fat fraction; MTR: magnetisation transfer ratio; MRC: Medical Research Council 
bedside strength assessment; SF-36: Short Form Health Survey; PF: physical 
functioning domain; CMTES: CMT Examination Score; IBM-FRS: IBM Functional 
Rating Score; NA: Not applicable.  Highlighted measures are those where follow-up 
value is significantly different from baseline AND where applicable change seen is 
significantly different from change in controls (both paired t-test and two-tailed t-test are 
significant).  
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5.4.3 Longitudinal assessment of fat atrophy 
Figure 5-1: Longitudinal fat fraction images 
 
Sample longitudinal fat fraction images for a subject in each group. Mean whole muscle 
FF for each slice is given below each image.  Greatest change in seen at thigh level in 
IBM and calf level in CMT1A.  
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5.4.3.1 Qualitative imaging 
Changes in T1w and STIR qualitative imaging scores were not significant in CMT1A 
patients either with paired t-test or compared with matched controls, who as expected 
also showed no significant change.  InT1w analysis of IBM patients there was a small 
increase in mean Mercuri grade at calf level over 12 months (+0.18, p=0.03) but this 
was not significant when compared with a small (non-significant) increase seen in 
controls (student t-test p= 0.17).  By contrast a significant increase in mean STIR 
grading was noted for IBM patients at both thigh and calf level, suggesting an increase 
in muscles with abnormal muscle water distribution over one year. 
5.4.3.2 Quantitative imaging 
Figure 5-2: Box and whisker plot of longitudinal change in fat fraction 
 
Group comparison against matched controls shows that significant increases in overall 
mean fat fraction are seen in IBM patients at thigh and calf level (p<0.001) and at calf 
level in CMT1A patients (p<0.01).  Bars indicate median, 25th, 50th and 75th centiles, 
lines: range, o: minor outlier 
The overall change in FF over 12 months is shown in Figure 5-2.  Significant change in 
FF is seen at both thigh and calf level in IBM patients, and at calf level in CMT1A 
patients.  As all quantitative parameters in this study exhibit strong interdependencies 
(see Table 3-14 and Table 4-7) due to their common sensitivity to changes in 
intramuscular fat accumulation, similar magnitude of change might be expected across 
these measurements with increases in FF and T2, and reductions in T1 and MTR in 
circumstances of progression. 
5.4.3.2.1 Controls 
With regard to the controls, there was no change in FF, T2 or MTR over the one year 
follow-up, as would be expected from the small magnitude of age dependency seen in 
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the cross-sectional volunteer data (see Table 3-12). There was however a small but 
significant increase in measured T1 time at both thigh and calf level, suggesting a 
systematic bias in either acquisition or analysis between the two time points.  Unlike 
with T2 (see 2.4.4.3.1), this difference did not clearly relate to the scanner software 
upgrade. 
5.4.3.2.2 CMT1A 
In the CMT1A group, at thigh level there were no changes in quantitative parameters 
significant in both paired-t-test and compared with controls by student t-test.  Of note, 
there was a significant increase in T1 time compared with baseline (+23±39ms, p 
=0.03), which could indicate a reduction in IFA, but with a near identical change seen in 
the healthy controls, systematic bias is the more likely explanation.  The overall change 
in FF at thigh level was not significant, though baseline pathology was rare here as 
would be expected from the distal predominant phenotype.  In the three CMT1A 
patients with thigh fat fraction over 5% at baseline, there was an average 0.93% 
increase in thigh fat fraction over 12 months, although the number here is clearly too 
small to allow any test of statistical significance.  There was no significant change in 
thigh muscle cross-sectional area. 
By contrast at calf level there was significant increase in whole ROI FF in CMT1A 
patients: 1.2 ± 1.5% (p=0.002 paired t-test, p=0.008 vs controls).  There was a similar 
magnitude of change (+1.1%) in small ROI FF, but greater variability (s.d. 2.4%), 
presumably due to lesser reliability, meant this change failed to reach statistical 
significance (p=0.07).  Similarly mean calf T2 was greater and mean calf MTR was 
smaller at follow-up than baseline, as would be expected from their common sensitivity 
to intramuscular fat accumulation, but again the change was more variable so did not 
approach statistical significance.  Calf muscle CSA was not significantly changed. 
5.4.3.2.3 IBM 
In IBM patients at 12-month follow up, all-muscle thigh- and calf-level FF for both small 
and whole muscle ROIs, and calf muscle T2 had increased significantly from baseline, 
whereas calf muscle MTR significantly decreased (Table 5-1).  Thigh level increases in 
T2 (p=0.03, p=0.07) and reductions in MTR (p=0.06, p=0.06) did not reach statistical 
significance for both paired-t-test and two-tailed t-test versus controls.  Consistent with 
observation in controls and CMT1A patients, T1 measurements were most variable, 
with a significant decrease at thigh level, but no change at calf level.  These data reflect 
a significant progression in IFA at both thigh and calf level over 12 months, with three-
point Dixon FF the most reliable and sensitive means of quantifying this.  There was 
also a progression of muscle atrophy at thigh level with all-muscle CSA decreasing 
versus baseline (p<0.05) at calf but not at thigh level (p=0.08). 
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The quadriceps and hamstrings reduced in CSA by a similar percentage (quadriceps: -
2.9 ± 7.6%; hamstrings -3.3 ± 11.3%), and increased in FF by a similar amount 
(quadriceps: 4.2 ± 5.7%; hamstrings: 2.7 ± 2.0%; p=0.33).  Individual patterns of 
progression varied with FF changes in quadriceps greater in early disease, and 
changes in hamstrings CSA greater in late disease, consistent with the clinically 
recognised progression of muscle involvement. 
5.4.4 Longitudinal clinical data 
5.4.4.1 CMT1A 
In the CMT1A group no clinical measure showed significant change over 12 months.  
Myometry measured ankle dorsiflexion and eversion strength showed an apparent 
increase at follow-up, though this was also seen in the CMT matched volunteers so 
may represent a learning effect. 
5.4.4.2 IBM 
Of the clinical parameters (Table 5-1), significant change was seen in the IBM patient 
group in MRC scores and IBM-FRS.  IBM patients showed a significant reduction in 
overall knee extension (p<0.001) compared with baseline and a trend to reduction in 
knee flexion strength (p=0.08).  However, the reduction in knee extension strength was 
not significantly different to age matched controls (p=0.55), whilst the reduction in knee 
flexion strength was (p=0.02).  In all groups, the standard deviations of change in 
muscle strength measurements were relatively high, suggesting overall poor reliability 
of these measurements. 
5.4.5 Longitudinal MRI - clinical correlation 
Correlations between change in clinical parameters and change in MRI parameters 
were not significant in the CMT group. However, in IBM the change in myometric 
strength of knee extension correlated with change in several MRI parameters including 
quadriceps remaining muscle area (right R=0·66, p=0·005, left R=0·81, p=0·0001, 
Figure 5-3). 
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Figure 5-3: Correlation of change in strength and remaining muscle area on MRI 
 
Change in the MRI metric of quadriceps remaining muscle area (RMA) correlated with 
change in quadriceps strength over 12 months in IBM patients on both left and right. 
thighs 
5.4.6 Predictors of change 
Annual change in fat fraction was found to relate to both baseline fat fraction and 
presence of STIR hyperintensity (Table 5-2).  Greatest change was seen when fat 
infiltration was moderate (20-60%) and STIR hyperintensity was marked.  Note that in 
the control group a small reduction in FF in those with baseline fat fraction greater than 
5% is likely due to a regression to the mean effect.  Data just for IBM thigh muscle are 
shown in Figure 5-4.  Across the range of baseline fat-fractions, progression was 
greater in muscles with STIR hyperintensity.  This difference was statistically significant 
for the <5%, 5-20% and 20-40% bands of baseline fat fraction.  The significant 
difference in muscles with “normal” (less than 5%) fat fraction at baseline suggests that 
STIR hyperintensity precedes fat accumulation in early disease. 
Table 5-2: Annual change in fat fraction within muscles varies with baseline 
characteristics  
Sequence Category CMT IBM Controls 
STIR 
hyperintensity 
Absent 0.5 ± 0.1 1.1 ± 0.3 0.0 ± 0.0 
Mild 1.8 ± 0.7* 3.9 ± 0.6* 0.0 ± 0.1 
Marked 2.4 ± 1.4* 5.9 ± 1.0* 0.4 ± 0.9 
Fat fraction 0 to 5 0.3 ± 0.1 1.0 ± 0.2 0.1 ± 0.0 
5 to 20 0.3 ± 0.5 6.2 ± 1.0* -1.0 ± 0.5* 
20 to 40 4.6 ± 2.2* 6.9 ± 1.3* ND 
40 to 60 7.3 ± 2.2* 3.3 ± 1.0 ND 
>60 1.6 ± 1.1 1.0 ± 0.9 ND 
Data are mean ± SEM, thigh and calf muscles combined, * statistically significant 
p<0.05 ANOVA/Tukey; CMT: Charcot-Marie-Tooth disease; IBM: inclusion body 
myositis; STIR: short-tau-inversion-recovery; ND: no data points. 
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Figure 5-4: Longitudinal change in thigh muscles in IBM patients grouped by baseline FF 
and STIR 
 
Annual change in fat fraction within thigh muscles in IBM patients varies depending on 
baseline fat fraction range and baseline STIR appearance, with greatest rate of change 
seen where baseline STIR hyperintensity is present and fat baseline fraction is 
moderate (5-40%). Green: STIR hyperintensity present; blue: STIR hyperintensity 
absent.  Values are mean ± 1 standard error. 
5.4.6.1 Baseline T2 as predictor of change 
As is noted above, the predominant effect of fat infiltration on T2 and MTR 
measurements means absolute values of T2 and MTR are not reliable markers of 
changes in muscle water distribution.  However due to the concurrent measurement of 
fat fraction within the same volume of tissue, it was possible to model the relationship 
between T2 and FF to calculate a “T2 excess” as a surrogate measure of muscle water 
T2.  This is defined as the difference in measured T2 and predicted T2 based on FF 
measurement.  Fit lines were drawn on the basis that changes in muscle water 
distribution tend to increase T2 rather than decrease T2, which was evident on a 
scatter plot of the T2/FF relationship (Figure 5-5).  Baseline T2 excess values were 
then grouped as less than 5ms, between 5 and 15ms and >15ms, as being roughly 
equivalent to the three qualitative STIR gradings, and subsequent change in FF 
calculated (Table 5-3).  At both thigh and calf level FF change was highest in muscle 
with greatest T2 excess. 
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Figure 5-5: Correlation between T2 and FF at baseline to estimate"baseline  T2 excess" 
 
Table 5-3: Change in FF grouped by "T2-excess" at baseline 
Baseline T2 excess 
(ms) 
<5 5 to 15 >15 
FF change Thigh (%) 2.33 3.72 4.51 
FF change Calf (%) 2.29 3.18 4.10 
5.4.7 Standardised Response Mean 
In the IBM group, significant 12-month change was observed in clinical, myometric and 
MRI measures. The highest SRMs, greater than 1, were for whole muscle FF at thigh 
and calf level, and T2 at calf level, whilst no clinical parameters had SRM greater than 
1 (Table 5-4.  In the CMT group, significant 12-month change occurred only in whole 
muscle FF at calf level, with an SRM of 0.83 (Table 5-5). 
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Table 5-4: Standardised Response Means in IBM 
Measure 
IBM 
Mean±s.d. (95% CI) 
Control (IBM) 
Mean±s.d. (95% CI) 
p vs 
baseline 
p vs 
control 
SRM 
Overall Clinical measures 
Lower Limb MRC -3·4 ± 5·6 (0·6;6·2) NA 0·02 NA 0·63 
SF-36 (%) -1·1 ± 7·0 (-2·7;4·8) NA 0·55 NA 0·16 
SF-36 PF (%) -4·1 ± 18·5 (-13·9;5·8) NA 0·39 NA 0·22 
IBM FRS (points) -2·8 ± 2·9(1·3;4·2) NA <0·001 NA 0·97 
Thigh Myometry 
Knee ext. (Nm) -6·0 ± 5·2 (-8·4;-3·6) -4·2 ± 11·4 (-9·5;1·1) <0·001 0·55 -1·15 
Knee flex. (Nm) -1·7 ± 4·3 (-3·7;0·2) 2·9 ± 7·1 (-0·4;6·2) 0·08 0·02 -0·40 
Calf Myometry 
Ankle PF (Nm) -0·7 ± 3·9 (-2·5;1·1) 5·6 ± 14·6 (-1·2;12·4) 0·42 0·09 -0·19 
Ankle DF (Nm) -0·4 ± 4·2 (-2·4;1·5) 2·0 ± 5·3 (-0·4;4·4) 0·65 0·14 -0·10 
Thigh MRI 
FF (%) 3·3 ± 4·0 (1·4;5·2) -0·1 ± 0·4 (-0·3;0·1) 0·005 <0·001 0·83 
T2 (ms) 2·6 ± 4·2 (0·5;4·7) 0·5 ± 1·6 (-0·3;1·3) 0·03 0·07 0·62 
MTR (p.u.) -0·9 ± 1·6 (-1·7;0·0) 0·0 ± 0·5 (-0·2;0·2) 0·06 0·06 -0·54 
FF whole (%) 3·3 ± 3·2 (1·8;4·9) 0·2 ± 0·8 (-0·2;0·6) <0·001 <0·001 1·06 
CSA (% change) -2·7 ± 7·9 (-6·5;1·1) 0·2 ± 5·7 (-2·5;2·9) 0·08 0·23 -0·34 
Calf MRI 
FF (%) 2·6 ± 2·7 (1·1;4·1) 0·0 ± 0·4 (-0·2;0·2) 0·004 <0·001 0·97 
T2 (ms) 4·5 ± 3·7 (2·6;6·4) 0·0 ± 1·5 (-0·7;0·7) <0·001 <0·001 1·21 
MTR (p.u.) -0·7 ± 0·7 (-1·1;-0·3) 0·2 ± 0·8 (-0·2;0·6) 0·004 0·003 -0·99 
FF whole (%) 2·6 ± 2·4 (1·3;4·0) 0·1 ± 0·4 (-0·1;0·3) 0·002 <0·001 1·07 
CSA (% change) -2·5 ± 3·9 (-4·4;-0·6) 0·1 ± 5·0 (-2·3;2·5) 0·01 0·11 -0·63 
p vs baseline: p-value of paired t-test in patient group; p vs control: p-value of two-
tailed t-test patient vs matched control; CI: confidence interval for mean change; IBM: 
inclusion body myositis; FF: fat fraction; MTR: magnetisation transfer ratio; MRC: 
Medical Research Council bedside strength assessment; SF-36: Short Form Health 
Survey; PF: physical functioning domain; IBM-FRS: IBM Functional Rating Score; NA: 
Not applicable. Highlighted measures are those where follow-up value is significantly 
different from baseline AND where applicable change seen is significantly different 
from change in controls (both paired t-test and two-tailed t-test are significant). 
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Table 5-5: Standardised Response Means in CMT1A 
Measure 
CMT 
Mean±s.d. (95% CI 
Control (CMT) 
Mean±s.d. (95% CI 
p vs 
baseline 
p vs 
control 
SRM 
Overall Clinical measures 
Lower Limb MRC -0·4 ± 3·8 (-1·5;2·3) NA 0·65 NA -0·11 
SF-36 (%) -2·5 ± 15·2 (-5·3;10·3) NA 0·51 NA -0·16 
SF-36 PF (%) -0·9 ± 12·3 (-5·4,7·2) NA 0·77 NA -0·08 
CMTES (points) -0·3 ± 1·3 (-0·9;0·4) NA 0·37 NA -0·23 
Thigh Myometry 
Knee ext. (Nm) 1·0 ± 8·1 (-2·8;4·8) -5·2 ± 10·2 (-9·9;-0·4) 0·57 0·06 0·12 
Knee flex. (Nm) 2·5 ± 6·8 (-0·7;5·8) 1·7 ± 7·6 (-1·7;5·2) 0·15 0·75 0·37 
Calf Myometry 
Ankle PF (Nm) 3·8 ± 7·6 (0·0;7·4) 2·1 ± 10·8 (-2·9;7·1) 0·06 0·59 0·51 
Ankle DF (Nm) 2·1 ± 4·0 (0·2;4·0) 0·5 ± 3·8 (-1·3;2·2) 0·05 0·24 0·51 
Thigh MRI 
FF (%) 0·4 ± 1·0 (-0·1;0·9) 0·0 ± 0·3 (-0·1;0·1) 0·15 0·12 0·36 
T2 (ms) 1·3 ± 1·5 (0·6;2·1) 0·6 ± 1·6 (-0·2;1·4) 0·003 0·21 0·86 
MTR (p.u.) 0·0 ± 0·7 (-0·3;0·3) -0·1 ± 0·3 (-0·3;0·1) 0·96 0·55 -0·01 
FF whole (%) 0·2 ± 0·8 (-0·2;0·6) 0·2 ± 0·8 (-0·2;0·6) 0·38 0·97 0·22 
CSA (% change) -0·6 ± 5·3 (-3·1;1·9) -0·7 ± 7·2 (-4·0;2·6) 0·62 0·96 -0·12 
Calf MRI 
FF (%) 1·1 ± 2·4 (0·2;2·2) 0·0 ± 0·4 (-0·2;0·2) 0·07 0·07 0·46 
T2 (ms) 1·4 ± 2·6 (0·0;2·6) 0·3 ± 1·1 (-0·2;0·9) 0·05 0·13 0·54 
MTR (p.u.) -0·2 ± 0·6 (-0·5;0·1) 0·0 ± 0·7 (-0·3;0·4) 0·30 0·28 -0·34 
FF whole (%) 1·2 ± 1·5 (0·5;1·9) 0·2 ± 0·4 (0·0;0·4) 0·002 0·008 0·83 
CSA (% change) 0·6 ± 6·6 (-2·5;3·8) 0·0 ± 4·4 (-2·0;2·0) 0·67 0·74 0·10 
p vs baseline: p-value of paired t-test in patient group; p vs control: p-value of two-
tailed t-test patient vs matched control; CI: confidence interval for mean change; CMT: 
Charcot-Marie-Tooth disease; FF: fat fraction; MTR: magnetisation transfer ratio; MRC: 
Medical Research Council bedside strength assessment; SF-36: Short Form Health 
Survey; PF: physical functioning domain; CMTES: CMT Examination Score; NA: Not 
applicable. Highlighted measures are those where follow-up value is significantly 
different from baseline AND where applicable change seen is significantly different 
from change in controls (both paired t-test and two-tailed t-test are significant) 
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 Discussion 
Significant changes in many MRI measurements over 12 months were seen in the IBM 
patients, with correlation between change in strength and change in MRI measured 
remaining muscle area providing evidence for longitudinal validity.  In CMT1A, only 
whole ROI fat fraction at calf level showed significant change over 12 months with large 
responsiveness (SRM 0.83).  Fat fraction progression was greatest in muscles with 
moderate baseline fat fraction and/or markers of abnormal water distribution, providing 
insights into disease pathogenesis and means to increase responsiveness. 
5.5.1 Outcome measure responsiveness 
Outcome measure sensitivity to change can be expressed by the standardised 
response mean (SRM), calculated as the ratio of mean change to standard deviation of 
change (Liang et al., 1990), categorised by magnitude according to Cohen’s rule of 
thumb: < 0.2 minimal responsiveness; 0.2-0.5 small responsiveness; 0.5-0.8 moderate 
responsiveness; >0.8 large responsiveness.  Responsiveness is a key determinant of 
study power, with an inverse square relation to sample size by Lehr’s formula (Lehr, 
1992), such that doubling outcome measure responsiveness results in a four-fold 
decrease in sample size required for equivalent study power. 
5.5.1.1 Responsiveness of outcome measures in CMT1A 
The development of responsive outcome measures has proven especially difficult to 
date in NMD such as CMT1A.  The CMTNS was selected as the most appropriate 
primary outcome measure for CMT trials at the 136th ENMC workshops and was  used 
in the ascorbic acid trials in adults with CMT1A (Lewis et al., 2013; Micallef et al., 2009; 
Pareyson et al., 2011a).  The calculated SRM of the CMTNS and other outcome 
measures in the largest of these (Pareyson et al., 2011a), together with five year 
natural history data (Verhamme et al., 2009), are shown in table 4.  On average, a 
0.3points per year CMTNS increase is observed, resulting in minimal responsiveness 
over two years and small responsiveness over five years.  Neurophysiology either 
showed no significant change from baseline (Pareyson et al., 2011a) or change no 
greater than seen in controls (Verhamme et al., 2009), so appears unsuitable as an 
outcome measure.  Ankle dorsiflexion showed moderate responsiveness over two 
years using a custom-built frame but no responsiveness over five years with hand-held 
myometry.  Timed functional tests and pinch or grip myometry showed small 
responsiveness over both two and five years.  The responsiveness of myometry, MRC 
strength assessment, CMTES and SF36-PF in this current study are consistent with 
those data (Table 5-6).  In marked contrast, in this thesis, calf-level MRI-quantified FF 
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showed large responsiveness (SRM=0.83) with a highly significant (p=0.002) increase 
in FF at 12 months. 
This has very important implications for future trial design.  For a hypothetical CMT1A 
treatment trial powered to detect a 50% reduction in disease progression over one year 
with 80% power at p<0.05 significance, the number of patients needed in active and 
placebo arms (Lehr, 1992) would be approximately 93 using calf-muscle MRI-
determined FF as the primary outcome measure, as opposed to 7700 patients for 
equivalent statistical power using CMTNS to quantify outcome.  MRI-quantified calf 
muscle FF is therefore the most responsive outcome measure proposed to date in 
CMT1A. 
Table 5-6: Comparison of outcome measure responsiveness with prior CMT1A studies 
Measure Baseline Change p SRM 
This study, 1 year 
Mean calf fat fraction (%) 15·5 ± 24·0 
1·22 ± 
1·47 
0·002 0·83 
CMTES (0-28) 8·0 ± 5·1 0·3 ± 1·3 ns 0·23 
MRC lower limb 95·4 ± 15·4 -0·4 ± 3·8 ns -0·11 
SF-36 PF (0-100%) 65·3 ± 23·2 -1·9 ± 14·9 ns -0·12 
Verhamme et al, 2009,, 5 years, 46 patients 
Adapted CMTNS^ (0-33) 11·6 ± 4·5 1·5 ± 3·0 0·003 0·49 
Nine-hole peg test (s) 26·0 ± 18·4 2·0 ± 5·8 0·02 0·35 
Three-point grip (N) 7 ± 32 -6·3 ± 10·5 <0·001# -0·60 
Ankle dorsiflexion (N) 190 ± 74 0·1 ± 28·1 ns 0·00 
Ankle plantarflexion (N) >250+ NA NA NA 
Ulnar CMAP (mV) 4·1 ± 1·5 -0·4 ± -0·7 0·001* -0·60 
Pareyson et al, 2011, 2 years, 133 patients (placebo arm) 
CMTNS (0-36) 13·9 ± 4·3 0·5 ± 2·7 <0·05 0·19 
CMTES (0-28) 8·6 ± 3·6 0·5 ± 2·1 <0·05 0·23 
CMT NCS (0-8) 5·2 ± 1·6 -0·1 ± 1·6 ns -0·06 
Nine-hole peg test (s) 23·4 ± 5·7 0·85 ± 2·7 <0·01 0·31 
SF-36 PF (0-100%) 62·9 ± 25·7 -1·1 ± 15·4 ns -0·07 
Hand grip (N) 85·8 ± 38·8 -6·9 ± 20·3 <0·001 -0·34 
Three-point pinch (N) 65·2 ± 29·4 -3·6 ± 18·8 <0·05 -0·19 
Ankle dorsiflexion (N) 62·8 ± 43·1 -9·8 ± 23·7 <0·001 -0·42 
Ankle plantarflexion (N) 97·0 ± 59·7 -2·7 ± 47·7 ns -0·06 
CMAP sum (mV) 7·1 ± 4·1 0·2 ± 2·9 ns 0·08 
Values expressed mean ± standard deviation. Non-significant (versus baseline or 
control) SRM depicted in grey. #: identical difference seen in controls; *: greater 
reduction seen in controls (p=0·05); +: measurement limited to 250N; ^: data for this 
measurement collected retrospectively; NA: not available; ns: not significant; SRM: 
standardised response mean, calculated from published data as mean 
change/standard deviation change.  Standard deviation in Pareyson study calculated 
from published 95% confidence interval by standard statistical formulae: 95%CI = 
mean - 1.96 s.d. to mean + 1.96 s.d.; standard error mean = s.d./√n. 
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5.5.1.2 Responsiveness of outcome measures in IBM 
Progression in IBM is somewhat faster than in CMT1A, with a 10 year median interval 
between symptom onset and significant disability (Cortese et al., 2013).  In contrast to 
the CMT1A group, in IBM significant change over 12 months was detected in IBM-FRS, 
knee extension strength, MRC scores, myometry measured knee extension and many 
MRI measures.  Only MRI measures’ SRMs exceeded 1.   
In terms of longitudinal validity, quadriceps remaining muscle area correlated with 
change in knee extension strength (Figure 5-3). This is a demonstration of external 
responsiveness, longitudinal correlation between MRI-detected change and functional 
deficit, only demonstrated previously in Duchenne muscular dystrophy (Willcocks et al., 
2014) 
5.5.2 Baseline predictors of change 
Also of note is the longitudinal demonstration that abnormal water distribution (baseline 
abnormalities in STIR) leads to greater progression in fat infiltration in the subsequent 
12 months.  In IBM, the difference was large with 5.9% and 1.1% increase fat 
infiltration in muscles with marked and no baseline STIR hyperintensity respectively 
(Table 5-2).  This difference was even apparent in CMT1A where STIR changes were 
not frequently seen.  Post-acquisition estimation of T2-excess at baseline was also a 
predictor of change in FF over the subsequent 12 months.  Future studies might utilise 
methods to separate out the fat and water T2 components at point of acquisition 
(Janiczek et al., 2011) so that this relationship can be investigated more directly. 
Rate of change can additionally be predicted in both groups from baseline fat fraction 
with moderate fat fractions between 5 and 40% in IBM and 20 and 60% in CMT1A 
being associated with the highest rate of disease progression (Table 5-2).  A similar 
effect has been noted in FSHD (Janssen et al., 2014).  Baseline predictors of interval 
change may be utilised to maximise outcome measure responsiveness by selecting 
patients or muscles predicted to show maximum change over trial duration, whilst 
methods to improve reliability (Fischmann et al., 2014) can further increase 
responsiveness by reducing measurement-related variability. 
5.5.3 Longitudinal insights into CMT1A 
The lack of significant change in thigh level indices in CMT1A is of no great surprise, 
given existing knowledge of disease distribution confirmed in the cross-sectional data 
in this thesis.  It stands to reason that normal muscle tissue has not progressed in the 
one year prior to baseline, so is unlikely to progress in the one year after baseline, 
unless it happens to be the year where pathology reaches this level.  Indeed, with the 
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length dependent distribution of CMT1A, one might envisage progression like water (or 
more accurately fat) gradually filling a pair of waders (Figure 5-6).  The orange 
represents a zone of active denervation. 
This model is largely borne out by the data presented in this thesis.  The youngest 
patients in the study had normal fat fraction at mid-calf level, and had no progression 
over 12 months at this level.   The oldest patients had the highest level of fat fraction, 
and showed little progression at this level over 12 months.  A small number of muscles 
were STIR positive, and these muscles showed greatest progression over 12 months 
(2.4% vs 0.5% in muscles with normal STIR intensity).  Furthermore, progression is 
greatest at intermediate levels of fat fraction (20-60%), peaking at 7.3% per year in the 
40-60% FF range.  The scatter-plot of upper calf-FF vs age (Figure 4-12) also shows a 
similar non-linear progression in FF when measured at a single anatomical level. 
Figure 5-6: A model of disease progression in CMT1A 
 
Black represents healthy muscle, orange muscle with active denervation and white fat 
replaced muscle.  The dotted lines show the anatomical levels analysed in this study. 
There are different ways in which this pattern of progression may be taken into 
consideration for a future clinical trial in CMT1A.  If the sole aim was to maximise SRM, 
one could select patients with a similar level of severity, or indeed select the planned 
site for analysis based on baseline severity.  The difficulty with this approach is that it 
may be that muscle tissue passes a point of no return, where even if innervation is re-
established, on-going progression of IFA occurs due to increasing biological strain on 
the remaining tissue, as occurs in chronic kidney disease.  On the other hand, 
choosing patients who are not affected at all at the anatomical level of analysis, will 
result in a very insensitive outcome measure.  The solution may be to collect FF data 
over a wide field of view, from the feet to the thighs, so that disease progression can be 
assessed in all patients.  This will however require careful consideration of how the 
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primary outcome measure will be defined and combined across different patients in a 
statistically meaningful way, whilst maintaining high responsiveness. 
We have already added 3D-Dixon acquisitions to the ongoing scanning in the patients 
reported in this study and have included this in international studies in CMT1A and 
local studies in other hereditary neuropathies such as hereditary sensory neuropathy, 
with further analysis of these data ongoing.  However, given that all previously tested 
outcome measures in CMT1A have proven entirely unresponsive to date, the 
demonstration of high responsiveness of muscle fat fraction at a single anatomical 
point in CMT1A is ground-breaking, with the clear potential to improve this even further. 
5.5.4 Longitudinal insights into IBM 
FSHD has more in common with IBM than may be apparent at first glance – although 
an inherited disease, and classified as a muscular dystrophy, prominent inflammation 
on biopsy may be seen on biopsy, periods of relatively rapid progression are 
recognised and some experts have advocated the use of immunosuppression in some 
cases.  On the other hand, inclusion body myositis, although considered an acquired 
inflammatory muscle disease, defects of muscle regeneration and repair are thought to 
be central to the pathogenesis, and immunosuppressive or immunomodulatory 
interventions have been universally unsuccessful in clinical trials.  Both diseases also 
show very specific (but different) patterns of muscle involvement, and often show 
asymmetry suggesting important environmental influences.  FSHD may therefore be 
considered at the inflammatory end of the dystrophy spectrum, and IBM at the 
dystrophic end of the myositis spectrum. 
It is interesting therefore to note the similarities between this study and the previous 
longitudinal quantitative MRI study in FSHD (Janssen et al., 2014).  Both studies 
demonstrate greatest progression in fat fraction in those muscles either STIR positive 
or showing intermediate levels of fat-fraction at baseline.  Indeed, with the overall 
longer duration of disease in FSHD, an hourglass distribution of FF within muscles was 
seen with most muscles either normal or end stage, and few with intermediate FF 
levels.  The supposition (Figure 5-7) has been that the disease process within muscle 
starts with abnormal muscle water distribution, as seen in 4.4.4.2, with increased T2 
and reduced MTR in muscles without significant IFA, followed (if untreated) by 
progressive intramuscular fat accumulation concurrent to ongoing abnormal muscle 
water distribution, leading ultimately to end stage fatty atrophy where there is not 
sufficient muscle water left to be abnormally distributed.  This thesis is the first work to 
conclusively show that this is indeed the case. 
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Figure 5-7: A model of disease progression in IBM 
 
Of course, as is evident in this and previous studies, at a single time-point, different 
muscles within the same patient will be at different stages in this process.  Indeed 
because of the selective involvement of muscles in IBM, this usually holds even within 
the same anatomical level.  This has interesting implications when considering 
application of MRI outcome measures to clinical trials in IBM, or indeed any primary 
muscle disease which follows the same schema.  Water sensitive measurements such 
as T2, ideally with separation of the confounding fat effects at acquisition stage, should 
be included to monitor the earliest stage of disease, and also provide an outcome 
measure which will potentially improve with effective therapy. Fat quantification 
measures, such as three-point Dixon can be used to assess for prevention of slowing 
of intramuscular fat accumulation, with muscles most likely to show this if STIR positive 
and/or with intermediate fat fraction levels (early to mid-stage disease).  Healthy 
muscles may be most amenable to physiotherapy type interventions, whilst end-stage 
muscles are unlikely to be responsive to any intervention, lacking the necessary 
scaffolding for even stem cell therapy to be effective. 
The consistent spread of muscle involvement – quadriceps before hamstrings in the 
thigh, medial gastrocnemius advanced even in early overall disease status in the calf – 
provides the opportunity to design outcome measures most likely to be responsive for a 
given patient group and intervention.  In the ongoing follow-up of the patients in this 
study we have added the IDEAL-CPMG sequence (Janiczek et al., 2011), which allows 
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separation of fat and water effects on T2 at the acquisition stage and should provide 
further insights. 
5.5.5 Longitudinal study limitations 
Outcome measure SRM derived from observational studies are only applicable to 
interventional studies when the intervention will affect the outcome measurement.  For 
example, if an intervention had an effect on muscle which improved strength without an 
effect on muscle size or quantitative MRI variables, a functionally important benefit may 
be missed. Or if an intervention improved upper limb but not lower limb strength, this 
improvement would not be measurable with the current protocol.   This relationship will 
need to be determined in a disease and intervention specific manner. 
 Conclusions 
MRI detected significant FF progression over 12 months in both disease groups. In the 
more slowly progressive CMT1A, calf-level MRI measured FF was the only measure to 
change significantly.  In the more progressive IBM, significant changes in multiple MRI, 
and some clinical and myometric measures were evident, with the MRI indices being 
most responsive.  Data from IBM patients also showed longitudinal validity, with 
correlation in change in remaining muscle area on MRI and myometric measured 
strength.  Moderate baseline fat fraction and baseline abnormal water distribution 
predict subsequent fat fraction progression over 12 months.  Quantitative MRI therefore 
provides valid and responsive outcome measures for future trials in CMT1A and IBM, 
with potential applicability for other neuromuscular diseases. 
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6 Conclusions 
There has been rapid progress in the molecular understanding of many muscle-wasting 
neuromuscular diseases. New targets have been identified and the opportunity for 
testing new therapies is increasing. However, accurately and reliably monitoring 
disease progression is an important obstacle to successful experimental clinical trials to 
test new agents. We have systematically investigated the utility and reliability of 
quantitative MRI biomarkers to track disease progression. We have also correlated 
findings with important measures of patient function. The biomarkers we selected 
detect and quantify the common findings of water and muscle fat accumulation which 
both occur across a range of different muscle-wasting diseases. We studied two 
common examplar neuromuscular diseases and controls. 
Previous studies in NMD have quantified fat fraction (Gaeta et al., 2011; Gloor et al., 
2011; Hiba et al., 2012; Willis et al., 2013; Wren et al., 2008), T2 (Gloor et al., 2011; 
Hiba et al., 2012; Huang et al., 1994; Kan et al., 2009; Kim et al., 2010a; Maillard et al., 
2004a), MTR (McDaniel et al., 1999; Sinclair et al., 2012a) and T1 (Huang et al., 1994) 
in myopathic  (Gaeta et al., 2011; Gloor et al., 2011; Hiba et al., 2012; Huang et al., 
1994; Kan et al., 2009; Kim et al., 2010a; Maillard et al., 2004a; McDaniel et al., 1999; 
Willis et al., 2013; Wren et al., 2008) and neuropathic (Gaeta et al., 2011; Sinclair et al., 
2012a) inherited (Gaeta et al., 2011; Gloor et al., 2011; Hiba et al., 2012; Huang et al., 
1994; Kan et al., 2009; Kim et al., 2010a; McDaniel et al., 1999; Sinclair et al., 2012a; 
Willis et al., 2013; Wren et al., 2008) or acquired (Maillard et al., 2004a; Sinclair et al., 
2012a) conditions at thigh (Gaeta et al., 2011; Gloor et al., 2011; Kan et al., 2009; Kim 
et al., 2010a; Maillard et al., 2004a; Willis et al., 2013) or calf (Gloor et al., 2011; Hiba 
et al., 2012; Huang et al., 1994; Kan et al., 2009; McDaniel et al., 1999; Sinclair et al., 
2012a) level, in one (Gaeta et al., 2011; Hiba et al., 2012; Huang et al., 1994) or many 
(Gloor et al., 2011; Kan et al., 2009; Kim et al., 2010a; Maillard et al., 2004a; McDaniel 
et al., 1999; Sinclair et al., 2012a; Willis et al., 2013; Wren et al., 2008) muscles, with 
(Gloor et al., 2011; Hiba et al., 2012; Huang et al., 1994; Kan et al., 2009; Maillard et 
al., 2004a; McDaniel et al., 1999; Sinclair et al., 2012a) or without (Gaeta et al., 2011; 
Kim et al., 2010a; Willis et al., 2013; Wren et al., 2008) controls.  The MRC Centre for 
Neuromuscular Diseases Prospective Cohort study is comprehensive in all these 
respects within a single scanning session of realistic duration. 
Whilst MRI may be criticised for lack of diagnostic specificity in that acute and chronic 
muscle pathology have similar appearance across NMD, this is advantageous for 
outcome measure applications.  As this study demonstrates, the same types of 
changes can be quantified in these two very different diseases: an acquired late-onset 
progressive proximal and distal myopathy and an inherited childhood-onset slowly 
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progressive distal predominant neuropathy.  Although this results in differences in 
magnitude and distribution of abnormalities, their presence, direction and clinical 
correlations are consistent, making these outcome measures applicable across any 
NMD with lower limb weakness.  Through selection of MRI sequences targeted to 
disease and intervention, MRI outcome measures can be optimised to provide 
maximum responsiveness for a specific clinical trial.  For example, in the diseases 
studied, the optimal MRI protocol for CMT1A would necessarily include assessment of 
fat infiltration of lower limb muscles with coverage targeted to disease severity; whilst to 
assess if an intervention in IBM reversed acute pathological processes, additional 
water sensitive sequences such as T2 and MTR quantification should be included.  For 
any NMD, understanding of basic pathomechanisms, disease distribution and 
treatment mechanisms will allow selection of the appropriate parts of this 
comprehensive protocol. 
In these representative NMD, MRI provides valid outcome measure closely correlated 
to strength, function and disease severity.  In CMT1A we have demonstrated 
responsiveness which far exceeds all existing outcome measures, allowing design of 
adequately powered clinical trials in this gradually progressive but debilitating disease.  
For the first time we show longitudinal evidence of correlation between decline in 
strength and MRI progression and also between baseline acute changes in water 
distribution and subsequent progression of irreversible fatty atrophy.  Together the 
methods provide objective, non-invasive, valid, responsive outcome measures in IBM 
and CMT1A, with potential application to the wide spectrum of neuromuscular 
diseases. 
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 Specific conclusions and future directions 
6.1.1 Study design 
For entirely novel MRI outcome measures, for example muscle diffusion imaging, it 
would be advised to follow the same outcome measure development process (Figure 
2-1, page 38): development of technique, application to healthy controls to assess 
reliability, cross-sectional assessment in patients and controls to assess validity, 
longitudinal assessment in patients and controls to assess responsiveness, before final 
application in an interventional study.  Each step is a necessary precursor to the next, 
for example without optimising reliability, responsiveness will be poor.  New techniques 
should be run in conjunction with established methods so that their relationships, co-
dependencies and relative responsiveness can be determined. 
For refinements of existing MRI methods, for example 3D three-point Dixon, or more 
sophisticated T2 measurement methods, the same development process is required, 
though some aspects will be known in advance, such as distribution of abnormalities 
for a given disease, or expected age and gender dependencies which will influence 
exact trial design.  Again the facility to compare established and refined method in 
terms of reliability, validity and responsiveness is key to demonstrating that the new 
method delivers on the expected improvements.  Applying the same methods to new 
diseases may be slightly different.  Qualitative imaging is sufficient to profile the 
disease in terms of type of pathology (acute vs chronic) and disease distribution which 
will inform the likely optimal protocol.  On the other hand, to allow accurate sample size 
calculations for an interventional study, responsiveness of the protocol in that specific 
disease must be determined in a longitudinal study. 
The process to allow the utilisation of an equivalent protocol (as far as hardware and 
software restraints allow) in an already studied disease at a new site, as will be 
necessary for phase 3 clinical trials in rare diseases, merits special consideration.  
More work needs to be done to demonstrate the feasibility of this; beyond the study in 
LGMD2I (Willis et al., 2014), data in this area are relatively lacking.  In interventional 
studies, longitudinal change is most relevant so inevitable systematic bias in 
measurements between sites would be acceptable if of small magnitude.  Inter-site 
quality control could be assessed by means of a phantom, or indeed human control or 
patient, scanned across multiple sites.  Inter-scan reliability at each site is of greater 
importance and therefore needs systematic assessment.  The processes here are well 
established in other domains, for example central nervous system imaging in multiple 
sclerosis trials, and need to be replicated in the peripheral nervous system domain. 
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The inclusion of healthy controls is vital in both cross-sectional and natural history 
patient studies.  When healthy control data are compared across different studies, 
whether T2 measurement or fat quantification, it is clear that exact healthy values 
depend on exact scanner and sequence configuration (see 3.2.1).  Therefore, in cross-
sectional studies the inclusion of healthy controls is vital to establish the healthy range 
for the specific configuration in the study, though an equal number of controls to 
patients may not be necessary for this purpose.  If studies are performed in children, 
fully age-matched controls are vital to allow correction of results for the effects of 
normal growth and development.  This thesis provides evidence that the effect of 
normal ageing will not have a strong confounding effect on quantitative MRI tissue 
parameter outcome measures, but this should ideally be shown in longer studies, and 
scanning of the healthy controls in this study is continuing. 
Beyond this control, data are needed in longitudinal studies to guard against systematic 
bias between study visits which may exaggerate or eliminate true change between 
time-points.  The effect of the software upgrade on the T2 measurements in this study 
was brought to light by the unexpected and isolated change in control data between the 
two time points; if this had been overlooked, T2 quantification would have incorrectly 
appeared the most sensitive outcome measure.  In  randomised placebo controlled 
clinical trials, healthy controls are not mandatory as the placebo group provides the 
internal control, however inclusion of some controls for inter-site standardisation and 
identification of systematic bias will still increase study power.  Conclusions from any 
study which includes no controls should be treated with caution. 
6.1.2 MRI protocol 
The protocol presented here is the most comprehensive ever undertaken in a large 
longitudinal series including T1-weight and STIR qualitative imaging, and three-point-
Dixon fat fraction, T1 mapping, T2 mapping and magnetisation transfer quantitative 
imaging, with coverage of both thighs and both calves.  These methods have advanced 
since the study and it is always difficult to balance continuing with established methods 
or using the newest, more advanced but untested sequences.  Whilst exact 
specifications will depend on disease of interest and local hardware, this thesis 
provides many important observations in this. 
6.1.2.1 MRI hardware 
The first issue is field strength: 1.5 tesla as is still the mainstay of clinical practice, while 
a 3 tesla scanner was used in this and commonly in other research studies.  There are 
advantages and disadvantages to both.  1.5T scanners are more widely available but 
3T scanners are most commonly used in neuromuscular disease research.  3T 
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scanners are faster, but have significant B1 field inhomogeneity artefact, which affected 
the T1 mapping and MTR methods significantly in this study especially in the right thigh 
anteriorly, even with B1 field mapping and correction.  Some methods such as three-
point Dixon FF should theoretically give equivalent results at both 1.5T and 3T field 
strength, whereas others such as T1 recovery time are inherently dependent on field 
strength(Henriksen et al., 1993).  The time intensive nature of many quantitative MRI 
sequences favours 3T MRI for research, and including scanners of different field 
strengths in a multi-site study would present significant but not insurmountable 
challenges, depending on the planned sequences. 
Similar challenges exist in including scanners of the same field strength but from 
different manufacturers, and even different MRI models from the same manufacturer 
or, as this study shows, different software versions on the same scanner.  Whilst these 
considerations were not examined in this thesis, where a single scanner was used, 
they are clearly an issue which needs to be addressed before large multi-site studies 
can be performed.   This has already been investigated using three-point Dixon in 
LGMD2I (Willis et al., 2013) which included the MRC Centre as a site, and measuring 
T2 and FF across three scanners from two manufacturers in DMD (Forbes et al., 
2014).  What is key in any trial design is that longitudinal assessments in an individual 
study subject are undertaken on the same scanner so that outcome measure 
responsiveness is not reduced by inter-scanner differences.  
6.1.2.2 Scan scheduling and subject positioning 
These are aspects which were specified in this study, but not as rigorously controlled 
for as in some other studies.  In terms of scan scheduling, MRI in patients usually 
occurred prior to strength testing, and if following, after at least a 1-hour resting 
interval, based on early studies which showed that acute T2 changes in muscle 
following exercise are short lived (see 3.2.2.1) and based on the good reliability of T2 
measurements in healthy controls in phase one of the study, where no specific 
recommendations with regard to exercise were stipulated.  Other studies though have 
shown T2 effects for up to 24 hours post exercise (Jia et al., 2015) and some protocols 
have had stipulations to avoid exercise for up to three days prior to scanning, though 
the other extreme of bed-rest also has significant effects on MRI parameters.  Although 
no effect of exercise on T2 was found in juvenile dermatomyositis (Maillard et al., 
2004a), further examination of these effects in other patient groups would provide 
clearer guidance as to adequate study design in this regard.  Good practice until such 
data are available would be to perform study procedures in the same order each visit, 
with MRI before any strenuous physical assessments (unless that is the object of 
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study) and where possible ask patients to travel to assessments by the same means 
each visit. 
Subject positioning in this study was only specified as far as “feet-first supine” but one 
of the qualitative observations through the study was that on occasion muscle 
deformation due to different calf positioning on the table, or rotation of the lower limb 
about the long axis, significantly affected the axial outline of muscles on baseline and 
follow up scans.  As long as tissue deformation occurs within the same axial plane, the 
same volume of tissue will be assessed, though even then defining equivalent ROI 
between two scans is made much more difficult with distorted anatomy.  For this 
reason we undertook a positioning study looking at this question specifically 
(Fischmann et al., 2014) and found that relaxed or more supported limb positioning 
methods were equally reproducible, but that reproducibility reduced significantly if 
different positioning methods were used.  In a clinical trial it could not be guaranteed 
that the same radiographer performs baseline and follow-up scans for each patient, so 
some specification to subject positioning is warranted. 
6.1.2.3 Anatomical coverage and slice positioning 
Whilst whole-body muscle MRI is gaining an increasing following in neuromuscular MRI 
for diagnostic purposes (Ohana et al., 2014; Quijano-Roy et al., 2012), lower limb MRI 
remains the mainstay of publications describing pattern of muscle involvement in 
different diseases (Wattjes et al., 2010) and is certainly the most common area imaged 
using quantitative studies (Gaeta et al., 2011; Gloor et al., 2011; Huang et al., 1994; 
Kan et al., 2009; Kim et al., 2010a; Maillard et al., 2004a; McDaniel et al., 1999; Willis 
et al., 2014; Wren et al., 2008).  The MRI trade-off between coverage and signal-to-
noise ratio for a fixed scanning time, together with additional technical difficulties of 
scanning other body parts, such as trying to position the upper limb at the centre of the 
bore where the magnetic field is most homogenous, or the additional breathing and 
cardiac motion artefacts in the trunk, are likely to result in lower limb protocols 
remaining most popular for quantitative MRI except in specific circumstances. For 
example recent quantitative studies in non-ambulant boys with Duchenne utilised an 
upper limbs protocol (Hogrel et al., 2016; Ricotti et al., 2014).  The choice between 
pelvis, thigh, calf and foot muscle will depend upon the disease being studied and the 
disease severity.  For example, in IBM just thigh imaging would be potentially adequate 
if an intervention is expected to affect all muscles equally, whilst in CMT1A foot, calf or 
thigh imaging would be most appropriate for early, moderate or late stage disease 
respectively.  The pattern of involvement can be adequately examined based on 
qualitative MRI data published in the literature, or when unavailable preformed as an 
initial pilot study. 
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Slice positioning is absolutely critical to test-retest reliability in patients due to the 
inhomogeneous distribution of pathology within a muscle, for example proximal-distal 
gradients within a muscle in CMT1A (Gallardo et al., 2006).  We recently presented 
data from this study showing proximal-distal gradients of FF within calf muscles in 
CMT1A patients of up to 8%/cm (Evans et al., 2015), which has clear implications 
regarding the reliability of FF as an outcome measure if near-identical axial slice 
positioning is not achieved between scans.  In this thesis, block positioning during 
acquisition was based on surface anatomical landmarks, which were inconsistently 
assessed and measured, resulting in a maximum inter-scan difference in slice 
positioning of 10cm from post-hoc assessment of bony landmarks, and a mean inter-
scan difference in slice positioning of 0.4±3.2cm, with a mean absolute inter-scan 
difference of 2.3±2.2cm.  In this thesis, it was possible to adjust for this shifted imaging 
block during the analysis phase due to the total block size of at least 19cm on all 
sequences (10 slices, 1cm slice thickness, 1cm slice gap).  ROI were drawn on the 
repeat slice closest anatomically to the slice used for the baseline ROI, based on 
measurement from an imaged bony landmark, the lateral tibial plateau (Figure 6-1). 
For more advanced sequences such as IDEAL CPMG (Janiczek et al., 2011) where 
only a small number of slices is possible due to long acquisition time, accurate block 
positioning is vital to ensure there is overlap between the volume of tissue imaged at 
baseline and follow up.  With the identification of this issue, we showed that reliability of 
anatomical localisation was much improved when clock location was based on a fixed 
distance from a bony landmark such as the knee joint (Fischmann et al., 2014).  This is 
therefore the method advocated in future studies. 
The observed gradients also raise issues concerning inter-slice distance.  In this study 
there was a 2cm total distance between adjacent axial slices (1cm slice thickness, 1cm 
gap), which meant that even with careful post-acquisition assessment of slice 
localisation in the proximal-distal direction, up to 1cm difference in sliced localisation is 
unavoidable. This difference occurs when slices are perfectly interleaved between 
baseline and follow-up.  Whilst increasing number of slices analysed can help if the 
inhomogeneity of intramuscular fat accumulation is random, with a gradient, increasing 
the number of slices analysed does not improve the accuracy (see Figure 6-2). A 
potential solution is to image and analyse on the entire volume of muscle tissue, but 
this is very labour intensive, boundary definition is more difficult at muscle ends, and 
different sampling within that volume will still affect results.  A method to minimise this 
is to reduce inter-slice distance, and we are now investigating the utility of a “3D” three-
point Dixon sequence with no slice gap and 5mm slice thickness in the proximal-distal 
axis, which means that slices within 2.5mm of each other can be assessed 
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longitudinally.  An analysis of the effects of these considerations on test-retest reliability 
is further discussed in 6.1.3.2 and depicted in Figure 6-1 and Figure 6-2. 
6.1.2.4 MRI sequences 
Two sequences in this study were included primarily to measure intramuscular fat 
accumulation: three-point Dixon and T1 mapping.  T1 mapping performed worse on 
almost every metric: presence of artefacts or unusable maps, lower test-retest reliability 
in volunteers, evidence of systematic bias on longitudinal study and reduced 
responsiveness on longitudinal analysis.  Compared with a sparse literature on T1 
mapping, there is a large and ever increasing body of literature utilising three-point 
Dixon, or similar techniques based on the same principle, which show consistent 
reliability, validity and responsiveness of fat quantification methods across a range of 
neuromuscular diseases, including in multi-site studies.  Without doubt therefore, 
chemical shift based fat-water separation quantification methods such as three-point 
Dixon are favoured.  Without further evidence, T1 mapping would not be recommended 
in future clinical trials. 
There are many different chemical shift based fat-water separation quantification 
methods, and even within a single method such as three-point Dixon, further 
refinements are possible, such as 3D coverage or accelerated acquisition algorithms 
(Hollingsworth, 2015).  A major factor in test-retest reliability in patients is having a 
small distance between axial slices (see 6.1.3.2).  Only one previous paper has 
compared methods directly in cross-sectional analysis, and found two-point Dixon to be 
superior to a steady state free precession method (Gloor et al., 2011).  No studies have 
compared methods longitudinally.  The exact choice of sequence will therefore depend 
on MRI hardware and software platforms available for the study. 
The measures sensitive to abnormal water distribution (acute pathology) in this study 
were T2 mapping and magnetisation transfer imaging.  Overall these performed 
similarly: as applied both were confounded by fat effects, MTR had overall more 
artefacts, T2 was affected by a routine software upgrade, both showed changes in 
early disease in muscle without significant fat accumulation.  For both there are more 
advanced methods to separate the confounding effect of fat (Janiczek et al., 2011; 
Sinclair et al., 2010), though these are significantly longer for the same anatomical 
coverage.  In early studies where full characterisation of changes in muscle tissue 
parameters are needed, it would still be reasonable to include both, but in clinical trials 
where scan duration is of greater importance and applicability across multiple scanners 
is important, just a T2 mapping measurement might be preferred.  More advanced T2 
sequences such as an increased number of echo times, or utilising methods to 
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suppress or separate fat signal at the point of acquisition, would be advised in future 
studies. 
T1-weighted sequences and STIR or equivalent sequences remain the mainstay of 
diagnostic imaging.  Their inclusion in quantitative studies remains helpful to provide a 
cross-reference for quantitative assessments of IFA and abnormal muscle water, as an 
internal control of the quantitative sequences validity (convergent validity).  The 
converse question could also be proposed: whether quantitative sequences could be 
used for diagnostic purposes – for example a three-point Dixon type sequence to 
demonstrate pattern of muscle involvement, or a T2 water mapping sequence to 
measure disease activity, to guide treatment or select sites for biopsy in inflammatory 
myopathies.  There is no theoretical reason why this could not be the case, but there 
remain significant practical obstacles to implementation. 
Whether both three-point Dixon (or equivalent) and T2 mapping methods both need to 
be included in a study protocol naturally depends on the study purpose and the disease 
being studied.  However, even in CMT1A, one of the most gradually progressive 
neuromuscular diseases, evidence of active disease was identified on T2 sequences, 
so the inclusion of both types of sequences would provide complementary information 
and would be recommended. 
6.1.2.5 Novel methods which might be considered for future studies 
In addition to the MRI methods used in this study and refinements thereof, there are 
novel approaches which are worthy of consideration in future studies, specifically 
diffusion tensor MRI and MR spectroscopy. 
6.1.2.5.1 Diffusion tensor MRI 
Diffusion tensor imaging is useful for studying organ structure and is widely used in 
imaging of the central nervous system and brain (Le Bihan et al., 1986).  Diffusion 
tensor imaging is based on the restriction of the diffusion of water by cell membranes 
and other structures.  This restriction results in an apparent diffusion co-efficient lower 
than the free diffusion coefficient.  Diffusivity is orientation dependent in elongated 
structures.  Thus in skeletal muscle diffusivity would be expected to be greater 
longitudinal to the axis of the myocytes (Damon et al., 2016; Longwei, 2012). 
Diffusion tensor MR has been applied to skeletal muscle in healthy volunteers including 
calf (Saupe et al., 2008; Sinha et al., 2006; Steidle and Schick, 2015) and thigh (Budzik 
et al., 2007) musculature.  It has further been examined in looking at the effects of 
ageing (Sinha et al., 2015) and exercise (Cermak et al., 2012) in humans, and 
denervation in a rat model (Ha et al., 2015).  Thus, diffusion tensor MRI parameters 
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may be sensitive to early changes in myocyte structure and integrity and is worthy of 
further study in neuromuscular diseases. 
6.1.2.5.2 MR Spectroscopy 
As already discussed, H1-spectroscopy can be used to quantify fat and has been 
applied to neuromuscular diseases (see 3.2.1.3.1).  H1-spectroscopic methods also 
allow the calculation of the T2 time of the water component independent of the fat 
component in DMD (Forbes et al., 2014).  However, employing spectroscopic MR to 
other elements such as phosphorus and sodium, provide additional means of 
assessing skeletal muscle function. 
Sodium plays an important role in cellular integrity and function, with a concentration 
gradient across the cellular membrane maintained by a sodium-potassium pump 
(Constantinides et al., 2000).  Sodium spectroscopy has been used to estimate the 
total sodium concentration in normal calf muscle (28.4 mmol/kg) and has been shown 
to be elevated post exercise and in dystrophic muscle (Constantinides et al., 2000).  A 
particularly enticing application of sodium spectroscopy is the skeletal muscle 
channelopathies, inherited muscle diseases where the primary genetic defects are in 
the ion channels in the muscle cell membrane, including mutations in the voltage gated 
sodium channel (SCN4A) which result in a periodic paralysis phenotype (Raja Rayan 
and Hanna, 2010).  Indeed sodium spectroscopy has been employed by Jurkat-Rott 
and colleagues in patients with hypokalaemic periodic paralysis showing increased 
sodium concentration within calf muscles, which normalised following treatment with 
acetazolamide (Jurkat-Rott et al., 2009).  Sodium spectroscopy may therefore provide 
novel insights and treatment responsive biomarkers in neuromuscular diseases and 
warrants further investigation. 
6.1.3 Analysis methods 
The key to optimising reliability of analysis is to ensure the same volume of tissue is 
selected at baseline and follow up, as any difference will result in variability which will 
reduce study responsiveness.  Ensuring similar patient positioning is key at the 
acquisition stage (see 6.1.2.1).  During ROI definition, capturing the same tissue needs 
to be considered in both the proximal-distal direction (z axis) and axial plane (xy axes). 
6.1.3.1 General considerations 
As in this study, ideally all ROI should be drawn by a single observer.  As has been 
demonstrated in studies assessing reliability, intra-observer reliability is greater than 
inter-observer reliability (see 3.2.4), and regardless, inter-observer variation can be 
removed entirely by only using one observer.  In a large study where that is not 
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possible, one observer should draw all ROI for a given subject to eliminate inter-
observer variation from the longitudinal assessments in each subject. 
The observer should be appropriately experienced or trained in neuromuscular MRI, 
although there are no studies specifically addressing this question.  The observer 
should be blinded as to the disease status of the subject, and all other clinical details, 
to eliminate any potential bias.  This is another benefit of including a control group – the 
observer will remain blinded to healthy control versus minimal disease such as the 
mildly affected CMT1A subjects in this thesis.  The observer should be blinded to visit 
number of the scan to eliminate any potential bias when drawing repeat ROI.  Exact 
positioning of ROI in heterogeneous tissue or close to muscle boundaries can have a 
significant effect on fat fraction, and knowledge of the scan order could lead to 
subconscious bias, which can easily be eliminated by blinding this information.  As the 
ROI in our study were performed for phase 2 then for phase 3, blinding to visit number 
was not done for this thesis, which is a weakness.  Conversely ROI should be drawn 
with reference to other ROI drawn in the same subject to ensure equivalent ROI are 
drawn between scans.  Some inter-muscle boundaries are not anatomical, for example 
between the three vasti muscles, and drawing ROI with reference to each other allows 
consistency in inter-muscle definition, or in the case of small ROI, equivalent placement 
within the muscle. 
In this study ROI were drawn on one of the raw Dixon acquisitions (se=345ms) rather 
than generated maps.   This sequence has good anatomical detail but relatively less 
fat-muscle contrast, which aids ROI definition, particularly in patients with severe 
disease.  On fat fraction maps for example, both muscle fascia and healthy muscle 
tissue have near zero fat fraction, so these images are not easy to use to define inter-
muscular boundaries, particularly in skinny patients.  Software should allow ROI to be 
saved so that a data checking and ROI correction process is possible, as in this study. 
6.1.3.2 Z-axis considerations 
The present of disease inhomogeneity within a muscle, in particular a gradient within 
the muscle, makes consistent localisation in the z-axis crucial.  As above (6.1.2.3), this 
should be applied at scanner set-up phase, most reliably by scanning at a fixed 
distance from a bony landmark – in lower limbs most easily the knee joint, or as 
specifically used in this study, the right lateral tibial plateau.  The same process can be 
applied at the analysis phase by defining the location of the anatomical landmark on 
the scout imaging, then calculating the slice closest to the desired distance proximal or 
distal to the knee joint.  This should be calculated for the right and left limbs separately 
as any degree of change in pelvic tint between scans will affect the relative positions of 
the right and left leg, and RO may need to be drawn on a different slice number 
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between right and left legs.  There are different considerations in children where the 
muscle tissue is a moving target due to participant growth in between scans.  In 
children therefore a fixed proportion of the distance between identified bony landmarks 
may be more appropriate. 
The effect of different slice positioning and analysis methods on test-retest reliability is 
considered in a hypothetical patient muscle with a fat fraction gradient of 4%/cm, the 
median gradient seen in an analysis of the CMT1A patients in this study (Evans et al., 
2015), and is depicted graphically in Figure 6-1 and Figure 6-2.  Using the same slice 
within the block as acquired (5th of 10 slices) for analysis would have the greatest 
effect on the measured value.  Figure 6-1-A depicts the effect with the median inter-
scan block acquisition displacement of 3cm seen in this thesis.  This results in a 12% 
difference on repeat imaging of the same muscle.  This degree of error would greatly 
limit the ability of MRI to detect small changes in FF longitudinally. 
The method use in this thesis was to define ROI on the anatomically closest slice.  
However, with 2cm between slices, the maximum distance between analysed slices 
would still be 1cm (Figure 6-1-B), resulting in a 2% test-retest difference.  
 
202 
Figure 6-1: Effect of slice selection on test-retest reliability 
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Figure 6-2: Methods to Improve test-retest reliability 
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One method to try and improve reliability would be to increase the number of slices 
analysed, for example to analyse three slices rather than a single slice.  Depending on 
the relationship between slice position and disease distribution this may in fact worsen 
test-retest reliability, and in our hypothetical patient with a constant gradient, there is no 
change in the test-retest difference of 2% (Figure 6-2-A).  Rather the best method to 
improve reliability is to reduce slice thickness, so that the z-axis displacement is 
minimalised.  In our model, reducing the slice thickness to 5mm, reduced the inter-scan 
difference to 0.5% (Figure 6-2-B).  This is indeed the method we have applied in 
ongoing scanning of this patient cohort, as well as in an international study extension, 
and would be recommended in any future studies where there is disease 
inhomogeneity within muscle tissue. 
6.1.3.3 X-Y plane considerations 
Different studies have utilised different sized regions of interest within the x-y plane: 
broadly small, subtotal and whole.  The best to utilise will depend on the aim of 
analysis.  Where correlation with strength is desired, whole ROI should be used to 
allow inclusion of cross-sectional muscle area, a major determinant of muscle strength.  
A disadvantage of using whole ROI is the partial volume effect, where voxels which are 
part muscle and part fascia/subcutaneous fat are included which can skew the results.  
In this study a systematic bias was present between observers for whole ROI muscle 
fat fraction in volunteers, with FF from one observer ~1% higher, which when assessed 
was due to inclusion of more voxels within the ROI at the muscle boundary.  
Conversely when small ROI are used, even with specific details of where within the 
muscle the small ROI should be drawn, small changes in the size or position will affect 
the result, especially in patients with heterogeneous disease within a muscle. 
In the T1, T2 and MTR methods used in this study, there were sometimes artefacts at 
tissue boundaries which limited usability of these ROI for these sequences.  
Furthermore, in order that the same volume of tissue could be compared across 
sequences, a single set of ROI was drawn on one of the Dixon acquisitions, which 
were then transferred to co-registered maps of the other sequences.  All these were 
manually checked to ensure they lay within the appropriate muscles.  If whole muscle 
ROI were used, any movement between sequences would have affected the extracted 
muscle values significantly.  The main advantage of small ROI is that an area of tissue 
without vessels or intramuscular septae or tendons can be chosen.  An intermediate 
option is a sub-total ROI which is drawn a set number of voxels inside the perceived 
tissue boundary.  Finally, in the CMT1A patients, whole FF was more responsive than 
small FF due to less variability of change – presumably due to greater reliability of 
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whole muscle FF. For future studies, size of ROI will depend on the planned purpose of 
the extracted data, with whole ROI preferred for FF outcome measures. 
6.1.3.4 Data checking 
Robust data checking procedures were undertaken in this study and would be 
recommended for future studies: 
 All ROI were checked directly on parameter maps to ensure accuracy. 
 All parameter maps were visually checked for artefact, and ROI affected by 
artefact excluded from all analysis. 
 Visual assessment was performed of scatter plots between quantitative 
parameters (e.g. T2 vs FF) for outliers whose corresponding maps/ROIs were 
re-reviewed for artefact and ROI placement. 
 Visual assessment was performed of scatter plots of baseline versus follow up 
values for outliers whose corresponding maps/ROIs were re-reviewed for 
artefact and ROI placement. 
 Examination of control data for possible systematic bias between scans (eg the 
T2 upgrade effect observed in this study). 
All these procedures should take place whilst still blinded to subject group status and 
scan order to avoid the potential for observer bias. 
A transparent data pipeline also needs to be in place: from saving ROI files so they can 
be re-examined, clear recording of data points excluded due to artefact, automated 
data extraction and collation processes to eliminate transcription errors, checking of a 
proportion of final data back to results directly derived from source data to ensure 
fidelity of data pipeline, keeping the final raw data set separate from any data analysis 
processes so its integrity is not compromised, and full recording of statistical analysis 
performed (in this case data files and output files from SPSS). 
6.1.4 Outcome measure selection and trial design 
In future clinical trials diseases, what specific MRI measure should be selected as the 
primary outcome, or one of the secondary outcome measures?  For a natural history 
study, exploratory analysis to determine the best outcome measure is reasonable 
(though still should be specified in advance), but for a clinical trial to be statistically 
valid any planned primary or secondary outcome measure should be defined before 
the study commences. 
6.1.4.1 CMT1A 
To consider the specific diseases studied first, in CMT1A these data demonstrate that 
the only sequence which showed significant change was the three-point Dixon, 
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specifically whole muscle ROI across all muscles from a single axial slice at calf level.  
Whilst this measure would therefore be the clear one to use in CMT1A based on the 
data in this thesis, there are many ways the responsiveness of this measurement might 
be improved.  We can consider the formula for standardised response mean to see 
how this might be achieved, either by increasing the mean change or reducing the 
standard deviation of the change. 
 SRM = mean change   /   standard deviation change 
This thesis has shown methods to increase mean change on fat fraction.  Change in fat 
fraction is greatest in muscles with intermediate fat fraction, therefore by selecting 
patients or muscles with intermediate fat fraction at baseline, the greatest degree of 
change over 12 months would be expected.  The options here would be to enrol 
patients of a similar disease severity, with intermediate fat fraction at mid-calf level, 
either measured directly or predicted based on clinical assessment or qualitative 
imaging.  The alternative is to include a broader spectrum of patients but to use fat 
fraction at an anatomical level appropriate to the patients as the outcome measure: foot 
for mildly affected, calf for moderately affected and thigh for severely affected.  Careful 
statistical consideration would be required as to how to combine measures at different 
anatomical levels.  One advantage of muscle FF in this regard over muscle strength or 
neurophysiology variables is that the normal range (<5%) and disease spectrum (5-
100%) are similar in skeletal muscle regardless of calf or thigh location (see 3.2.1.3 
and 3.4.3).  Muscles with STIR positivity in addition to moderate fat fraction have the 
greatest change, but these are relatively infrequent in CMT1A so would limit 
recruitment; however it would be interesting to focus on the response to treatment in 
these muscles.  The final means to increase mean change is to increase duration of 
follow-up, and scanning our cohort of CMT1A patients over five years is ongoing. 
There are two methods of reducing standard deviation of change.  One is to reduce 
apparent change due to poor reliability.  Optimising all aspects of the protocol as 
outlined in the above sections is important in this regard, most crucially in CMT1A by 
ensuring accuracy of ROI placement in the z-axis (distal-proximal direction) due to the 
presence of a gradient, by utilising the smallest slice thickness practical.  Beyond this, 
standard deviation of change may also be reduced by selection of a patient population 
and outcome measure where a consistent change in the outcome measure is 
expected.  For example, a patient population with a mean change over 12 months of 
1% FF, with a standard deviation of change of 0.5%, has an SRM of 2; this is more 
responsive than a patient population with a mean change over 12 months of 4% and a 
standard deviation of change of 4%  with an SRM of 1.  Therefore, purely maximising 
degree of change may not be optimal if at the expense of a wide degree of variability.  
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On the other hand, including very mild patients who show no progression, has a doubly 
negative effect on the responsiveness by reducing the mean change AND increasing 
the variability of change. 
The final consideration is that a very responsive outcome measure based on SRM 
assessment is of no use for study power if the intervention has no effect on that 
measure: 
 N=16/(SRM x E)2 
Whilst E may be 0 because the intervention is ineffective on the disease process as a 
whole, it may also be low if the intervention has no effect on the disease stage being 
measured.  One potential concern in maximising SRM as outlined above is that 
muscles with 20-60% FF may have passed a pathological point of no return where 
even halting any further progression of denervation does not prevent further fatty 
atrophy.  Indeed, there may be a point in the pathogenesis of fatty atrophy where even 
restoration of normal nerve supply, would not prevent further progression to end stage 
muscle.  The difficulty is that as there is currently no effective treatment in CMT1A 
these thresholds cannot be directly investigated.  The advantage of MRI is that 
anatomical coverage can include the entire lower limbs or indeed the entire body 
(Horvath et al., 2015), and thus different disease stages can be examined in every 
individual.  Whilst in clinical trials the primary outcome measure needs to be pre-
specified, treatment response at different pathological severities could be included as 
secondary outcome measures, to identify any treatment effect present. 
Putting all these considerations together, the best balance between outcome measure 
responsiveness and disease responsiveness to treatment might be at the point of early 
but quantifiable pathology, roughly 5-20% fat fraction.  Baseline scans could be used to 
determine where in the lower limbs (thighs/calves/feet) fat fraction was in this range, 
and change in fat fraction at this level could be used as the primary outcome measure, 
with secondary outcome measures including assessment of fat fraction at other 
anatomical levels.  If feasible, T2 water measurement as a marker of early and active 
disease should also be included as a secondary outcome measure. 
6.1.4.2 IBM 
In IBM, there were both MRI and clinical measures which changed significantly over 12 
months.  However, no myometry measure changed in patients both compared with 
baseline and compared with controls (see Table 5-1), which highlights some of the 
difficulties in using myometry as an outcome measure.  The IBM-FRS is undoubtedly 
an important outcome measure to include in future clinical trials in IBM, but whilst some 
improvements might be possible, for example utilising Rasch analysis to convert to an 
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interval scale, however with MRI many refinements are possible to improve 
responsiveness even further. 
As in CMT1A, SRM may be increased by increasing mean change or reducing 
standard deviation of change.  In particular the same considerations with regard to 
optimising reliability as outlined in the sections above apply.  IBM however has three 
advantages over CMT1A in utilisation of MRI outcome measures.  First, disease 
progression is faster in IBM, both clinically and on MRI, with progression in fat fraction 
more than double that seen in CMT.  Second, a greater spectrum of disease stages is 
usually seen at a single anatomical level, as IBM displays a non-length dependent 
disease pattern with selective and sequential muscle involvement at a single level.  For 
this reason, mean fat fraction at a single level such as mid-thigh may detect change 
across a wide range of disease severity, with progression in quadriceps fat fraction in 
early disease and progression in hamstrings at a later disease phase.  Third, there is a 
greater degree of acute pathology (abnormal muscle water) to quantify which would 
potentially be reversible and is predictive of subsequent disease progression, which 
would allow baseline stratification. 
In a clinical trial therefore, a detailed yet short protocol could be undertaken at a single 
level with high resolution quantification of intramuscular fat accumulation as the primary 
outcome measure, and sophisticated quantification of the T2 water component a 
secondary outcome measure to assess reversibility of acute changes with treatment. 
6.1.5 Application to clinical trials of other diseases 
Whilst this thesis cannot determine the optimal means to utilise quantitative MRI in all 
neuromuscular diseases, by including such different diseases as CMT1A and IBM, it 
does suggest that these methods will have wide applicability across most 
neuromuscular diseases where progressive muscle weakness is a feature.  This is very 
much supported by a rapidly increasing body of literature with both cross-sectional 
(4.2.2) and longitudinal (5.2) data, using similar methods across a wide range of 
neuromuscular diseases.  General lessons learnt from this study would apply to any 
clinical trials in other neuromuscular diseases:  
1. The need for a healthy control group in both cross-sectional and natural history 
studies, and probably clinical trials. 
2. The importance of a comprehensive protocol measuring both acute water 
abnormalities and chronic intramuscular fat accumulation in cross-sectional and 
natural history studies to allow full characterisation of quantifiable disease 
processes and therefore the best outcome measures for clinical trials. 
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3. The importance of optimising reliability as far as possible, in particular with 
regard to ensuring the volume of tissue being analysed across time points is the 
same in both the x-y plane and in the z-axis. 
The work from this thesis informed the selection and refinement of sequences utilised 
in quantitative muscle MRI protocols for subsequent studies at the MRC Centre for 
Neuromuscular Diseases.  These are examples of how a quantitative MRI protocol can 
be tailored to specific disease and trial design factors. 
6.1.5.1 Quantitative MRI protocol in hypokalaemic periodic paralysis 
The skeletal muscle channelopathies provide two attractive characteristics for studying 
quantitative muscle MRI: transcellular fluid shifts are a direct consequence of the 
underlying genetic defects, and effective treatment of these fluid shifts exists (Jurkat-
Rott et al., 2009; Raja Rayan and Hanna, 2010).  The protocol designed therefore 
included sequences to measure muscle water parameters as accurately as possible.  
Sequences performed at mid-thigh and mid calf-level were: standard T1-weighted 
sequence; semi quantitative STIR sequence normalized to saline reference (Jurkat-
Rott et al., 2009); 3-point Dixon fat quantification; IDEAL-CPMG (Janiczek et al., 2011) 
with independent quantification of muscle water T2; and MTR imaging.  Other 
modifications of the protocol based on the results from this thesis included fixed-
distance from bony landmark slice positioning, and reduced interslice distance to 
10mm.  The rapid response to treatment demonstrated in this condition (Jurkat-Rott et 
al., 2009), meant that a 4 week interscan interval was employed. 
6.1.5.2 Quantitative MRI protocol in Hereditary Sensory Neuropathy 
Hereditary sensory neuropathy type 1 is caused by mutations in the SPTLC1 (Serine 
Palmitoyltransferase Long Chain Base Subunit 1) gene.  Although the initial feature is 
of sensory loss, length dependent motor weakness is also common as the disease 
progresses, and the condition can be thought of as on the CMT spectrum (Reilly et al., 
2011).  The pathogenesis of the condition suggests oral serine supplementation as an 
effective therapy, and has been utilized in both mouse models and in humans 
(Garofalo et al., 2011).  Unfortunately it is a very rare disease which severely limits the 
potential size of any clinical trial, necessitating outcome measures optimized for 
maximum responsiveness. 
We therefore included quantitative lower limb muscle MRI as an outcome measure in a 
natural history study with a 12 month inter-assessment interval.  Due to the similarity 
with CMT, fat quantification was selected as the primary outcome measure, but the 
three point-Dixon sequence employed in this thesis was further refined by employing 
full 3D coverage with 5mm slice thickness in the z-axis; and anatomical coverage of the 
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foot, whole lower leg and distal thigh to mitigate against the floor effect noted in this 
thesis.  The protocol also included standard T1w and STIR sequences to allow 
assessment of convergent validity.  Preliminary analysis of the longitudinal data 
showed that MRI provided the only responsive outcome measure in this disease 
(Evans et al, in preparation). 
6.1.5.3 Quantitative muscle MRI protocol in other neuromuscular 
diseases 
As demonstrated by the two examples above, the challenges for each specific disease 
will be different.  Another example is whilst in IBM there is concern regarding the 
confounding effects of healthy ageing, in Duchenne the concern is over the 
confounding effects of normal growth. The solutions are often similar – in this case 
inclusion of an appropriate control group.  The exact role of MRI within the drug 
development pipeline would also vary by disease.  Often in may be used in phase 2 
clinical trials where it can provide sensitive measures of efficacy and valuable insights 
into the nature and distribution of treatment response, whereas in many diseases it 
may be chosen as a secondary outcome measure in pivotal phase three trials.  On the 
other hand, for slowly progressive conditions such as CMT1A, where no other 
responsive outcome measure exists, an argument can be made that MRI measured 
intramuscular fat accumulation should be used as the primary outcome measure in 
phase three trials, as other current outcome measures would be futile. This is a stance 
which would require careful dialogue with the drug licensing agencies such as the FDA 
and European Medicines Agency. 
 Final conclusions 
We are at the dawn of an exciting new era of treatment in neuromuscular diseases with 
medicines which alter the natural history of the disease being licensed, such as 
enzyme replacement therapy in Pompe disease (van der Ploeg et al., 2010) and 
ataluren in Duchenne muscular dystrophy (Bushby et al., 2014), with other gene 
therapies in late stage clinical trials.  Pivotal to these studies will be valid, reliable and 
responsive outcome measures to allow accurate identification of effective treatments 
and to exclude ineffective treatments. 
This thesis has demonstrated the enormous potential of quantitative MRI to provide 
such outcome measures in two exemplar neuromuscular diseases: inclusion body 
myositis and Charcot-Marie-Tooth disease type 1A.  Three-point Dixon fat-
quantification provides a robust measure of chronic muscle pathology whilst T2 and 
magnetisation transfer methods probe acute water changes within skeletal muscle.  
Test-retest reliability is excellent and can be improved further; construct, criterion and 
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longitudinal validity have been demonstrated; and responsiveness exceeds all other 
outcome measures assessed.  Quantitative MRI should be considered for inclusion in 
all natural history studies and clinical trials in neuromuscular diseases. 
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